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Approximately 8% of the human genome is composed of long terminal repeat (LTR) 
elements which originate from ancient retroviral germline infections. LTRs have the potential 
to act as alternative promoters and enhancers meaning that their expression is usually under 
tight epigenetic control to prevent aberrant gene expression.  LTR activation has been 
reported in a number of diseases including Hodgkin’s Lymphoma (HL) where an LTR acts as 
a promoter for the growth factor receptor gene CSF1R which is required for HL cell survival. 
To investigate the genome-wide activation of LTRs in HL and their impact on gene 
expression we developed a novel targeted next generation sequencing approach (RACE-
Seq) and integrated this data with global gene expression RNA-Sequencing as well as 
chromatin profiling data from HL and non-HL cell lines.  
We discovered a unique pattern of LTR activation in each cell line, which correlated with 
changes in gene expression, including a number of HL-associated genes. We also showed 
that LTR expression can be induced by activation of inflammatory signalling pathways. 
Together these results show that LTR activation presents an additional level of gene 
expression deregulation in HL and highlight the potential for the impact of genome-wide LTR 
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1.1. Chromatin and Nuclear Organisation 
1.1.1. Chromatin 
The presence of chromosomes within the nuclei of cells was first discovered in the mid-19th 
century long before Franklin provided the data for Watson and Crick to elucidate the double 
helix structure of DNA (Watson and Crick 1953). Flemming demonstrated that during cell 
replication the material within the nucleus formed thread like structures and he went on to 
identify the different stages of mitosis (Flemming 1882, Paweletz 2001). We now know that 
the nucleus of human cells contains around 3 billion base pairs of DNA equalling around 2 
metres in length which require intricate packaging to fit within the nucleus (Bloom and 
Joglekar 2010). To achieve this level of compaction, the double helix of DNA is coiled around 
nucleosomes which fold to produce fibres and are then tightly coiled into the chromatids of 
chromosomes. Although it is important to neatly package DNA within the nucleus it is also 
necessary to maintain accessibility at specific regions for replication and transcription which 
is mostly achieved by modifications at the nucleosome level. 
1.1.2. Nucleosome Structure 
A nucleosome is formed of 147 bp of DNA coiled 1.65x around an octamer of histones. Each 
nucleosome contains 2 of each of 4 different histones, H2A, H2B, H3 and H4. Each histone 
has a structural domain with 3-alpha-helices separated by 2 loops which are essential for 
DNA interaction (Kornberg 1974, Kornberg and Lorch 1999). H2A heterodimerizes with H2B 
and H3 with H4, and the two H3/H4 dimers then form a central tetrameric axis. The two 
H2A/H2B dimers join the tetramer to form the complete nucleosome octamer. Histone H1 
attaches to the outside of the nucleosome and serves to both lock the DNA in place and as a 
linker to other nucleosomes to form higher order chromatin. It is essential to maintain 
accessibility to regions of DNA for transcription. This is achieved by a combination of post-
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translational modifications (PTMs) to the protruding amino-terminal tails of the histones, 
through histone variants and nucleosome remodelling complexes (Fig. 1.1). 
 
Figure 1.1.Nucleosome Structure – Two H3-H4 dimers form a central tetramer which Two 
H2A-H2B dimers join to form the final octamer structure of the nucleosome. Histone tails can 
be seen protruding from the nucleosome. Adapted from: (Cockerill 2011). 
 
1.1.3. Histone Variants 
The canonical histones that make up the nucleosome can be replaced with variants that 
have anywhere from a few amino acid substitutions to entire domains being gained or lost. 
The integration of these histones into nucleosomes can change the properties of the 
nucleosome impacting on chromatin structure and DNA – protein interactions (Kornberg 
1974). 
The canonical histone H3.1 is upregulated during mitosis and substitutes for variant H3.3 at 
replication origins to destabilise nucleosomes allowing access to the DNA for replication 
(Tagami, Ray-Gallet et al. 2004). H3.3, unlike H3.1 is a replication-independent variant. 
Replication-independent variants have a continuous level of expression throughout cell cycle. 
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H3.3 differs from H3.1 only by 5 amino acids and shows no other major structural 
differences. However, it plays an important role in transcriptional regulation as H3.3 is highly 
dynamic and is able to contribute to a more rapid activation of genes silenced by histone 
modifications independent of replication (Ahmad and Henikoff 2002, Tagami, Ray-Gallet et 
al. 2004). 
H2A.Z is another important histone variant which is expressed in all organisms along with 
H2A (Talbert and Henikoff 2010). The incorporation of H2A.Z in a nucleosome only produces 
subtle structural changes, however, this is enough to destabilise the nucleosome allowing for 
transcription and DNA repair to take place (Meneghini, Wu et al. 2003, Venkatesh and 
Workman 2015). Both H3.1 and H2A.Z are also associated with transcription start sites 
(TSS’s). H3.1 is often associated with silenced genes whereas the H3.3 variant is often 
located in proximity to TSS’s of transcribed genes (Tagami, Ray-Gallet et al. 2004). H2A.Z is 
incorporated into the +1 phased nucleosome that sits upstream of the nucleosome free 
region at TSS’s and is often associated with genes which have a moderate expression level 
(Soboleva, Nekrasov et al. 2014). 
1.1.4. Histone exchange 
Histone exchange is a critical process for the integration of histone variants and also to allow 
chromatin to have a fluid structure for replication, repair and transcription to take place.  A 
number of factors contribute to histone exchange including chromatin re-modellers, histone 
chaperones and post translational histone modifications (PTM), which each play roles in 
either weakening the histone-histone or histone-DNA interactions (Venkatesh and Workman 
2015).  
Chromatin remodellers act in an ATP dependent manner driving a DNA translocase and are 
able to slide or remove nucleosomes, opening DNA for interaction with histone chaperones 
and for transcription (Tsukiyama, Becker et al. 1994). In the context of transcription the 
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INO80 and SWR chaperones (yeast orthologue to human SRCAP) are needed to exchange 
H2A histones for the H2A.Z variant which reduces the stability of the nucleosome allowing 
transcription to take place (Ruhl, Jin et al. 2006). SWR functions by carrying out ATP 
hydrolysis in the presence of the H2A-H2B dimer meaning that it will only be active at sites 
where the H2A.Z variant is not present so it can add the variant but cannot remove it. It is 
thought that the INO80 complex functions in opposition to SWR and removes non-acetylated 
H2A.Z dimers avoiding miss-targeting of the histone variant to areas of chromatin which 
should remain closed and avoiding aberrant transcription (Papamichos-Chronakis, Watanabe 
et al. 2011, Watanabe, Radman-Livaja et al. 2013). 
Unlike chromatin remodellers, histone chaperones are not usually ATP dependent and rely 
on spontaneous DNA movement (Hondele, Stuwe et al. 2013). Chaperones perform a 
number of functions including assisting in maintaining the stability and organisation of 
nucleosomes. They are able to interact with remodellers to act as histone sinks and also to 
regulate histone post translational modifications (PTMs). For example the repressive 
H3K9me3 histone modification has been shown to be maintained at heterochromatin by 
deposition of H3.3 by the ATRX/DAXX chaperone complex (Voon and Wong 2016)  
Chaperones are also required for the assembly of newly synthesised nucleosomes following 
replication as part of the FACT complex (discussed further in 1.2.4). Finally following histone 
modifications of other domains within the nucleosome octamer chaperones are needed to 
provide access to the PTM enzymes (Youdell, Kizer et al. 2008). 
1.1.5. Post-translational modifications (PTMs) of Histones 
The presence of an amino-terminal tail on each of the histones which protrudes from the 
nucleosome allows for many potential post-translational modifications to be easily added to 
histones (Luger, Mader et al. 1997, Margueron and Reinberg 2010). It has been shown in 
numerous studies that these histone modifications play an important role in the control of 
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chromatin accessibility and therefore gene expression (Brownell, Zhou et al. 1996, Vaquero, 
Loyola et al. 2003, Kouzarides 2007).  Many different histone modifications have been 
identified and there are no doubt still more to be discovered. Although many modifications 
occur on amino acids in the protruding tails of the histones there are also a number which 
occur at other amino acids including those of the globular domain. 
Post-translational histone modifications have a number of important functions in biological 
processes including transcriptional initiation and repression, elongation, mitosis and 
maintenance of both euchromatin and heterochromatin (Table 1.1)(Lawrence, Daujat et al. 
2016). Histone modifications can act alone or in the case of double modifications can 
influence each other (Cheung, Tanner et al. 2000, Lee, Smith et al. 2010). This can be 
achieved by 3 main routes: (1) altering the histone-DNA interaction (increasing or decreasing 
the binding affinity of the nucleosome), (2) acting as an interaction partner to recruit proteins 
and regulate transcription and (3) to prevent other proteins from binding. Heterochromatin 
displays a generally repressed transcriptional state which is predominantly maintained 
through methylation of H3. Although generally transcriptionally inactive it is now recognised 
that it can be split into 2 groups, facultative and constitutive (Bannister and Kouzarides 
2011). Facultative heterochromatin contains genes which are differentially regulated often 
during cell differentiation where gene activation is only required at certain stages, this 
chromatin often has H3K27me3 and H2AK119ub modifications. Constitutive 
heterochromatin, often with marked H3K9me2/3, is found at the repeat regions of telomeres 
and centromeres where genes are permanently silenced. H3k9me3 is also often found at 
transposable elements throughout the genome to maintain silencing preventing the elements 
from acting as transposons, promoters or enhancers (Hurst and Magiorkinis 2017). 
Euchromatin represents the less tightly packed chromatin incorporating H2A.Z histone 
variants and contains many transcriptionally active genes. Expressed protein coding genes 
have a fairly well defined set of histone modifications spread throughout the gene. H3K4me3 
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is present at the promoters of actively transcribed genes (Liang, Lin et al. 2004).  These 
marks are added to H3 by the SETD1/MLL complex which has a preference for methylating 
histones in vicinity to CpG islands, a common feature of eukaryotic promoters (Deaton and 
Bird 2011). The presence of H3K4me3 has been shown to both have involvement in the 
recruitment of Pol II and specific transcription factors to the promoter and also as part of a 
positive feedback loop to reinforce its own deposition (Yokoyama, Wang et al. 2004, Zhang, 
Cooper et al. 2015). 
Another notable histone modification on nucleosomes of actively transcribed genes is 
H3K36me3 which accumulates towards the 3’ end of the gene (Pokholok, Harbison et al. 
2005). In mammals this modification is carried out by the SETD2 enzyme (Wagner and 
Carpenter 2012). It has been shown that the presence of H3K36me3 recruits HDACs which 
deacetylate histones within the gene body. This activity is the opposite to that of H3K4me3 
which causes an increase in acetylation at promoters and an increase in transcription 
initiation complex recruitment. By promoting deacetylation of gene bodies H3K36me3 helps 
to prevent the formation of spurious transcription start sites within genes (Zhang, Cooper et 
al. 2015).  
In addition to the role of histone modifications at promoters they can also play a role at other 
transcriptional regulatory elements such as enhancers. Studies have shown that many 
elements in the genome which act as enhancers are flanked by H3K4me1, H3K4me2 and 
H3K27ac. Further studies attempting to classify subgroups of enhancers have also shown 
presence of H3K27me3 and H3K36me3 (Zentner, Tesar et al. 2011). It is thought that 
H3K4me1 facilitates the binding of readers to enhancers which then leads to their interaction 
with promoters (Calo and Wysocka 2013). However the exact function of enhancer histone 






Figure 1.2. Distribution of histone modifications at active (A) and inactive (B) protein coding 



















Table 1.1. Post translational histone modifications (human) and their role in chromatin. 
Adapted from(Lawrence, Daujat et al. 2016) 
Histone Modifications Role 
H2A K4/5ac,K7ac Transcriptional Activation  
S1P Mitosis, Chromosome Assembly 
K119P Spermatogenesis 
119uq Transcriptional Repression 
H2B S14P Apoptosis 




H3 K4me2 Permissive euchromatin 
K4me3 Transcriptional elongation, active 
euchromatin 
K9me3 Transcriptional repression; 
imprinting; DNA methylation 
R17me, K4ac, K27ac Transcriptional Activation  
K27me3 Transcriptional silencing; X-
inactivation; bivalent genes/gene 
poising 
K36me3 Transcriptional Elongation  
K9ac Histone deposition; transcriptional 
activation 
K14ac, K23ac Transcriptional activation; DNA 
repair 
K18ac Transcriptional activation; DNA 
repair; DNA replication 
T3P, T11/S28P Mitosis 
S10P 
S28P 
Mitosis; meiosis; transcriptional 
activation 
H4 R3me Transcriptional Activation 
K20me1 Transcriptional silencing 
K20me3 Heterochromatin 
K5ac Histone deposition; transcriptional 
activation; DNA repair 
K8ac Transcriptional activation; DNA 
repair; transcriptional elongation 
K12ac Histone deposition; telomeric 
silencing; transcriptional activation; 
DNA repair 
K16ac Transcriptional activation; DNA 
repair 






1.2. Eukaryotic Transcription 
1.2.1. Promoters 
The core promoter region of a gene lies upstream of the transcription start site (TSS) and 
defines the location of the TSS. Promoters are traditionally classified into 2 groups, TATA 
box and CpG island promoters.  The TATA box is recognised by TBP or a TAF mediating the 
formation of the RNA Pol II initiation complex. CpG island promoters are sequences 
containing an atypically high proportion of CpG sites and are spread throughout the human 
genome. They are able to bind transcription factors which can then recruit TBP and the Pol II 
initiation complex (PIC) (Illingworth and Bird 2009). 
Although the TATA-box promoters were the first to be discovered a far more diverse range of 
promoters have since been identified. These can include combinations of a number of 
elements including Inr (initiator motif), DPE (downstream core promoter element), MTE (motif 
ten element) which act as TFIID binding sites. A number of other elements can also be 
involved including BRE a TFIIB recognition element and DCE (downstream core element) 
(Juven-Gershon, Hsu et al. 2008). These elements work in combination with tissue specific 
transcription factor motifs to initiate the formation of the PIC. 
It should be noted that many CpG island have been identified at sites which are not 
annotated gene promoters (Illingworth and Bird 2009). It is thought that these sequences 
may still act as promoters for other elements and many of these sites may be long terminal 
repeat elements from endogenous retroviruses (discussed in 1.3.7). 
 
1.2.2. Enhancers 
Enhancers are transcriptional regulatory elements defined by their ability to activate 
transcription regardless of their distance from the promoter of a gene as shown in 
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transfection assays of reporter genes such as luciferase (Bulger and Groudine 2010). 
Enhancers are often around 200-400bp in size and can reside within a gene or be located 
many hundreds of kilo-bases from the promoter with which they interact (de Villiers and 
Schaffner 1981, He, Meyer et al. 2010). Enhancers contain motifs to attract binding of 
specific transcription factors which in turn recruit cofactors. Through looping of the DNA 
these complexes interact with the PIC at a promoter increasing the transcriptional activity 
and the expression level of the gene. The looping activity of enhancers was first shown in 
vivo at the locus control region (LCR) of the β-globin locus which is located 40-60 Kb away 
from the gene promoter but is in close spatial proximity (Carter, Chakalova et al. 2002, 
Tolhuis, Palstra et al. 2002). Individual enhancers are often tissue specific and not 
necessarily required for the transcription of a gene per se but mediate tissue specific 
expression. Enhancer promoter interactions can be highly specific and often do not involve 
the promoter of the nearest gene and some promoters have interactions with more than one 
enhancer in different tissues (Sanyal, Lajoie et al. 2012, Mifsud, Tavares-Cadete et al. 2015). 
A recent study also demonstrated that many promoters can also act as distal enhancers for 
unrelated genes (Dao, Galindo-Albarran et al. 2017). This means that the enhancer effect of 
a gene promoter becoming active should also be considered along with expression of its 
transcribed gene. 
1.2.3. Transcriptional Initiation 
Almost every cell in a eukaryotic organism carries the same DNA within its nucleus, providing 
the code for every protein that is required by the organism. As every cell contains the same 
set of genes it is necessary to regulate the expression of genes on a cell type specific basis 
to ensure correct functioning of a cell. For tissue-specific genes, the largest part of gene 
expression control occurs at the stage of transcription initiation, where DNA is processed by 
RNA Polymerase II (Pol II) to form mRNA which is later translated to amino acid sequences 
and functional proteins. 
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The initiation of transcription of a protein coding gene starts with the formation of the Pol II 
initiation complex (PIC) which is formed by a group of proteins termed general transcription 
factors (GTF) (Liu, Bushnell et al. 2013). The process begins with the binding of TFIID, TATA 
box binding protein (TBP) and TBP associated factors (TAFS) to double stranded DNA at the 
promoter of a gene. This forms a complex with TFIIB which assists with TBP binding forming 
the core initiation complex(Kostrewa, Zeller et al. 2009).  
The TBP and TFIIB complex has been shown to be sufficient for the recruitment of Pol II and 
for transcription (Tyree, George et al. 1993). TBP recognises and binds to TATA box 
sequences (TATAWAWR) which are often located around 30 bp upstream of the 
transcription start site, however, only 10-20% of promoters have a TATA box (Basehoar, 
Zanton et al. 2004). As TBP is an essential member of the initiation complex, it is thought 
that in TATA-less promoters binding is assisted by the TAFs recognising elements around 
the promoters. Once bound to the minor groove of double stranded DNA at a promoter, TBP 
bends the DNA at almost 90° which effectively functions to wrap the DNA around Pol II and 
this feature may be the reason that TBP is required even at TATA-less promoters 
(Sainsbury, Bernecky et al. 2015).  
The binding of TBP and its bending function is further assisted by TFIIB which binds to 
upstream and downstream recognition elements. Through the interaction with recognition 
elements TFIIB also acts to orientate the complex for transcription towards the direction of 
the gene. It should be noted that many Pol II promoters also act in a bidirectional manner 
(Fong, Saldi et al. 2017). TFIIB also serves to recruit Pol II through the binding of the B-
ribbon of TFIIB to the dock domain of Pol II (Chen and Hahn 2003). Once the core initiation 
complex is formed Pol II and TFIIF are recruited to the complex and are joined by TFIIE and 
TFIIH forming the complete PIC. 
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The TFIIF component of the complex forms a heterodimer binding to the Pol II near the 
downstream DNA. The winged helix domain of TFIIF interacts with TFIIB and its downstream 
recognition elements thereby helping to prevent non-specific interaction of Pol II with DNA 
(Cabart, Ujvari et al. 2011). The final two components of the complex, TFIIE and TFIIH are 
required for the opening of the double stranded DNA to form a transcription bubble. TFIIE 
binds to Pol II and acts as a bridge for the binding of TFIIH. TFIIH functions as an ATP 
dependent molecular ‘wrench’ which creates torque, melting the double stranded DNA to 
form a single stranded DNA bubble which the Pol II can use as a template to produce an 
mRNA (Grunberg, Warfield et al. 2012). 
Once the PIC has formed at a promoter the process of elongation can begin. Transcription 
usually begins around 30 bp downstream of the TATA box for TATA box containing 
promoters.  
1.2.4. Transcriptional Elongation 
The process of elongation can be split into two stages, early elongation and productive 
elongation. Early elongation begins once around 12 nucleotides of nascent RNA have been 
produced, at this point RNA is capped and the GTFs are no longer needed(Tang, Roy et al. 
2009). Although not required for elongation TFIID, TFIIA and TFIIH can remain bound at the 
promoter of some genes acting as a scaffold for the re-initiation of transcription (Yudkovsky, 
Ranish et al. 2000).  TFIIF can also remain bound to Pol II as an elongation factor (Cabart, 
Ujvari et al. 2011). In the initial models of transcription it was thought that once Pol II 
escaped the initiation complex it would then proceed uninterrupted to produce the full RNA 
transcript. Based on observation of accumulation of Pol II in close proximity to promoters of 
many genes it has been shown that Pol II pauses after transcribing 20-60 nucleotides at 
many genes (Kwak and Lis 2013).  
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Pol II pausing is an important level of regulation in gene expression and the strongest rate 
limiting step for Pol II (Kwak and Lis 2013). Pausing can be explained by three different 
mechanisms. The kinetic model suggests that pausing is dependent on the energy state of 
the DNA-RNA hybrid and is influenced by factors such as the initial rate of elongation. An 
example for this notion is that in a higher energy state Pol II can backtrack and requires 
TFIIS interaction to restart elongation from a paused state (Adelman, Marr et al. 2005). The 
second model is based on a physical barrier being present which pauses elongation. This 
barrier can be a nucleosome which is supported by the observation that pausing often occurs 
between the promoter and first nucleosome (Izban and Luse 1991). These 2 models alone 
do not account for all promoters with proximal Pol II pausing. The third model demonstrates 
pausing as a result of specific binding factors which interact with Pol II and the RNA 
transcript. In particular NELF and DSIF bind the nascent RNA and are associated with Pol II 
pausing (Missra and Gilmour 2010). For transcription to proceed it is necessary for Pol II to 
escape into the productive-elongation phase. 
The majority of genes which show promoter proximal pausing are expressed at least some of 
the time, showing that Pol II can escape from the paused state. Two processes are required 
for Pol II to escape from pausing. Firstly 5’ capping of the nascent RNA transcript which is 
has been shown to occur as the Pol II escapes from its paused state (Rasmussen and Lis 
1993). The second process is the phosphorylation of Pol II and pausing factors DSIF and 
NELF. This phosphorylation is carried out by P-TEFb which can be recruited to Pol II by 
activators such as RelA which recruits P-TEFb to TNF-α genes (Barboric, Nissen et al. 
2001). It can also be recruited by co-activator Brd4 which recognises acetylated histone tails 
and by the Mediator complex which also assists Pol II in passing the +1 nucleosome barrier 
(Yang, Yik et al. 2005, Takahashi, Parmely et al. 2011, Nock, Ascano et al. 2012).   
Following escape from pausing the remaining barrier to transcription is the presence of 
nucleosomes along the gene body. Passing these barriers is achieved using a number of 
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different factors including FACT, Spt6, PARP and PAF complex. FACT assists in progression 
of elongation by breaking the H2A-H2B dimer from a nucleosome which allows Pol II to 
continue through the remaining histones. FACT has also been shown to reassemble the 
H2A-H2B dimer with the other histones to restore the nucleosome (Orphanides, LeRoy et al. 
1998, Xin, Takahata et al. 2009). Spt6 has also been shown to play a similar role of 
disassembling and reassembling nucleosomes through interaction with histones H3 and H4 
(Bortvin and Winston 1996). After successful elongation transcription then needs to undergo 
termination. 
1.2.5. Termination, cleavage and polyadenylation 
The final stages of transcription are termination, cleavage of the RNA transcript and also 
polyadenylation of the transcript. Termination occurs anywhere between a few bases and 
several kilobases downstream of the 3’ end of a transcript (Proudfoot 1989, Richard and 
Manley 2009). Termination is directed by the 3’-end processing of the mRNA transcript which 
involves cleavage and polyadnylation specific factor (CPSF) binding to an AAUAAA 
sequence along with cleavage stimulation factor (CstF) which binds at a GU rich sequence. 
These complexes include a polymerase which is able to polyadenylate the mRNA which 
signals for termination of Pol II elongation. There were 2 models proposed in the 1980’s for 
the termination of Pol II elongation (Richard and Manley 2009). The allosteric model 
suggests that transcription through the poly A site leads to a conformational change in the 
elongation complex(Logan, Falck-Pedersen et al. 1987). The Torpedo model suggests that 
the rapid degradation of 3’ RNA allows the entry of an exonuclease which releases the Pol 
II(Connelly and Manley 1988). More recent studies would suggest a combination of these 
theories is more likely to be true with Xrn2 degradation of the RNA transcript downstream of 
the poly A cleavage site either prior or post cleavage resulting in RNAPII release(West, 
Proudfoot et al. 2008). 
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1.2.6. Transcription Factors 
Transcription factors bind specific DNA motifs and through protein-protein interaction 
domains are able to activate or in some cases repress transcription (Kadonaga 2004). The 
first specific transcription factors were identified and purified in the 1980’s. Specificity protein 
1 (Sp1) was one of the first transcription factors to be purified, it was shown to bind to the GC 
box of the SV40 enhancer (Dynan and Tjian 1983). Many transcription factors have since 
been discovered most of which bind to defined unique DNA binding motifs and are 
expressed in a tissue specific manner (von Strandmann, Nastos et al. 1997). Transcription 
factors can interact with each other and also recruit cofactors and bridging factors to maintain 
specific chromatin states as well as to recruit other proteins to activate or repress 
transcription.  Through these interactions transcription factors play a central role in defining 
the gene expression programme of cells and therefore the specification of cell types from 
embryonic development through to adult tissues. Transcription factors can also act in a 
signalling dependent manor to trigger gene expression in response to certain stimuli. For 
example the transcription factors AP-1 (Activator protein 1) and NF-κB are stimulated by 
cytokines, growth factors and infection to produce an inflammatory response in cells (Hess, 
Angel et al. 2004, Brasier 2006).  
1.2.7. Silencers and Insulators 
There are a number of other elements which can influence control of gene expression. 
Silencers share many of the properties of enhancers, however effectively have the opposite 
function resulting in repression of gene expression (Baniahmad, Steiner et al. 1990). 
Silencers can function in a similar way to enhancers, by a looping mechanism interacting 
with a specific promoter via cofactors and preventing transcription. Silencers can also act 
through the generation of double stranded (duplex) RNA which can also interact with 
promoters to downregulated gene expression (Kolovos, Knoch et al. 2012). Through 
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interaction with binding factors such as the zinc-finger protein NRSF/REST (neuron-
restrictive silencer factor) silencers are also able to act in a tissue specific manner repressing 
transcription in all but specific tissues (Schoenherr and Anderson 1995, Jones and Meech 
1999).  
Insulators act as boundaries preventing unwanted interaction between enhancers or 
silencers and promoters of genes which should not be targeted by the regulatory element 
(Kolovos, Knoch et al. 2012). The importance of insulators has been clearly demonstrated by 
the  mutation or deletion of these regions which results in developmental defects (Gaszner 
and Felsenfeld 2006). Insulators, however, play a far larger role than just blocking unwanted 
chromatin interaction (Yang and Corces 2011). Studies have shown that through the binding 
of the transcription factor CTCF insulators are responsible for the looping of chromatin, its 
localisation within the nucleus and therefore potential interactions of regulatory elements 
(Reviewed by (Deng, Patel et al. 2015). 
1.2.8. Chromatin Conformation 
As previously discussed interaction of enhancers with promoters allows a physical proximity 
between promoter and enhancer elements. In recent years the importance of the 
conformational chromatin structure as a regulator of gene expression has been highlighted 
by the use of new techniques such as chromatin conformation capture (3C)(Dekker, Rippe et 
al. 2002) and genome wide approaches including Hi-C which enable the physical interactions 
between regions of DNA to be observed(Lieberman-Aiden, van Berkum et al. 2009). These 
studies have enabled the identification of topologically associated domains (TADS), regions 
which exhibit a high level of topological interactions internally with very few if any interactions 
passing the boundaries into neighbouring TADs (Dixon, Selvaraj et al. 2012). This 
observation has been further confirmed by mouse studies where the boundary sequences 
have been mutated, resulting in developmental defects (Lupianez, Kraft et al. 2015). The 
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binding of the transcription factor CTCF plays a crucial role in demarcating the boundaries of 
TADS and has been shown to be required at insulators to block enhancers (Bell, West et al. 
1999). CTCF is further responsible for genome-wide chromatin looping, however it has been 
recently shown that in the absence of CTCF transcription is disrupted but not genomic 
compartmentalisation (Nora, Goloborodko et al. 2017). This suggests that other factors play 
a role in the overall topological arrangement of the genome.  
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1.3. Repeat Elements in the Human Genome 
The disparity between genome size and organism complexity puzzled many early 
researchers, however, in the 1970s the discovery of functional non-coding DNA helped to 
resolve this puzzle (Gregory 2005). Many theories were proposed for the existence of what 
was assumed to be ‘junk DNA’. The three main theories were that it consisted of functionless 
copies of genes or ‘pseudogenes’, that it consisted entirely of introns or that it served a 
structural purpose forming a nuclear skeleton (Comings 1972, Cavalier-Smith 1978, Gilbert 
1978).   
A number of studies followed the discovery of non-coding DNA, however, the biggest step 
forward in this field was no doubt the sequencing of the human genome. We now know that 
only ~1.5% of DNA codes for proteins and a further ~26% resides within introns of these 
genes which leaves ~73% of DNA outside of protein coding genes (Lander, Linton et al. 
2001, Gregory 2005). A large proportion of the non-coding DNA is made up of repeat 
elements. A conservative estimate based on the RepeatMasker approach is that ~50% of the 
entire genome is composed of repeat elements (Figure 1.3) (Smit 2013-2015). This estimate 
is based on alignment of genomic DNA to repeat family consensus sequences from Repbase 
(Jurka 2000). Alternative estimates using a de novo approach would suggest that up to 69% 
of the genome is repeat derived (de Koning, Gu et al. 2011).  
Repeat elements can be split into two distinct groups based on sequence structure, tandem 




Figure 1.3. Percentage of repeat genome occupied by types of repeat element in humans 
(adapted from (Treangen and Salzberg 2011)). 
 
1.3.1. Tandem Repeats 
Tandem repeats can range anywhere from single bases to mega-bases in length and are 
divided into 5 groups; satellites, mini-satellites, micro-satellites, centromeric satellites and 
telomeric repeats. Mini-satellite repeats have a repeat length of 30-35 bp with a conserved 
10-15 bp core sequence and can total 1-15 kb in length. Microsatellites are composed of 
dinucleotide to pentanucleotide repeats with a total length of up to 100’s of base pairs (Fig 
1.4, Table 1.2) (Padeken, Zeller et al. 2015). The reason for the formation of the 
microsatellite repeats is most likely slipped strand mispairing (Levinson and Gutman 1987). 
Slipped strand mispairing occurs when the polymerase briefly dissociates from the template 
strand and re-associates slightly up- or downstream which can result in repeated sequence. 
This occurs most often at short tandem repeats and in germ line cells which means that the 
length of the tandem repeats can vary greatly even between individuals of the same species. 
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There is also a reasonable amount of variability in the length of mini-satellite repeats, 
however, the reason for this is much less clear as the length of the repeats means it is much 
less likely to occur by chance (Ahmed and Liang 2012). The most likely cause for this 
variation is during gene conversion in meiosis (Richard and Paques 2000) although some 
are also thought to be derived from transposable elements (Ahmed and Liang 2012). The 
final class of tandem repeats are the centromeric and telomeric repeats. Telomeric repeats 
are simple arrays of tandem repeats (TTAGG in humans) located at the ends of 
chromosomes and through interaction with telomerase binding proteins serve a number of 
roles including protecting the chromosomes from exonuclease activity (Wai 2004). The 
centromeric repeats are also arrays of tandem repeats and are located at the centromere of 
chromosomes. They are bound by the histone variant CENH3 which plays an important role 
in mitosis (McKinley and Cheeseman 2016). 
The general function of the tandem repeats in the human genome is not clear. However, in 
specific cases tandem repeat elements can act as origins of replication(Liu, Bissler et al. 
2007), promoter components (Alakurtti, Virtaneva et al. 2000), enhancers (Tassone, 
Hagerman et al. 2000, Tassone, Beilina et al. 2007), gene silencers (van Overveld, Lemmers 
et al. 2003), transcriptional elongation blockers and translational regulators (Krol, Fiszer et al. 
2007). These different functions are often influenced by the expansion or contraction of a 
tandem repeat element and in a number of cases have been linked to diseases, often 
resulting from the dysregulation of expression of a particular gene linked to such a repeat 
(Usdin 2008). Examples of this have been shown in triplet repeat neurological diseases. 
Regions of tandem repeats often form heterochromatin and through position effect 
variegation (PEV) nearby genes can also be silenced in a proportion of cells. It has been 
shown that in a number of neurological diseases such as myotonic dystrophy and 
Friedreich's ataxia small expansions of triplet-repeat regions results in PEV which contributes 
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to deregulation of gene expression (Saveliev, Everett et al. 2003, Nageshwaran and 
Festenstein 2015).  
1.3.2. Interspersed Repeats 
Interspersed repeats, also known as transposable elements (TEs), make up a far larger 
proportion of the human genome than tandem repeats and have the potential to play 
significant functional roles. The interspersed repeat elements can be classified into 2 general 
groups: DNA transposons making up around 9% of repeat elements in the human genome 
and retrotransposons which account for 82% of repeat elements. Retrotransposons are 
further classified into the Long-terminal-repeat (LTR) retrotransposons and the non-LTR 
retrotransposons.  
Transposons were first identified by McClintock in the 1960’s who observed ‘jumping genes’, 
showing for the first time that the genome was not stationary and fixed but that some 
sections of DNA could move around within the genome (McClintock 1968, Ravindran 2012). 
Transposons are basically defined as sections of DNA which are able to move around within 
the genome and can be found in all organisms (Munoz-Lopez and Garcia-Perez 2010). 
Table 1.2.Length of different repeat element classes within the human genome Adapted from 
(Padeken, Zeller et al. 2015)  
Repeat Class Repeat Type Length (bp) 
Minisatellite, microsatellite or satellite Tandem 2-100 
SINE Interspersed 100-300 
DNA Transposon Interspersed 200-2,000 
LTR Retrotransposon Interspersed 200-5,000 
LINE Interspersed 500-8,000 
rDNA (16S, 18S, 5.8S and 28S) Tandem 2,000-43,000 







1.3.3. DNA Transposons 
A DNA transposon is formed of a pair of TIR (Terminal Interspersed Repeat) elements which 
sit either side of a transposase gene (Fig. 1.4). It is thought that DNA transposons became 
integrated into the genome ~50 million years ago following infection with dsDNA viruses 
termed virophages (Fischer and Suttle 2011). DNA transposons work in a ‘cut and paste’ 
manner where the transposase recognises the TIR elements, excises the DNA and reinserts 
it elsewhere in the genome. The reintegration sites vary based on the family of DNA 
transposon but in the most common family, Tc1/mariner (originally discovered in Drosophila) 
this can be any TA dinucleotide. On reintegration into the genome the target site DNA is 
duplicated producing sequences known as Target Site Duplications (TSD) which are a 
hallmark of transposed DNA (Munoz-Lopez and Garcia-Perez 2010).  
Current evidence suggests that the DNA transposons within the human genome became 
inactive around 37 million years ago although the reason for this is currently unknown (Pace 
and Feschotte 2007).  The inactivation of DNA transposons is essential to maintain genome 
stability as theoretically the expression of only one transposase is required to activate many 
DNA transposon elements (Padeken, Zeller et al. 2015). The random insertion of 
transposable elements within promoters, enhancers and gene bodies could easily 
dysregulate gene expression resulting in any number of developmental defects and 
diseases. There are exceptions to this where DNA transposons have been repurposed within 
the genome for essential functions. The best example of this is the RAG proteins which are 
involved in V(d)J recombination in B-Cell development which are most likely to have 
originated from DNA transposons (Agrawal, Eastman et al. 1998). The RAG proteins, 





Figure 1.4.Structure of repeat elements of different classes within the human genome 
(adapted from (Padeken, Zeller et al. 2015)). 
 
1.3.4. Retrotransposons  
Unlike the DNA transposons the retrotransposons or RNA transposons carry out 
transposition through an RNA intermediary. A retrotransposon must first be transcribed and 
then uses a reverse transcriptase to convert the RNA back into DNA before insertion back 
into the genome. The endogenous retrotransposons within the human genome are classified 
based on the presence or absence of long terminal repeat (LTR) elements in their sequence. 
1.3.5. Non-LTR Retrotransposons 
In humans there are 2 main families of non-LTR retrotransposons: Long Interspersed 
Elements (LINE) and Short Interspersed Elements (SINE). LINE retrotransposons have an 
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internal 5’ promoter which allows for initiation of transcription by RNAPII expressing a 
reverse-transcriptase and an endonuclease. The reverse-transcriptase complex recognises 
the 5’ poly-A tail of the element following transcription which allows for transposition to take 
place (Fig. 1.4). The most abundant LINE in humans is L1 which has ~500,000 copies in the 
genome and is overall the most abundant transposable element based on genome coverage. 
The L1 elements are fully autonomous expressing all required enzymes for transposase 
activity and are the only TE’s which have been shown to still have transposon activity within 
the Human genome. However, only ~100 still retain their complete retrotransposon sequence 
out of the potential 500,000 (Cordaux and Batzer 2009).  
SINE retrotransposons are non-autonomous and only have a 7SL promoter and a poly-A tail 
(Fig. 1.4). For these elements to become active a reverse-transcriptase is required from an 
active LINE transposon. In the same way as LINEs, SINEs are recognised by the 
transposition machinery based on the poly-A tail. The most abundant family of SINEs in 
humans is the Alu elements totalling ~1 million copies. The Alu family is derived from 7SL 
RNA and possess the 7SL RNA Pol III promoter sequence (Ullu and Tschudi 1984, Kriegs, 
Churakov et al. 2007).  
1.3.6. Non-LTR Retrotransposons function in the Human genome 
Although mostly no longer active L1 and Alu elements played a critical role in inducing 
genomic variation in early primate evolution mainly through insertional mutagenesis. A small 
proportion of Alu elements are still active particularly within the germ line, with an estimated 1 
in 20 human births having an Alu insertion (Xing, Zhang et al. 2009). Alu insertions can occur 
within coding regions and close to splice junctions giving them the potential to disrupt gene 
expression (Deininger 2011). As a result of this Alu retrotransposons are responsible for 1 in 
every 1,000 new genetic diseases in Humans (Deininger and Batzer 1999). L1 elements are 
also active within the genome and are required for the Alu elements to function. A number of 
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studies have shown a significant role for L1 elements within neuronal and brain development 
and it is suggested that L1 elements contribute to variation between neurons (Muotri, 
Marchetto et al. 2010, Vogel 2011, Upton, Gerhardt et al. 2015). L1 elements also contribute 
to genetic disease and this was first discovered in patients with haemophilia A who have an 
L1 insertion into the Factor VIII gene which resulted in the disease in the affected individuals 
(Kazazian, Wong et al. 1988). 
1.3.7. LTR Retrotransposons – Human Endogenous Retroviruses (HERVs) 
LTR retrotransposons also often referred to as Human Endogenous Retroviruses (HERVs) 
account for around 8% of the Human genome (Lander, Linton et al. 2001). Unlike the other 
transposable elements which often originate from early evolutionary mutations LTR 
retrotransposons originate from retroviral germ line infections. These infections primarily 
occurred over 35 million years ago and those which became integrated into the germ line 
have persisted throughout evolution (Bannert and Kurth 2006). At least a proportion of 
HERVs have also undergone ‘exaptation’, through evolution, becoming functional units within 
the genome (Gould and Vrba 1982, Brosius and Gould 1992). 
The basic structure of an LTR retrotransposon is a pair of LTRs flanking 4 ORFs which code 
for the viral proteins Gag, Pol, Pro and Env (Fig 1.4). The Gag protein forms the central 
structural core of the virus, Pol codes for a retrotranscriptase and integrase, Pro for a 
protease and finally Env is a viral envelope protein. This means that a LTR retrotransposon 
has the ability to form complete viral particles (Bannert and Kurth 2006).  
Upon retroviral infection a virion would usually bind to the cell membrane and be transported 
into the cell. Following entry into the cytoplasm, the viral RNA is then reverse-transcribed by 
the viral reverse transcriptase enzyme to produce double stranded DNA (dsDNA). This 
dsDNA is assembled into a pre-integration complex which is imported into the nucleus and is 
integrated into the host genome by the viral integrase enzyme. The presence of the flanking 
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LTRs which act as RNAP II promoters allow the viral components to be transcribed by the 
host cell machinery. Following transcription, some of the RNA is spliced and exported from 
the nucleus to produce the viral proteins and the remainder is exported to be encapsulated 
into the virus. In most cases the virion is assembled at the plasma membrane and expelled 
from the cell in preparation to infect a new host cell. The viral DNA remains integrated within 
the genome and will be replicated if the cell undergoes mitosis. The production of virions will 
continue in cells with the integrated viral DNA unless the cell is targeted as part of an 
immune response or the viral DNA silenced by epigenetic mechanisms (Deininger and 
Batzer 2002). 
1.3.8. Classification of Human Endogenous Retroviruses 
Exogenous retroviruses are classified into the family Retroviridae which is then further 
subdivided between 7 genera; alpha-, beta-, gamma-, delta-, epsilon-, lenti- and spuma-
retrovirus (ICTV 2017). The taxonomy of endogenous viruses however, was carried out 
separately to this because many years of evolution mean that many endogenous retroviruses 
have only a distant relationship to current exogenous viruses. Endogenous viruses are 
classified into 3 groups, class I which has a resemblance to gamma- and epsilon-
retroviruses, class II which is similar to beta-retroviruses and has a distant relationship to 
delta- and lenti-retroviruses and finally class III which has a similarity to spuma-retroviruses 
(Bannert and Kurth 2006). From this point the classification becomes much more 
complicated due to lack of a unified system. 
Traditionally the classes are split into families which are named based on the amino acid 
code of the tRNA which would have originally bound to the primer binding site (PBS) for 
reverse transcription. Therefore the HERV-K family would denote those with a lysine tRNA 
PBS (Lavie, Medstrand et al. 2004). The HERVs are then further sub-classified under these 
groups based on phylogenetic analysis (Polavarapu, Bowen et al. 2006). The downside of 
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this classification system, other than the incorrect use of the term ‘family’, is that many of the 
tRNA annotations are wrong. For example it is now thought that many of the HERV-K family 
would have associated with methionine tRNA rather than lysine tRNA (Lavie, Medstrand et 
al. 2004). Regardless of these shortcomings, the most complete classification system is that 
used by RepBase, a fairly comprehensive database of human repeat elements. The repeats 
are grouped into 4 classes; ERVL, MaLR, ERV1 and ERVK, each of which is split into 
numerous families totalling over 500 members (Jurka 2000).  
1.3.9. ERVL 
The ERVL family was first identified in 1995 in human placenta tissue and was shown to 
have an integrase domain and also a pol domain which closely resemble that of foamy 
retroviruses (Cordonnier, Casella et al. 1995). It is now known this family accounts for ~22% 
of HERVs and is the oldest detectable family at 100-150 Myr (million years) old. It has been 
shown that ERVL retrotransposons had a significant burst of transposon activity at 45 – 65 
Myr ago, however, this has since ceased and no recent activity has been reported (Benit, 
Lallemand et al. 1999).  
1.3.10. MaLR 
The MaLR or Mammalian Like Retrotransposons are the largest HERV family (48%) and are 
very similar to the ERVL family both of which fit within class III  (Bannert and Kurth 2006). 
They were actually described prior to the ERVL family in 1993, when the similarity between a 
number of human and rodent repeat elements was noted and these were combined to form 
the new family MaLR (Smit 1993). The family was named based on the absence of any 
retroviral protein sequence between the LTRs which was likely lost as a result of homologous 
recombination leaving many solitary LTRs spread throughout the genome (Lander, Linton et 
al. 2001). The family has a further 10 subfamilies classified based on phylogenetic analysis 
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(Fig 1.5). Although MaLR elements no longer have coding regions for viral proteins the LTRs 
still play significant roles in both healthy and diseased tissue (discussed further in 1.3.13). 
 
Figure 1.5. Evolutionary development of the MaLR super family of repeats (adapted from 
(Smit 1993)). 
1.3.11. ERV1 
ERV1 are class I HERVs and encompass the HERV-H and HERV-F subfamilies. The first 
HERV-H element was discovered in the β-globin gene cluster where the presence of a pair of 
LTRs was noted in the sequence and homologous recombination was occurring between the 
LTRs during cloning experiments (Mager and Henthorn 1984). The ERV1 family has much 
more recent history than the previously discussed families and can be dated to a common 
ancestor between the new and old world monkeys around 35 Myr ago (Bannert and Kurth 
2006). Although no recent transposition events were reported, an increase in transcription of 
ERV1 elements has been described in both healthy and diseased tissue. This includes the 
placenta and lung tissue as well as cancer tissue of the colon, squamous cells and a number 
of other tumours (discussed further in 1.3.16) (Hirose, Takamatsu et al. 1993). 
1.3.12. ERVK 
ERVK are class II HERVs and are a family recently integrated into the Human genome with 
the earliest example dating to ~40 Myr ago. HERVK10 is thought to be the most recently 
active germ line transposable element of the HERVs with evidence of transposition since the 
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chimpanzee divergence 7 Myr ago (Medstrand and Mager 1998). The family includes a 
number of full length copies of retrotransposons spread throughout the human genome 
which theoretically have the potential to both retrotranspose and produce viral particles 
(Lower, Lower et al. 1996). It has been shown that at least 6 of the ERVK elements have 
retrotransposon activity in vitro when cloned and also that the Env proteins show activity 
against the antiviral protein tetherin (Berkhout, Jebbink et al. 1999, Lemaitre, Harper et al. 
2014). Although there is no reported viral activity from ERVK elements in healthy tissue a 
recent study has shown viral-like particles from some teratocarcinoma and breast cancer cell 
lines are able to infect and become integrated into healthy cells in vitro (Contreras-Galindo, 
Kaplan et al. 2015). 
1.3.13. LTRs as Promoter and Enhancers 
Most HERVs have lost the ability to code viral proteins through mutation and homologous 
recombination over millions of years of evolution. This means that many LTRs are now 
solitary elements within the genome. Because LTRs act as Pol II promoters during their viral 
function solitary endogenous LTRs have potential to play significant roles as promoters and 
enhancers. 
It was shown using luciferase reporter assays in a number of human cancer cell lines that 
ERVK LTRs had promoter activity ranging from undetectable in some cell lines to very strong 
in Tera-1 (a testicular carcinoma cell line). In the same study the enhancer activity of ERVK 
LTRs was also measured with activity only detectable in the Tera-1 cell line (Ruda, Akopov 
et al. 2004). 
 LTRs are split into 3 sections 3’ Unique (U3), Repeat (R) and 5’ Unique (U5) and have a 
number of shared sequence characteristics. Most LTRs have a 5’ TG and a 3’ CA 
dinucleotide along with a TATA box often with the sequence TAATAAA and may also include 
a polyadenylation signal, an initiator motif, a splice site and transcription factor motifs 
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(Benachenhou, Jern et al. 2009, Benachenhou, Sperber et al. 2013). The transcription start 
site usual resides at the boundary between the R and U5 regions (Kovalskaya, Buzdin et al. 
2006).  
LTRs have been shown to have promoter activity and produce transcripts through the 
binding of TBP to the TATA box present in many LTRs. There are also a number of LTRs, 
particularly those of the HERVK family which have been shown to not have a TATA box 
sequence but instead rely on Sp1 and Sp3 proteins binding to GC rich elements to initiate 
transcription (Fuchs, Kraft et al. 2011). Along with regulation by the main transcriptional 
machinery, LTRs have been shown to have transcription factor (TF) motifs for many tissue 
specific transcription factors. This means that LTRs can have tissue specific promoter activity 
both in healthy and diseased tissue.  
The particular transcription factor motifs present within LTRs vary by family. The HERVK 
family is the best studied of the HERV families and 39 potential TF binding motifs including 
NF-κB, AP1, POU5F1-SOX2 and GATA have been identified (Bourque, Leong et al. 2008, 
Manghera and Douville 2013). Of these factors only a small number of factors have been 
experimentally validated as binding to the HERVK LTRs including YY1, NF-κB, NFAT-1, 
MITF-M, PR, AR and ER (Manghera and Douville 2013). One study has also identified the 
tumour suppressor P53 to be bound to many members of the HERVK family and to play a 
significant role in the P53 regulatory network (Wang, Zeng et al. 2007). An enrichment of P53 
binding sites is also seen in members of the ERV1 family (Bourque, Leong et al. 2008). The 
transcription factor Ying Yang 1 (YY1) is ubiquitously expressed and frequently 
overexpressed in inflammatory diseases such as cancers (Nicholson, Whitehouse et al. 
2011). The binding of YY1 to LTRs has been shown to increase their activation by up to 50% 
implicating at least HERVK LTRs in inflammatory diseases (Knossl, Lower et al. 1999).  
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It has been shown that members of the MaLR family of LTRs also have Sp1, AP1, GATA and 
NF-κB motifs and in the inflammatory environment of Hodgkin lymphoma NF-κB is involved 
in the activation of LTRs (Lamprecht, Walter et al. 2010).  NF-κB is also involved in many 
other diseases with an inflammatory signature. Along with the regulation of LTRs by various 
transcription factors there is evidence to suggest that HERVs actually played a critical role in 
the distribution of transcription factor motifs in the genome throughout evolution (See 1.3.15). 
LTR promoters have been shown to act in sense, antisense and as bidirectional promoters 
(Dunn, Romanish et al. 2006, Huh, Kim et al. 2008, Faulkner, Kimura et al. 2009). As 
alternative promoters LTRs not only have the potential to simply induce gene expression in a 
tissue specific manner but also to change splicing of a gene including or excluding exons and 
producing different isoforms. This process can potentially change the conformational 
structure of the protein and its function or cellular localisation (Xin, Hu et al. 2008). Most 
LTRs however, have been shown to generate only subtle deregulatory effects in healthy 
tissue (Cohen, Lock et al. 2009). This is supported by the theory that LTR promoters have 
the potential to induce subtle phenotypic effects between individuals due to a population wide 
mosaic effect in the silencing of LTRs  (Whitelaw and Martin 2001). An exception to this is 
seen in tissue of the placenta where LTRs act as the main tissue specific promoter for certain 
genes. 
1.3.14. HERV role in Healthy Human Tissue 
The placenta is one of the best-studied healthy tissues where LTRs act as regulatory 
elements. HERVs are highly transcribed in the placenta, testis and germ line cells meaning 
that LTR promoters are more active in these tissues (Cohen, Lock et al. 2009). There are 2 
potential theories to explain this high level of activity. It is generally accepted that cells in the 
early developmental stages have less methylation so this could allow activity of LTRs, which 
would be supressed in somatic tissue (Fuke, Shimabukuro et al. 2004). However, studies 
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have suggested that this does not exclusively account for the level of activity (Reiss, Zhang 
et al. 2007). The other potential reason is that because retroviral infection levels were 
generally higher in reproductive tissue it is a side effect of the LTRs becoming endogenous 
parts of the genome (Cohen, Lock et al. 2009). 
 A number of HERVs are involved in gene expression in the placenta; the most significant of 
these is located in the ERVWE1 locus which harbours a complete ERV1 provirus including 2 
LTRS, gag, pol and env coding regions. The envelope protein coded for by this HERV has 
been repurposed to be essential for trophoblast cell fusion and differentiation in the 
syncytiotrophoblast layer of the placenta (Mi, Lee et al. 2000, Prudhomme, Oriol et al. 2004). 
There are also a number of other genes within the placenta which use an LTR as a tissue 
specific promoter. The P450 Aromatase gene contains a MER21A LTR from the ERVL family 
which acts as a placenta specific promoter (Conley and Hinshelwood 2001). The EDNRB, 
Pleotorphin and Mid1 genes also display placenta specific transcripts from LTR promoters, 
however these genes also contain active native promoters meaning that the LTRs are just 
acting to increase expression (Cohen, Lock et al. 2009). 
There are a number of other genes which use LTRs as alternate promoters. Apolipoprotein 
C-I is expressed from both its native and an ERV1 LTR promoter in most tissues but is 
significantly up-regulated from its LTR promoter in the liver (Medstrand, Landry et al. 2001). 
AMY1C, a human salivary amylase gene shows parotid tissue specific expression from an 
LTR promoter (Ting, Rosenberg et al. 1992). Other tissue specific expression from LTR 
promoters includes NAIP in the testes, β1,3-galactosyltransferase in the colon and Mid1 in 
the foetal kidney  (Landry, Rouhi et al. 2002, Dunn, Medstrand et al. 2003, Romanish, Lock 
et al. 2007). 
Overall it would appear that the most active family of LTRs in healthy tissue is the ERV-9 
sub-family which is part of the ERV1 family. The ERV-9 LTRs are unique within the HERV 
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families as they have TF binding motifs for NF-Y, MZF1 and GATA (Yu, Zhu et al. 2005, Liu 
and Eiden 2011, Hu, Pi et al. 2017). An ERV-9 LTR forms a novel transcript within the P63 
gene in the testes and germ cell precursors which has been shown to be lost in testicular 
cancer cells (Liu and Eiden 2011). It has also been shown that solitary ERV-9 LTRs in many 
human cell types produce both sense and anti-sense transcripts whereby the anti-sense 
transcript is expressed at a higher level than the sense transcript. The level of the antisense 
transcript has been shown to drop in many cancer cell lines and when over-expressed in 
vitro it slows the rate of growth in many cancer cell lines. It is thought that this occurs 
because the anti-sense transcript acts as a decoy or trap for NF-Y a key factor in cell 
proliferation (Xu, Elkahloun et al. 2013). Finally, the -globin locus contains an upstream 
control region, which incorporates an ERV-9 LTR. The ERV-9 LTR acts as a tissue specific 
enhancer in erythroid progenitor cells priming the expression of globin genes in erythroid 
cells (Pi, Yang et al. 2004). 
As in the case of the β-globin locus LTRs can also act as tissue specific enhancers. As 
previously mentioned a mild enhancer activity from ERVK LTRs was shown by luciferase 
reporter assays in the TERA-1 cell line (Ruda, Akopov et al. 2004). The LEP gene which 
codes for leptin in adipose tissue is also known to have an upstream LTR enhancer element 
which increase expression in the placenta (Bi, Gavrilova et al. 1997). There are few other 
examples however the identification of enhancer elements tends to be more challenging than 
promoters as it is much harder to directly associate them with genes which may be many 
killobases away (Cohen, Lock et al. 2009). With new techniques such as ‘chromatin 
conformation capture’ it may be easier to build up a picture of HERV enhancer activity which 
has not yet been identified.  
An ERV-9 LTR is also responsible for the upregulation of the GSDML (gasdermin-like) 
protein coding gene in the alimentary tract, oesophagus, stomach and skin. Rather than 
acting as a direct promoter for the GSDML gene the LTR produces an antisense transcript 
34 
 
which interacts with the native promoter to positively regulate transcriptional activity (Huh, 
Kim et al. 2008). Many long non-coding RNAs (lncRNA) also originate from ERV-9 LTRs. It 
has been shown that knockdown of ERV-9 lncRNAs in erythroid cells results in significantly 
reduced transcription of a number of genes, many of which are erythroid specific. Depletion 
of these RNAs also resulted in the inhibition of ex vivo erythropoiesis (Hu, Pi et al. 2017). 
1.3.15. HERV role in Human Evolution 
HERVs have clearly had an effect on the evolution of the human genome as shown by their 
use as tissue specific promoters for a number of genes. To have remained through millions 
of years of evolution suggests that the presence of HERVs confers a survival advantage. 
Currently only a small number of such elements have been linked directly to being required 
for regulation of gene expression and many are kept in an inactive methylated state 
(discussed in 1.3.17). This would suggest that many may have been simply retained because 
of the difficulty in removing them (Nelson, Carnegie et al. 2003). 
Using comparative genomics approaches between mouse and human on all transposable 
elements including ERVs it has been shown that there is strong selective pressure to retain 
TEs in the genome (Silva, Shabalina et al. 2003, Lowe, Bejerano et al. 2007). It has also 
been suggested that ERVs are an important source of regulatory elements within the 
genome as they have significantly increased the proportion of TF motifs to allow for tissue 
specific regulation (Feschotte 2008). This notion combined with the fact that the majority of 
examples of LTR-driven expression in healthy tissue only result in subtle changes in 
expression of already active genes would suggest that ERVs are acting to fine tune gene 
expression levels (Sverdlov 2000, Wray 2007, Bohne, Brunet et al. 2008). Although HERVs 
have been retained through evolution and have roles in the genome they have also been 




1.3.16. HERVs in Human disease 
There are 2 main routes by which HERVs can play a role in disease, through the production 
of viral proteins or as regulatory elements disrupting gene expression either through 
activation or repression of a gene. The presence of viral proteins from HERVs has been 
shown in several inflammatory diseases. In multiple sclerosis it has been shown that HERVs 
from the ERV1 and ERVK families are active and produce virus like particles which bud from 
the cell surface (Perron, Garson et al. 1997, Christensen, Dissing Sorensen et al. 1998, 
Christensen 2005). Although it is not clear whether these are able to infect other cells they do 
create a pro-inflammatory response which has potential to exacerbate the condition (Clerici, 
Fusi et al. 1999). Antibodies towards the viral proteins can also be detected in patient 
samples(Jolivet-Reynaud, Perron et al. 1999). Nucleic acid binding of gag proteins which 
originate from the HERVs has been shown which could also increase the immune 
response(Christensen, Dissing Sorensen et al. 2000). Antibodies towards antigens from 
HERVs have also been detected in the synovial compartment in Rheumatoid Arthritis, 
another pro-inflammatory disease (Nakagawa, Brusic et al. 1997, Nelson, Lever et al. 1999). 
There is currently a lack of evidence for roles of HERV proteins in disease development and 
it is hypothesised that HERV activation may result from immune system activity and via 
inflammation rather than be causative of the disease (Johnston, Silva et al. 2001). This 
theory is based on evidence that treatment of cell lines with pro-inflammatory cytokines such 
as TNF can induce activity in ERVK and ERV1 families (Katsumata, Ikeda et al. 1999, 
Johnston, Silva et al. 2001). 
HERVs have also been linked to many cancers, which also supports their activation by an 
immune response as many cancers have an inflammatory component. Patients with 
seminoma, a form of testicular cancer, have been shown to express antibodies against the 
HERV-K9 gag protein (Sauter, Schommer et al. 1995) and 85% of patients with germ cell 
tumours have been reported to exhibit antibodies against HERV Env proteins (Sauter, 
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Roemer et al. 1996). Proteins from the HERVK family have also been identified in 
melanoma, breast cancer and ovarian cancer (Wang-Johanning, Liu et al. 2007, Golan, Hizi 
et al. 2008, Wang-Johanning, Radvanyi et al. 2008, Schmitt, Reichrath et al. 2013). In 
cancers it would seem that the protein coding role of HERVs is a minor player in cancer 
progression and survival, however, the regulatory role of LTRs has been associated with cell 
survival in several cancers. 
There are a number of routes by which an LTR can act to dysregulate gene expression and 
lead to cancer. The most straightforward of these is the ectopic or over expression of a gene, 
which occurs when the LTR is upstream of the genes native promoter and induces 
expression without modifying the open reading frames (ORFs) of the gene.  The first 
identified example of this which was shown to be required for cancer cell survival was in 
Hodgkin’s Lymphoma (HL). It was shown that the Colony Stimulating Factor 1 Receptor 
(CSF1R) gene was essential for survival of HL cell lines and that it was driven by an 
upstream THE1B (MaLR) LTR (Lamprecht, Walter et al. 2010). CSF1R is normally 
expressed in myeloid and trophoblast cells from 2 different promoter elements. In myeloid 
cells expression is strictly regulated by an upstream purine-rich promoter within exon 2 and 
an intronic enhancer element known as FIRE (Fms-Intronic Regulatory Element)(Himes, 
Tagoh et al. 2001). The FIRE enhancer contains transcription factor binding sites for PU.1, 
RUNX1, SP1 and AP1, of which PU.1 is most essential for CSF1R expression (Ross, Yue et 
al. 1998, Bonifer and Hume 2008, Sauter, Bouhlel et al. 2013).  PU.1 is expressed in myeloid 
cells but expression is lost in Hodgkin/Reed-Sternberg (HRS) cells meaning that CSF1R 
cannot be activated by the same regulatory elements as in myeloid cells (Jundt, Kley et al. 
2002).  
In human placental trophoblasts a second promoter 25 kb upstream has been shown to be 
active (Visvader and Verma 1989). Based on this Lamprecht, et al. (2010) also looked for 
CSF1R activation from this promoter, however, they showed that in HRS cells CSF1R was 
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expressed from a promoter approximately 6.2 kb upstream. Further study showed that this 
site corresponded to the sequence of a long terminal repeat (LTR) from the MaLR THE1B 
family. The THE1B-CSF1R transcript was shown to be essential for cell growth and survival 
in cell lines and to be present in 39-48% of patient samples (Lamprecht, Walter et al. 
2010).This region which is normally methylated to prevent activity was shown to have a 
DNaseI Hypersensitive site in HRS cells which was in contrast to control cells confirming that 
this was an active promoter which could be initiating the transcription of CSF1R.  
A follow up study by Babaian, et.al. showed that the IRF5 gene is also expressed in HL from 
a solitary LOR1a LTR. This finding differs slightly from that of CSF1R as IRF5 also has a low 
level expression from its native promoter. IRF5 is known to be upregulated in HL and to be a 
central regulator of the HL transcriptome (Kreher, Bouhlel et al. 2014). As well as acting as a 
promoter the LTR insertion upstream of IRF5 also creates an interferon regulatory factor 
binding element (IRFE) which factors including IRF5 can interact with. This means that the 
LTR creates a positive feedback loop strengthening IRF5 expression (Babaian, Romanish et 
al. 2016). 
LTRs can also be implicated in cancer through expression of truncated proteins, often 
occurring when the LTR is located within an intron downstream of the canonical promoter. 
This can result in the loss of regulatory elements within the protein, therefore giving it 
oncogenic potential. The best example of this is the receptor tyrosine kinase gene, 
Anaplastic Lymphoma Kinase (ALK) which carries an alternative LTR16B2 promoter in intron 
19 (Wiesner, Lee et al. 2015). This promoter results in expression of 3 different isoforms of 
ALK which lack the extracellular domain but retain the catalytic intracellular tyrosine kinase 
domain. The LTR promoter is active in 11% of skin cutaneous melanomas and LTR driven 
isoforms have been shown to increase oncogenic signalling, cell proliferation and also 
tumour formation in mice. There is also evidence for activation of this promoter in monocyte-
derived macrophages, however the function of this transcript is currently unknown. 
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ALK-negative anaplastic large-cell lymphoma (ALCL) was investigated by Scarfo et al. 
(2016) and it was shown that in 24% of cases cells displayed high expression of ERBB4 and 
COL29A1. Intriguingly 2 isoforms of ERBB4 were identified, neither of which originated from 
the native promoter (Scarfo, Pellegrino et al. 2016). Both transcripts were shown to originate 
from MaLR family LTRs and it was noted that two thirds of the samples had a ‘Hodgkin-like’ 
morphology which is only usually seen in 3% of ALCL cases. Both isoforms are thought to be 
potentially oncogenic and mutations in the ERBB4 gene have previously been associated 
with other cancers (Scarfo, Pellegrino et al. 2016). 
Finally, an additional direct way in which an LTR promoter has been shown to drive cancer is 
through the formation of chimeric proteins where non-coding DNA becomes fused to 
downstream exons. This has the potential to form proteins with significantly altered structure 
and function. In 5% of Diffuse Large B-Cell Lymphomas (DLBCL), Fatty acid binding protein 
7 is expressed as a fusion to an anti-sense LTR2 element. The chimeric protein which is 
produced has an altered N-terminus and has been shown to be required for optimal cell 
growth and cellular localisation in DLBCL cell lines (Lock, Rebollo et al. 2014). 
Many active solitary LTRs also produce long non-coding RNA (lncRNA) transcripts which can 
interact with other genes (Babaian and Mager 2016). A study in hepatocellular carcinoma 
identified a subset of ncRNAs expressed by LTRs which were 10-fold upregulated in most 
tumour samples suggesting that they may play a significant role in liver cancer pathogenesis 
(Hashimoto, Suzuki et al. 2015). The SchLAP1 lncRNA is known to be overexpressed in 25% 
of prostate cancer cases and originates from an ERV-9 LTR SchLAP1 has been shown to 
inhibit the function of the SWI/SNF complex which can act as a tumour repressor. This 
supports the observation that SchLAP1 overexpression is associated with cell survival and 




Non-coding RNAs can also produce antisense transcripts of genes, for example a THE1A 
LTR promoter produces an anti-sense transcript of the AFAP1 gene. Changes in expression 
of AFAP1 have been associated with several types of cancer including HL. The antisense 
transcript of AFAP1 results in a loss of gene expression (Babaian and Mager 2016). It is 
thought that down-regulation of AFAP1 results in up-regulation of RhoA/Rac2 signalling 
which increases cell proliferation (Zhang, Weng et al. 2016). 
Finally LTRs have been shown to play a role in cancer through enhancer activity which is 
probably the least studied LTR function due to the challenges of linking enhancers to genes. 
In prostate cancer hypomethylation of many HERVs is seen although only a specific subset 
appear to produce transcripts (Goering, Ribarska et al. 2011). It is known that the KLK3 gene 
encoding a prostate specific antigen is highly androgen sensitive and is located in a cluster of 
androgen responsive genes. It has been shown that the cluster is regulated by an upstream 
region which is formed of an LTR40a element. The LTR40a acts as an androgen responsive 
element, particularly when it has a specific duplication in the LTR sequence, and this 
upregulates expression of the surrounding cluster of androgen responsive genes (Lawrence, 
Stephens et al. 2012). 
1.3.17. Regulation of HERVs 
It is now clear from multiple studies that the presence of active HERVs in the genome has 
the potential to contribute to multiple diseases. For HERVs to have remained throughout 
evolution, cells must have developed strict control mechanisms to avoid negative selection 
and for the overall maintenance of genome stability (Glinsky 2015). It has long been known 
that CpG methylation is largely directed towards transposable elements within the genome 
(Yoder, Walsh et al. 1997). Methylation is mostly removed from the genome during sexual 
reproduction but is replaced early in embryonic development and was originally thought to 
permanently silence transposable elements (Altun, Loring et al. 2010). 
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We now know that methylation of retrotransposons within the human embryo employs more 
complicated developmental mechanisms with only a fraction of LTRs being hypermethylated 
at the preimplantation stage. A transition was observed following fertilisation with MaLR 
family LTRs becoming methylated and down-regulated and ERV1 and ERVK elements 
becoming demethylated and having up-regulated expression (Smith, Chan et al. 2014). The 
same study showed that following implantation a stable LTR methylation programme is 
established which remains into adult somatic cells. It has also been suggested that the loss 
and rewriting of methylation during the early developmental stages is not perfect and 
produces a mosaic pattern which varies between individuals of the same species therefore 
contributing to subtle variation in phenotype (Whitelaw and Martin 2001). It is also possible 
that in some cases the methylation pattern of certain ERVs could cross the germ line being 
inherited across generations (Chong, Vickaryous et al. 2007). 
Loss of CpG methylation has been shown in multiple studies to result in HERV activation 
often contributing to disease states. It has been shown that expression of HERK LTRs in the 
human teratocarcinoma cell line, TERA-1, is differentially regulated based on the level of 
methylation (Lavie, Kitova et al. 2005). This same finding was reproduced in melanoma cell 
lines (Stengel, Fiebig et al. 2010). The MaLR family of LTRs are also regulated by CpG 
methylation in Hodgkin’s lymphoma (HL). Both the THE1B LTR found upstream of the 
CSF1R gene and the LOR1A LTR upstream of the IRF5 gene show a loss of methylation at 
CpG element when compared to human B-cell lines (Lamprecht, Walter et al. 2010, Babaian, 
Romanish et al. 2016). 
There are very few studies which investigate the causes of demethylation to induce LTR 
activation in humans, however, there is evidence that a hypomorphic allele of DNA 
methyltransferase-1 (Dnmt1) results in activation of ERVs and leads to T-cell lymphomas in 
mice (Eden, Gaudet et al. 2003, Howard, Eiges et al. 2008). A mechanism has been 
proposed for the demethylation seen in HL. Surprisingly in HL there is no loss of the DNA 
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methylating enzymes, however it was shown that there is a loss of the transcriptional 
repressor ETO2. ETO2 (also called CBFA2T3) acts via interaction with histone deacetylases 
(HDACs) (Hug and Lazar 2004). When ETO2 is not expressed demethylation is seen at the 
CpG element within the THE1B LTR which causes activation of the THE1B-CSF1R transcript 
in HL. It was further shown that when combined with NF-κB constitutive activation, a central 
feature of HL, a strong activation of the LTR was achieved (Lamprecht, Walter et al. 2010). 
This also highlights the role that tissue specific transcription factors play in activation of 
ERVs. 
An alternative repressive mechanism that has been proposed for HERV silencing is Krüppel-
associated box zinc finger proteins (KRAB-ZFP) (Wolf, Greenberg et al. 2015). For reverse 
transcription of a retroviral genome to take place a tRNA primer sequence is required to 
prime the minus strand synthesis. In mice the KRAB-ZFP protein ZFP809 has been shown to 
bind to the tRNA primer binding site (a sequence required for the priming of the minus strand 
during reverse transcription) of murine leukaemia virus in stem cell and recruit corepressors 
KAP1 and SETDB1 which, in turn, induces H3K9me3 (Wolf, Yang et al. 2015). It was further 
shown that ZFP809 and KAP1 are not required to maintain repression of ERVs in adult 
somatic tissues, however, SETDB1 is required in some differentiated cell types 
(Wiznerowicz, Jakobsson et al. 2007, Fasching, Kapopoulou et al. 2015). There is also 
evidence to suggest that in humans ERVs of the ERVK and ERV1 families are repressed by 
KRAB-ZFPs, although follow up validations are yet to be performed (Turelli, Castro-Diaz et 
al. 2014, Wolf, Greenberg et al. 2015). A recent study has also suggested a requirement for 
Histone H3.3 in ERV silencing in embryonic stem cells, however the significance of the role 





1.3.18. Methods for Identifying Active HERVs 
The study of active HERVs and particularly the solitary LTRs poses a number of challenges, 
particularly for genome wide bioinformatics analysis. The nature of repeat elements having 
little or no unique sequence makes them intrinsically hard to align meaning that they often 
get overlooked in genome wide screens such as RNA-Seq. A number of lab based and 
bioinformatics approaches have been developed to overcome this issue.  
The use of 5’ Rapid Identification of cDNA ends (RACE) has long been used to validate 
individual transcripts originating from LTRs. It uses a known tagging sequence ligated to the 
5’ end of the transcript and a primer within the transcript to allow for amplification. RACE 
however does not allow for the full complement of active LTRs to be determined. Capped 
analysis of gene expression (CAGE) has been used in a number of studies and is a 
technique which makes use of the 5’ cap (modified nucleotide) which is present on mature 
mRNA transcripts. The mRNA transcripts are captured on biotinylated beads using the 5’ cap 
and digested to form short fragments representing the transcription start site. These 
fragments can then be sequenced and mapped back to the genome (Hashimoto, Suzuki et 
al. 2015, Babaian, Romanish et al. 2016). This method produces a map of all transcription 
start sites across the genome which would therefore identify LTRs which were acting as 
transcription start sites. Although CAGE only produces 27 bp reads the identification of LTR 
promoters is likely to be better than RNA-Seq as the level of background should be far lower.  
A significant challenge is the ability to identify active LTR transcripts in sequencing data 
which has not been produced specifically for this purpose. The lack of unique mapping to 
LTR sequences poses a significant problem in the accurate estimation of enrichment of a 
particular element. This is because current alignment approaches either discard multiple 
aligning reads or assign them randomly to one of the locations, meaning that many reads at 
a particular element may be lost. This is particularly a problem with short sequencing read 
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data from experiments such as ChIP-Seq and DNaseI-Seq. It has been proposed that the 
estimation of enrichment can be improved by mapping the multiple aligning reads to repeat 
sub-families defined by RepBase and combining that enrichment information with the 
uniquely mapping tags on the LTRs on that family (Day, Luquette et al. 2010). 
Paired end RNA-seq data helps to alleviate the problem of lack of unique LTR sequence to 
align by overlapping splice junctions and retrieving sequence from a gene which an LTR may 
be spliced to. As most LTR promoters will produce unannotated isoforms the challenge with 
this method is the requirement to identify unique splice junctions when aligning the RNA-Seq 
data. A technique has been developed which helps to overcome this problem by assigning 
the LTR sequences to a virtual chromosome composed of genome specific LTR sequences 
(Sokol, Jessen et al. 2016). Following alignment, paired reads are filtered for those where 
one read of the pair maps to an LTR within the artificial chromosome. These reads can then 
be mapped back to the reference genome using the BLAT algorithm (Kent 2002). A similar 
technique has also been used successfully to identify active LTRs in other studies (Lock, 




1.4. B-Cell Development 
The B cell lineage originates from haematopoietic stem cells (HSC) located within the bone 
marrow, which are able to self-replicate and differentiate into all blood cell types (Fig. 1.6).  In 
the initial stage of differentiation the HSC first develops into a multipotent progenitor (MPP) 
still with the potential of differentiating into all blood cell types but losing its self-renewal 
abilities. From this population of cells develop cells which differentiate towards the lymphoid 
lineage known as Lymphoid-Primed multipotential progenitors (LMPP). At this point cells 
have lost the ability to become megakaryocytes or follow the erythroid lineage but still have 
potential to become either myeloid or lymphoid cells. The main deciding factor in how 
differentiation of these cells proceeds is the level of transcription factor PU.1. It has been 
shown that a high level of PU1 at the LMPP stage results in cells committing to the myeloid 
lineage whereas a low level results in commitment to the lymphoid lineage (DeKoter and 
Singh 2000, Leddin, Perrod et al. 2011). This being said, the presence PU.1 is also required 
for the lymphoid lineage since it has been demonstrated that knock-outs result in a 
differentiation block at the MPP stage (McKercher, Torbett et al. 1996) (Fig. 1.6). 
In the following stage the cells become committed lymphoid progenitors (CLP), which lose 
the ability to become myeloid cells and have the ability to differentiate into either T cells or B 
cells. A number of transcription factors regulate this transition, including E2A (Herblot, Aplan 
et al. 2002).  The most essential of these transcription factors for B cell development is 
PAX5, which is regulated by E2A, Ebf1 and FOXO1. PAX5 is thought to be responsible for 
the activation of the main B cell factors and repression of non-B cell genes (Nutt, Heavey et 
al. 1999). Once fully committed to the B cell lineage (pro-B cells), cells begin to express 
B220 (an isoform of CD45) but at this stage still do not express cell surface immunoglobulin 
(Ig) (Bauer, Rodiger et al. 2005). The main functional component of B cells, which is required 
for their survival, is the B Cell Receptor (BCR). The BCR is a complex including the 
Immunoglobulin and CD79 subunits (Duncan, Webster et al. 2010), which is responsible for 
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binding to antigens as part of the humoral immune system. To achieve adaptive immunity to 
a wide range of different antigens the immunoglobulin genes undergo a large amount of 
genetic rearrangement to produce many different variable sites.  The basic immunoglobulin 
protein is made up of 2 identical heavy chains and 2 identical light chains with the 2 heavy 
chains linked together and one light chain attached to each heavy chain. 
To achieve a diverse range of antigen receptors a process known as V(D)J recombination 
occurs, resulting in the rearrangement of the variable (V), diversity (D) and joining (J) regions 
(Dudley, Chaudhuri et al. 2005). During this process the D and J segments are first 
recombined and are then attached to a V segment. Once this has occurred, a complex is 
formed with the light chains which can be one of two isotypes, either kappa or lambda. The 
light chains also undergo recombination of the V and J segments, once combined with the 
heavy chains this forms an immunoglobulin known as IgM or IgD (Geisberger, Lamers et al. 
2006, Kirkham 2014) (Fig. 1.6). 
Once V(D)J recombination is complete and the BCR is presented on the surface of the B 
cell, it then leaves the bone marrow and moves into the blood stream where it travels to the 
spleen to undergo further maturation (Cariappa, Chase et al. 2007). Within the spleen further 
selection is carried out and B cells can either develop into marginal zone B cells or follicular 
B cells (Reviewed by (Pillai and Cariappa 2009)).  Follicular B cells recirculate through the 
secondary lymphoid organs awaiting activation by a specific antigen. Marginal zone B cells 
are selected based on the expression of less specific BCRs, which will react to many 
different antigens. The marginal zone B cells then inhabit regions of the spleen, which 
interface with the blood and are able to rapidly produce plasma cells on activation (Mackay 
and Browning 2002, Cerutti, Cols et al. 2013). The follicular B cells then remain in the spleen 
and lymph nodes until presented with an antigen by a T-helper cell. At this point the cell 
migrates into the dark zone of the germinal centre where it is known as a centroblast and 
undergoes rapid proliferation (Bannard, Horton et al. 2013). Activation also results in 
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upregulation of activation induced cytidine deaminase (AID) by PAX5 and E2A (Kirkham 
2014). AID results in point mutation in the variable region of the immunoglobulin known as 
somatic hypermutation. Following this the cells migrate to the light region of the germinal 
centre where they are known as centrocytes. In the light region the cells are selected based 
on whether the mutation is advantageous or not. Within the light region there are T-helper 
cells, which present the antigen to the newly mutated immunoglobulin, based on this binding 
affinity the cells then undergo apoptosis or class switch recombination swapping IgM or IgD 
for IgA or IgG. More recent imaging data suggest that the processing of B cells within the GC 
is slightly more complex with cells cycling between the light and dark zones and possibly with 
higher affinity Ig removing antigens from other lower affinity Ig (Allen, Okada et al. 2007, 
Kuppers 2009). Following this selection process, the highest affinity cells will either form 
long-lived plasma cells which produce large quantities of antibodies, which are secreted into 
the blood or memory B cells which display high affinity binding to the specific antigen so that 
a fast immune response is possible in the future if the immune system is again exposed to 





Figure 1.6. Simplified B Cell development pathway from undifferentiated HSCs in bone 
marrow through V(D)J recombination of Immunoglobulin and to activation by an antigen in 
the spleen, somatic hypermutation and production of antibodies as part of the humeral 
immune response. Adapted from: (Mackay and Browning 2002, Klein and Dalla-Favera 
2008, Kirkham 2014). 
 
The V(D)J recombination and somatic hyper-mutation processes have to be strictly 
controlled because there is  a high risk of developing unfavourable mutations in the B cell 
genome resulting from the formation of double strand breaks. Once developed, a 
homeostatic balance of follicular B cells has to be maintained in preparation for antigen 
recognition. Cell survival is maintained by a combination of BCR and BAFF signalling.  BAFF 
is a ligand of the tumour necrosis factor family (TNF) has also been shown to play an 
important role in B cell survival (Mackay and Browning 2002, Mackay, Figgett et al. 2010). It 
has been shown that mature B cells are not present in BAFF knockout mice and it is thought 
that BAFF interacts with the BCR signalling.  
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Within the germinal centre apoptosis of cells with lower antigen binding affinity occurs 
through the FAS pathway. At the GC stages of B cell development the cells are destined for 
apoptosis throughout the process and are saved by positive selection by high affinity binding 
to an antigen and signalling involving CD40 and CD154 (Guzman-Rojas, Sims-Mourtada et 




1.5. Hodgkin’s Lymphoma 
Hodgkin’s Lymphoma (HL) is split into two main sub-types, Classical Hodgkin’s Lymphoma 
and Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma (NLPHL)(Kuppers 2009). 
Classical Hodgkin’s Lymphoma affects 2.8 per 100,000 people in the US and 3.0 per 
100,000 people in the UK. It is predicted that in the UK the overall likelihood of developing 
HL at some point during a person’s lifetime is 0.2%. The age at which classical HL has the 
highest rate of occurrence has two peaks at 20-24 years old and again at 70-79 years old, 
particularly in men(CRUK 2013).  A survival rate of 83.25% at 5 years and 77.65% at 10 
years is reported in the UK and this figure has risen steadily over the past 30 years (CRUK 
2012). Classical Hodgkin’s Lymphoma usually presents as a tumour mass on lymph nodes 
but can also occasionally be found in the spleen, bone marrow, liver, and lungs (Connors 
2009). NLPHL is much less common only accounting for around 5% of Hodgkin’s lymphoma 
cases. Current treatment for early stage Hodgkin’s lymphoma is four to six rounds of ABVD 
chemotherapy (Adriamycin, bleomycin, vinblastine and imidazole carboxamide). In cases 
with predicted poorer clinical outcome this is complimented with radiation therapy (Derenzini 
and Younes 2011). 
Hodgkin’s Lymphoma was first described by Thomas Hodgkin in 1832 who reported cases of 
lesions on the ‘absorbent glands’ (now known as the lymph nodes) and spleen, later named 
Hodgkin’s Disease (Hodgkin 1832). At a cellular level the main identifying features of 
Classical HL are the mononucleated Hodgkin and multinucleated Reed-Sternberg (HRS) 
cells identified by Dorothy Reed (1902) and Carl Sternberg (1898) (Kuppers and Hansmann 
2005)(Fig. 1.7). It has since been shown (see 1.5.2) that these cells are most likely derived 
from B cells therefore the disease was renamed Hodgkin’s Lymphoma. The predominant 
cells in NLPHL are known as lymphocytic and histiocytic (L & H) cells and have very different 
expression patterns to HRS cells (Nogova, Rudiger et al. 2006). The characterisation of the 
cells in both classical HL and NLPHL is problematic as in most cases they only account for 
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around 1% of the tumour bulk with the majority of the tumour comprised of an infiltrate of 
other immune cells (Kuppers 2009). 
Based on variation in the cellular composition of classical HL it has now been split into 4 sub-
types. These are nodular sclerosis, mixed cellularity, lymphocyte depletion and lymphocyte 
rich (Kuppers and Hansmann 2005).   
 
Figure 1.7. Bi-Nulceated RS cell surrounded by lymphocytes (NCI 2008). 
 
1.5.1. HRS cells 
HRS cells are the main identifying feature of classical HL. Phenotypically they have a very 
visible nucleolus in each nucleus and can be over 50μm in diameter (Kuppers and 
Hansmann 2005). The most commonly used expression marker to identify HRS cells is 
CD30 a member of the tumour necrosis factor (TNF) receptor family. CD30 is also the 
hallmark of a number of other lymphomas including Anaplastic Large Cell lymphoma (de 
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Leval and Gaulard 2010).  The gene expression patterns of HRS cells do not resemble any 
other hematopoietic cell, expressing genes from a wide range of lineages making identifying 
the origin of these cells challenging.  
1.5.2. Origin of HRS cells 
The combination of the unusual expression pattern and the scarcity of the cells within tumour 
tissue mean that the B cell origin of HRS cells was long debated. In 1994, Kuppers, et al. 
demonstrated by micromanipulation of cells from histological sections that HRS cells were 
likely to have originated from a range of differentiation stages in the B cell lineage. 
The B cell origin of most HRS cells was eventually confirmed by the analysis of 
immunoglobulin genes which showed rearrangement consistent with V(D)J recombination 
(Kuppers and Hansmann 2005). It was also shown that cells in each case were of 
monoclonal origin (a common feature of tumour cells), with identical Ig variable region 
rearrangements (Kuppers and Hansmann 2005). There was still debate as to whether this 
confirmed the B cell origin of HRS cells as T-cell receptors (TCR) also undergo similar 
recombination. However further study by (Kanzler, Kuppers et al. 1996) showed that the 
rearranged V regions had high levels of somatic mutation consistent with those occurring in 
the Germinal Centre (GC) confirming the B cell origin. For this reason it is also thought that in 
the majority of cases HRS cells originate from GC B cells or Post-GC B cells.  It was also 
shown that in 25% of cases the somatic mutation resulted in non-functional immunoglobulins 
through the introduction of stop codons (Kuppers 2009). This suggests that HRS cells 
originate from pro-apoptotic GC B cells, which for some reason have avoided apoptosis. It is 
further suggested that as mutations resulting in non-functional immunoglobulins are not 
detectable in HRS cells from many patients that in the majority of cases HRS cells are 
probably cells which were selected for apoptosis. It is still thought that in rare cases HRS 
cells could originate from T-cells, as they have been shown to express the T-cell Receptor 
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and lack Ig mutations (Kuppers 2009). It should however be noted that these cases may not 
be Hodgkin’s Lymphoma and instead T-cell lymphomas which are expressing the markers 
usually used to identify HL, CD30 and CD15 (Barry, Jaffe et al. 2003). 
1.5.3. HRS Cell Development 
If HRS cells develop from B cells marked for apoptosis this must mean that they somehow 
manage to escape the apoptosis pathway. To achieve this escape anti-apoptotic or pro-
survival signals are necessary along with suppression of differentiation. A number of 
transcription factors which are important for the differentiation of B-cells are downregulated 
including OCT-2, SPI1 and EBF1 (Stein, Marafioti et al. 2001, McCune, Syrbu et al. 2006, 
Bohle, Doring et al. 2013) resulting in the downregulation of many B-cell specific genes and 
therefore creating a block in differentiation (See 1.5.5 HRS cell expression patterns). To 
survive within the germinal centre HRS cells have to avoid their predisposition to apoptosis 
through the FAS pathway. Through the expression of the FAS cell surface receptor germinal 
centre B-cells are predisposed to apoptosis on interaction with the Fas ligand which is 
present on CD4+ Th1 cells (Rothstein 2000, Mizuno, Zhong et al. 2003). This predisposition 
should prevent cells with unfavourable mutations such as auto-reactivity from developing 
further. The most obvious route for this to be overcome in HRS cells is through FAS gene 
mutations; however studies have shown that these mutations are very rare therefore the cells 
must survive by other routes (Maggio, Van Den Berg et al. 2003). HRS cells express c-FLIP, 
an anti-apoptotic gene, which is usually only expressed in B cells with high affinity antigen 
binding and is a potent inhibitor of FAS activity (Thomas, Kallenborn et al. 2002). It is 
therefore possible that this may assist to prevent apoptosis of HRS cells, however the exact 
signalling route in the absence of the BCR is unclear (Thomas, Re et al. 2004). It has also 
been suggested that the significant deviation of HRS cells from the B cell gene expression 
program may also play a role. Mimicking other cell types such as granulocytes with CD15 
expression and T-cells with CD30 expression may prevent the cells from being recognized 
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as GC B cells (Thomas, Re et al. 2004). This helps the cells to evade immunological 
surveillance within the germinal centre. 
To survive, HRS cells also require growth signals, which would usually originate from the 
BCR. The full complement of factors involved is not fully understood, however, NF-κB and 
the JAK/STAT pathway have been suggested to play a major role (Liu, Sattarzadeh et al. 
2014). Expression of STAT3, STAT6 and STAT5a has been demonstrated in HRS cells 
which all have involvement in maintaining cell survival signals (Thomas, Re et al. 2004). 
Colony Stimulating Factor 1 Receptor (CSF1R) has also been shown to play a vital role in 
HRS cell survival (Lamprecht, Walter et al. 2010). It was shown that in the absence of 
CSF1R HRS cells were unable to survive making this another critical factor for survival 
without the BCR.  
1.5.4. NF-κB Expression in HRS Cells 
In 1997 Bargou, et al. showed that constitutively active NF-κB is essential for survival and 
proliferation of HRS cells. NF-κB is primarily a transcription factor activated as part of an 
inflammatory response. NFkB can become activated through 2 pathways the canonical 
pathway and the alternative pathway. The canonical pathway is activated by microbial 
products or inflammatory cytokines and results in the activation of RelA and RelC NF-κB 
complexes (Karin and Ben-Neriah 2000). Activation of this pathway results in the 
phosphorylation and ubiquitination of IkB by IkKβ and IkKγ which allows NF-κB to translocate 
to the nucleus and become active. The alternative pathway is activated by TNF-family 
cytokines and signalling. The alternative pathway functions through the phosphorylation of 
p100 which is a precursor to p52 (Lawrence 2009). Once activated p52 and RelB localise to 
the nucleus allowing NF-κB to activate expression of target genes. 
There have been many studies attempting to determine the cause of NF-κB activation and 
there appears to be a lot of variation between HL cases (Kuppers, Engert et al. 2012). In a 
54 
 
study 44% of HL cases were shown to have a mutation of the TNFAIP3 gene, which codes 
for protein A20 (an inhibitor of NF-κB) (Schmitz, Hansmann et al. 2009). This protein was 
also shown to function as a tumour suppressor as reactivation in HL cell lines resulted in 
impaired survival (Brauninger, Schmitz et al. 2006). In 30% of HL cases an increased level of 
REL expression has been detected resulting in an increased activation of NF-κB (Martin-
Subero, Gesk et al. 2002, Kuppers, Engert et al. 2012). Other factors increasing NF-κB 
activation include activation of the alternative NF-κB pathway through NIK upregulation and 
mutations in the NκB inhibitors IκBα and IκBε (Kuppers, Engert et al. 2012). In most cases 
several of these pathways are active which suggests that strong NF-κB activity is needed for 
HRS cell survival (Kuppers, Engert et al. 2012). 
1.5.5. HRS Cell Expression Patterns 
As well as the factors required for HRS cell survival, these cells have a unique gene 
expression pattern unlike any other immune or blood cell. Firstly, there is an overall down 
regulation of expression of B cell specific transcription factors including OCT2, PU.1 and 
BOB1 which leads to down-regulation of their target genes (Stein, Marafioti et al. 2001, 
Torlakovic, Tierens et al. 2001). There is also increased expression of ectopic factors such 
as NotchI (a T-cell factor) and ID2 (usually found in NK cells) (Thomas, Re et al. 2004). 
Upregulation of non-B cell factors further down-regulates B cell factor genes.  The ID2 
protein acts as an inhibitor of E2A which contains E12 and E47 both of which are essential 
transcription factors in B cell development (Mathas, Janz et al. 2006). It is also suggested 
that ID2 may play a role in inhibition of PAX5 which has a significant role maintaining the B 
cell phenotype (Renne, Martin-Subero et al. 2006). As well as the expression of genes 
related to survival and development, HRS cells are also known to express high levels of 
chemokines which are responsible for attracting the infiltrate of immune cells which makes 
up the majority of the tumour mass. The most significant chemokine expressed is CCL17 
(TRAC) which attracts Th2 cells making up the main infiltrate (Liu, Sattarzadeh et al. 2014). 
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Added to this are also extra chemokines produced by the cells in the microenvironment 
around the HRS cells, which further increases immune cell infiltrate.  Finally, the HRS cells 
also produce other cytokines, which contribute to the tumour microenvironment, particularly 
migration inhibitory factor (MIF), which attracts M2 macrophages to the tumour (Liu, 
Sattarzadeh et al. 2014). 
1.5.6. EBV 
Epstein Barr Virus infection is seen in cells in around 40% of HL cases and has been shown 
to be a major initiating factor (Kapatai and Murray 2007). It was initially thought that maybe 
an earlier but undetectable EBV infection may have resulted in non-EBV HL cases, however, 
further studies suggest that there is no evidence of this (Staratschek-Jox, Kotkowski et al. 
2000).  The presence of EBV within HRS cells results in the expression of the viral proteins 
EBNA1, LMP1 and LMP2a (Kuppers 2009). LMP1 mimics CD40 which is able to induce NF-
κB expression, aiding the development and survival of HRS cells (Kilger, Kieser et al. 1998). 
It is also suggested that LMP2a can replace the signalling of the BCR which also promotes 
survival allowing cells the escape apoptosis and become HRS cells (Caldwell, Wilson et al. 
1998).  
1.5.7. CSF1R 
Expression of Colony Stimulating Factor 1 Receptor (CSF1R) has been shown to have an 
important role in the survival of HRS cells (previously discussed in 1.5.3) (Lamprecht, Walter 
et al. 2010). CSF1R is encoded by the FMS gene and its expression is usually restricted to 
myeloid cells but has also been demonstrated in cells of the female reproductive tract and 
neuronal cells (MacDonald, Rowe et al. 2005, Bonifer and Hume 2008, Droin and Solary 
2010). It is a tyrosine kinase receptor for the ligand CSF-1 but has also been shown to bind 
to a new ligand IL-34 (Droin and Solary 2010). CSF-1 is responsible for regulating survival, 
proliferation and differentiation in mononuclear phagocytes and osteoclasts and also has a 
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role in fertility (Droin and Solary 2010). CSF1R and CSF-1 have been implicated in the 
pathology of a number of cancers, in particular, prostate cancer, breast cancer and 
leukemias (Ide, Seligson et al. 2002, Aikawa, Katsumoto et al. 2010, Morandi, Barbetti et al. 
2011). In most cases it was shown that upregulation of CSF-1 results in increased 
proliferation within cancer cells. In several cases it is also suggested that an autocrine loop is 
involved whereby the cells express both CSF1R and CSF-1 resulting in a rapid proliferation 
of cells (Patsialou, Wyckoff et al. 2009). This autocrine loop has also been suggested to play 
a major role in the proliferation and survival of HRS cells. Lamprecht, et al. (2010) 
demonstrated that the expression of CSF1R was essential for the survival of HRS cells. They 
also went on to show expression of CSF-1 in HRS cells supporting the theory of an autocrine 
loop. Interestingly (Ingram, Valeaux et al. 2011) showed that in B cells the expression of 
CSF1R is further supressed by PAX5 which binds to the CSF1R promoter and an enhancer 
(Tagoh, Ingram et al. 2006). This is however less relevant in HRS cells as PAX5 is rarely 
expressed and Lamprecht et al. (2010) confirmed that CSF1R is activated by an upstream 
THE1B LTR not the canonical promoter (discussed in 1.3.16). 




1.6. Aims and Objectives 
Lamprecht et al. (2010) demonstrated that the activation of a THE1B LTR in HL 
acted as a promoter for the CSF1R gene which is required for the survival of HL 
cells. They also showed that LTR activation in HL resulted from a loss of epigenetic 
control due to down-regulation of CBFA2T3 and the constitutive activation of NF-κB. 
Finally they presented preliminary results indicating that LTR activation may be a 
genome-wide phenomenon. Based on these data the aims of this thesis were to: 
1) Investigate the impact of the Hodgkin’s Lymphoma specific 
transcriptional network on chromatin structure and gene expression. 
a) Microarray data have previously been published for the L428, L1236 and 
KM-H2 HL cell lines. However, microarray data lack important information 
such as the expression of splicing variants and low abundance transcripts, as 
well as alternative transcription start sites. Therefore we plan to generate high-
quality RNA-Seq data to enable us to study HL-specific gene expression 
patterns and alternative transcription start sites, in particular those residing 
within LTRs.  
  
b) Previous work mapping DNaseI HS sites at low resolution has shown the 
involvement of a number of inducible transcription factors driving the HL gene 
expression program, including IRF, NF-κB and AP-1. Here we aim to extend 
this work by producing high resolution DNaseI data which can be used for 
digital foot-printing to determine the occupied DNA binding motifs present 
within regions showing transcription factor binding. This will allow us to 




2) Determine the global activation pattern of Long Terminal Repeat 
elements within HL cell lines. 
We aim to develop a next generation sequencing technique (RACE-Seq) 
based on 5’ Rapid Amplification of cDNA Ends (RACE) to map the global 
activation of THE1B LTRs within HL and non-HL cell lines. The LTR activation 
patterns of HL and non-HL cell lines will be compared to determine a HL 
specific pattern of LTR activation. 
  
3) Elucidate the impact on gene expression of long terminal repeat 
activation in Hodgkin’s Lymphoma. 
By integrating the RACE-Seq and RNA-Seq data we will investigate the 
genome-wide impact of LTRs as alternative promoters and enhancers in HL. 
We also aim to investigate whether other genes besides CSF1R are LTR-
driven. We aim to identify specific target genes which are up-regulated as a 
result of LTR activation and assess the impact of these on the HL phenotype. 
  
4) Explore the impact of inflammation driven LTR activation on the control 
cell line, Reh. 
The HL phenotype displays a significant inflammatory gene expression 
signature which is caused by the constitutive activation of NF-κB, MAPK-
signalling via AP-1 factor family members and a number of other inflammatory 
pathways. Constitutive NF-κB and AP-1 activity has also been shown to drive 
LTR promoter activity.  
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Firstly, we will evaluate the impact of inflammatory stimuli by the treatment of 
Reh cells with phorbol 12-myristate 13-acetate (PMA) which is known to 
activate NF-κB, MAPK and a number of other pathways through PKC 
signalling. We will then investigate LTR activation by RACE-Seq and examine 
its impact on gene expression using RNA-Seq. Finally we aim to study the 
impact of NF-κB activation alone using an inducible activation system.  
These studies will allow us to determine the direct effects of LTR activation on 
gene expression and highlight the first steps of transforming a normal B cell 




2. MATERIALS AND METHODS 
2.1. Cell Culture 
Three Hodgkin’s lymphoma cell lines (L428, L1236 and KM-H2) were cultured in IMDM 
(Sigma) with 10% heat-inactivated foetal calf serum (FCS), 2mM Glutamine, 100u penicillin 
and 100u streptomycin (GIBCO). The two control cell lines Reh and Namalwa were cultured 
in RPMI 1640 (Sigma) with 10% heat-inactivated FCS, 2mM glutamine, 100u penicillin and 
100u streptomycin (GIBCO). All cultures were incubated at 37°C in a humidified incubator 
with 5% CO2. Sub-culturing was carried out based on the cell densities in Table 2.1. 
The 293T cell line used for the production of viral particles was cultured in DMEM (Sigma) 
with 10% FCS, 2mM Glutamine, 100u penicillin, 100u streptomycin (GIBCO). Sub-culturing 
of cells was carried out by removing media from the plate, washing with PBS and treating 
with 3ml trypsin (GIBCO) in PBS (Sigma) solution and re-suspending the cells in full growth 
media (DMEM, as above). 
Table 2.1. Culture densities of cell lines. 
Cell Line Maximum Culture 
Density 
Sub-Culture Density 
Reh 5x106/ml  0.5x106/ml  
Namalwa 2x106/ml  0.5x106/ml  
L428 1x106/ml  0.3x106/ml  
L1236 0.6x106/ml  0.3x106/ml  
KM-H2 1x106/ml  0.3x106/ml  








2.2. Gene Expression Analysis 
2.2.1. RNA Extraction 
RNA was extracted from between 0.5x106 and 5x106 cells which were first pelleted by 
centrifugation at 300 x g for 5 minutes. The cells were lysed using 350 µl RA1 buffer 
(Macherey-Nagel) and 3.5 µl β- mercaptorthanol (Sigma).  RNA extraction was carried out 
using the NucleoSpin® RNA kit (Macherey-Nagel) in accordance to the manufacturer’s 
instructions. On column DNase digestion was also carried out to remove any genomic DNA 
from the sample according to the manufacturer’s protocol (Macherey-Nagel). The final RNA 
was eluted in between 30 and 50 μl H2O and quantified using   NanoDrop™ 2000 (Thermo 
Scientific). For RNA-Seq the quality of the RNA extracts was validated by running on a 
Bioanalyzer 2100 (Agilent) and only RNA with a RIN value of 9 or more was used for library 
preparation.   
2.2.2. cDNA Synthesis 
cDNA was produced from RNA extracts using Superscript III reverse transcriptase (Thermo 
Fisher) as follows: 2 μg of RNA were added to 1 μl of oligo (dT) 500 μg/ml and the mix was 
made up to 11 μl with H2O. It was then incubated at 65°C for 5 minutes using a thermo-cycler 
and held at 4°C. In the next stage 10 μl of 5x RT buffer, 5 μl 0.1M DTT, 5 μl 10mM dNTP, 1 
μl RNase out, 1 μl Superscript III RT Enzyme and 17 μl of H2O were added. This was then 
incubated for 1 hour at 50 °C, 15 minutes at 70 °C and stored at -20°C ready for use in 
qPCR. 
2.2.3. qPCR 
Gene expression was measured by qPCR using Sybr ® green master mix (Sigma) and 
normalised to GAPDH expression. Each reaction contained 0.5 μl of 10 μM primer mix (Table 
2.2), 5 μl Sybr® Green Master mix, 2.5 μg DNA and was made up to 10 μl with dd H2O. 
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Quantitative real time PCR was run using an Applied Biosystems StepOne Plus RT PCR 
system and the default PCR program (95°C – 10’, 40 x 95 °C  - 15” and 50 °C – 60” followed 
by a melting curve from 60°C to 95°C in 0.3°C steps). Quantitation was carried out using a 
standard curve with mixed cDNA samples and dilutions of 25ng, 5ng, 1ng, 0.2ng, 0.04ng. For 
DNaseI, ChIP and ATAC validation a genomic DNA standard curve was used instead. 
Table 2.2. Expression primers were designed based on DNA sequences from RefSeq 
or from PrimerBank (*). 
Primer Forward Reverse 
CSF1R EX13/14 AGCACGAGAACATCGTCAACC TTCGCAGAAAGTTGAGCAGGT 
CSF1R EX2/3 CACCTGCCTGCCACTTCC CCACACATCGCAAGGTCAC 
CSF1R-LTR TTGGATGTGATTCTGCTCCTC CCACACATCGCAAGGTCAC 
PAX5 CCATGTTTGCCTGGGAGATC GGTTGGTTGGGTGGCTGCTG 
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
LTA2  CATCTACTTCGTCTACTCCCAGG CCCCGTGGTACATCGAGTG 



















IL13 CATCGAGAAGACCCAGAGGA TTTACAAACTGGGCCACCTC 
IL6 CGAGCCCACCGGGAACGAAAG GTGGCTGTCTGTGTGGGGCG 
IRF4 (*305410879c1) GCTGATCGACCAGATCGACAG CGGTTGTAGTCCTGCTTGC 
IRF5 CAGGGGAGCTATCTTGGTCA GATGGAGCTCCTTGAATTGC 
TNF (*25952110c2) GAGGCCAAGCCCTGGTATG CGGGCCGATTGATCTCAGC 






TNFRSF11A LTR AGCCACATGGAACTGTAAGTC ACTGGTACATGGAGGAGCGA 
Chr18 ACTCCCCTTTCATGCTTCTG AGGTCCCAGGACATATCCATT 
TBP Promoter CTGGCGGAAGTGACATTATCAA GCCAGCGGAAGCGAAGTTA 
 
2.2.4. RNA-Sequencing 
RNA Sequencing libraries were produced in duplicate using the TruSeq Stranded Total RNA 
Library Prep Kit with Ribo-Zero Human/Mouse/Rat (Illumina) according to manufacturer’s 
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protocol. RNA was extracted using the NucleoSpin® RNA kit (Macherey-Nagel) with on 
column DNase digestion as previously described (2.2.1). RNA quality was assessed using a 
Bioanalyzer 2100 with a Eukaryote Total RNA Pico chip (Agilent). Ribosomal RNA was 
removed by diluting between 100ng and 300ng of total RNA to 10 µl with H2O and adding 
rRNA Binding Buffer (5 µl) and rRNA Removal Mix (5 µl) and incubating at 68°C for 5 
minutes. Magnetic rRNA removal beads were warmed to room temperature (35 µl) and the 
RNA mix added to them and incubated at room temperature for 1 minute. Ribsomal RNA 
bound to the beads was then removed by magnetic separation. 
RNA clean-up was carried out using RNAClean XP beads by mixing 100 µl with of beads 
each sample, incubating at room temperature for 15 minutes and magnetic separation prior 
to the removal of the supernatant. The beads were then washed with 70% EtOH and dried 
for 15 minutes before eluting in 11 µl of elution buffer for 2 minutes. Elute, Prime and 
Fragment mix (8.5 µl) was added to the eluted RNA (8.5 µl) and incubated at 94°C for 8 
minutes. To synthesise the first strand DNA 1 µl Superscript II reverse transcriptase 
(Invitrogen) was added to 9 µl First Strand Synthesis Act D mix and 8 µl transferred to each 
sample prior to incubation (25°C 10 minutes, 42°C 15 minutes, 70°C 15 minutes). For 
second strand synthesis 5 µl of resuspension buffer and 20 µl of Second Strand Mix (TruSeq 
kit) was added to each sample and incubated at 16°C for 1 hour. DNA from the reaction was 
purified using AMPure XP bead (Beckman) by addition of 90 µl of beads to each sample. 
DNA was bound to the beads by 15 minute incubation at room temperature and the 
supernatant removed following magnetic separation. The beads were washed twice with 
80% EtOH and dried for 15 minutes at room temperature before eluting in 17.5 µl 
resuspension buffer. 
The 3’ ends of the DNA fragments were adenylated by addition of 12.5 µl A-Tailing mix 
(TruSeq kit) and 2.5 µl resuspension buffer to 15 µl elute and incubation at 37°C for 30 
minutes and 70°C for 5 minutes. Indexed Illumina Adaptors were ligated to the DNA 
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fragments to allow for multiplexed sequencing by addition of 2.5 µl resuspension buffer, 2.5 
µl Ligation Mix and 2.5 µl RNA Adaptor Index (diluted 1:4). The ligation was incubated for 10 
minutes at 30°C and the reaction stopped by addition of Stop Ligation Buffer (5 µl). The 
adaptor ligated DNA was purified using 42 µl AMPure XP beads as previously described and 
eluted in 52.5 µl resuspension buffer. The purification was repeated with 50 µl supernatant 
and 50 µl beads with the final elution in 22.5 µl. Finally a 15 cycle PCR amplification of the 
library was carried out using 20 µl of eluted DNA, 5µl PCR Primer Cocktail and 25 µl PCR 
Master Mix (98°C 30 seconds, 15 x 98°C 10 seconds, 60°C 30 seconds, 72°C 30 seconds 
and final extension 72°C 5 minutes). A final AMPure purification with 50 µl of beads was 
carried out and the final library eluted in 30 µl.  
The libraries were run on a Bioanalyzer 2100 with a High Sensitivity DNA Assay chip 
(Agilent) to determine the average fragment size and quantified by PCR using the Kappa 
Illumina Library Quantification Kit on an Applied Biosystems StepOne Plus RT PCR system. 
Sequencing was carried out using an Illuimina NextSeq 500 with each library run as 1/12 of a 
150 cycle flow cell. 
2.3. Chromatin Accessibility Assays 
Two assays were used for the genome-wide assessment of open chromatin. DNaseI 
hypersensitive site mapping works by carrying out a short digestion with the DNaseI enzyme 
on permeabalised cells. The DNaseI initially cuts the DNA preferentially in open regions of 
chromatin where the DNA is not bound by nucleosomes. By limiting the length of digestion 
this technique produces a library of fragments representing these regions. The second 
method, Assay for Transposase Accessible Chromatin (ATAC-Seq) uses a transposase 
enzyme. In the same way as DNaseI the TN5 transposase will function preferentially in 
regions of open chromatin. This results in the DNA in these regions being cut into fragments 
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and tagged with a known sequence that can be amplified to produce a genome-wide library 
for sequencing. 
 
2.3.1. DNaseI Hypersensitive Site Mapping 
DNaseI Hypersensitive Site (DHS) mapping was carried out using the protocol from Bert, et 
al. (2007). Cell pellets of 4.5x106 cells were washed in PBS and then suspended in 150 μl of 
DNaseI sucrose buffer (60mM KCl, 15 mM NaCl, 5 mM MgCl2, 10 mM Tris pH 7.4, 300 mM 
sucrose). DNaseI dilutions ranging between 90u and 200u were produced in DNaseI dilution 
buffer (60mM KCl, 15 mM NaCl, 5 mM MgCl2, 10 mM Tris pH 7.4, 0.4% NP40 and 2mM 
CaCl2). Each sample was incubated at 22oC for 3 minutes and then 150ul of diluted DNaseI 
stocks were added to each reaction and incubated for a further 3 minutes. To stop the 
digestion after 3 minutes 300ul of Cell lysis buffer (3oo mM NaAcetate, 10 mM EDTA pH 7.4, 
1% SDS and 1 mg/ml proteinase K) was added. The samples were then incubated overnight 
at 45 °C to allow the proteinase K to digest the protein. RNaseA (6 µl, 10 mg/ml) was added 
and incubated for 30 minutes prior to running 6 µl of the DNA on a 0.7% TAE agarose gel to 
visualize the digestions (Figure 2.1). The samples with optimal digestion were chosen for 




Figure 2.1. DNaseI digestion validation gel 
DNaseI digestions from the DHS assay were run on a 0.7% agarose gel to determine the 
degree of digestion. The samples digested with 30u, 40u and 50u of DNaseI (highlighted in 
red) were chosen as the optimal level of digestion. 
 
Further validation was performed by qPCR to assess the best digestion points for optimal 
enrichment of open chromatin in the cells. Primers were used to amplify a known highly 
DNaseI hypersensitive region (TBP promoter) a region of low sensitivity (IVL) and a region of 
minimal or no sensitivity (Chr18). The ideal digestion was chosen based on high TBP/Chr18 
and a low IVL/Chr18 ratio. 
The best DNaseI concentrations giving the highest open chromatin enrichment based on the 
initial qPCR results were chosen and size selection of fragments between 50 and 250 bp 
was carried out. Briefly, 12 μg of each digested DNA sample was run on a 0.8% gel and a 
fragment of between 50 and 250 bp cut out from each lane. DNA was extracted from the gel 
using a Qiagen mini-elute gel extraction kit in accordance to the manufacturer’s instructions 
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and the extracted DNA was eluted in 30 ul of H2O. The size-selected samples were again 
analyzed by qPCR using primers for low hypersensitivity regions ACTB (actin, beta) and 
Chr18 (a gene desert on chromosome 18) and highly hypersensitive region, TBP promoter 




Figure 2.2. qPCR validation of DNaseI digestion levels 
qPCR validation was carried out on size selected DNaseI samples to determine the optimal 
digestion level to use for library preparation. In this example 40 units was chosen as the 
optimal DNaseI concentration due to a high ratio of TBP/B-Actin and TBP/Chr18. 
 
Indexed Illumina libraries were prepared using the MicroPlex Library Preparation Kit v2 
(Diagenode) following manufacture’s protocol. Briefly, 10 µl of DNA from the DNaseI assay 
was prepared with Template Preparation Buffer (2 µl) and Template Preparation Enzyme (1 
µl ) and incubated at 22 °C for 25 minutes and 55 °C for 20 minutes. The samples were then 
treated with Library Synthesis Buffer and Enzyme (1 µl of each) and incubated for a further 
40 minutes at 22 °C. The library then underwent a step to amplify the library and add 








Amplification Buffer and Enzyme (25 µl and 1 µl), H2O (5 µl) and Indexing Barcode reagent 
(5 µl). The libraries were then incubated as follows; 72 °C - 3 minutes, 85 °C – 2 minutes, 98 
°C – 2 minutes, 4 cycles of 98 °C – 20 seconds, 67 °C – 20 seconds, 72 °C – 40 seconds, 
followed by 12 cycles of 98 °C – 20 seconds and 72 °C – 50 seconds. The libraries were 
then run on a 2% agarose gel and size selected between 190-300 bp. The libraries were 
finally quantified by qPCR using the Kappa library quantification kit (Kappa Biosystems), 
pooled and run on an Illumina Hi-Seq 2000 75bp paired end.  
2.3.2. Assay for Transposase Accessible Chromatin 
ATAC-Seq was performed using the protocol originally developed by Buenrostro, et al. 2015 
and modified by Corces, et al. 2016. The cells were first pelleted by centrifugation at 300 x g 
from 5 minutes, re-suspended in a volume of cold PBS to 1x106 cells/ml and 50 µl (50,000 
cells) were then pelleted by centrifugation at 300 x g for 5 minutes. The PBS was then 
removed and 50 µl transposition mix (25 µl 2 x TD Buffer (Illumina), 2.5 µl TN5 Transposase 
(Illumina), 5 µl digitonin (0.1% stock) and 17.5 µl H2O) was added. The cells were gently 
pipetted to mix and re-suspend and then incubated at 37 °C in a 300 rpm shaking heat block 
for 30 minutes. The resulting product was purified using the Qiagen MiniElute Reaction 
Cleanup kit following manufacturer’s protocol and eluted in 20 µl H2O.  
The transposase treated DNA was then amplified in 2 PCR amplification steps. Firstly by the 
addition of 2.5 µl 25 µM Nextera PCR Primer 1, 2.5 µl 25 µM Nextera Barcoded PCR Primer 
and 25 µl NEBNext Master Mix followed by incubation at 72 °C – 5 minutes, 5 cycles 98 °C – 
30 seconds, 63 °C – 30 seconds and 72 °C 1 minute. A qPCR step was then carried out 
using 5 µl of the amplified library, H2O (4.4 µl), primers as before (0.25 µl of each), 10 x 
SYBR Green I (0.6 µl) and NEBNext Master Mix (25 µl) and run for 40 cycles using the 
program as before. This step allowed for the optimal number of cycles to be calculated to 
achieve 25% amplification of the library, therefore minimising clonal duplication of sequences 
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in the library. The remaining material was further amplified based on the cycle number 
determined from the qPCR. The libraries were finally purified using AMPure XP beads 
following manufacturer’s protocol and eluting in 22.5 µl elution buffer. The purified libraries 
were quantified by Kappa Library Quantification kit (Kappa Biosystems) and Bioanalyzer 




2.4. Rapid Amplification of cDNA Ends followed by Sequencing (RACE-Seq) 
We developed the RACE-Seq protocol to allow for the identification of active LTRs related to 
the THE1B LTR family. Briefly this technique works by the addition of a known adaptor 
sequence to the 5’ end of all transcripts which then allows for the amplification of fragments 
between the 5’ adaptor and a primer degenerate primer designed to target the THE1B 
elements. This allows for the production of a library of active LTRs which can then be 
barcoded and sequenced using the Illumina platform to produce a genome-wide dataset of 
LTR activation.  
 
Figure 2.3 THE1B primer design 
Alignment of the THE1B consensus sequence and the THE1B primer upstream of CSF1R. 
The THE1B primer was designed based on the region of the consensus sequence with 
greatest homology to the CSF1R THE1B LTR. 
2.4.1. 5’ RACE 
RACE was carried out based on the ExactSTART™ Eukaryotic mRNA 5’-& 3’-RACE Kit 
(Epicentre) and supplied protocol, however due to the discontinuation of the Tobacco Acid 
Pyrophosphatase enzyme and therefore the above kit a number of modifications were made 
(Figure 2.4). RNA was treated with Alkaline Phosphatase for 15 minutes at 37°C (10 µl Apex 
Buffer, 5 µl Apex Heat-liable Alkaline Phosphatase (Epicentre), 1 µg RNA, made up to 100 µl 
with H2O). An Ampure RNA-clean bead purification then was carried out prior to treatment 
with RNA 5’ Pyrophosphohydrolase (RppH) for 1 hour at 37 °C (Purified RNA (40 µl), 10 x 
71 
 
Thermopol Buffer (NEB)(5 µl), RppH Enzyme (NEB)(5 µl)). The RppH reaction was stopped 
by addition of 1 µl of 500 mM EDTA solution and then purified with a further Ampure RNA-
clean bead purification and eluted in 16 µl H20. The 5’ RACE acceptor oligonucleotide was 
ligated at 37 ° for 30 minutes (4 µl H2O, 2 µl RNA ligase buffer, 1 µl 5’ acceptor 
oligonucleotide, 1 µl 2mM ATP solution and 1 µl T4 RNA ligase (NEB)). First strand cDNA 
synthesis was carried out by addition of 14 µl H2O, 1 µl cDNA synthesis primer, 2 µl dNTP 
PreMix, 2 µl MMLVV RT Buffer and 1 µl MMLV RT, the reaction was incubated at 37°C for 1 
hour and 85°C for 10 minutes. The reaction then had 1 µl of RNase added  and was 
incubated at 55°C for 5 minutes The second strand cDNA synthesis reaction components 
were added at 55°C. A degenerate biotinylated THE1B LTR primer (20 µM, 2 µl ) was used 
along with a primer for the 5’ RACE linker (5 µl ), 21 µl  H2O, 30 µl PCR mix and 1 µl (2.5 U) 
PfuUltra II polymerase and incubated for 21 cycles (95°C 30 seconds, 21 x 95°C 20 seconds, 
60 °C 20 seconds, 72°C 3 minutes).  
Following second strand synthesis the fragments incorporating a biotinylated primer were 
selected using T1 Dynabeads (Thermo Fisher Scientific) as follows. T1 dynabeads (20 µl) 
were washed in B&W buffer (10 mM Tris-HCL, 1 mM EDTA, 2 M NaCl) using magnetic 
separation and re-suspended in 50 µl of 2 x buffer B&W buffer. An equal volume of RACE 
product was added and samples were mixed on a slow rotating wheel at room temperature 
for 1 hour. The beads were then captured using a magnetic separator and following washes, 
with B&W buffer and TE, were re-suspended in 33.75 µl 1 x TE. 
The selected DNA was amplified off the beads by a 3 cycle PCR ((95°C 2 minutes, 3 x 95°C 
20 seconds, 56 °C 20 seconds, 72°C 30 seconds and 72°C 3 minutes) using a non-
biotinylated THE1B LTR primer (1.25 µl, 20µM), the 5’ RACE adaptor primer (4 µl), 5 µl 
dNTPs (10mM), 5 µl PFU Ultra Buffer and 1 µ PFU Ultra polymerase. Finally purification was 
carried out using the Qiagen MiniElute PCR Cleanup Kit and eluted in 11 µl elution buffer. 
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2.4.2. RACE Validation by Cloning 
To validate the genome wide LTR libraries produced by RACE, fragments were blunt-end 
cloned into the pBlueScript vector which allowed for Blue/White selection of positive clones. 
The individual clones could then be picked and the inserts were Sanger sequenced to 
determine the sequences of a number of fragments within the library. 
The pBlueScript vector was digested with SmaI (NEB) using a standard protocol and the 
RACE fragments were ligated into the vector using T4 DNA ligase (NEB). The ligation 
reaction was then incubated for 5 hours at room temperature. Transformation of the ligated 
vectors into DH5α competent E.coli was carried out by heat shock at 42 °C and the culture 
was plated and incubated overnight on 1.5% agar LB plates containing ampicillin (100ng/ml) 
with added X-Gal to a concentration of 200 µg/ml. Clones containing fragments were picked 
based on blue/white selection and grown in culture (+ ampicillin 100ng/ml) at 37 °C overnight 
prior to mini-prep using the Qiagen Mini-Prep kit. The resulting DNA was digested using 
BamHI and EcoRI to ascertain inserted fragment sizes. The digested samples were 
separated on a 1% TAE agarose gel stained with ethidium bromide. All positive clones were 
then sequenced using the pBlueScriptKS primer Table 2.3. Sequenced clones were mapped 
to the genome individually using UCSC Blat to establish whether they aligned uniquely and 
which regions they aligned to. 












Libraries for genome wide RACE-Seq were produced using the MicroPlex Library 
Preparation Kit v2 (Diagenode). Purified RACE material (10 µl) was added to 2 µl of template 
preparation buffer and 1 µl of Template Preparation Enzyme and incubated at 22°C for 25 
minutes and 55°C for 20 minutes. The prepared template was then mixed with 1 µl Library 
synthesis buffer according to the manufacturer’s instructions and 1 µl Library synthesis 
enzyme and incubated at 22°C for 40 minutes. The libraries were then mixed with 
amplification buffer (25 µl), amplification enzyme (1 µl), H2O (4 µl) and a Barcoded Indexing 
Reagent (5 µl) to allow for the samples to be multiplexed for sequencing. The mix was split 
into 2 reactions of 25 µl which were amplified at 12 and 14 cycles to allow for selection of 
enough material to sequence without introducing clonal amplification (Extension and 
Cleavage: 72°C 3 minutes, 85°C 2 minutes, Denaturation: 98°C 2 minutes, Addition of 
Indexed oligonucleotides: 4 x 98°C 20 seconds, 67°C 20 seconds, 72°C 40 seconds, Library 
Amplification: 12 or 14 x 98°C 20 seconds, 72°C 50 seconds).   
Finally size selection and purification of the libraries was carried out by running products on a 
1.2% TAE agarose gel (with 0.05% ethidium bromide) and excising fragments between 190 
and 300 bp. These were then extracted using the Qiagen mini-elute gel extraction kit and 
eluted twice in 12 µl H2O. The libraries were run on a Bioanalyzer 2100 with a High 
Sensitivity DNA Assay chip (Agilent) to determine the average fragment size and quantified 
by PCR using the Kappa Illumina Library Quantification Kit on an Applied Biosystems 
StepOne Plus RT PCR system. 
The indexed libraries were pooled and sequenced on Illumina MiSeq using the 150-Cycle 













To study the distribution of H3K4me3 at transcribed LTRs chromatin immune-precipitation 
followed by sequencing (ChIP-Seq) was used. ChIP-Seq was carried out using double cross-
linked chromatin to ensure that we were able to capture all protein-DNA interactions. 
To produce double cross-linked chromatin cultured cells were washed three times in PBS 
(Sigma) with centrifugation for 5 minutes at 300xg between washes and finally re-suspended 
in PBS at 1x107 cells per ml. The first crosslinking step was performed by adding 8.3 μl of 
100mg/ml disuccinimidyl glutarate (DSG) (Sigma Aldrich) per ml of cells and incubating for 
45 minutes on a roller at room temperature. The cells were then washed a further 4 times in 
PBS using the previous conditions. The second cross-linking step was performed by re-
suspending the cells in 1 ml of 1% formaldehyde (Thermo Scientific) diluted in PBS and 
incubated at room temperature on a roller for 10 minutes. The reaction was then stopped by 
addition of 1/10th volume of 2M Glycine and mixed by pipetting. The cross-linked cells then 
pelleted by centrifugation at 400xg for 5 minutes and washed twice in ice-cold PBS.  
The chromatin was prepared by firstly re-suspending the cross-linked cells at 1x107 cells/ml 
in ice cold Buffer A (10 mM HEPES pH 8.0, 10 mM EDTA, 0.5 mM EGTA, 0.25% Triton X-
100, 1:1000 PIC (Protease Inhibitor Cocktail)(Sigma) and 0.1 mM PMSF) and incubated at 4 
°C on a rotating wheel for 10 minutes. The nuclei were then pelleted by centrifugation for 5 
minutes at 400 x g and resuspended at 1x107 cells/ml in ice-cold Buffer B (10 mM HEPES pH 
8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.01% Triton X-100, 1:1000 PIC and 0.1 
mM PMSF). The resuspended pellet was incubated on a rotating wheel at 4°C for 10 minutes 
and pelleted by centrifugation at 500 x g for 5 minutes. Finally the nuclei were resuspended 
in ice-cold IP Buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 
0.25% SDS, 1:1000 PIC and 0.1 mM PMSF) at 3.3x107 cells/ml. 
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The chromatin was fragmented by sonication in aliquots of 300 μl using a Picorupter 
(Diagenode) for 8 cycles (30 seconds on, 30 seconds off). The sonicated chromatin was 
centrifuged at 16,000 x g for 10 minutes and the supernatant was diluted with 2 volumes of 
IP Buffer II (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 2mM EDTA, 1% Triton X-100, 7.5% 
glycerol, 1:1,000 PIC and 0.1 mM PMSF). 
Prior to ChIP the antibody was bound to Protein G Dynabeads as follows; 10 μl of beads 
were washed by addition of 500 μl 0.1M citrate-phosphate buffer pH 5.0. The beads were 
then immobilised using a magnetic rack and resuspended in 15 μl 0.1 M citrate-phosphate 
buffer. The beads were then mixed with 2 μg H3K4me3 antibody (Millipore 07-473) and 5% 
BSA (final concentration 0.5%), this was then incubated on a rotating wheel at 4°C overnight. 
At this point 10% of the cross-linked chromatin was taken as an input control and mixed with 
4 μl 5M NaCl and 0.5 μl 50 mg/ml proteinase K (Sigma) The input control was then reverse 
cross-linked overnight at 65 °C. 
An additional pre-clearing step was performed to reduce the level of background in the ChIP. 
Firstly 10 μl Protein G Dynabeads were washed with 500 μl, 0.1 M citrate-phosphate buffer 
pH 5.0 prior to immobilisation using a magnetic rack and resuspention in 440 μl of prepared 
chromatin. The pre-clearing mix was then incubated on a rotating wheel at 4°C for 1 hour 
before immobilisation of the beads using a magnetic stand.  
The Protein G Dynabeads with the pre-bound H3K4me3 antibody were washed in 500 µl 0.1 
M citrate-phosphate buffer. The beads were then separated from the buffer by magnetic 
separation and resuspended in 15 µl citrate-phosphate buffer with 5% BSA. The pre-bound 
beads were then added to the supernantant from the pre-clearing step and incubated 
overnight a 4 °C on a rotating wheel.  
Following overnight incubation the beads with bound chromatin were separated from the 
supernatant by magnetic separation and the following washes were performed each with 500 
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µl wash buffer; one wash with Wash Buffer 1 (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM 
EDTA pH 8.0, 10% Triton-X 100, 0.1% SDS), two washes with Wash Buffer 2 (20 mM Tris-
HCl pH 8.0, 500 mM NaCl, 2 mM EDTA pH 8.0, 10% Triton-X 100, 0.1% SDS), one wash 
with LiCL Buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 1 mM EDTA pH 8.0, 0.5% NP-40 and 
0.5% Na-Deoycholate) and finally two washes with TE/NaCl Buffer (10 mM Tris-HCl pH 8.0, 
50 mM NaCl and 1 mM EDTA pH 8.0). The beads were then resuspended in 50 µl elution 
buffer and incubated at 65 °C for 15 minutes. The beads were then removed by magnetic 
separation and the supernatant mixed with 5 µl of 5M NaCl and 0.5 µl proteinase K (50 
mg/ml) and incubated at 65 °C overnight. 
The final ChIP step was to purify the DNA using AMPure XP beads (BD) following 
manufactures protocol and eluting in 50 µl 0.1 x TE pH 8.0. The ChIP experiment was then 
validated by qPCR using primers designed to a known region of H3K4me3 (TBP promoter) 
and a known region with no H3K4me3 (IVL). This data was normalised to input DNA and 
measured against a standard curve of genomic DNA. Following validation libraries were 
produced using the Kappa Hyperprep Kit (Kappa Biosystems) following manufacturers 
protocol with an amplification step of 12 cycles. The library was size selected between 250 – 
500 bp by gel electrophoresis on a 1% TAE gel followed by extraction using the Qiagen 
MiniElute Gel Extraction kit, following manufacturer’s instructions and eluting in 15 µl. A final 
qPCR validation step was carried out using the previous primers to determine the library 
enrichment. The library was quantified by Bioanalyser (Agilent) and Kappa Library 
Quantification Kit and sequenced on a NextSeq 500 (Illumina). 
Table 2.4 ChIP-Seq Primers 
Name Sequence - Fwd Sequence - Rev 
TBP-promoter CTGGCGGAAGTGACATTATCAA GCCAGCGGAAGCGAAGTTA 





2.6. siRNA Knockdown TNFRSF11A 
Small interfering RNA knockdown of TNFRSF11A was performed in the L1236 cell line by 
electroporation. Briefly, 1x107 cells were pelleted by centrifugation at 300 x g for 5 minutes 
and resuspended in 700 µl Optimem medium (Sigma). This was mixed with siRNA 
(SMARTpool: siGENOME TNFRSF11A, Dharmacon) to a final concentration of 200 Nm in a 
0.4mm electroporation cuvette and electroporated using a Gene-Pulser X-cell (Bio-Rad) with 
960 µF and 0.18 kV. The cells were then returned to culture for down-stream analysis. 
2.7. Nuclear Protein extraction and Western Blotting 
Nuclear protein extraction was carried out using the Active Motif Nuclear Extraction Kit 
following manufacturer’s protocol and the extracted protein was quantified by using the 
Pierce BCA Protein Assay Kit. The quantified protein was mixed with 6x loading buffer 
(0.3125M Tris-Cl pH6.8, 10% SDS, 25% glycerol, 10% -2 Mercaptoethanol and 0.05% 
Bromophenol blue) and was heated to 95 °C for 5 minutes. The denatured protein was then 
run on a Mini-PROTEAN TGX precast gel (Bio-Rad) in SDS-PAGE running buffer (0.025M 
Tris Base pH8.3, 0.192M Glycine and 0.1% SDS). The protein was transferred onto a 
nitrocellulose membrane using Trans-Blot Turbo transfer system with the default turbo blot 
program. 
The membrane was then blocked with 5% milk in TBST (0.2% TweenTM 20, 0.075 M NaCl 
and 0.01 M Tris pH 7.5) for 30 minutes. The membrane was then probed with primary 
antibody (Table 2.5) diluted in 5% milk TBST by rocking at 4 °C overnight. Following this the 
membrane was washed 3 times in TBST and re-probed with the appropriate HRP secondary 
antibody in 5% milk TBST (Table 2.5). The membrane was then developed using ECL 




Table 2.5 Western blotting antibodies 
Antibody Dilution 
NF-κB p65 Mouse (6956s - Cell Signalling) 1:1,000 
β-Actin (A1978 - Sigma) 1:5,000 
Anti-Mouse HRP (Jackson ImunoResearch) 1:5,000 
 
2.8. iIkKβ Cloning 
To investigate the impact of constitutive NF-κB activation on LTR activation in the Reh cell 
line, a doxycycline inducible lentiviral vector was produced containing cDNA for IκBKβ and 
IRES GFP. This vector was transduced into Reh cells, making a stable cell line with 
doxycycline inducible NF-κB constitutive activation. 
 
2.8.1. Cloning iIkKβ into PCW57.1 
THE PCW57.1 (Adgene) vector uses the Gateway cloning system meaning that all cDNA 
was first cloned into the pENTR vector (Addgene). IRES GFP was excised from the pSIEW 
vector by restriction enzyme digest with BamHI (20U), SalI (20U) and 5 µl SmartCut Buffer 
(NEB) in a 50 µl reaction and incubated at 37°C for 1 hour. The pENTR vector was digested 
with BamHI and XhoI using the same protocol and both digests were run on a 1% agarose, 
TAE electrophoresis gel. The digested fragments were excised from the gel and extracted 
using the Qiagen gel extraction kit in accordance to the manufacturer’s instructions and the 
extracted DNA was eluted in 30 ul of H2O. The IRES GFP fragment was then ligated into the 
pENTR vector by addition of T4 DNA Liagse (1 µl, NEB), T4 DNA Ligase Buffer (1 µl, NEB) 
with an insert to vector ratio of 3:1 and incubation at room temperature for 2 hours. 
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The ligation product was used to transform chemically competent Sub-cloning Efficiency™ 
DH5α™ E.Coli (Invitrogen) by heat-shock at 42°C. The bacteria were grown on LB plates 
with Kanamycin (50 µg/ml) selection and colonies picked to grow up for mini-prep. Mini-
Preps were carried out using the Qiaprep® Spin Miniprep Kit (Qiagen) following the supplied 
protocol and eluting in 50 μl H2O. The resulting clones were sequenced by sanger 
sequencing using primers designed to either side of the insert site (pENTR-Fwd 
(CTACAAACTCTTCCTGTTAGTTAG) and pENTR-Rev (ATGGCTCATAACACCCCTTG)). 
Clones matching the correct sequence were chosen and Maxi-Prepped using the 
NucleoBond ® Xtra Midi Plus EF kit following manufacturer’s instructions.  
 The cDNA for IκBKβ was excised from a vector obtained from Stephan Mattas, Charité–
Universitätsmedizin, Berlin, by digestion with 20 U SmaI and 20 U NotI (plus 5 µl CutSmart 
Buffer in 50 µl reaction) with a sequential incubation of 25°C 1 hour and 37°C for 1 hour. The 
digested fragments were separated on an agarose electrophoresis gel and the correct size 
fragment extracted as before. The pENTR IRES GFP construct was digested with BamHI 
following the previous protocol and both the vector at IκBKβ were blunt-ended using 3.75 µl 
T4 DNA polymerase (Promega), 10 µl T4 Buffer and 4 µl dNTPs (10 mM). The reaction was 
incubated at 37°C for 5 minutes and stopped by addition of 4 µl 0.5M EDTA and the DNA 
purified using the Qiaquick ® PCR Purification kit and eluted in 30 µl. The IκBKβ fragment 
was ligated into the vector at a 3:1 ratio with 1 µl T4 DNA Ligase (NEB), 2 µl T4 DNA Ligase 
Buffer (NEB) in a 20 µl reaction and incubated at room temperature for 2 hours.  
Sub-cloning Efficiency™ DH5α™ chemically competent E.Coli (Invitrogen) were transformed 
as previously described and the resulting DNA preps sequenced.  
2.8.2. Lentivirus Production and Transduction of Reh cells 




The 293T cells were transfected using TransIT293 (Mirus) which was firstly warmed to room 
temperature. The plasmid DNA was mixed; 12 µg PCW57.1, 0.6 µg Tat, 06 µg Rev, 0.6 µg 
gag/pol and 1.2 µg vsv-g. The DNA was then mixed with 1.5 ml of Optimem media and 45 µl 
TransIT293 was added and mixed by pipetting then incubated for 30 minutes at room 
temperature. The transfection mix was then added dropwise to the 293T cells in 15.5 ml of 
DMEM and incubated for 24 hours. Virus containing media was collected at 12 hour intervals 
for 3 days and refrigerated until day 3.  
The virus was concentrated prior to infection of the Reh cells as follows. The collected virus 
containing media was centrifuged at 500 x g for 15 minutes at 4 °C and the supernatant 
filtered using a 0.45 µm acrodisk syringe filter (PVDF low protein binding)(Sigma). 
Concentration was then carried out using protein purification columns with 100-kD cut-off 
(Centricon Plus concentrators, Millipore) with centrifugation at 2,000 x g for 20 minutes.  
This virus was then used to infect Reh cells by spin infection. Reh cells were plated at 1x106 
cells/ml and the concentrated virus and 8 µg/ml polybrene was added. The plate was then 
centrifuged for 2 hours at 1,500 x g at 32 °C. Following spin infection the plate was returned 
to the incubator and the media changed after ~12 hours. The cells were then selected by 
treatment with puromycin and used for downstream experiments. 
2.9. Data Analysis 
2.9.1. RNA-Seq 
RNA-Seq reads were mapped to the hg19 human reference genome using Tophat2 (Kim, 
Pertea et al. 2013). Reads mapping to the sense and anti-sense strands were split into 
separate files and histogram density plots were created from the mapped reads using 
Bedtools genomecov with the ‘–d –split’ option and uploaded to UCSC genome browser 
(Quinlan and Hall 2010). To obtain normalised FPKM (fragments per kilobase of transcript 
per million mapped reads) values for gene expression CuffNorm was used (Trapnell, Roberts 
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et al. 2012). Further analysis was carried out using LOG2 FPKM values in R and Microsoft 
Excel (R-Development-Core-Team 2008). Expressed genes were defined as any gene with a 
LOG2 FPKM value of 0 or above and differential expression between cell lines was defined 
based on at least a 2-fold change in expression. 
To perform clustering of the RNA-seq data from the cell lines pairwise Pearson correlation of 
gene expression was used to produce a correlation matrix. Clustering of the RNA-Seq data 
by Pearson correlation was performed using R with the heatmap.2 function in the gplots 
package using hierarchical clustering with Euclidean distance and average linkage.  
Gene Ontology analysis was performed using DAVID on lists of up and down regulated 
genes as previously defined. KEGG Pathway analysis was carried out using the ClueGo and 
CluePedia packages in Cytoscape with lists of up and down regulated genes combined from 
each HL cell line compared to each control cell line (Shannon, Markiel et al. 2003, Bindea, 
Mlecnik et al. 2009, Bindea, Galon et al. 2013). The network was produced based on KEGG 
terms with a pV < 0.05 and the layout was manually adjusted to enable all interactions to be 
visualised.  
2.9.2. DNaseI-Seq, ATAC-Seq and ChIP-Seq 
Quality control data was obtained for DNaseI-Seq, ATAC-Seq and ChIP-Seq reads using 
FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The reads were the 
mapped to the hg19 version of the human reference genome using Bowtie2 with the ‘–very-
sensitive’ parameter (Langmead and Salzberg 2012). Histogram alignment density plots 
were produced using the genomecov function of Bedtools and the plots uploaded to UCSC 
genome browser. Regions of enrichment (peaks) in DNaseI-Seq, ATAC-Seq and ChIP-Seq 
data were identified using Macs 1.4 with default parameters (Zhang, Liu et al. 2008). 
Overlaps of ATAC-Seq, ChIP-seq and DNaseI-Seq datasets with other datasets were 
performed using the intersect function of bedtools (Quinlan and Hall 2010).  
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Clustering of the DNaseI-Seq and ATAC-Seq datasets from each cell line was performed 
based on the Pearson correlation of read (tag) counts at the summit of each peak. To define 
a set of hypersensitive sites (peaks) for correlation to be performed the summits of peaks 
identified in all datasets were concatenated and any summits occurring within 400 bp of each 
other were merged using Bedtools merge. The count of reads overlapping with the summit of 
these newly defined peaks was then obtained using the annotatePeaks function of Homer 
(Heinz, Benner et al. 2010). Pairwise correlation of this data was then performed in R and 
hierarchical clustering and heatmap production carried out using the heatmap.2 function of 
the gplots package in R as previously described.  
2.9.3. Digital Genomic Foot-printing 
Digital genomic footprinting was performed using the Wellington algorithm (Piper, Elze et al. 
2014), using standard parameters. Input files were peaks identified via MACS (Zhang, Liu et 
al. 2008) for high-depth sequencing DNaseI-Seq runs performed in resting Reh, KM-H2 and 
L428 cells. Retained footprints were those identified with an FDR ≤ 0.01, as per standard 
parameters of the algorithm. 
2.9.4. Digital genomic footprinting motif co-occurrence clustering 
Digital genomic footprinting motif co-occurrence clustering was performed as previously 
described (Cauchy, James et al. 2015, Obier, Cauchy et al. 2016). Briefly, motif discovery 
was first performed in footprints via the Homer findMotifsGenome algorithm (Heinz, Benner 
et al. 2010), using -size given as a parameter. 16 motifs representing motifs found in HL and 
NHL cell lines were selected for computing constraints. Motif mapping to footprints was 
performed via Homer annotatePeaks on specific populations. Motif co-occurrences within 
50bp were computed via pyBedTools intersection_matrix (Dale, Pedersen et al. 2011). To 
assess for significance of co-occurrence enrichments, background co-occurrences of 
footprinted motifs were computed using whole footprint populations of the reference cell type, 
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using 1000 random subsamplings of sizes equal to the specific population in focus.  An 
enrichment score was then derived using co-occurrences of the specific population versus 
the background as Z=(x-μ)/σ, where x is the co-occurrence in the specific population for a 
given motif, μ and σ are the average co-occurrence and standard deviation of co-occurrence 
as computed from the background. 
2.9.5. RACE-Seq 
RACE-Seq reads were first trimmed using Cutadapt to remove the RACE adaptor sequence  
(TCATACACATACGATTTAGGTGACACTATAGAGCGGCCGCCTGCAG 
GAAA) and the THE1B primer sequence (CATGGCTGGGGAGGCCTC). The trimmed reads 
were then mapped to the hg19 version of the human reference genome using Bowtie2 with 
the ‘—very-sensitive’ parameter (Langmead and Salzberg 2012). Histogram density plots 
were produced for each biological replicate and for the merged replicates using bedtools 
genomecov and the resulting plots uploaded to UCSC genome browser. Regions of 
enrichment (peaks) were identified using Macs1.4 with the ‘–keep-dup=all’ parameter. The 
resulting peaks from each biological replicate were overlapped to identify the shared peaks 
using the ChipPeakAnno package in R and venn diagrams produced. High-confidence 
RACE-Seq peaks were defined by the presence of a peak in at least 2 out of 3 biological 
replicates. High confidence peaks were selected using an in house bedtools script and used 
for all further analysis. All further venn diagrams comparing the RACE-Seq peaks between 
cell lines were performed using the ChipPeakAnno package in R and lists of overlapping and 
specific peaks were created using the intersect function in bedtools (Zhu, Gazin et al. 2010). 
Annotation of repeat elements also made use of the bedtools intersect function overlapping 
the datasets with the Repeat Masker annotation track obtained from UCSC genome browser. 
The clustering of RACE data between cell lines was carried out by creating a matrix of the 
number of peaks shared between each pair of cell lines using the ChipPeakAnno package in 
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R. To compare these binary datasets the Dice index coefficient was calculated for each 
pairwise comparison in the context of the entire population and clustering was carried out as 
previously described using the heatmap.2 function in the gplots package of R.  
Annotation of the genomic regions in which the active LTRs (RACE peaks) resided was 
performed using the annotatePeaks function of Homer. This function was also used to create 
the average profile plots by using the –hist parameter to plot average RNA-Seq tag counts 
within 20 bp bins 250 bp around the RACE peaks.  
Closest genes to RACE peaks were identified using bedtools closest and a hg19 gene 
annotation reference. To determine closest genes in the same orientation and on the same 
strand the expressed LTR strand was first determined using bedtools intersect with the ‘–
wao’ parameter to obtain strand annotation form the repeat masker annotation. The closest 
genes which shared the same strand as the active LTR were then annotated using bedtools 
closest with the ‘-s -t first -iu -D a’ parameters.  
Finally supervised clustering of the individual LTRs was performed by concatenating high 
confidence RACE peaks identified in all cell lines and merging any which overlapped using 
bedtools merge. The newly defined set of peaks were annotated for their presence or 
absence in each of the sets of high confidence peaks from the cell lines and these were then 
sorted based on which cell lines the peaks were shared in. The resulting clusters were 
plotted as a heatmap using the heatmap.2 in the gplots package of R and carrying out 
hierarchical clustering of the overall LTR activation pattern in each cell line.  
2.9.6. LTR presence by gene expression fold change 
Pairwise RNA-Seq datasets were ranked by log2 FPKM fold change, as defined as FC=(log2 
sample A FPKM+1)/(log2 sample B FPMK+1) to avoid dividing by 0, with all genes ranked 
accordingly. Separately, LTRs identified via RACE-Seq were annotated to the closest gene 
using bedtools closest –a <LTR peak file.bed> -b hg19_refGene.bed -t first as parameters 
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(Quinlan and Hall 2010). LTR presence for all genes was thus computed by performing a left 
outer join of all genes and genes annotated as closest to LTR peaks via the merge function 
of R, using merge(<all genes sorted by log2 FPKM fold change>, <gene list of annotated LTR 
peak file>, all.x=T), then replacing all matches with the value 1 and NULL values by 0 in the 
column originating from the gene list of the annotated LTR peak file. Resulting files were 
subsequently written as text files via write.table in R, then visualised and saved as heatmap 
images using Java TreeView (Saldanha 2004). 
 
(Buenrostro, Wu et al. 2015) 






3.1. The Hodgkin’s Lymphoma transcriptional network has a global impact on 
chromatin structure and gene expression. 
3.1.1. Hodgkin’s Lymphoma displays a unique gene expression pattern 
It is known from many studies that the HRS cells of Hodgkin’s Lymphoma (HL) have a very 
different gene expression pattern to cells of the B-Cell lineage with loss of B cell receptor 
expression and gain of a number of other factors required for cell survival (Schwering, 
Brauninger et al. 2003). The majority of published genome-wide HL expression data is based 
on micro-array technology which has limited utility. To enable us to investigate the use of 
alternative promoters (including LTRs), splicing patterns, quantitative gene expression 
patterns in HL we used RNA-Seq technology. RNA-Seq was performed in duplicate, on 3 HL 
cell lines (L428, L1236 and KM-H2) and 2 control cell lines, Reh; a B-cell leukaemia 
(Rosenfeld, Goutner et al. 1977) and Namalwa; a Burkitt’s lymphoma (Klein, Dombos et al. 
1972). The RNA-Seq duplicates were validated by calculation of linear regression producing 
R2 values between 0.97 and 0.87 (Figure 3.1). The slight level of variation seen between 
replicates of the HL cell lines compared to the control cell lines is likely caused by a number 
of gene with unstable expression due to the global deregulation of gene regulation. This 
probably also accounts for the variation in cell size, adherent properties and other phenotypic 




Figure 3.1 High level of correlation between biological replicates of RNA-Seq  
Comparison of RNA-Seq biological replicates from 2 control cell lines (Reh and Namalwa) 
and 3 HL cell lines (L428, L1236 and KM-H2). Log2 FPKM values for each gene with an 
FPKM of at least 1 were plotted and linear regression calculated to showing a high similarity 
between replicates. 
 
To illustrate the variation in gene expression between the cell lines a pairwise Pearson 
correlation was calculated between the FPKM values. Hierarchical unsupervised clustering of 
these correlations showed that the 3 HL cell lines cluster together and the 2 control lines 
cluster also cluster together but away from the HL cell lines (Figure 3.2). The clustering also 
showed heterogeneity between the HL cell lines, with L428 clustering further away from 
L1236 and KM-H2. The L428 cell line also has the least correlation with the control cell lines 





Figure 3.2. Correlation clustering of gene expression patterns of the HL and non-HL 
cell lines  
Pearson correlation of gene expression patterns determined by RNA-Seq and clustered by 
hierarchical unsupervised clustering. The HL cell lines (L428, L1236 and KM-H2) cluster 
independently to the control cell lines (Reh and Namalwa) and L428 clusters further away 
from the other HL cell lines indicating heterogeneity between the HL cell lines. 
To further validate the global gene expression data of the different cell lines we assessed 
gene expression of a panel of genes known to be upregulated in HL compared to normal B-
cells (Kreher, Bouhlel et al. 2014) (Figure 3.3). The panel was made up of 10 pro-
inflammatory cytokines and 3 transcription factor genes known to be involved in the survival 
and proliferation of HL. The analysis showed expression of the entire panel of genes in the 
HL cell lines and HL specific expression of IL13, IL6 and CSF2. The Reh and Namalwa cell 
lines also showed expression of CCL5, IRF5, JUNB, CCR7, LITAF, LTA, IRF4 and TNF. 
Additionally a low level of expression of CXCL10 and CXCL11 was also seen in Namalwa. 
The expression of many of these genes in the control cell lines, many of which are cytokines 
involved in immune and inflammatory response, is not surprising as both cell lines are 
derived from cancers, most of which have some degree of inflammatory signature. The 
expression pattern of these genes shows a large amount of variation between the 3 HL cell 
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lines. This could be partially down to experimental variation although the biological replicates 
should help to avoid this. Variation between the cell lines is also to be expected as they 
originate from patients with different genetic backgrounds.  
 
Figure 3.3 Gene expression level of a panel of 13 genes with a known involvement in 
HL 
Mean Log2 FPKM values obtained from RNA-Seq replicates in HL and control cell lines were 
plotted for each of a panel of 13 HL associated genes (Kreher, Bouhlel et al. 2014) . 
Expression of all of the genes is observed in the HL cell lines, 3 of which show no expression 
in the control cell lines (IL13, IL6 and CSF2). The other genes all have expression in the 
control cell lines but in most cases at a lower level to that seen in the HL cell lines. 
To validate the RNA-Seq data, qPCR primers were designed against the same panel of 
genes using RNA from independent experiments. Overall the gene expression measured by 
qPCR showed a similar pattern with the entire panel being expressed in the HL cell lines 
(Figure 3.4). The qPCR results showed little expression of all but LITAF, LTA and TNF in the 
control cell lines. The relative levels of expression between the cell lines vary from what is 
seen in the RNA-Seq data. It is likely this is the result of a combination of variable primer 
efficiency, normalisation between the cell lines and the small region of the genes which are 




Figure 3.4. Gene expression of a panel of 13 genes with a known involvement in HL 
measured by qPCR 
Gene expression relative to housekeeping gene GAPDH of a panel of 13 genes associated 
with HL in 3 HL cell line (L428, L1236 and KM-H2) and 2 control cell lines (Reh and 
Namalwa). Expression of all genes is observed in the HL cell lines although some are only 
present at low levels. Expression of LITAF, LTA and IRF4 is also observed in the control cell 
lines.  
 
3.1.2. B-Cell specific gene expression is downregulated and pro-inflammatory genes 
are upregulated in HL. 
We next wanted to assess how the global de-regulation of gene expression seen in HL 
impacted on the pathways and processes within HL cells. To achieve this any genes which 
were at least 2-fold up- or down-regulated compared to the control cell lines underwent Gene 
Ontology (GO) analysis (Figure 3.5). The resulting GO terms showed some variation 
between the HL cell lines which is to be expected from the variation in gene expression 
between the cell lines.  
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All 3 HL cell lines show a down-regulation of genes involved in transcription and 
transcriptional regulation. Many genes which are involved in maintaining the B cell gene 
expression programme are down-regulated such as BCL6, EBF1, PRMT5, MYC and PAX5. 
CBFA2T3 and FOXO1 (Lamprecht, Walter et al. 2010, Xie, Ushmorov et al. 2012). A large 
number of the ZNF family of transcription factors are also down-regulated, many of which are 
known to be associated with the transcriptional regulation of repeat elements (see 1.3.17). 
The down-regulation of these genes involved in transcriptional regulation contributes to the 
overall deregulation of gene expression seen in HL through the loss of B cell specific 
transcriptional regulation.  
The GO terms also highlight genes associated with chromatin regulation including, 
nucleosome assembly and chromatin silencing as being down-regulated. The down-
regulation of these genes which are mainly histone coding may result from the slower cell 
cycle of HL cells compared to the control cell lines. 
There was also a significant down-regulation of B-cell specific genes including those involved 
in B cell receptor signalling, V(D)J recombination and B-cell differentiation.  These become 
particularly prominent when combining the downregulated genes from all HL cell lines. The B 
cell signalling genes included known cell surface markers of the B cell lineage including 
CD19, CD38, CD79A and CD79B.  A down-regulation of the RAG1 and RAG2 genes both of 
which are important for V(D)J recombination in B cells was also observed. The decrease in 
expression of all of these genes shows the overall move from B cell lineage gene expression 
to a HL specific expression pattern.  
The GO analysis also showed an upregulation of genes associated with cell adhesion and 
inflammatory and immune responses including response to cytokines and signal 
transduction. These ontology groups incorporated 172 up-regulated genes including all of the 
HL associated cytokines used in the expression validation panel (Figure 3.3).  Based on the 
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known phenotype of HL cells, producing high levels of inflammatory cytokines and 
chemokines and producing an inflammatory microenvironment the upregulation of immune 
and inflammation genes is not entirely surprising. 
There was also some up-regulation of genes associated with positive regulation of 
transcription and cell proliferation. Many of these genes were shared with the inflammatory 
response groups including CXCL10, TNFRSF11A, CSF2 and TNFSF13B.  There were also 
many transcription factors up-regulated including SOX9, RUNX2, GATA3, GATA4, JUN and 
JUND. The up-regulation of these factors represents a change in the regulation of gene 
expression from the B cell lineage with a HL specific regulatory network. 
There was also evidence for an up-regulation of genes associated with negative regulation of 
apoptosis. The combination of this with up-regulation of transcription factors and growth 
factors may be at least in part responsible for the survival of HL cells after escaping 
apoptosis in the germinal centre. The up-regulated features appeared to remain common 









Figure 3.5. Gene Ontology analysis shows a down-regulation of genes associated with 
B cell processes in HL cell lines and an up-regulation of inflammatory and immune 
response genes. 
Gene ontology analysis was carried out on genes which were at least 2-fold up- or down-
regulated in HL cell lines (L428, L1236 and KM-H2) compared to 2 control cell lines (Reh and 
Namalwa). The gene ontology groups show the top 15 GO terms in each cell line for either 
up- or down-regulated genes. (A) HL cell lines show a downregulation of genes associated 
with transcription and chromatin regulation and B cell signalling and (B) an up-regulation of 
cytokine signalling and inflammatory response genes. When the list of down-regulated genes 
from all 3 HL cell lines was combined, B cell receptor signalling became the most down 
regulated group of genes (A - All HL). 
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To further examine the de-regulated pathways within the HL gene expression programme, 
KEGG pathway analysis was carried out to determine how the overall changes in gene 
expression impact on the functions of the HL cells (Figure 3.6). This analysis again showed a 
down-regulation of genes involved in B cell receptor signalling and primary immunodeficiency 
and a move of gene expression away from the B cell programme. The upregulated pathways 
give a very clear picture of the HL cellular environment and processes. These include 
cytokine receptor interaction, TNF signalling, NF-κB signalling and several other pathways 
involved in an inflammatory immune response. Again this supports the findings from the GO 
analysis and the contribution of gene expression to the cells inflammatory phenotype. 
 
Figure 3.6. KEGG pathway analysis of up- and down-regulated genes in HL 
The genes in all 3 HL cell lines (L428, L1236 and KM-H2) which are up and down regulated 
at least 2-fold compared to control cell lines (Reh and Namalwa) were subjected to KEGG 
pathway analysis. This analysis showed a down-regulation of genes in the B cell signalling 
pathways and an upregulation of inflammatory and immune signalling genes. 
 
To understand how the identified KEGG pathways may be interacting, a gene expression 
network of KEGG pathways was produced showing the shared genes between pathways. 
This revealed that the gene expression programme was very much centred on cytokine-
cytokine receptor signalling upregulation and interaction with other inflammatory signalling 
pathways including TNF, JAK-STAT and NF-κB (Figure 3.7). 
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It also showed the upregulation of many genes involved in transcriptional deregulation in 
cancer including PLAU, SIX1, SIX4, CCR7 and CSF2 which have all been previously 
associated with HL (Mathas, Hinz et al. 2002, Kuppers 2009, Nagel, Meyer et al. 2015, de 
Oliveira, Kaergel et al. 2016). We also observed the down-regulation of genes related to B 
cell signalling and primary immunodeficiency. However, the majority of genes related to 
primary immunodeficiency are also linked to B cell signalling and those that aren’t such as 
RAG1 and RAG2 are involved in B-cell development. This analysis identifies a number of 
other genes which are deregulated in HL and may pose previously undiscovered pathological 





















Figure 3.7. Network of up- and down-regulated genes in HL and their involvement in KEGG pathways 
The results of KEGG pathway analysis linking 2-fold dysregulated genes in HL cell lines (L428, L1236 and KM-H2) to control cell lines (Reh 
and Namalwa were plotted as a network to show genes which are shared between multiple pathways. Orange represents genes which are up-
regulated in at least one HL cell line compared to the control cell lines (Reh and Namalwa) and blue represents genes which are down-
regulated. The pie charts and colour of the lines for each pathway indicate the proportion of the dysregulated genes which are up- (orange) or 
down-regulated (blue) in that pathway. 
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Characterisation of cis-regulatory elements driving Hodgkin’s Lymphoma–specific gene 
expression - the HL transcriptional programme is driven by the transcription factors NF-
κB and AP1. 
Kreher et al. 2014 published an analysis using low resolution DNase-Seq to identify the cis-
regulatory regions driving the unique gene expression profile of HL and comparing it to non-HL 
cells. This study identified enriched motifs within HL-specific DHS and used functional assays to 
identify IRF5 as a major regulator of the HL phenotype. However, this study was unable to 
identify the full complement of HL-specific transcription factors binding to HL-specific DHS. We 
therefore carried out DNaseI-Seq to identify regions of open chromatin, highlighting the 
presence of regulatory regions bound by transcription factors in HL cell lines, L428 and KM-H2 
and control cell lines Reh and Namalwa (Figure 3.8). To test whether these sequences were 
actually occupied, we ran our DNase-Seq libraries at high sequencing depths to be able to 
conduct high resolution digital foot-printing experiments which identify transcription factor 
binding motifs. 
 
Figure 3.8 DNaseI-Seq data UCSC Genome Browser screenshot 
Screenshot of UCSC genome browser showing DNaseI-Seq and RNA-Seq data at the TBP 
promoter in the Reh, L428 and KM-H2 cell lines demonstrating the low background of the high 
quality DNaseI-Seq data. 
The sensitivity of open chromatin to nucleases was first demonstrated by Weintraub and 
Groudine, (1976) which lead to the development of genome wide DHS mapping (Weintraub and 
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Groudine 1976, Boyle, Davis et al. 2008). DNaseI hypersensitive sites have been shown to 
represent genomic elements including   enhancers, promoters, locus control regions and 
insulators (Cockerill, Bert et al. 1999, Cockerill 2011). 
The sequences existing as regions of open chromatin in each cell line were clustered and 
showed a high correlation between L428 and KM-H2 and also a high correlation between Reh 
and Namalwa (Figure 3.9). The HL cell lines again clustered separately to the control cell lines 
and showed little correlation with them, most of which is likely to be associated with shared 
housekeeping genes. This data confirms Kreher et al and demonstrates that HL-specific gene 
expression is driven by a specific set of cis-regulatory elements. 
 
 
Figure 3.9. Correlation of HL and control cell lines based on chromatin accessibility. 
Regions hypersensitive to DNaseI, indicating regions of open chromatin, were determined by 
DNaseI-Seq. The sequences found in each of the cell lines were combined and the Pearson 
correlation of the tag counts for each site in each cell line was calculated. The correlation was 
then clustered by hierarchical unsupervised clustering showing that the HL cell lines (L428 and 
KM-H2) cluster together separately from the control cell lines (Reh and Namalwa).  
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As of today, only very limited information exists regarding the genome-wide binding activity of 
transcription factors involved in driving the unique expression profile in HL, most of which 
centred on NF-κB (de Oliveira, Kaergel et al. 2016). Most importantly, it was largely unclear how 
such factors would interact with each other. To understand the transcriptional regulation network 
in HL it was therefore important to establish which transcription factors were likely to be bound 
in HL-specific cis-regulatory regions. This information was determined by analysing our high-
read depth DNAse-Seq data from Reh, L428 and KM-H2 cells using the Wellington algorithm to 
identify regions which were likely to be bound by transcription factors at the point of DNaseI 
digestion.  
The binding of transcription factors to DHS’s can be identified due to their presence protecting 
the DNA from cleavage. Piper et al. (2013) observed that in high read-depth DNaseI-Seq data a 
strand imbalance of aligned reads is present when a DHS is bound by a transcription factor. The 
Wellington algorithm is able to identify DHS’s with bound transcription factors by analysing 
testing for this strand imbalance and has been shown to accurately predict foot-printed DHS’s 
(Piper, Elze et al. 2013). 
Using Homer (See 2.9.4) analysis of motif enrichment within foot-printed regions was performed 
to determine the transcription factors most likely to be producing the footprint. This analysis 
showed an enrichment of CTCF, AP1, NF-κB, NFY, SP1 and IRF in HL specific footprints. 
Analysis of the Reh specific footprints showed enrichment of NFY, SP1 and CTCF motifs which 
highlights AP1, NF-κB and IRF as the HL specific motifs (Figure 3.10). This result suggests that 
AP1, NF-κB and IRF have a significant involvement in the deregulated gene expression 
programme in HL and also links to the inflammatory signatures observed in the GO and KEGG 






Figure 3.10. Transcription factor binding motif enrichment in DNase-I footprints in L428, 
KM-H2 and Reh 
Digital foot-printing analysis was carried out on high read-depth DNaseI-Seq data from L428, 
KM-H2 and Reh cell lines using the Wellington algorithm (Piper, Elze et al. 2013). This method 
identifies regions with likely transcription factor binding. A motif enrichment analysis was then 
carried out on cell line specific foot-printed regions which showed AP-1, NF-κB and IRF were 
enriched at distal foot-printed DHS’s in the HL cell lines. This indicates that these transcription 
factors likely play a role in HL gene expression. 
 
To assess the co-localisation of motifs within foot-prints are therefore potentially the co-
localisation of transcription factors which may interact a bootstrapping analysis was carried out. 
This analysis determines the co-localisation of motifs, selected from the motif enrichment 
analysis, within 50 bp of each other by comparing it to what would be expected by random 
based on the background of the sample. This showed that the control of gene expression in HL 
is dependent on AP-1 and NF-κB which have motifs co-localising with each other in addition to 
many other transcription factors known to be drivers of gene expression in HL (Figure 3.11).  
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It was also noted that motifs for the B cell specific transcription factor Pax5 were not enriched in 
the boot strapping analysis indicating its lack of involvement in HL. This is to be expected as 
Pax5 is an important transcription factor in B cell signalling and expression is lost in HL (Figure 
3.12). This analysis was also repeated for KM-H2 specific footprint motifs and showed a similar 






Figure 3.11. The transcriptional programme in HL cell lines is driven by the transcription 
factors NF-κB and AP-1 
Bootstrapping analysis was performed on L428 and KM-H2 specific footprints in comparison to 
all Reh footprints to determine the co-localisation of transcription factor binding motifs. This 
showed a statistically significant co-localisation of the AP-1 and NF-κB motifs with many motifs 
of transcription factors known to be involved in HL. The implication of this was that the main 
transcription factors involved in the gene expression regulation in both HL cell line (L428 and 






Figure 3.12. PAX5 expression is lost in HL cell lines 
RNA-Seq Log2 FPKM values show a downregulation of PAX5 expression in the HL cell lines 
(L428 and KM-H2), compared to the control B cell lines (Reh and Namalwa). 
 
3.1.3. THE1B LTRs are more active in HL cell lines than control cell lines. 
Lamprecht, et al. (2010) showed that an active LTR of the THE1B sub-family was acting as a 
promoter for CSF1R in HL, demonstrating that the activation of an LTR can impact on gene 
expression in HL and be required for cell survival. If LTR activation was a genome wide 
phenomenon it could contribute to and account for some of the gene expression patterns seen 
in HL. To assess whether this may be the case, the RNA-Seq reads around annotated THE1B 
LTRs were plotted. This analysis showed an increase in reads originating from THE1B LTRs in 
all 3 HL cell lines when compared to the control cell lines (Figure 3.13). There was also some 
variation in the level of LTR activation within HL cells which could suggest there is more THE1B 
LTR activation in KM-H2 and L428 than in L1236. The overall background level of reads around 
the annotated LTRs was also higher the HL cell lines. This would suggest that at least a 
proportion of the active THE1B LTRs also have up and downstream transcripts meaning that 
they may be acting as bidirectional promoters. It is also possible that the upregulated LTRs 
could act as enhancers for other genes even in the absence of downstream reads.  This 
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increase in LTR activation could account for some of the changes in chromatin accessibility and 
gene expression seen in HL cells when compared to control cell lines. 
 
Figure 3.13. Intergenic THE1B LTRs are more active in HL cell lines than control cell lines 
Normalized RNA-Seq signals were plotted against intergenic THE1B LTRs annotated by repeat 
masker with reads centred on the LTR transcription start site and orientated by the annotated 
LTR direction. This analysis shows an increase in the overall level of transcription at LTRs in the 
HL cell lines (L428, L1236 and KM-H2) and also an increase in up- and down-stream 









3.2. HL cells display a global activation of long terminal repeat elements. 
3.2.1. CSF1R is expressed from an active THE1B LTR in HL cell lines 
Following the identification of an overall increase in THE1B LTR activity based on the RNA-Seq 
data from the HL cell lines we wanted to further investigate which THE1B LTR elements were 
active in HL compared to the control cell lines. Lamprecht, et al. (2010) showed expression of 
CSF1R from an upstream THE1B LTR in HL. To confirm whether this finding could also be seen 
in our assays, qPCR was carried out using primers designed in exon 2 and 3 of CSF1R to 
assess the level of gene expression and also in the THE1B LTR and exon 2 of CSF1R to 
assess expression originating from the LTR (Figure 3.15). The qPCR results using the exonic 
primers showed a significant increase in expression of the CSF1R gene in the HL cell lines 
compared to the control cell lines (Figure 3.14). This expression originated from the LTR as 
there was also a significant increase in expression occurring from the THE1B LTR. The LTR 
transcript appears lower than the exon 2/3 transcript however this is likely to be an artefact of 
qPCR primer efficiency.  
This experiment confirmed the presence of an active LTR upstream of CSF1R which has a 
transcript running into the second exon. As well as confirming the finding by Lamprecht et al., 
2010 this established the use of qPCR with primers designed for transcripts between the LTR 
and gene body as a viable method for experiments assaying the molecular mechanisms of 




Figure 3.14. CSF1R is expressed from an upstream THE1B LTR in HL cell lines 
qPCR gene expression analysis was carried out using primers designed in exon 2 and 3 of 
CSF1R and in the upstream THE1B LTR and exon 2, the resulting values were normalised to 
GapDH expression. The primers within exon 2 and 3 and the primers within the LTR and exon 2 
both showed a significant up-regulation (P<0.002) of expression in all 3 HL cell lines (L428, 
L1236 and KM-H2) when compared to control cell lines (Reh and Namalwa). N=3, Error bars 
show standard deviation. 
 
3.2.2. 5’ RACE-Seq can be used to identify active THE1B LTRs. 
The analysis of RNA-Seq reads around annotated THE1B LTRs showed a genome-wide 
activation of LTRs in HL cell lines. To identify which particular LTRs were active genome-wide I 
developed a novel approach based on 5’ Rapid Amplification of cDNA Ends (5’ RACE) (See 
2.4.3). The 5’ RACE technique works by the addition of a known RNA adaptor sequence to the 
5’ end of all transcripts, effectively tagging the transcription start site (TSS). Following 
conversion to cDNA by reverse transcriptase a primer complementary to the adaptor sequence 
can be used along with a second primer which is specific to a region downstream of the TSS in 
a PCR reaction to amplify this fragment. In the traditional 5’ RACE protocol this could then be 
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used to determine the size of the fragment and therefore the distance between the TSS and 
downstream region. The fragment could also be sequenced using Sanger sequencing to 
determine the sequence of the region between the TSS and downstream primer.  
To enable all THE1B LTRs to be captured by this method a primer was used which was 
designed against the most homogenous region of the LTR sequence which is shared between 
many of the THE1B LTRs (Figure 3.15 & Figure 2.3). This technique allowed many active 
THE1B LTRs to be identified in a single assay effectively producing a library of active THE1B 
LTRs and was initially performed in the Reh, L428 and KM-H2 cell lines.  
 
Figure 3.15. Scheme depicting CSF1R transcription start sites and 5' RACE strategy 
 Schematic showing the 3 potential transcription start sites of CSF1R in different cellular 
contexts. The RACE-Seq strategy is also shown, amplifying fragments between the TSS and a 
promoter designed within a conserved region of the THE1B LTR. 
To initially examine the validity of the assay and to deconvolute this pool of active LTR DNA 
sequences we blunt end ligated isolated fragments into the pBluescript vector allowing 
individual clonal populations of bacteria to be obtained each containing a single LTR DNA 
sequence (see 2.4.2) This DNA was extracted from a number of clones and Sanger sequenced. 
Alignment of these sequences to the human genome showed that 6 out of 8 positive clones 
uniquely aligned to LTR elements. These included three THE1B elements and one MALT1A 
element from the L1236 cell line, one THE1B element from the L428 cell line and surprisingly 
one THE1D element from the Reh cell line (Table 3.1).  
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These cloning experiments not only validated the technique for identifying active LTRs but also 
showed evidence of active THE1B LTRs in HL other than the previously identified LTR. The 
clone from the Reh cell line showed that there was also clearly a level of LTR activation present 
in other B cell lines as well as the HL cell lines. The identification of a THE1D element in the 
Reh cell line and a MALT1A element in the L1236 cell line also demonstrated that the THE1B 
primer was able to detect other related members of the MalR family of LTRs.  
Table 3.1 Multiple active MalR family LTRs can be identified using 5' RACE and a THE1B 
primer 
 Sanger sequencing and alignment to the human genome using BLAT shows that 5’ RACE 
fragments produced by amplification using a primer designed to the THE1B LTR can be 
uniquely aligned to different regions of the genome. 
Cell Line Total Number of 
Positive Clones 
Repeat Element Genomic Position 
Reh 2 THE1D chr8:16314495-16314551 
L428 1 THE1B chr8:78849291-78849333 
L1236 5 THE1B chr2:155062150-155062203 
THE1B chr4:38552326 -38552386 
MLT1A chr5:106774949-106774968 
 
We next wanted to make the 5’ RACE assay truly genome wide to identify the full complement 
of active TH1B related LTRs in the HL cells. To achieve this we used Ilumina’s short read next 
generation sequencing platform allowing for all of the LTR fragments in the pool of amplified 
RACE DNA to be sequenced simultaneously. The sequences were then uniquely aligned to the 
human genome and were uploaded onto the UCSC genome browser as well as being subjected 
to numerous downstream analyses. To initially validate that the aligned reads were identifying 
active THE1B LTRs the presence of an active LTR at CSF1R was confirmed which showed a 
peak in all 3 HL cell lines and no peak in the control cell lines (Figure 3.16). The identification of 




Figure 3.16. The THE1B LTR which acts as a promoter for CSF1R in HL can be detected 
by RACE-Seq 
Alignment of RACE-Seq fragments to the human genome displayed on the UCSC genome 
browser. The alignments produce a peak at the THE1B LTR (annotated by the Repeat Masker 
track) upstream of the CSF1R gene. This peak is present in all 3 HL cell lines (L428, L1236 and 
KM-H2) and absent in the 2 control cell lines (Reh and Namalwa). The black bars below the 
aligned reads represent peaks called by MACs (See 2.9.5). 
 
 
3.2.3. THE1B RACE-Seq identifies other associated MalR sub-families of repeats. 
Before commencing further analyses and experiments we wanted to ensure that the RACE-Seq 
technique identified active LTRs reproducibly in each cell line. To this end 3 independent 
replicates were performed in each of the 5 cell lines. Overlap of the replicates showed that only 
between 7% and 30% of identified peaks were shared between all 3 replicates (Figure 3.17). 
We hypothesised that the reason for this low reproducibility, besides technical variation in the 
processing of samples, could have been the fact that we were using a partly degenerate 
consensus primer for the first amplification. Variation in sequence of the related THE1B family 
members would display weaker binding of the THE1B primer and may not have always been 
detected. However, selecting only LTRs which were associated with THE1B elements for 
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analysis did not improve the replicate overlap. Another possibility was that the less active LTRs 
could be harder to detect and therefore may have been missed in replicates, however, again 
selecting the peaks with highest read counts again did not improve the overlap. We believe that 
the reason for replicate variation was most likely down to the binding nature of the THE1B 
primer. The experimental procedure was optimised to allow annealing of the primer with 
mismatches to capture the widest array of MalR active LTRs possible. The sequencing data 
showed that overall only 10% of peaks had no mismatches in the primer sequence, half of the 
sequences had up to 5 mismatches and the remainder had up to 8 (Figure 3.18). This means 
that because of the clonal nature of the PCR reaction used during RACE the variation of 
annealing in the first PCR cycle dictates the LTRs which are detectable at the final stage, 
introducing a stochastic element into the assay. The LTRs shared by all replicates are most 
likely those which the primer anneals to with fewest mismatches.  
Although the proposed theory for replicate variation would suggest that all identified peaks are 
genuinely active LTRs, we used a conservative approach of only carrying out further analysis on 





Figure 3.17. Overlap of biological replicates of LTRs detected by RACE-Seq 
Peak regions representing active LTRs were determined from RACE-Seq fragment alignments 
and overlaps of the peaks between 3 biological replicates for each of the 5 cell lines were 
performed. The areas highlighted in blue represent those peaks which are shared by at least 2 
replicates in a cell line (p<0.01) and are the peaks which were selected for further downstream 
analysis.  
 
Figure 3.18. The THE1B primer anneals with multiple mismatching bases during the 
RACE-Seq PCR 
The number of mismatches between the primer sequence and the identified active LTRs was 
determined by comparison of the primer sequence to the genome transcript aligning to the 
primer sequence in the vicinity of the aligned fragments. The overall cumulative percentage of 
RACE peaks based on the number of mismatches to the primer sequence was plotted showing 
that up to 5 mismatches were present in 50% of identified RACE peaks and over 5 mismatches 
were present in the remainder. 
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From the original cloning experiments we knew that the THE1B RACE primer was able to 
recognize and cause amplification of other associated members of the MalR family of LTRs. To 
determine the array of repeat elements in the RACE-Seq data, the aligned sequences were 
annotated to repeat elements using the hg19 RepeatMasker data. This annotation showed an 
array of MalR LTRs including, THE1B, THE1D, THE1C, THE1A, MSTA and MSTB. A 
predominance of THE1B elements was seen in all cell lines, however with a lower overall 
percentage in the control cell lines (33%) as compared to the HL cell lines (58%). As the primer 
is based on the THE1B sequence it is expected that THE1B LTRs would primarily be observed 
and it is likely that the full array of other active MalR LTRs is not captured. The lower proportion 
of THE1B activity in the control cell lines could be related to a different activation mechanism 
resulting in both a smaller number and different types of repeat elements being active (Figure 
3.19). This analysis confirmed the activation of many MalR LTRs throughout both the HL and 





Figure 3.19. RACE-Seq using a THE1B primer identifies a wide range of MalR repeat 
elements 
Overlap of THE1B RACE-Seq peaks in HL and control cell lines with the Repeat Masker hg19 
annotation shows a prevalence of THE1B elements but also a number of other repeat element 
types of the MalR family in each of the HL and control cell lines. Averages across all HL and all 
control cell lines also show a similar pattern. 
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3.2.4. HL cell lines have a unique activation pattern of LTRs 
The alignment data from the RACE-Seq experiments showed an activation of LTRs in both the 
HL and control cell lines. To determine whether a HL specific pattern of LTR activation existed 
we overlapped the peaks from all 3 HL cell lines with the peaks from the 2 control cell lines. This 
analysis showed the presence of 2822 HL specific active LTRs and 340 active LTRs specific to 
the control cell lines. The presence of a HL unique pattern of LTR activation suggests LTRs may 
play a significant role in the regulation of the HL genome. The control cell lines unique LTR 
activation also suggest that LTRs may play a role in these cell lines, however, at a lower level 
than in HL.  
 
Figure 3.20. HL and control cell lines have a unique pattern of LTR activation 
Overlap of active LTR sequences detected by RACE-Seq in 3 HL cell lines (L428, L1236 and 
KM-H2) (green) and 2 control cell lines (Reh and Namalwa) (Red). A unique LTR activation 




To further investigate the pattern of LTR activation in HL, the RACE-Seq peaks from active 
LTRs in each of the HL cell lines were compared. Although there was overlap, this particular 
analysis showed a number of unique active LTRs in each of the HL cell lines with 411 active 
LTRs shared between all lines. Given the partly stochastic nature of the assay the extent of the 
overlap is likely to vary, nevertheless based on hypergeometric analysis  there was significant 
variation between the cell lines (p<0.01). This feature may have developed as a result of them 
being immortalised cell lines that have acquired mutations through many rounds of replication. 
However, it is also possible that all 3 cell lines represent different subtypes of HL which may 
have different survival and proliferation mechanisms promoted by the many active LTRs.  
 
Figure 3.21. Comparison of active LTRs in three HL cell lines  
Overlap of the active LTRs detected by RACE-Seq in each of the 3 HL cell lines shows a shared 
group of 411 active LTRs between all HL cell lines and also a large group of unique peaks for 
each cell lines representing a unique LTR activation pattern. 
118 
 
To visualise the overlap of active LTRs between each of the 5 cell lines a DICE index score was 
calculated for each pair showing the similarity in LTR activation between each pair. This method 
allowed for the correlation between the binary data sets (presence or absence of active LTRs) 
to be clustered to determine the relationship between the cell lines based on LTR activation 
(Figure 3.22). The clustering showed clearly that the control and HL cell lines clustered 
separately and that the HL cell lines clustered together, confirming a specific LTR pattern in HL 
cells as compared to non-HL cells. Based on LTR activation the L1236 and L428 cell lines 
cluster more closely together than with KM-H2. It is possible this could be an artefact of 
sequencing read depth with a higher read depth in KM-H2 resulting in the discovery of more 
active LTRs which may have been missed in the L428 and L1236 cell lines. Although the Reh 
and Namalwa cell lines cluster together the similarity based on DICE index is not as high as 
between the HL cell lines. As both of the control cell lines are derived from patients with different 
diseases, B cell leukaemia (Reh) and Burkitt’s Lymphoma (Namalwa), this may point towards a 




Figure 3.22. HL cell lines correlate based on LTR activation determined by RACE-Seq 
DICE index scores were calculated for each pair of cell lines based on active LTR presence 
identified by RACE-Seq allowing for correlation of LTR activation between the cell lines to be 
determined. Clustering analysis shows that the HL cell lines (L428, L1236 and KM-H2) cluster 
together and the control cell lines (Reh and Namalwa) also cluster together but separately from 








3.3. LTR activation contributes to global deregulation of gene expression in HL cell 
lines.  
We know from previous studies and our own RNA-Seq data that HL cells have a vastly different 
gene expression pattern to cells from the B cell lineage and that they cluster separately based 
on gene expression (Stein, Marafioti et al. 2001, Torlakovic, Tierens et al. 2001) (Figure 3.2).  It 
has been shown in many studies that LTRs can act as promoter and enhancer elements (See 
1.3.13), therefore the genome-wide activation of LTRs observed in HL could be at least in part 
responsible for the HL gene expression pattern. Lamprecht, et al. 2010, showed that CSF1R in 
HL is expressed from an active LTR promoter, so we wanted to determine whether other genes 
in HL were also being expressed from active LTRs. 
3.3.1. Active LTRs are mainly located in intergenic and intronic regions 
To elucidate the overall impact of active LTRs we firstly determined the genomic regions in 
which active LTRs could be detected. This allowed us to establish the proportions of active 
LTRs which were already annotated as promoters and exonic elements and whether there was 
a bias of LTR activation to specific regions.  
All cell lines showed a predominance of active intergenic LTRs, with an average of 63% in the 
HL cell lines and 56% in the control cell lines (Figure 2.22). This finding indicated that the active 
LTRs were mainly located in regions, which have potential to act as upstream promoters for 
genes. A large proportion of the active LTRs were also intronic, an average of 29% in the HL 
cell lines and 24% in the control cell lines. As in the case of CSF1R, these LTRs may also be 
acting as alternative promoters for shorter isoforms of genes either expressing an additional 




The percentages of intergenic and intronic active LTRs are comparable to the overall 
distribution of all MaLR family LTRs (Figure 3.23). Notably the promoter and exon annotated 
LTRs were observed at a higher percentage in the active LTRs in HL cell lines and to an even 
greater extent in the control cell lines. The overall bias towards LTRs being located in intergenic 
regions is most likely due to insertional bias. It has been reported in a number of studies that 
viral integrations into the genome are more prevalent in open chromatin and at regions with 
active histone marks (reviewed by (de Jong, Wessels et al. 2014)), therefore a bias towards 
LTR integration within intergenic regions would be expected. The active LTRs in intergenic 
regions identified in HL which reside in active genes may also be examples of LTRs which have 





Figure 3.23 Active LTRs are primarily located in intergenic and intronic regions in HL and 
control cell lines 
Active LTRs identified by THE1B RACE-Seq in the HL and control cell lines were annotated to 
genomic regions, this showed that active LTRs are mainly intergenic and intronic. Annotation of 
all MaLR family LTRs annotated by Repeat Masker showed a similar distribution of LTRs in the 
intergenic and intronic regions and far less in the promoter and exonic regions than was seen in 
the HL and control cell lines. 
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3.3.2. Active LTRs in HL act as alternative promoters 
We next wanted to establish whether the active LTRs were acting as promoters based on 
histone marks. It is known that most actively transcribed promoters are marked with H3K4me3 
(Liang, Lin et al. 2004). To study this in our genome-wide LTR activation datasets we performed 
chromatin immunoprecipitation with sequencing (ChIP-Seq) for H3K4me3, in the L428 and Reh 
cell lines. The ChIP signal around active LTRs was overall very low, however, overlaps of 
H3K4me3 peaks with the RACE-Seq datasets for the corresponding cell lines showed that 
5.03% of Reh active LTRs and 11.86% of L428 active LTRs corresponded to genomic regions 
containing H3K4me3.  This finding would suggest that only a small proportion of the active LTRs 
are active promoters and the remainder may be acting as enhancers which may have different 
histones marks. Although the presence of histone marks other than H3k4me3 is a possibility for 
some active LTRs the overlaps performed may be an underestimate due to the difficulty of 
aligning ChIP-Seq data uniquely to repeat elements with shared sequence. The difference 
observed between the Reh and L428 cell lines may also indicate that a higher proportion of the 
active LTRs are acting as promoters in HL when compared to the control cell line.  
Finally to further confirm the activity of LTRs as alternative promoters we integrated the RACE-
Seq data with the RNA-Seq data to study the downstream transcripts originating from active 
LTRs. The nature of the RACE assay means that strand information is lost during library 
preparation. The disadvantage of this being that if an LTR is acting as a promoter the strand 
information would help to infer which nearby gene may be affected. It has however been shown 
in a number of studies that LTRs can act as bi-directional promoters.  
In the same way as ChIP-seq the alignment of RNA-Seq to repeat sequences is challenging, 
however as shown in figure 3.13 it is possible to detect active LTRs on a genome-wide basis . 
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To investigate the transcripts originating from the active LTRs strand information was inferred 
from the Repeat Masker annotation. 
RNA-Seq reads were centred on the active LTRs and a peak corresponding to the active LTR 
region was seen in the average profiles for all cell lines Figure 3.24. Further to this there was a 
notably higher level of downstream transcription in the HL cell lines suggesting that the LTRs 
are functioning as promoters. There was little evidence of transcripts in the anti-sense direction, 
however if only a small number of promoters were acting bi-directionally these transcripts could 
be masked in the profiles. 
 
Figure 3.24. Active LTRs produce downstream RNA transcripts 
Average profiles produced using RNA-Seq data centred on active LTRs identified by THE1B 
RACE-Seq and orientated based on LTR strand annotated by Repeat Masker show an 
increased level of transcription around active LTRs in both HL and control cell lines indicating 
the potential activity of LTRs as promoters.  
3.3.3. LTR activation in HL contributes to global deregulation of gene expression 
Following the observation that a proportion of LTRs were marked as promoters by H3K4me3 
and that on average active LTRs have downstream transcripts, in at least the HL cell lines, we 
wanted to determine the impact on expression of genes in the vicinity of active LTRs. To 
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achieve this we mapped the active LTRs in each cell line to their closest gene and plotted the 
expression of the genes in relation to the control cell lines (Figure 3.25) (See supplementary 
tables 1-6 for full list of closest genes). This analysis showed an increase of active LTRs close 
to the genes which are up-regulated in each of the HL cell lines compared to the control cell 
lines. The same pattern was not generally observed for the active LTRs specific to the control 
cell lines. There was however a slight increase in active LTRs close to the Reh and Namalwa 
specific genes when compared to the L428 cell line.  
 
Figure 3.25. Active LTRs cluster with up-regulated genes in HL cell lines 
Fold-change of gene expression obtained by RNA-Seq for each of the HL cell lines over each of 
the control cell lines was plotted. The presence of active LTRs closest to these genes was 
plotted based on the gene expression fold-change axis. This showed an increased proportion of 
active LTRs close to the genes up-regulated in HL compared to the control cell lines. The 





The presence of active LTRs close to genes specifically up-regulated in HL confirmed a 
genome-wide relationship between HL gene expression and LTR activation. The LTRs may be 
acting as promoters or enhancers for the up-regulated genes, however the enhancer effect is 
much harder to determine as many enhancers do not interact with the promoters of their nearest 
genes (Sanyal, Lajoie et al. 2012, Mifsud, Tavares-Cadete et al. 2015).  
Because the function of LTRs as promoters was easier to validate we focused on LTRs which 
were most likely to be acting as promoters assuming that the majority of LTRs acting as 
promoters would produce downstream transcripts on the same strand based on the average 
profiles (Figure 3.24). To study this on a gene specific basis we reassigned the closest genes to 
the LTRs based on the strand annotation from repeat masker. Correlation clustering of the 
expression of these genes close to active LTRs showed that the HL cell lines and control cell 
lines formed 2 separate clusters. The L428 cell line clustered further away from the L1236 and 
KM-H2 cell lines the same as when clustering the cell lines using expression of all genes 
(Figure 3.26). This finding implies that the action of LTRs as promoters of their nearest 
downstream gene is sufficient to differentiate between the cell lines and plays a significant part 




Figure 3.26. HL cell lines cluster based on expression of genes down-stream of active 
LTRs 
The orientation of active LTRs identified by RACE-Seq was inferred from annotation of LTR 
orientation by repeat masker. The closest genes downstream of active LTRs were annotated 
and the expression values obtained from RNA-Seq data. The expression of these genes was 
correlated by Pearson correlation and the result clustered. The clustering showed 2 separate 
groups for the HL and control cell lines based on expression of these genes. 
 
To understand how active LTRs influenced expression of individual genes and how this may 
contribute to the HL phenotype we manually curated the active LTRs using UCSC genome 
browser to observe changes in RNA expression around the active LTRs. Although this method 
is far from definitive as many active LTRs have very few reads associated with them in the 
RNA-Seq data it proved to be useful for identifying at least a proportion of the LTR driven 
transcripts without having to individually validate every active LTR by qPCR. The overall finding 
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of this analysis was that LTRs produced 4 different types of transcript: those originating from an 
upstream promoter or from an intragenic promoter as well as generating an RNA anti-sense to a 
protein-coding gene or as an un-annotated, intergenic long non-coding RNA. 
As an upstream promoter an LTR can either be solely responsible for the expression of the 
gene or increase the level of expression of a gene with an active native promoter. The NLRP1 
gene displayed an increase in expression from an upstream LTR in all HL cell lines. The THE1C 
LTR located ~35 Kb upstream of the native NLRP1 promoter was active in all HL cell lines and 
not active in the control cell lines. The LTR was in a DNaseI hypersensitive site and carried the 
H3K4me3 mark in the L428 cell line but not in the Reh cell line. The RNA-Seq data showed a 
clear read-through transcript linking the LTR to the first exon of NLRP1 (Figure 3.27). RNA-Seq 
data showed that NLRP1 was active in all cell lines, however, there was at least a 4-fold 
increase in expression observed between the Reh and HL cell lines and at least an 8-fold in the 
between the Namalwa and HL cell lines (Figure 3.28 A). To confirm that the transcript from the 
LTR shown by the RNA-Seq data was linked to the up-regulation of NLRP1 we performed a 
qPCR using primers designed in the LTR and second exon of NLRP1. The results confirmed 
expression of this transcript in the HL cell lines with the highest level in L428 and an absence of 




Figure 3.27. Intergenic LTRs act as alternative promoters in HL 
UCSC genome browser screen shot showing an active THE1C LTR only active in HL cell lines 
and acting as a promoter for NLRP1. The LTR also lies within a region of open chromatin and is 
marked with H3K4me3 in the L428 cell line. RACE Peaks represent the regions identified as 
peaks by Macs and were used to define active LTRs in RACE-Seq data. A RNA-Seq transcript 






Figure 3.28. NLRP1 is expressed from a THE1B LTR promoter in HL 
A. NLRP1 was more highly expressed in HL than control cell lines based on normalised RNA-
Seq expression data. B. qPCR data relative to GapDH, using primers designed in the upstream 
LTR and exon 2 of NLRP1. Expression of the LTR transcript is present in all HL cell lines and 
absent from the control cell lines indictating the role of the THE1C LTR as a HL specific 
promoter for this gene. qPCR n=3, error bars show standard deviation. 
 
An intragenic LTR promoter has the potential to produce a longer isoform of a gene 
whereas an intragenic promoter will always produce a shorter isoform. Depending upon 
the gene in question this may produce a non-functional protein or a protein with 
modified function. The activity of intragenic LTRs is more difficult to determine by visual 
inspection of genome browser tracks as many genes with intragenic LTRs also have 
some degree of native promoter activity meaning that an alternate isoform can be 
hidden by the full length isoform. An example of an intragenic LTR where the activity 
could be determined was seen in the CACNA2D1 gene in the KM-H2 cell line (Figure 
3.29). This gene carried an active intronic THE1B LTR located between exons 3 and 4. 
A low level of expression was present in exons 2 and 3 prior to the LTR and the exon 
expression level following the LTR was dramatically increased, producing an isoform 3 




Figure 3.29 Intragenic LTRs produce shorter isoforms of some genes in HL 
UCSC genome browser screen shot showing a THE1B LTR only active in the KM-H2 cell line 
and acting as a promoter for CACNA2D1. As an alternative intragenic promoter it produces a 
shorter isoform of the gene without exons 1-3. RACE Peaks represent the regions identified as 
peaks by Macs (See Methods 2.9.5) and were used to define active LTRs in RACE-Seq data. A) 
Showing transcript running into downstream exons. B) Magnified version showing exact position 
of THE1B LTR. 
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An anti-sense RNA promoter can be either intergenic or intragenic and produces an 
anti-sense transcript of a gene often resulting in reduced gene expression through 
disruption at the initiation, transcriptional processing or the post-transcriptional 
processing stages of the genes sense transcript (Pelechano and Steinmetz 2013). Our 
RNA-Seq data showed that the gene expression of CHD1L was reduced in the HL cell 
lines L428 and KM-H2. A downstream THE1B LTR, 20Kb from the termination site of 
the CHD1L transcript, was observed producing an anti-sense RNA. The active LTR was 
also within a DNaseI hypersensitive site and carried H3K4me3 in L428 cells, both of 
which were absent in Reh cells (Figure 3.30). The expression data obtained from the 
RNA-Seq showed an average ~1.5 fold decrease in CHD1L expression in both the L428 
and KM-H2 cell lines when compared to the cell lines without the active LTR (Figure 
3.31). This demonstrates that when transcribed in the antisense direction, active LTRs 
have the potential to reduce the level of gene expression. Therefore, highlighting 
another potential route by which LTR activation could influence the overall gene 





Figure 3.30. Active LTRs can produce anti-sense RNA transcripts correlating with 
reduced gene expression 
UCSC genome browser screenshot showing a THE1B LTR only active in the L428 and KM-H2 
HL cell lines and acting as a promoter for and anti-sense RNA as seen in the RNA-Seq data. 
The LTR also lies within a region of open chromatin and is marked with H3K4me3 in the L428 
cell line. The anti-sense RNA overlaps with the CHD1L gene and correlates with a reduction in 
gene expression. RACE Peaks represent the regions identified as peaks by Macs and were 






Figure 3.31 CHD1L is down-regulated in HL cell lines compared to control cell lines 
Normalised FPKM expression values obtained from RNA-Seq data shows a down-regulation of 
CHD1L in HL cell lines when compared to the control cell lines. 
 
Finally, our data show that many of the active LTRs produce un-annotated long non-coding 
RNAs (lncRNAs) which do not overlap with protein-coding genes. These transcripts were often 
10’s of kilobases in length and located in gene deserts with an RNA transcript that gradually 
reduced in expression level with length (Figure 3.32). The function of these elements is far 
harder to determine as they may just be a benign side effect of an LTR being active and 
inducing transcription of RNA with no function, which is simply degraded. It is also possible, 
however, that some of these lncRNAs physically interact with the promoters of other genes to 
inhibit or enhance transcription. A proportion of these un-annotated transcripts also showed 
indications of splicing events in the RNA-Seq data. An example of this phenomenon was seen 
on chromosome 12 where a THE1B LTR was acting as a promoter in all HL cell lines for an un-
annotated RNA transcript. As with the other active LTR promoters both a DNaseI hypersensitive 
site and H3K4me3 were present at the LTR in L428 and not in Reh. The transcript lay ~1 Mb 
from the nearest annotated coding gene and appeared to have a number of peaks in RNA-Seq 
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data which could represent spliced exons. It is possible that this could be a previously 
unidentified protein coding gene although it is more likely to be a non-coding transcript which 
may influence with the expression of another gene.  
 
Figure 3.32. Active LTRs produce unannotated lncRNA transcripts 
UCSC genome browser screenshot showing a THE1B LTR only active in the HL cell lines and 
acting as a promoter for an unannotated long non-coding RNA. The LTR also lies within a 
region of open chromatin and is marked with H3K4me3 in the L428 cell line. RACE Peaks 
represent the regions identified as peaks by Macs and were used to define active LTRs in 
RACE-Seq data. 
 
Overall it is clear that active LTRs in HL have both a direct impact through their activity as 
alternative promoters and the potential for an indirect impact through non-coding RNAs on the 
expression of genes. Active LTRs also have the potential to act as enhancers, which may be 
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seen to some extent in the link between LTRs and the up-regulated HL genes (Figure 3.25). It is 
much more difficult, however, to identify which enhancers may be acting on which genes. 
3.3.4. TNFRSF11A is expressed from an active LTR in the L1236 cell line and is involved 
in the up-regulation of NF-κB activation 
After showing that LTR activation had a global impact on gene expression in HL we next wanted 
to determine whether any of the up-regulated genes were critical regulators of the HL 
phenotype. An active THE1B LTR was identified 1.2 Kb upstream of the TNFRSF11A (tumour 
necrosis factor receptor superfamily member 11a) gene, producing a transcript of TNFRSF11A 
in the L1236 cell line and also a weak transcript in the L428 cell line (Figure 3.33). A DNaseI 
hypersensitive site and H3K4me3 were not observed in the L428 or Reh datasets which would 
suggest in the case of L428 the histone mark and DHS may be too weak to detect or may just 
be present in a small subset of L428 cells. The expression of TNFRSF11A was clearly up-
regulated in L1236 and this was confirmed by qPCR (Figure 3.34). To validate the existence of 
the LTR driven transcript, qPCR was also performed using primers in the LTR and in exon 2 of 
TNFRSF11A demonstrating expression of the LTR driven transcript at a level at least as high as 





Figure 3.33. TNFRSF11A is expressed in the L1236 HL cell line from an active upstream 
THE1B LTR 
UCSC genome browser screen shot showing a THE1B LTR only active in the L1236 and L428 
HL cell lines and acting as a promoter for the TNFRSF11A gene. A low level of H3K4me3 in the 
L428 cell line around the LTR can be observed. RACE Peaks represent the regions identified as 





Figure 3.34 High levels of TNFRSF11A are expressed from a THE1B LTR in the L1236 HL 
cell line. 
A. Normalised FPKM values from RNA-Seq data showed a high level of TNFRSF11A 
expression in the L1236 cell line. B. The high level of expression seen in RNA-Seq data was 
confirmed by qPCR with primers design in exon 2 and 3 of TNFRSF11A and the transcript 
originating from the LTR was confirmed using primers in the LTR and exon 2 of TNFRSF11A. 
Average of 3 biological replicates, error bars show standard deviation. 
The discovery of another LTR driven gene with specificity to the L1236 cell line was an 
interesting finding as it showed that an LTR with cell line specific expression could have a cell 
specific impact on a cellular phenotype and may indicate that a sub-type specific LTR activation 
in HL. The other reason that TNFRSF11A was of particular interest is because it has been 
shown in other studies to be up-regulated in HL patient samples and it is involved in the 
regulation of NF-κB signalling through its interaction with its ligand TNFSF11 (Steidl, Diepstra et 
al. 2012). TNFRSF11A interacts with tumour necrosis factor receptor-associated factors 
(TRAFs), which feed in to the NF-κB and JNK pathways resulting in increased activity (Fiumara, 
Snell et al. 2001).  This is of particular relevance to HL as we known that the central control 
mechanisms for gene expression in HL are through NF-κB and AP-1. NF-κB also potentially 
plays a very important role in the activation of LTRs as the THE1B consensus sequence has an 
NF-κB motif and it was shown that the CSF1R LTR required aberrant NF-κB activation to 
become fully active (Lamprecht, Walter et al. 2010). 
TNFRSF11A is primarily activated through interaction with its ligand TNFSF11, however, our 
RNA-Seq data showed no expression of TNFSF11 in any of the HL or control cell lines. 
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Although TNFSF11 is the major activating partner of TNFRSF11A it was shown by Anderson et 
al. (1997) that overexpression of the receptor alone could induce NF-κB activation. To 
determine whether TNFRSF11A was a driving factor in HL pathology we performed an siRNA 
knockdown in the L1236 cell line. The knockdown successfully reduced the level of 
TNFRSF11A mRNA (Figure 3.35). However, there was no observable difference in the growth 
rate or cell morphology following the knock down.  
 
Figure 3.35. TNFRSF11A can be knocked down by siRNA 
RNA interference was used to knockdown of TNFRSF11A in theL1236 cell line. Expression of 
TNFRSF11A using primers designed for exon 3 and the upstream LTR and exon 2 was 
measured by qPCR comparing cells treated with siTNFRSF11A to cells treated with a non-
targeting control (siCon). Treatment with siTNFRSF11A showed a good level of knockdown of 
both transcripts. Error bars show standard deviation, n=3. 
 
 
We next wanted to establish whether TNFRSF11A expression had an impact on NF-κB 
activation. When NF-κB becomes active it is translocated to the nucleus (Trask 2004). We 
therefore determined activation by analysing nuclear NF-κB levels in L1236 cells with an siRNA 
knockdown of TNFRSF11A and compared to non-targeting control siRNA treated cells. 
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Following knock down of TNFRSF11A the level of NF-κB p65 present within the nucleus 
decreased showing a role for TNFRSF11A in NF-κB activation in the L1236 cell line (Figure 
3.36). This finding shows the exciting potential of a positive feedback loop where the LTR 
activation supports and enhances its self via the increase of NF-κB signalling. 
 
Figure 3.36. Knockdown of TNFRSF11A in L1236 cells results in reduced NF-κB 
activation. 
Western blot showing nuclear protein extract from L1236 cells treated with either a control 
siRNA (siCon) or a siRNA against TNFRSF11A probed for NF-κB p65. Two biological replicates 
are shown and beta-Actin was also probed as a loading control. A nuclear specific protein 
loading control was not performed, although would have been useful to confirm the purity of the 
nuclear protein fraction. The right panel shows the relative expression values normalised to the 
loading control demonstrating a drop in NF-κB protein in the nuclear fraction resulting from 









3.4. Long Terminal Repeats can be activated by inflammatory signalling 
Lamprecht et al. 2010, demonstrated that activation of the CSF1R LTR could be recapitulated in 
the Reh cell line by the knockdown of transcriptional repressor ETO2 and constitutive activation 
of NF-κB, both of which are features of HL. We have shown in our foot-printing data that NF-κB 
and AP-1 are the main driving factors of the HL phenotype and know that the overall HL gene 
expression pattern comprises many genes involved in inflammation. To study the factors 
involved in transcriptional activation of the THE1B LTR we analysed its consensus sequence 
and observed an NF-κB binding motif up-stream of the transcription start site (Figure 3.37), 
which had also been previously identified (Lamprecht et al. 2010). Based on this result we 
wanted to determine whether inflammatory signalling particularly in relation to NF-κB activation 
could be driving the genome-wide activation of LTRs in HL. 
 
Figure 3.37. THE1B consensus sequence contains an NF-κB binding motif. 
THE1B LTR consensus sequence obtained from RepBase and annotated with transcription 
factor binding motifs. The consensus sequence includes AP-1 and NF-κB motifs both of which 
have the potential to bind these transcription factors which are critical for driving the HL gene 
expression programme.  
3.4.1. Treatment of the Reh cell line with PMA induces CSF1R-LTR expression 
The compound phorbol 12-myristate 13-acetate (PMA) is a potent activator of the protein kinase 
C (PKC) enzyme due to its similarity to diacylglycerol, a natural activator of PKC (Slater, Kelly et 
al. 1994). Activation of PKC drives many downstream cellular pathways which have been linked 
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to inflammation and tumour growth including MAPK and NF-κB pathways, both of which are up 
regulated in HL (Zheng, Fiumara et al. 2003). To establish whether the inflammatory signalling, 
particularly NF-κB activation, was able to induce LTR activation we treated Reh cells with 
2ng/ml PMA for a period of 8 or 16 hours.  
At both time points transcription of the CSF1R LTR was induced as measured by qPCR (Figure 
3.38). The induction was slightly reduced at the 16 hour time point, therefore further 
experiments were carried out following 8 hours of PMA treatment. It was previously shown by 
Lamprecht et al. (2010) that loss of the transcriptional repressor CBFA2T3 (ETO2) was also 
required to activate the CSF1R LTR. To establish whether PMA had an effect on CBFAT23 
expression, qPCR was performed. This showed a downregulation of ETO2 upon treatment with 
PMA (Figure 3.39). Although the route by which this downregulation occurs is not clear, it shows 
that the LTRs may be activated by a combination of ETO2 loss and NF-κB activation as 
previously published. 
 
Figure 3.38. Treatment of Reh cells with PMA induces CSF1R LTR expression 
Treatment of Reh cells with 2ng/ml PMA for 8 or 16 hours followed by measurement of CSF1R 
LTR expression by qPCR. Induction of CFS1R expression can be observed following PMA 





Figure 3.39. ETO2 expression reduces following PMA treatment of Reh cells 
Gene expression measured by qPCR showing a drop in ETO2 expression following treatment of 
Reh cells with 2ng/ml PMA for 8 or 16 hours. N=3 error bars show standard deviation. 
3.4.2. Treatment of the Reh cell line with PMA induces global THE1B LTR activation   
Following the discovery that PMA treatment induced activation of the CSF1R LTR in Reh cells, 
we wanted to use our RACE-Seq technique to determine the impact of PMA treatment on 
THE1B related LTRs genome-wide. RACE-Seq was carried out in triplicate on cells treated with 
PMA for 8 hours. The RACE-Seq data was validated by the observation of reads aligned to the 
CSF1R LTR using UCSC Genome Browser (Figure 3.41). The replicates had a similar level of 
overlap to the previous RACE experiments and the same strategy of using RACE peaks present 
in at least 2 replicates for further analysis was applied (Figure 3.40). Previous analysis of the 
RACE data obtained from the Reh cell line showed that a proportion of LTRs were already 
active. Therefore we next wanted to find out how activation changed following PMA treatment 
and whether the LTR activation pattern became more HL like. Overlap of the RACE-Seq peak 
regions from the untreated Reh cells, the union of HL cell lines and PMA treated Reh cells 
showed a loss of 153 Reh specific sites and a gain of 1,295 sites resulting from PMA treatment 
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(Figure 3.42). Following treatment with PMA the Reh cells gain activation of 295 HL specific 
LTRs indicating that the PMA induces a partial move towards the HL LTR activation pattern.  
 
Figure 3.40. Overlap of biological replicates of LTRs detected by RACE-Seq in PMA 
treated Reh cells 
Overlap of active LTR peaks identified by THE1B RACE-Seq in 3 biological replicates following 
PMA treatment of Reh cells. Further analysis was carried out on peaks shared in at least 2 






Figure 3.41. Activation of transcription from the CSF1R LTR can be detected by RACE-
Seq in Reh cell line following PMA treatment 
UCSC genome browser screenshot showing aligned RACE-Seq reads at the THE1B LTR 




Figure 3.42. Following PMA treatment LTRs are transcriptionally activated 
Peaks representing active LTRs determined by RACE-Seq were overlapped to compare the 
LTR activation in Reh cells following 8 hours of PMA treatment to untreated Reh cells and the 
union of all HL active LTRs. This showed that 295 LTRs activated by PMA treatment were also 





3.4.3. LTRs activated by PMA treatment have a genome-wide impact on gene expression 
Having shown that LTR activation has an impact on the gene expression pattern in HL but to a 
much lesser extent in Reh cells it was important to examine whether PMA activated LTRs also 
influenced the expression of their associated genes. We first carried out RNA-Seq on the PMA 
treated Reh cells, with two biological replicates which showed very good correlation (Figure 
3.43). Pearson correlation of the LOG2 FPKM values obtained from RNA-Seq between the PMA 
treated Reh cells and the control and HL cell lines, followed by clustering, showed the PMA 
treatment moved the overall gene expression pattern of the cells away from the control cell lines 
(Figure 3.44). A slight increase in correlation of the PMA treated Reh cells to the HL cell lines 
was also observed,  which suggests the PMA treatment changes the gene expression pattern to 
be more like that of the HL cells. 
 
Figure 3.43. Correlation of RNA-Seq biological replicates from PMA treated Reh cells 
Correlation of Log2 FPKM values from 2 biological replicates of RNA-Seq data obtained from 





Figure 3.44. PMA treatment of Reh cells results in an increased correlation of its gene 
expression pattern with that of HL cells 
Pearson correlation between the FPKM values from RNA-Seq in each of the HL and control cell 
lines including PMA treated Reh cells was carried out followed by clustering of the gene 
expression correlations for the cell lines.  This showed that PMA treatment of Reh cells made 
their gene expression correlate less with untreated cells and begin to correlate slightly more with 
HL cell lines. 
In addition to the gene expression pattern shifting towards that of HL, a number of genes 
dysregulated following PMA treatment are known to be involved in HL. B-cell specific genes 
including Pax5, CD79B, RAG1 and Rag2 were down-regulated by PMA treatment and genes 
which contribute to the HL phenotype such as CSF1R, JUNB, LTA and TNF were up-regulated. 
As shown by the correlation of the gene expression data, PMA did not induce a complete move 
to the HL gene expression programme. Many important genes were not up-regulated including 
IL13, CCL5, IL6, IRF5 and CCR7. We were unable to determine whether expression of these 
genes was upregulated at a later time point following PMA treatment as long term PMA 




Figure 3.45 Reh cell growth is stopped following PMA treatment 
Following treatment of Reh cells with 2ng/ml PMA a growth curve was created over a 48 hour 
period showing that proliferation of Reh cells is down-regulated following treatment. Cell counts 
normalised to 1x106 at 0 hours. Error bars show standard deviation across 3 biological 
replicates. 
As PMA impacts on the cellular environment through many different pathways we wanted to 
establish which part of the gene expression pattern resulted from LTR activation. We carried out 
the same analysis previously conducted on the HL cell lines by first determining the closest 
genes to the active LTRs in the Reh and Reh+PMA RACE-Seq data. The change in expression 
levels of such genes based on RNA-Seq data was then plotted against the presence or absence 
of active LTRs in PMA treated and untreated Reh cells (Figure 3.46). Genes up-regulated in 
Reh+PMA cells showed an increased presence of active LTRs in their vicinity which was not 
seen for active LTRs in the untreated Reh cells. This finding suggests that the LTRs which are 
activated by PMA treatment have an impact on the regulation of gene expression in the treated 




Figure 3.46. Transcriptionally active LTRs in PMA treated Reh cells are associated with 
up-regulated genes 
Gene expression Log2 fold change for PMA treated Reh cells over untreated Reh cells was 
plotted (Red; up-regulated genes, Green; down-regulated genes). The presence of active LTRs, 
observed by RACE-Seq, close to the genes was then plotted on the same axis for treated and 
untreated cells. This showed a larger proportion of active LTRs associated with up-regulated 
genes in the treated cells than the untreated. 
 
PMA treatment most likely results in the activation of LTRs in Reh cells via a similar route to that 
in HL as the induced signalling pathways mimic those seen in HL. To compare LTRs activated 
by PMA treatment with gene expression in HL cells, we ranked the gene expression fold change 
of several HL cell lines over Reh and aligned ranked genes with the presence of neighbouring 
LTRs (Figure 3.47). This analysis showed that PMA treatment of Reh cells induced LTRs which 
were associated with up-regulated genes in the L428 and KM-H2 HL cell lines and to a lesser 
extent with genes from the L1236 cell line. When compared to the L428 cell line we also found a 
group of LTRs which were associated with down-regulated genes. The reason for this could be 
LTRs which produce anti-sense transcripts and decrease the expression of nearby genes. 
However, as most THE1B related LTRs contain NF-κB binding sites, it is likely that a number of 
these LTRs are already active in Reh cells and are further activated following PMA treatment. 
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It should be noted that although PMA activates a proportion of active LTRs in Reh cells which 
are also active in HL many remain inactive. These include the LTRs involved in the up-
regulation of NLRP1 and the expression of TNFRSF11A in the L1236 cell line. This finding may 
point towards additional control mechanisms for LTR expression other than the loss of ETO2 
and constitutive activation of NF-κB which was sufficient for the activation of the CSF1R LTR 
(Lamprecht, Walter et al. 2010). 
 
Figure 3.47. LTRs activated by PMA treatment of Reh cells associate with genes which 
are highly expressed in HL cell lines 
Gene expression Log2 fold difference for HL cell lines over the Reh cell line was plotted (Red; 
up-regulated genes, Green; down-regulated genes). The presence of active LTRs, observed by 
RACE-Seq, close to the genes was then plotted on the same axis for PMA treated Reh cells 
showing PMA driven LTR activity close to genes upregulated in HL. 
3.4.4. PMA treatment of Reh cells induces global changes in chromatin accessibility and 
pushes the cells towards the HL chromatin accessibility pattern 
Following our finding that PMA treatment of Reh cells shifted gene expression patterns towards 
those seen in HL cells, we also wanted to assess whether these changes were associated with 
alterations in chromatin accessibility. Global changes in chromatin accessibility could play a role 
in genome-wide LTR activation and may lead to the up-regulation of genes not associated with 
LTRs. To this end, we carried out ATAC-Seq on the PMA treated Reh cells. This assay provides 
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the same information as the DNaseI-seq assay but has the advantage of needing a smaller 
amount of starting material. We also performed ATAC-Seq on the L428 cell line for comparison 
to the data produced by the DNaseI-Seq assay. The regions of open chromatin in each cell line, 
either determined by ATAC-Seq or DNaseI-Seq were correlated using Pearson correlation and 
clustered based on the correlations (Figure 3.48). The result showed that the ATAC-Seq and 
DNaseI-Seq data from the L428 cell line correlated very well showing that the assays are very 
comparable for the identification of open chromatin regions. As seen in the gene expression 
clustering the Reh cells treated with PMA still clustered with the control cell lines but have an 
increased correlation with the HL cell lines. This shows that the changes chromatin accessibility 
following PMA treatment of Reh cells follows a similar pattern to the changes in gene 






Figure 3.48. Following PMA treatment chromatin accessibility patterns of Reh cells shift 
towards those of HL cell lines 
Regions of open chromatin identified by DNaseI-Seq or ATAC-Seq were determined. The 
sequences found in each of the cell lines were combined and the Pearson correlation of the tag 
counts for each site in each cell line was calculated. The correlation values were then clustered 
by hierarchical unsupervised clustering showing that the DNaseI-Seq data for L428 clusters with 
the ATAC-Seq data for L428 and also that the Reh cells treated with PMA have a higher 
correlation with the HL cell lines than the untreated cells have with the HL cell lines. 
 
 
The induction of LTRs by PMA treatment is an exciting finding as it points towards inflammatory 





3.4.5. Constitutive NF-κB activation can be triggered in Reh cells using doxycycline 
inducible IκKβ expression 
The use of PMA as a trigger of inflammatory signalling leading to LTR activation worked 
effectively, however due to PMA affecting many cellular pathways by acting through PKC it was 
not possible to link LTR activation to a specific regulator. The presence of an NF-κB binding 
motif within the consensus sequence of THE1B LTRs and the findings by Lamprecht et al. 2010 
suggest that NF-κB activation is the most likely reason for the LTR activation induced by PMA. 
To test this idea, we constructed a system to allow NF-κB activation to be induced in Reh cells 
by treatment with doxycycline (Figure 3.49). The advantage of this inducible system was that we 
were able to grow a stably transduced cell line and induce NF-κB activation at a short time prior 
to any downstream assays. This meant that we were more likely to observe the direct effects of 
NF-κB activation on LTRs rather than the indirect effects resulting from down-stream changes in 
gene expression produced by NF-κB.  
 
Figure 3.49. Inducible NF-κB activation scheme 
Reh cells with doxycycline inducible NF-κB activation were produced by the transduction of cells 
with an inducible lentiviral expression vector (PCW 57.1) containing the IκKβ gene and IRES 
GFP. This produced a stable cell line in which NF-κB activation could be induced by treatment 
with doxycycline.  
The doxycycline (dox) inducible system worked by expressing an IκKβ with the activating 
mutation S117E, S181E (IκKβ(EE)) upon dox treatment which is unable to become 
phosphorylated. Wild type IκKβ mediates phosphorylation of IκBα resulting in its proteasomal 
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degradation which, in turn, allows NF-κB to localise to the nucleus and become active (Figure 
3.50) (Delhase, Hayakawa et al. 1999). IκKβ(EE) was cloned into the PCW 57.1 inducible 
lentiviral vector to achieve NF-kB constitutive activation (Delhase, et al. 1999) (See 2.8 for 
cloning strategy).  
 
Figure 3.50. Scheme depicting the mechanism of NF-κB activation  
Activation of NF-κB is achieved through over-expression of mutant IκKβ which does not require 
phosphorylation by MEKK1 and leads to the phosphorylation and degradation of IκBα allowing 
NF-κB to localise to the nucleus and become active. 
 
An IRES GFP sequence was also added to the mutant IκKβ sequence to allow for easy 
monitoring of induction efficiency. The efficiency of induction was tested by flow cytometry 
analysis comparing the percentage of GFP positive cells with and without treatment with 2 µg/ml 
dox for 48 hours (Figure 3.51). Cells containing the IκKβ and IRES GFP (iIκKβ) construct 
showed an induction of GFP expression in ~33% of cells compared to only ~0.3% without dox 
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treatment. The iIκKβ cells were also compared to a control cell line with only an inducible IRES 
GFP (iGFP). The control cell line showed ~78% of cells induced following dox treatment. The 
reason for the reduced induction in the cells containing the IκKβ is likely due to the increased 
size of the inducible cassette making activation less stable. To observe the effect of IκKβ 
induction on the cells without the data being diluted by the cells which had not induced all 
further experiments were conducted on GFP positive cells sorted from the induced population 
by FACS. 
 
Figure 3.51. Flow cytometry analysis showed induction of IκKβ and IRES GFP construct 
following doxycycline treatment 
Reh cells containing a dox inducible IκKβ and IRES GFP construct were treated with 2 µg/ml 
doxycycline for 48 hours and the GFP levels of cells measured by flow cytometry. This result 




To ensure that expression of the IκKβ was being induced we performed qPCR to measure the 
expression of the endogenous IκKβ and the inducible mutant IκKβ (Figure 3.52). This analysis 
showed a fairly consistent level of endogenous IκKβ expression and little of the mutant IκKβ 
prior to dox treatment. Following dox treatment for 48 hours a large increase of mutant IκKβ 
expression was seen. We next wanted to establish the level of NF-κB activation in the cells by 
measuring the level of NF-κB protein localising to the nucleus. We measured the level of NF-κB 
protein within the nuclear fraction in dox induced iGFP cells, induced iIκKβ cells and in the L428 
cell line. This experiment showed a ~3.5 fold up-regulation of nuclear NF-κB protein after 
induction which was higher than the constitutive level observed in the L428 cell line. By 
achieving a level of NF-κB activation at least as high as in the L428 cell line this shows that our 
inducible system should be fairly representative of the activation state in HL. 
 
Figure 3.52. IκKβ(EE) is induced by dox treatment 
iIκKβ cells were treated with2 µg/ml doxycycline for 48 hours and induction was measured by 
qPCR using primers deigned for either the endogenous IκKβ of the cloned mutant (IκKβ(EE)). 





Figure 3.53. Nuclear NF-κB protein level increases following IκKβ induction 
A) The level of NF-κB protein in the nuclear fraction was measured by western blotting B) the 
level of protein calculated by densitometry relative to the level in iGFP cells and normalised to β-
Actin loading control n=2. 
 
3.4.6. LTR activity can be induced by aberrant NF-κB activation 
After establishing that we were able to induce high levels of active NF-κB activation in Reh cells, 
we wanted to investigate the impact of NF-κB on genome-wide activation of LTRs. To achieve 
this aim, we carried out THE1B RACE-Seq in triplicate on the iGFP cell line with dox treatment 
and the iIκKβ cell line with (iIκKβ+Dox) and without (iIκKβ –Dox) dox treatment. The overlap of 
the data from the biological replicates of RACE-Seq data was determined and as in the previous 
approach, peaks appearing in at least 2 replicates were selected (Figure 3.54). We then 
compared the 2 control data sets (iGFP and iIκKβ-Dox) and the NF-κB induced dataset 
(iIκKβ+Dox) (Figure 3.55). This analysis showed a small number of peaks unique to each of the 
control datasets, most likely resulting from experimental variation. The remainder of the peaks 
within the control datasets were also present in the iIκKβ+Dox data which would be expected as 
all of these cells have the same Reh cell background. Finally the iIκKβ+Dox showed a large 
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number (660) of uniquely active LTRs, this confirmed that activation of NF-κB at a high level 
induces the activation of many THE1B related LTRs.  
 
Figure 3.54. Overlap of RACE-Seq biological replicates 
The peaks identified by Macs in the biological replicate THE1B RACE-Seq data sets for iGFP, 
iIκKβ-Dox and iIκKβ+Dox were overlapped and the peaks shared in at least to replicates (shown 
in blue) were selected for downstream analysis. 
 
 
Figure 3.55. High levels of NF-κB activation induces activation of LTRs 
Overlap of RACE-Seq data for active THE1B related LTRs with and without constitutive NF-κB 
activation induced by Dox treatment of cells. A large set (660) of uniquely active LTRs were 




To study whether the set of active LTRs induced by NF-κB in Reh cells resembles that of HL 
cells, we compared the RACE-Seq data from the iIκKβ-Dox and iIκKβ+dox cells with all active 
‘high-confidence’ LTRs identified in the HL cell lines(Figure 3.56). A proportion of the peaks 
(179) shared between the iIκKβ+Dox and iIκKβ-Dox datasets were also seen in the HL cell 
lines. This was to be expected as Reh cells share a number of active LTRs with the HL (see 
3.2.4). A further 174 which were activated following Dox treatment were also shared with the HL 
cell lines. This indicates that NF-κB activation alone is able to induce activation of some HL 
specific LTRs. However, we found also 939 active LTRs identified in the IκKβ+Dox cells which 
were not shared with the HL cell lines. We also visualised this data in a supervised clustering 
analysis showing the shared and unique peaks between each cell line and the PMA treated and 
IκKβ+Dox cells (Figure 3.57). This analysis showed a large number of LTRs in each cell line 
and Reh cell treatment which were unique and only a small number shared between all of the 
HL and IκKβ+Dox cells.  
It is possible that some LTRs may have been included or excluded through experimental 
variation, however due to the large number it is likely that this finding points towards additional 
control mechanisms preventing the activation of many LTRs purely through high levels of active 
NF-κB. There was also an absence of activation of the CSF1R LTR which is active in HL cells 
and was activated by PMA treatment. This finding points to the requirement of a different 
epigenome driven by ETO2 downregulation for the activation of at least a subset of the LTRs 





Figure 3.56. A proportion of LTRs active in HL is activated by constitutive NF-κB 
activation in Reh cells 
The RACE-Seq data identifying active LTRs in control cells (IκKβ-Dox), cells with induced NF-
κB activation (IκKβ+Dox) and in HL cell lines (L428, L1236 and KM-H2) was overlap to examine 
the LTR activation shared between the datasets. A proportion of the LTRs activated by NF-κB 





Figure 3.57 Supervised clustering of LTR activation across cell lines 
Supervised clustering of LTR activation across all cell lines and IκKβ+Dox cells shows a unique 
pattern of LTR activation in each condition and also subsets of LTRs which are active in the HL 
cell lines and following PMA treatment of NF-κB activation. 
 
Finally, to study the impact that constitutive NF-κB activation had on gene expression we 
performed RNA-Seq on the iIκKβ cells before and after doxycycline treatment. The overall gene 
expression pattern showed very little change in correlation with the NF-κB induced cells 
clustering with the un-induced cells. We did however observe an up-regulation of IκKβ which 
confirmed the functionality of the inducible system and we also saw the up-regulation of a 






Figure 3.58 Clustering of gene expression data from cells with induced NF-κB activation 
showed little change in overall gene expression 
Clustering of RNA-Seq data for HL cell lines, control cell lines and Reh cells with untreated, with 
PMA treatment and constitutive NF-κB activation (IκKβ+Dox). This analysis shows that induced 
constitutive NF-κB activation does not change the overall gene expression pattern in Reh cells 




Figure 3.59 Up-regulation of HL gene expression following constitutive NF-κB activation 
Following constitutive NF-κB activation by induction of IκKβ an up-regulation in gene expression 





4.1. The Hodgkin’s Lymphoma transcriptional network has a global impact on 
chromatin structure and gene expression. 
 
4.1.1. Generating a novel RNA-Seq dataset 
The HL gene expression network has been investigated in many studies and is known to differ 
greatly from the gene expression network of B-cells. B-cell lineage genes such as BCR, CD19 
and CD20 are down-regulated and genes from many other cell lineages, particularly those with 
pro-inflammatory properties are up-regulated (Kuppers, Klein et al. 2003, Kuppers 2009). The 
majority of published HL gene expression studies use expression data obtained from qPCR and 
micro-array experiments. The disadvantage of this is that crucial data such as different isoforms 
of genes, low-abundance transcripts and alternative transcription start sites cannot be detected 
(Zhao, Fung-Leung et al. 2014). To overcome these disadvantages, particularly for the study of 
LTRs as alternative promoters, we performed RNA-Seq as no such data-set was available. 
RNA-Seq data allowed us to both study alternative isoforms of genes and also to further study 
the overall gene expression patterns in a set of HL cell lines (L428, L1236 and KM-H2). The 
gene expression patterns were then compared with those of control cell lines which more 
closely resemble the B-cell lineage (Reh and Namalwa).  
The RNA-Seq data we produced confirmed the large difference in gene expression between the 
HL and control cell lines, and also showed a variation in gene expression between the HL cell 
lines. The variation in gene expression between the HL cell lines originates from 2 sources. 
Firstly the clonal expansion of the cell lines over many passages may have resulted in the 
introduction of random mutations or epigenetic drift in genes which have conferred further 
survival advantage and therefore been propagated through the cell line. The second and likely 
165 
 
predominant source of variation between the cell lines is the pathology of the patient samples 
from which they were derived.  
All 3 HL cell lines were originally defined based on the expression of CD15 and CD30 surface 
markers and lack B-cell lineage antigens CD20 and CD19 and T-cell lineage antigens CD45 
and CD3, which are the standard clinical markers for identification of HRS cells (Schaadt, Diehl 
et al. 1980, Kamesaki, Fukuhara et al. 1986, Wolf, Kapp et al. 1996, Piccaluga, Agostinelli et al. 
2011). The L1236 and KM-H2 cell lines have highly complex karyotypes with at least 10% of 
each population displaying polyploidy and a proportion of cells in each population forming large 
multinucleated cells (Kanzler, Hansmann et al. 1996, Uehira, Amakawa et al. 2001). The L428 
cell line also contains a proportion of multinucleated cells, however the karyotype is more stable 
than the other cell lines with all L428 cells lacking one copy of chromosome 14 and having an 
additional copy of chromosome 12 (Schaadt, Diehl et al. 1980). 
Variation in the treatment received by the patients from whom the cell lines were derived is also 
likely to contribute to their gene expression patterns. The L428 and KM-H2 cell lines were both 
obtained from pleural effusions of relapse patients who had originally received chemotherapy 
and also radiotherapy in the case of L428 (Schaadt, Diehl et al. 1980, Kamesaki, Fukuhara et 
al. 1986). The L1236 cell line has a more complex background. L1236 cells originate from a 
patient who presented with advanced HL following treatment with radiotherapy of initial 
presentation.  Chemo-therapy was then administered on a second relapse, surgery but no 
chemo- or radio-therapy on a third relapse and finally unsuccessful anti-CD25 immunotoxin 
therapy at the stage of a fourth relapse. Following the immunotoxin therapy the cell line was 
derived from separated lymphocytes obtained from peripheral blood (Wolf, Kapp et al. 1996). 
Although the overall phenotype of the cell lines matches that of primary HRS cells the treatment 
received by the patients prior to extraction of cells had the potential to impact significantly on the 
overall gene expression pattern, contributing to the gene expression differences between the 
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cell lines. It is also possible that the cell lines each represent a different subset of gene 
expression either specific to a particular case of HL or representing a particular subset of the 
disease.  
Studies comparing the gene expression patterns of micro-dissected primary HRS cells and HL 
cell lines have shown that the expression of genes involved in cell proliferation and growth are 
significantly up-regulated in HL cell lines (Tiacci, Doring et al. 2012). However, we have shown 
that the main HL gene expression signature such as that dependent on constitutive NF-κB 
activation is present in the cell lines.  This has also been confirmed in other studies suggesting 
that cell lines are still a good model for the study of HL (Steidl, Diepstra et al. 2012). This finding 
highlights the importance of comparing the results obtained in the cell lines to data from primary 
samples (See future work 4.6.5). 
When analysing the overall gene expression patterns we observed a down-regulation of B-cell 
lineage genes in the HL cell lines when compared to the control cell lines. The loss of B-cell 
lineage genes in HL is well known; in particular the markers CD19, CD38, CD79A and CD79B 
are lost in the majority of patient samples (Tzankov, Zimpfer et al. 2003). We also observed a 
down-regulation of EBF1 which plays a major role in down-regulating the B-cell lineage genes in 
HL (Bohle, Doring et al. 2013). RAG1 and RAG2 which are involved in recombination during B-
cell development are also down-regulated in the HL cell lines in our gene expression data which 
has also been previously reported in patient samples (Meru, Jung et al. 2001). We also 
observed the down-regulation of BCL6 which acts as a transcriptional repressor in B-cells and is 
also expressed in the majority of lymphomas with the exception of classical Hodgkin’s. It has 
been demonstrated that BCL6 and CD138 can be used to determine the stage in B-cell 
development which the malignant cells originated. The L1236 and KM-H2 cell lines express a 
very low level of BCL6 and no CD138 indicating that they originate from late germinal 
centre/early post germinal centre cells. These represent the most common type of HRS cells 
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found in ~59% of patients. The L428 cell line still lacks expression of CD138 but has a higher 
level of BCL6 indicating a far less common indeterminate phenotype seen in only ~18% of 
patients (Bai, Panoulas et al. 2006). 
Our RNA-Seq data also confirmed an up-regulation in expression of genes associated with 
inflammatory signalling and pathways. HRS cells reside within an infiltrate of immune cells 
attracted by the HRS cells highly inflammatory signature, composed of a wide range of 
chemokines and cytokines. We observed up-regulation of a number of genes known to be 
expressed in HL including CCL5 (RANTES) which is involved in the recruitment of TH2 cells, 
TReg cells, eosinophils and mast cells and the inflammatory cytokines IL-6 and IL-13 which are 
involved in both B-Cell maturation and stimulation of growth in HL (Kurzrock, Redman et al. 
1993, Kapp, Yeh et al. 1999, Skinnider and Mak 2002, Fischer, Juremalm et al. 2003, Aldinucci, 
Lorenzon et al. 2008). Many other genes known to be involved in the recruitment of immune 
response cells in HL were also up-regulated including CCL17, CCL22, IL-5, IL-8 and GM-CSF 
(Skinnider and Mak 2002, Kuppers 2009).  
We additionally found many up-regulated genes related to cytokine interactions which were 
shared with the JAK-STAT, TNF and NF-κB signalling pathways. These pathways form a 
complex network of interactions which jointly drive the survival and proliferation of HL cells. The 
JAK-STAT (Janus kinase/signal transducers and activators of transcription) pathway is central 
to many processes within the cell and is the signalling mechanism for cytokines and growth 
factors to induce cell proliferation, differentiation and apoptosis (Rawlings, Rosler et al. 2004). 
Signalling through the Jak-STAT pathway is required for HL cell survival which is driven in part 
through the cells own production of cytokines. It has been shown that in HL STAT5a can be 
activated through interaction with NF-κB signalling which is also upregulated in HL (Hinz, Lemke 
et al. 2002). This particular interaction is not seen in our KEGG pathway analysis for 
deregulated genes in HL. The absence of a number of interactions specific to HL is due to the 
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pathways being based around signalling in healthy tissue and not specific to the deregulated 
signalling in HL.  
There is also evidence from a number of studies that members of the TNF pathway can interact 
directly to activate the JAK-STAT pathway, particularly as part of an inflammatory response 
(Guo, Dunbar et al. 1998, Ahmad, Ansari et al. 2015). The TNF pathway can also drive 
activation of NF-κB signalling through both the canonical and non-canonical pathways (Wajant, 
Pfizenmaier et al. 2003, Sun 2011). Reciprocally NF-κB can also drive TNF signalling which can 
trigger further inflammation (Dong, Jimi et al. 2010). 
Besides the activation of STAT, constitutive NF-κB signalling is also central to driving the HL 
phenotype and inhibition of NF-κB results in rapid apoptosis (Izban, Ergin et al. 2001). Members 
of the NF-κB transcription factor family play an important role in the activation of inflammatory 
and immune responses. In healthy lymphocytes strictly controlled NF-κB activation promotes 
expression of caspase inhibitors to prevent apoptosis, cytokines involved in proliferation and cell 
survival including IL2 and IL6 and also a number of cell cycle regulators (Jost and Ruland 
2007). Due to the loss of BCR signalling in HL, aberrant NF-κB signalling is required for cell 
survival. Up-regulated NF-κB signalling results from interaction of a number of factors seen in 
our pathway analysis. CD40, which we show to be shared between the NF-κB signalling, 
cytokine-cytokine receptor interactions and the transcriptional misregulation in cancer pathways, 
is an important activator of NF-κB signalling in HL (Gruss, Hirschstein et al. 1994, O'Grady, 
Stewart et al. 1994). The ligand of CD40 is expressed by CD4+ T-cells which accumulate 
around HRS cells leading to activation of NF-κB through TRAF proteins. Internal mechanisms of 
NF-κB activation also include TNFRSF8 (CD30) up-regulation which undergoes self-
oligomerization to recruit TRAF proteins to activate NF-κB. Up-regulation of TNFRSF8 in 
particular has been demonstrated as a requirement for HL cell survival (Thakar, Ovchinnikov et 
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al. 2015). We have also shown that upregulation of TNFRSF11A also plays an important role in 
NF-κB activation in HL (Discussed in 4.3.2).  
The pathways which we have identified form a complex inflammatory response network which 
has been shown across many studies to drive the survival and proliferation of HL cells (Kuppers 
2009). To achieve the diverse and inflammatory gene expression pattern in HL cells significant 
changes to gene expression regulation are required. So far no RNA-Seq data from HL cell lines 
have been published and our new data will provide an important resource to the field. Using the 
RNA-Seq data we have been able to show the presence of previously unannotated non-coding 
transcripts and anti-sense transcripts that impact gene expression, for example in the case of 
the CHD1L gene. We have also been able to integrate this data with RACE-Seq data to show 
unannotated alternative transcription start sites. 
 
4.1.2. Generating a high-resolution DNAseI-Seq dataset for digital foot-printing 
Kreher, et al. 2014 published an analysis using low resolution DNaseI-Seq data identifying the 
cis-regulatory regions driving the HL-specific gene expression pattern.  From an analysis of 
enriched motifs within DHS peaks they identified IRF5, which we also see upregulated in all HL 
cell lines, as a major regulator of the HL phenotype. Due to the low resolution of their DNase-I 
data they were unable to identify the full complement of HL-specific transcription factor binding 
sites. Moreover, from this data it is unclear which binding motifs are actually occupied. We 
therefore performed a high read-depth DNaseI-Seq experiment to generate better data and to 
enable us to carry out high-resolution digital foot-printing to determine the full complement of 
bound transcription factors. Our data show an enrichment of occupied IRF, NF-κB and AP-1 
motifs in distal, HL specific, foot-printed regions when compared to Reh cells. This showed that 
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expression of distal regulatory regions in HL is driven by IRF, NF-κB and AP-1 which also 
confirms the findings of Kreher, et al. 2014.  
The up-regulation of both NF-κB and AP-1 are hallmarks of the regulatory network of HL gene 
expression as shown by a number of studies (Mathas, Hinz et al. 2002, Kreher, Bouhlel et al. 
2014). The AP-1 family transcription factors function by the formation of a DNA binding 
heterodimer between c-Jun or JunB and c-Fos, all of which were up-regulated in our HL 
expression data (Shaulian and Karin 2002). AP-1 activation usually occurs as a result of a 
number of stimuli including cytokines, growth factors and infections which means that in HL 
activation most likely occurs as a result of a number of inflammatory mechanisms (Hess, Angel 
et al. 2004). AP-1 activation pathways include signalling through JNK, MAPK and NF-κB 
phenotype (Chang and Karin 2001) all of which are central to the HL. It has been shown that in 
HL, AP-1 DNA binding activity is driven by IRF5 which induces JUN, JUNB and ATF3 forming a 
HL-specific AP-1 complex. 
To determine which transcription factors were likely to be interacting in the regulation of HL 
gene expression we performed bootstrapping analysis which tests the probability of the co-
occurrence of transcription factor motifs within foot-printed regions, indicative of a interacting 
factor complex. Our data showed AP-1 and NF-κB as the main drivers of gene expression in HL 
cells both by co-localising with each other and with a number of other transcription factors 
including GATA, IRF, STAT and RUNX. Interestingly GATA is not expressed in B cells but is 
aberrantly expressed in HL, the finding that GATA motifs co-localise with the AP-1 and NF-κB 
motifs shows that GATA participates in the regulation of HL gene expression.  The likely 
interaction between these factors in the activation of the unique HL gene expression pattern is 
an exciting finding. AP-1 and NF-κB have previously been shown to be involved in the 
regulation of CD44 a pro-oncogene in breast cancer (Smith and Cai 2012). This study went on 
to show that AP-1 and NF-κB have been implicated in a number of other inflammation driven 
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diseases including keratitis, rheumatoid arthritis and hepatocellular carcinomas (Han, Boyle et 
al. 1998, Liu, Kimmoun et al. 2002, Dong, Jimi et al. 2010). Interestingly hepatocellular 
carcinoma and rheumatoid arthritis also both exhibit a genome-wide pattern of ERV expression 
which may implicate AP-1 and NF-κB in LTR activation in inflammatory diseases. It is also 
known that THE1B LTRs have binding sites for both NF-κB and AP-1 (Kreher, Bouhlel et al. 
2014). To our knowledge there is currently no published data to show that AP-1 and NF-κB 
physically interact however their interaction with the same cis-element has been reported in the 
expression of CD44 in breast cancer (Smith and Cai 2012).  
 
4.2. RACE-Seq is an effective technique for the genome-wide identification of specific 
types of active LTRs 
Lamprecht et al. (2010) showed for the first time that an active LTR could induce pathological 
gene expression required for cell survival in a disease state. The finding that an active THE1B 
LTR in HL was acting as the sole promoter for CSF1R and that the expression of this gene was 
required for cell survival opened up the possibility that LTRs activation could be playing an 
important role in disease. To investigate the genome-wide activation of LTRs related to the 
THE1B family in HL we developed a targeted next-generation sequencing approach based on 
the 5’ RACE technique. The 5’ RACE technique was pioneered in the 1980’s, originally 
developed as a method for cloning low-abundance mRNA transcripts (Frohman, Dush et al. 
1988). The technique has since been repurposed and is now used mainly to identify the 
transcription start site for alternative isoforms of genes, such as genes which have an LTR 
acting as an alternative promoter (Lamprecht, Walter et al. 2010, Babaian, Romanish et al. 
2016). In its simplest form 5’ RACE works by the ligation of a known adaptor sequence to the 5’ 
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end of transcripts which can then be used in conjunction with a single primer located within the 
transcript in a PCR reaction to amplify the region between the 5’ end and the primer.  
To harness RACE technology for genome-wide screening of LTR activation we used a 
degenerate primer based on the most conserved region of the THE1B LTR consensus 
sequence. By carrying out PCR using a low annealing temperature to promoter the binding of 
the primer with mismatches we were able to successfully produce genome-wide libraries of 
THE1B LTR activation. When combined with Illumina next-generation sequencing this allowed 
for datasets to be produced showing the global activation of LTRs in cell lines. The RACE-Seq 
technique was also able to identify a number of other related LTR families. It is however not 
likely that the full complement of activated LTRs in families other than THE1B is seen in our 
data as it is known that the efficiency of PCR reactions drops rapidly with the introduction of 
mismatching nucleotides between the primer and template sequence (Bru, Martin-Laurent et al. 
2008). The use of a degenerate primer also introduced an issue with regard to the 
reproducibility of the assay. Due to the primer annealing with 8 or more mismatches 50% of the 
time when compared to the genomic sequence the amplification of LTRs with greater sequence 
variation produced variable levels of reads in each replicate. It may be possible to overcome this 
issue by higher read-depth sequencing of the libraries to allow for detection of the less amplified 
transcripts. The advantage of higher read-depth was seen in the 3rd replicate of RACE-Seq on 
the KM-H2 cell line which showed higher overlaps with replicates 1 and 2 due to an overall 
higher read-depth. To our knowledge there are currently no published studies which assess the 
influence of read-depth on the identification of regions selected by PCR however in terms of 
peak size, ChIP-Seq for factors binding to narrow regions (point-source factors) is the nearest 
comparison. In ChIP-Seq for point-source factors such as sequence-specific transcription 
factors a read-depth of 20 million reads is recommended by the ENCODE project and it has 
been shown that saturation for identification of all peaks can require up to 100 million reads 
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(Sims, Sudbery et al. 2014). The number of peaks expected in a ChIP-Seq experiment may be 
greater than what is expected for the number of active LTRs in a particular cell type and also the 
specificity of the reads should be higher in RACE-Seq due to the targeted amplification. 
However it would suggest that an increase from the average 5 million reads per replicate 
currently obtained in our RACE-Seq experiments may improve the reproducibility.  
There are very few other reports of RACE being used in conjunction with next-generation 
sequencing (NGS) approaches. 5’ RACE has recently been used with NGS to determine the 
multiple transcription start sites of 2 genes which have a large amount of variation in their start 
site (Leenen, Vernocchi et al. 2016). ‘RACE-Seq’ has also been used for the investigation of 
long non-coding RNAs for which the transcription start site is unknown. ‘RACE-Seq’ was carried 
out on 398 lncRNAs as a proof of principle and fragments amplified between the 5’ or 3’ end 
and a known exon within the lncRNA followed by long-read high-throughput sequencing 
(Lagarde, Uszczynska-Ratajczak et al. 2016). As far as we are aware our RACE-Seq approach 
is novel, particularly in terms of the identification of active LTRs. 
Other techniques have been developed for the purpose of identifying genome-wide LTR 
activation. Both CAGE (Capped Analysis of Gene Ends) and RNA-Seq have been used in other 
studies to identify LTR activation.  The RNA-seq techniques are based on the development of 
bioinformatics pipelines which align reads specifically to ERV sequences prior to mapping these 
back to the genome (Sokol, Jessen et al. 2016). The downside of this technique is that due to 
the limited coverage of active LTRs in an entire RNA-Seq library only a small number of reads 
are likely to be able to uniquely map in the vicinity of active LTRs. It is also not possible with this 
technique to conclusively determine whether the LTR is acting as a transcription start site or is 
expressed as part of another transcript. The use of CAGE technology overcomes this problem 
as it specifically identifies transcription start sites. CAGE has been successfully used to identify 
the expression of ncRNAs driven by LTR promoters in virus-induced hepatocellular carcinoma 
174 
 
(Hashimoto, Suzuki et al. 2015). The expression of families of ERVs in a range of healthy tissue 
including developmental tissue has also been shown by CAGE (Faulkner, Kimura et al. 2009, 
Fort, Hashimoto et al. 2014). These studies show that CAGE data can be successfully used for 
the identification of active ERVs. However, the unique alignment of CAGE reads to repeated 
regions of the genome is potentially more challenging than with RACE-Seq due to the very short 
read length lacking unique binding data. To further investigate the efficacy of the 2 techniques in 
identifying the full complement of active LTRs CAGE data would be required for the HL cell 
lines. 
Due to the challenges of aligning uniquely to repeat elements which have a high sequence 
homology we believe that our targeted approach is likely to be able to identify a greater 
proportion of the active THE1B LTRs in a cell line (see future work 4.6.1). 
4.3. HL cells display wide-spread activation of long terminal repeat elements 
The potential for genome-wide activation of LTRs in HL was demonstrated by Lamprecht at al. 
(2010), who identified an overall activation of LTRs in HL by using both 3’ and 5’ RACE followed 
by cloning. The study showed that a number of members of the THE1 family were active in HL 
including THE1A, THE1B and THE1C, but did not attempt to map all of the expressed LTRs 
genome-wide. To follow up on the findings of Lamprecht at al. (2010) we aimed to identify the 
full complement of LTR activation in HL cell lines. By using RACE-Seq we were able to identify 
the activation of a novel set of LTRs specific to HL when compared to our control cell lines. A 
number of studies have identified active LTRs in both diseased and normal tissue however 
there are few published datasets of genome-wide LTR activation. Genome-wide disease 
specific LTR activation has been shown in hepatocellular carcinoma by the use of CAGE 
(Capped Analysis of Gene Ends) to identify novel transcription start sites (Hashimoto, Suzuki et 
al. 2015). This analysis identified 935 active distal LTRs which were specific to hepatocellular 
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carcinoma (HCC) tumour cells and not transcribed in healthy hepatocytes. Mining of RNA-Seq 
data from diffuse large B-cell lymphoma patient samples has also been used to identify ERVs 
acting as alternative promoters (Lock, Rebollo et al. 2014). It is clear based on these studies 
that the genome-wide activation of LTRs in cancerous cells is not an exclusive phenomenon to 
HL cells and this is supported by our observation that our control cell lines also exhibit LTR 
activation. 
A unique set of activated LTRs in each cell line, both HL and control was also displayed in our 
data. It is possible that some of the variation between cell lines is due to activation of a 
proportion of LTRs being missed due to low sequencing depth. However, we are able to show 
by statistical comparison of the cell line specific transcribed LTRs to the total LTR population 
that the cell line specific LTR activation is significant. Variation in LTR expression between the 
cell lines most likely results from the different epigenetic background of the both the HL and 
control cell lines (discussed in 4.1.1).  Variation in LTR activation between different but closely 
related cell types has been shown during early embryonic development (See 1.3.14). In this 
study it was shown that ~2% of RNA-Seq reads at the 2 and 8 cell stage of human embryonic 
development map to ERVs including some of the THE1 family. They also observed that the 
proportion of active ERVs reduced as embryonic development progressed and also that the 
expressed ERVs changed throughout development marking specific cell populations. The 
epigenetic landscape during early embryonic development is known to change rapidly so the 
variation in LTR activation in not surprising. However, it does highlight the possibility that 
changes in LTR activation can to some degree define a cell type. The large variability in active 
LTRs which we observed in HL is an exciting finding as the variability in LTR activation may 
define different subsets of the disease and also may contribute to both the gene expression and 




4.3.1. LTR activation contributes to global deregulation of gene expression in HL cell 
lines.  
A number of studies have shown that expressed LTRs can act as promoters and enhancers. 
The exaptation of LTRs as promoters in HL has been shown at both the CSF1R gene and the 
IRF5 gene (Lamprecht, Walter et al. 2010, Babaian, Romanish et al. 2016). Based on these 
findings we wanted to determine whether other expressed LTRs in HL were also acting as 
promoters. To study the promoter activity of LTRs in HL we performed ChIP-Seq for the active 
promoter histone mark H3K4me3. 
We observed that 11.86% of LTRs corresponded to genomic regions containing H3K4me3 in 
the L428 cell line compared to only 5.03% in the Reh cell line. H3K4me3 is known to mark 
active promoters and has been previously shown at transcribed LTRs acting as promoters in 
HCC tumour cells (Liang, Lin et al. 2004, Hashimoto, Suzuki et al. 2015). The presence of 
H3K4me3 at only a small percentage of expressed LTRs does not necessarily accurately reflect 
that only these LTRs are active promoters. The alignment of short fragments produced by the 
ChIP-Seq experiments is intrinsically challenging due to the shared nature of sequence at 
repeat elements which means that reads either have to be assigned to all matching sequences 
or at random to one of the sites with corresponding sequence (Trapnell and Salzberg 2009). 
The potential alignment issues mean that many of the ChIP-Seq reads located around LTRs 
may be lost. It is however also possible that active LTRs are not active in all cells 
simultaneously and may not be captured by ChIP which is less sensitive than RACE due to its 
reliance on antibody binding. It is also possible that some LTRs may harbour alternative histone 
marks such as the enhancer mark H3K4me1. H3K4me1 has been observed at ERV-9 LTRs 
which act as promoters for the transcription of lncRNAs in human erythroblasts and at ERV 
driven enhancers in many cell types (Xie, Hong et al. 2013, Hu, Pi et al. 2017). An array of 
activating histone marks has also been described at LTRs in CD4+T cells including H3K37me1, 
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H3K36me1 and H3K27me1 (Huda, Marino-Ramirez et al. 2010). This implies that the absence 
of H3K4me3 on active LTRs in HL does not mean that these LTRs have no impact on gene 
expression in the HL cells but may indicate that a proportion are acting as enhancers. 
We also screened active LTRs for DNaseI hypersensitive sites (DHS) primarily with the aim of 
developing computational methods of identifying active LTRs in DHS data. Following high read-
depth DNaseI-Seq only a proportion of active LTRs were shown to coincide with a DHS. This 
finding was difficult to understand as to be transcriptionally active, chromatin needs to be in an 
accessible state. However, another study reported a similar finding that active repeat elements 
could not be identified in DNaseI-Seq or ATAC-Seq datasets but could be identified by 
Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE-Seq). They also went on to 
show, by MNase, that the sites of active repeat elements were located between phased 
nucleosomes. This led to the hypothesis that the repeat regions have unstable nucleosome 
binding so are less susceptible to digestion by DNaseI but are susceptible to the biochemical 
extraction process of FAIRE-Seq (Gomez, Hepperla et al. 2016).  
To determine the influence of active LTRs on gene expression in HL we integrated our RACE-
Seq and RNA-Seq data which showed clustering of active LTRs with up-regulated genes in 
each of the HL cell lines. Clustering of the cell lines based on correlation of gene expression for 
genes in the vicinity of active LTRs also showed the same clusters as correlation based on total 
gene expression. These findings would suggest that active LTRs in HL influence the expression 
of their nearest genes and in part define the expression pattern of each cell line. There are few 
other studies which compare actively transcribed LTRs to the expression of coding genes on a 
genome-wide basis, however there are a number of studies which identify individual genes 
regulated by LTRs (See 1.3.13). In HL cell lines we identified a number of cases where an 
active LTR could be linked directly to the expression of a down-stream transcript. Based on the 
transcripts observed we defined 4 different types of transcript; expression of a coding gene from 
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an alternative up-stream promoter, a shorter isoform of a coding gene from an intronic promoter, 
an anti-sense transcript or a lncRNA. The observation of these different transcripts originating 
from an LTR is not exclusive to HL cell lines and is seen across published studies of LTR 
activation (reviewed by (Babaian and Mager 2016)). 
4.3.2. HL specific genes transcribed from activated LTRs may be part of HL pathology 
We identified 3 new protein-coding genes which were directly up-regulated as a result of LTR 
promoters in HL. These genes were initially defined based on the presence of a read-through 
transcript, displayed in the RNA-Seq data, originating from the LTR to the downstream gene. To 
be able to find genes based on this technique requires manual curation therefore there are likely 
to be other LTR driven genes in HL yet to be identified. The first gene we identified was NLRP1 
which is up-regulated from an up-stream THE1C LTR. 
NLRP1 (NLR family pyrin domain-containing 1) is a cytosolic pattern recognition receptor which 
triggers an immune response to a microbial infection (Chavarria-Smith and Vance 2015). 
Following the recognition of a pathogen NLRP1 activates CASPASE-1 through interaction with 
its CARD (caspase activating and recruitment) domain. In turn CASPASE-1 cleaves precursors 
to the inflammatory cytokines Il-1β and Il-18 enabling these cytokines to be secreted triggering 
an immune response (Cerretti, Kozlosky et al. 1992, Ghayur, Banerjee et al. 1997). CASPASE-
1 is also able to induce cell death via pyropotosis in the absence of Il-1β and Il-18 (Masters, 
Gerlic et al. 2012). A recent study has shown that the up-regulation of NLRP1 expression can 
promote tumour growth through increasing inflammatory signalling in metastatic melanoma 
(Zhai, Liu et al. 2017). The findings in melanoma point towards a possible pathological function 
of NLRP1 which could also apply following the upregulation which we observed in HL. However, 
the inflammatory function that NLRP1 plays in melanoma is through the activation of Il-1β which 
based on our RNA-Seq data is not expressed in HL. A number of other potential targets for 
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caspase-1 cleavage have been identified but further study is required to determine whether 
these can be linked to an inflammatory response (Denes, Lopez-Castejon et al. 2012). Further 
work would be required to determine whether the up-regulation of NLRP1 resulting from LTR 
activation plays a significant role in the HL phenotype or whether it is simply a non-functional by-
product of LTR activation.  
We have also shown that WNT5A is expressed in the KM-H2 cell line from an active THE1D 
LTR. WNT5A is a member of the WNT family of ligands which are involved in development and 
many cellular processes (Logan and Nusse 2004). WNT proteins interact with the Frizzled (Fzd) 
family of receptors and in particular WNT5A interacts with Fzd3, Fzd4, Fzd5 and Fz8 (Kikuchi, 
Yamamoto et al. 2012, Linke, Zaunig et al. 2017). WNT5A activates the β-catenin independent 
pathway, which is best known for the modulation of cell movement at the stage of gastrulation 
during embryogenesis (Veeman, Axelrod et al. 2003). The involvement of WNT5A in cell motility 
has been identified as an important factor in the metastasis of a number of cancers including 
gastric, brain, colon and breast cancer (Kurayoshi, Oue et al. 2006, Klemm, Bleckmann et al. 
2011, Bakker, Das et al. 2013).  A number of studies have noted the up-regulation in gene 
expression of WNT5A in HL, however none have identified that this originates from a promoter 
in an upstream LTR (Klemm, Bleckmann et al. 2011, Tiacci, Doring et al. 2012, Linke, Zaunig et 
al. 2017). A recent study implicated WNT5A in cell migration in HL cell lines and the potential for 
this activity in HL tumours. The study showed that WNT5A interacted with the Fzd5 receptor 
which activates DVL3 leading to activation of RHOA which regulates the actin cytoskeleton and 
promotes motility in the cells (Tkach, Bock et al. 2005). When combined with our findings with 
regard to the role of LTR activation in the expression of WNT5A, this may suggest that LTR 
activation promotes metastasis of HL tumours. 
The WNT signalling pathways also play a role in a number of other cellular processes which 
may be implicated in HL. The interaction of WNT5A with Fzd5 does not only activate DVL3 but 
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also upregulates PKC signalling through release of CA2+ which has been shown to contribute to 
increase invasion of melanoma cells (Weeraratna, Jiang et al. 2002). In HL PKC signalling also 
has the potential to increase activation NF-κB which in turn is essential for the maintenance of 
the HL gene expression pattern, particularly in relation to the activation of LTRs. There is also 
evidence that PKC activity plays a role in the DNA binding capacity of both NF-κB and AP-1 (Li, 
Ping et al. 2000). The interaction of WNT5A with PKC and the potential for involvement in NF-
κB and AP-1 activity may point towards a positive feedback loop in the regulation of the WNT5A 
LTR.  
Our study also found that the expression of TNFRSF11A (RANK) is driven from a promoter 
within a THE1B LTR. The TNFRSF11A gene has been identified in a number of studies to be 
up-regulated in HL cell lines and in an average of 75% of HRS cells from primary tumour 
samples (Fiumara, Snell et al. 2001, Kuppers 2009). However, the expression of an isoform 
originating from an LTR promoter had previously not been reported. TNFRSF11A is a member 
of the TNF receptor family and acts as the receptor for TNFSF11A (RANKL) (Anderson, 
Maraskovsky et al. 1997). Activated TNFRSF11A interacts with TNF receptor associated factors 
(TRAFs) to up-regulate signalling in a number of pathways including NF-κB and JNK (Anderson, 
Maraskovsky et al. 1997, Darnay, Ni et al. 1999). A study into the impact of TNFRSF11A 
signalling on HL cell lines L428 and KM-H2 has shown that following incubation of cells with 
TNFSF11A the level of NF-κB activation increases (Fiumara, Snell et al. 2001). Because 
expression of the TNFSF11A ligand has also been shown in HL this would suggest 
TNFRSF11A expression may play a significant role in the up-regulation of NF-κB activation in 
HL cells (Fiumara, Snell et al. 2001). Further to this it has also been shown that the 
overexpression of TNFRSF11A even in the absence of its ligand can increase the activation of 
NF-κB (Anderson, Maraskovsky et al. 1997). To investigate the influence of TNFRSF11A 
expression on NF-κB activation in HL cell lines we performed a siRNA knockdown of 
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TNFRSF11A in the L1236 cell line, which our data showed to have the highest gene expression. 
The knockdown resulted in reduced NF-κB activation in the cell line although no obvious change 
in phenotype. This finding demonstrates another potential positive feedback loop for the 
activation of LTRs in HL.  
Our study also highlighted the ability of transcribed LTRs to produce anti-sense RNA transcripts 
and potentially reduce the expression of a gene by RNA interference. In particular we observed 
the reduction in expression of the CHD1L gene which contains an LTR driven anti-sense 
transcript. CHD1L has been shown to carry out chromatin remodelling functions in early 
development and may acts as a transcription factor (Chen, Chan et al. 2010, Snider, Leong et 
al. 2013). The overexpression of CHD1L is linked to hepatocellular carcinoma and 
overexpression in mice promotes spontaneous tumour formation (Chen, Huang et al. 2009). 
There is no published data with regard to the impact of reduced expression of CHD1L, however 
its role in DNA damage repair may suggest that the genome would be more susceptible to 
damage (Ahel, Horejsi et al. 2009). In HL it is likely that the knock-down in gene expression 
resulting from the anti-sense RNA has no overall impact on the cell phenotype, however it does 
highlight the potential for LTR driven down-regulation of gene expression.  
Our final observation with regards to LTR driven transcripts concerned a high abundance of 
unannotated lncRNAs resulting from active LTRs. These may be non-functional transcripts 
which are degraded soon after transcription and are formed simply as a result of an LTR 
promoter being actively transcribed. Long non-coding RNAs, however, have been shown to play 
a regulatory role in gene expression through interaction with chromatin remodelling, 
transcription and post-transcriptional processing (Cao 2014). The production of lncRNAs and 
vlincRNAs (very long non-coding RNAs) from LTR promoters has also been observed in other 
studies and linked to driving the progression of cancer.  Knock-down of 10 vlncRNAs specific to 
the K562 myeloid leukaemia cell line and expressed from ERV promoters resulted in an 
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increase in apoptosis within the cells showing that ERV driven vlncRNAs can promote cell 
survival and potentially cancer cell growth (St Laurent, Shtokalo et al. 2013).  
The remaining transcribed LTRs identified in our RACE data show no associated RNA-seq 
transcripts. The lack of RNA-seq transcripts at the LTRs is most likely due to the inability to 
generate unique alignments when mapping the RNA-Seq reads, however the lack of 
downstream transcript would suggest that these LTRs are not acting as promoters. The lack of 
transcript does not necessarily mean that the LTRs have no function though as they may be 
acting as enhancers for topologically close promoters. A study of the DNA methylation of a 
range of cell types including both foetal tissue and adult epithelial and haematopoietic cells 
identified a large number of TEs with the enhancer related histone mark H3K4me1 and showed 
enhancer activity in gene reporter assays (Xie, Hong et al. 2013). The fact that many TEs are 
able to act as enhancers opens up an additional level of gene regulation which may be 
occurring as a result of LTR activation in HL.  
 
4.4. Long Terminal Repeats can be activated by inflammatory signalling 
Our data has shown a clear genome-wide activation pattern of the THE1B family of LTRs in HL 
and additionally cell line specific LTR activation. Transcribed LTRs pose a significant threat to 
regulation of gene expression and therefore can contribute to the survival and growth of 
malignant cells. This means that strict control mechanisms are be required to ensure that ERVs 
are not expressed and these control mechanisms are lost in HL and other diseases which 
display LTR activation. The expression of subsets of LTRs in each HL cell line also implies that 




Loss of DNA methylation was the first genome-wide epigenetic change to be reported in cancer 
and overall genomic hypomethylation has since been reported in many types of cancer (Gama-
Sosa, Slagel et al. 1983, Ehrlich 2009). A large proportion of DNA hypomethylation in cancer is 
targeted towards repeat elements including Alu, LINE1, Satellite and LTRs (Qu, Dubeau et al. 
1999, Florl, Steinhoff et al. 2004, Rodriguez, Vives et al. 2008, Benesova, Trejbalova et al. 
2017). The THE1B LTR upstream of CSF1R was shown to be methylated at 2 CpG elements in 
mononuclear cells from healthy donors and this methylation is lost in HL (Lamprecht, Walter et 
al. 2010). To further investigate the epigenetic mechanisms controlling the expression of the 
CSF1R LTR Lamprecht, et al. (2010) screened for the expression of a number of corepressors, 
histone deacetylases and DNA methyltransferases in HL. No changes in the expression of any 
of these proteins were shown, however, a loss of the expression of the transcriptional repressor 
CBFA2T3 (ETO2) was discovered. ETO2 acts as a repressor through interaction with HDACs, a 
number of corepressors and possibly also EZH2 which is a component of the polycomb 
repressor complex and H3K27 methyltransferase complex (Hug and Lazar 2004, Wael, 
Fujiwara et al. 2011). It was further demonstrated that loss of ETO2 expression in Reh and 
Namalwa cell lines could induce weak expression of the CSF1R LTR and when this was 
combined with constitutive NF-κB activation a strong expression could be observed (Lamprecht, 
Walter et al. 2010).  
Knowing that constitutive NF-κB activation is a part of the inflammatory signalling network in HL 
and that THE1B LTRs harbour NF-κB, AP-1 and IRF motifs we wanted to establish whether 
inflammatory signalling alone could induce LTR expression. To achieve this we treated the cells 
with PMA which activates NF-κB and a number of other inflammatory pathways through PKC 
signalling.  We showed that PMA treatment of Reh cells was able to induce the expression of 
the CSF1R LTR and a number of other LTRs. The PMA treatment recapitulated the previous 
findings as it not only resulted in NF-κB activation but also the down-regulation of ETO2 by an 
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unknown mechanism. Our data also showed a correlation of LTR expression with changes in 
the gene expression and chromatin accessibility patterns indicating a move towards the HL 
phenotype. This finding demonstrated that inflammatory signalling alone through PKC was able 
to induce the expression of many LTRs and a partial HL phenotype. 
The presence of inflammatory transcription factor motifs has been previously noted in ERVs of 
the HERV-K and THE1B families (Lamprecht, Walter et al. 2010, Manghera and Douville 2013). 
Further to this HERV-K activation has been shown in a number of inflammatory diseases 
including rheumatoid arthritis, schizophrenia and several types of cancer and THE1B activation 
in HL (Frank, Giehl et al. 2005, Ruprecht, Mayer et al. 2008, Freimanis, Hooley et al. 2010, 
Lamprecht, Walter et al. 2010). The induction of ERV expression by treatment with PMA has 
also been shown previously, however not on a genome-wide scale. Induction of monocytic 
differentiation of the U-937 cell line by PMA treatment results in expression of an ERV3 element 
of the HERV-R family which is usually expressed in placental tissue (Larsson, Venables et al. 
1996). An increase in expression from an already active LTR can also be induced by PMA 
treatment, as described in a study of a HERV-K ERV in MeWo melanoma cells (Katoh, Mirova 
et al. 2011). Additionally several studies have shown that the activity of LTRs driving HIV 
infections can also be induced by PMA treatment (West, Lowe et al. 2001). 
The move we observed towards the HL phenotype following PMA treatment of Reh cells is not 
likely to be solely driven by LTR activation. Through interaction with PKC, PMA induces many 
pathways which are up-regulated in HL including NF-κB, MAPK, JNK and AP-1 (Schultz, Engel 
et al. 1997, Sharma and Richards 2000, Bagowski, Besser et al. 2003). Due to the interaction 
between these pathways and the transcription factor activity of AP-1 and NF-κB PMA has the 
potential to induce wide spread gene expression changes which are additional to those resulting 
from LTR expression.  
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To study the impact of LTR expression in a more tightly regulated system we produced an 
inducible NF-κB activation system through the overexpression of IkKβ.  The induction of NF-κB 
activity resulted in the expression of a large number of LTRs shown in our RACE-Seq data. 
However, only a small proportion of these LTRs were also expressed in the HL cell lines and the 
CSF1R LTR was not expressed. This finding suggests that the transcriptional repression of at 
least the CSF1R LTR by ETO2 is sufficient to prevent expression even in the presence of 
constitutive NF-κB activation.  Very little overall change in gene expression was observed, 
however, we did see the up-regulation of a number of inflammatory response genes. The 
induction of inflammatory gene expression is not surprising as constitutive NF-κB activation has 
long been known to play a significant role in the inflammatory signature of HL cells (Izban, Ergin 
et al. 2001).  
The LTR expression which we observe both following PMA treatment and induction of 
constitutive NF-κB activation only displayed a partial overlap with the LTR expression in HL 
cells. This finding implies that additional epigenetic mechanisms for transcriptional control are 
inhibiting the activation of some LTRs including those responsible for the expression of CSF1R, 
WNT5A, NLRP1 and TNFRSF11A. We already know from the work of Lamprecht et al. (2010) 
that the transcription of the CSF1R LTR is repressed by ETO2, however, this does not account 
for many other LTRs which are not expressed following PMA treatment. A number of other 
mechanisms for controlling the expression of ERVs have been shown in other studies, including 
histone acetylation, histone methylation and KRAB-ZFP binding  (Hurst and Magiorkinis 2017). 
However a recent study has also suggested that, in the case of the L1HS-Ta subfamily of LINE1 
elements, activation only occurs when the element is in a region of chromatin which is already 
primed for expression (Philippe, Vargas-Landin et al. 2016). 
Acetylation of lysine residues in histones has been linked to the activation of HERV-Fc1 when 
combined with a loss of CpG methylation (Laska, Brudek et al. 2012). Acetylation of lysine 
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residues by histone acetyltransferases (HATs) blocks positive charges and therefore 
destabilises nucleosome binding allowing for transcription to take place. To maintain stable 
chromatin at these regions histone deacetylases (HDACs) remove acetylation from the lysine 
residues (Bannister and Kouzarides 2011). In a disease state the loss of HDACs could 
potentially lead to chromatin destabilisation and the activation of ERVs, however, it has been 
shown that inhibition of HDACs alone is not sufficient to upregulate ERV expression (Laska, 
Brudek et al. 2012). Our gene expression data does not show any significant change in the 
levels of HDAC proteins compared to the control cell lines with the exception of HDAC9. HDAC9 
overexpression has been linked to other B-cell malignancies but there is a lack of research into 
the impact of HDAC9 down-regulation (Gil, Bhagat et al. 2016). 
 Histone methylation also has potential to play a role in the epigenetic regulation of ERV 
expression. We show the presence of the activating lysine methylation mark H3K4me3 at a 
proportion of active LTRs in HL, however, we did not study potential repressive marks residing 
at inactive LTRs in both the control and HL cell lines. A strong association has previously been 
shown between repressed HERV-K elements and the repressive histone mark H3K9me3 
(Campos-Sanchez, Cremona et al. 2016). H3K9me3 at ERVs is driven largely by Krüppel 
associated box zinc finger proteins (KRAB-ZFP) which exhibit sequence specific DNA binding 
and interact with KAP1 (TRIM28) to recruit histone modification complexes. In particular KARB-
ZFPs have been shown to recruit SETDB1 to ERVs resulting in the repressive H3K9me3 
modification (Imbeault, Helleboid et al. 2017). There is also evidence to suggest that the wide 
array of KRAB-ZFP proteins within the human genome developed as a result of new ERV 
integrations (Thomas and Schneider 2011). Although the action of KRAB-ZFPs is yet to be 
investigated at MalR LTRs, this finding highlights an interesting potential regulatory mechanism 
as the binding of different KRAB-ZFPs could account for the different activation patterns which 
we observed in each cell line.  
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The final factor which is known to play a role in control of ERV expression and may be 
contributing to the LTR expression patterns in HL is DNA methylation. As discussed previously 
(1.3.17) CG-hypomethylation is a major phenotype of many cancers and may contribute to 
increased LTR activation. A recent study has highlighted this notion by showing that the 
treatment of lung cancer cells with histone deacetylase inhibitors (HDACi) and DNA 
methyltransferase inhibitors (DNMTi) resulted in the genome wide activation of LTRs, 
particularly of the ERV9 family (Brocks, Schmidt et al. 2017). A number of other studies have 
also shown that although global hypomethylation occurs in cancer that some tumour suppressor 
genes are hypermethylated which suggests a more complex role for DNMTs (Mager and 
Lorincz 2017). We know from previous studies (discussed above) that a combination of 
activation and loss of repression is required for activation of other LTR families and these 
findings with regard to DNA methylation add an additional level of complexity. 
4.5. Conclusion 
In conclusion, we have developed a new genome-wide technique for the identification of active 
THE1B LTRs and used this technique to investigate the activation of LTRs in HL. We have 
shown that HL cell lines exhibit a specific activation pattern of LTRs both in comparison to 
control cell lines and to each other. Moreover, the expressed LTRs have also been shown to 
play a role in the up-regulation of potentially pathological gene expression.  
The inflammatory signature and the involvement of NF-κB and AP-1 in HL had been previously 
described, however for the first time we have shown co-localisation of AP-1 and NF-κB motifs 
with many other transcription factors motifs in HL suggesting that these factors may co-localise. 
This demonstrates the central role of AP-1 and NF-κB in contributing to the deregulated HL 
gene expression program. We have also shown that the inflammatory signature of HL may be 
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the driving force in the genome-wide activation of LTRs, which highlights the potential 
involvement of LTR expression in other inflammatory disease. 
These exciting new insights into the activation and function of LTRs within the genome of HL 
cells highlight the significance of LTR activation and the role that it may play in the pathogenesis 
of HL. We have also shown LTR activation as a significant gene regulatory mechanism which 
may have implications for the pathogenesis of other diseases.   
4.6. Future Work 
4.6.1. Further examination of the cis-regulatory elements driving HL 
We have shown that NF-κB and AP1 motifs co-localise in regions of chromatin which show 
transcription factor binding, based on our footprinting data. This finding implies that there may 
be an interaction between the NF-κB and AP-1 transcription factors. To further study this idea 
we could obtain ChIP-Seq data for NF-κB and AP-1 to determine their actual binding pattern 
rather than just that inferred from the presence of their motifs. The co-localisation of these 
factors could also be studied using immune florescence and confocal microscopy. We also now 
have an IRF4 ChIP-Seq dataset which can be used to analyse the binding at the IRF motifs 
which we also identified in foot-printed regions.  
4.6.2. Genome-wide mapping of LTRs 
We have successfully demonstrated the utility of our THE1B LTR RACE-Seq technique in the 
identification of expressed LTRs in both HL and control cell lines. Although successful our 
RACE-Seq technique currently has a significant variability between biological replicates. We 
hypothesised that this was due to the low sequencing depth capturing only a proportion of the 




We believe that the RACE-Seq technique should have significant advantage over CAGE for the 
identification of expressed LTRs due to the longer read length producing more accurate unique 
mapping. To determine whether there is a significant advantage to the RACE-Seq technique it 
would be necessary to perform CAGE on the HL cell lines. The RACE-Seq data could also be 
compared to RNA-Seq bioinformatics based approaches for the identification of active LTRs 
(discussed in 1.3.18), however, it is expected that the lower abundance LTR transcripts would 
be missed in the RNA-Seq data. 
Currently the RACE-Seq technique has only been targeted towards the THE1B LTR family and 
through sequence homology we have shown that other members of the THE1 family are active 
and can influence gene expression. To further investigate the other active ERVs in HL an array 
of primers could be designed allowing a far broader spectrum of expressed ERVs to be studied. 
The RACE-Seq technique could also prove valuable for the genome-wide identification of 
expressed LTRs in other diseases. LTR activation has been reported in many diseases, 
particularly those with an inflammatory aspect and it would be exciting to build up datasets for 
the LTR activation in these diseases to both analyse the impact on gene expression and to 
compare activation in different disease contexts. RACE-Seq could also be used to identify cells 
with chronic inflammation based on the identification of chronic LTR activation. 
 
4.6.3. LTRs as Alternative Promoters and Enhancers 
We successfully identified a number of protein coding genes which exhibit expression from an 
upstream expressed LTR promoter in HL. The WNT5A gene has shown involvement in the HL 
phenotype in a number of studies and we have proposed a number of other regulatory 
mechanisms which may form a positive feedback loop for the regulation of gene expression 
from the LTR. It may be of interest to further investigate the role of this gene in the overall HL 
190 
 
phenotype by performing siRNA knockdown. The NLRP1 gene which we showed to be up-
regulated from an LTR has not before been associated with HL before and may prove to be an 
interesting target particularly if it is functioning through a novel pathway. Again in the first 
instance an siRNA knockdown of NLRP1 would be require to assess the influence of cell 
phenotype and survival. 
We also identified many unannotated lncRNAs originating from expressed LTRs. The function of 
lncRNAs is more complicated to determine than protein coding genes as they are most likely to 
act as regulatory elements. Other studies have shown a significant impact on the survival and 
proliferation of cells resulting from the knockdown of LTR driven lncRNA transcripts. To study 
this would require a large scale screening method, a number of which have been developed in 
recent years. A particularly successful method has been the use of CRISPR interference 
(CRISPRi) which recruits a non-functional Cas9 enzyme to the transcription start site of 
lncRNAs preventing their transcription (Liu, Horlbeck et al. 2017). The efficacy of this technique 
when targeting lncRNAs with LTR transcription start sites would have to be assessed as the 
repeated nature of the sequence through the genome would make them more difficult to 
uniquely target. 
Many active LTRs did not display any associated transcript in our RNA-Seq data. We have 
suggested that these LTRs may be acting as enhancer for promoters of coding genes which are 
topologically associated. The enhancer function of active LTRs could play an important role in 
HL and potentially other disease. The function of LTRs as enhancers could be investigated by 3 
routes. Firstly performing genome-wide ChIP-Seq for histone modifications often associated 
with enhancer elements such as H3K4me1 (Calo and Wysocka 2013). Secondly promoter 
capture-Hi-C technology could be used to identify the topological association of active LTRs 
with promoters (Mifsud, Tavares-Cadete et al. 2015). Finally there are a number of luciferase 
reported based assay which have been developed for enhancer screening and luciferase 
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assays would be required to validate the function of any enhancers identified by the other 
methods (Dailey 2015). 
Both the RACE-Seq and CAGE techniques suffer the significant problem of identification of 
down-stream transcripts originating from active LTRs because both techniques only identify the 
transcription start sites. We have overcome this to some degree by the manual screening of 
read-through transcripts in RNA-Seq data followed by the use of qPCR to confirm the presence 
of a transcript originating from an expressed LTR. This technique is not ideal as it is not possible 
to rapidly identify entire LTR driven transcripts. A potential way to overcome this would be the 
development of a capture RNA-Seq technique whereby entire transcripts containing an LTR 
could be captured and sequenced on a genome-wide basis. To achieve this biotinylated baits 
targeted towards the homologous LTR sequences could be designed and used to pull down 
RNA containing an LTR. For the THE1B elements this may be possible with a single bait and an 
annealing step allowing binding with mismatches. The selected RNA could then be used in an 
RNA-Seq library preparation protocol which would produce a genome-wide library of transcripts 
which incorporate an LTR. This technique could have a number of advantages including the 
opportunity to create a capture array for many families of ERV and potentially a simplified 
mapping strategy as alignment to the LTR its self may not be necessary. This capture technique 
combined with either RACE-Seq or CAGE to identify transcription start sites could prove to be a 
valuable and rapid technique to determine the true impact of LTRs as alternative promoters in 
HL and other healthy and diseased tissue.  
4.6.4. Direct Impact of LTR activation 
In the current study we began to assess the potential direct impact of LTR activation in the Reh 
cell line by the constitutive activation of NF-κB. We showed the activation of a large number of 
LTRs, however, only a small proportion of these were shared within the HL datasets. Based on 
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previous work it is clear that for at least the expression of the CSF1R LTR the knockdown of 
ETO2 is also required (Lamprecht, Walter et al. 2010). To establish the direct impact that 
genome-wide LTR activation has on gene expression we have already begun to carry out 
siRNA knockdown of ETO2 in our iIkKβ cells with the aim to carry out RNA-Seq and RACE-Seq, 
however time constraints prohibited it’s inclusion in this thesis. This will allow us to both 
establish the genome-wide LTR activation pattern generated by combined ETO2 knockdown 
and constitutive NF-κB activation and the impact on gene expression at an early time point prior 
to downstream changes in the cell phenotype. Hopefully this will provide us with exciting 
insights into how LTR expression can deregulate gene expression. 
 
4.6.5. Epigenetic control mechanisms for LTR repression 
Although we know from the work of Lamprecht et al. (2010) that loss of ETO2 expression is 
involved in the up-regulation of LTRs the way in which ETO2 interacts with the LTR sequence to 
inhibit transcription is not known. It is known that ETO2 does not directly bind DNA and 
functions as part of a complex. To determine the way in which ETO2 contributes to LTR 
activation in HL ChIP-Seq could be performed to identify the ETO2 complex binding site. It is 
known, however, from previous work in our lab that ETO2 is notoriously difficult to ChIP 
(Bonifer, personal communication). Therefore, to overcome this it may be necessary to produce 
a tagged version of the ETO2 protein which could be expressed in Reh cells and the ChIPed 
based on the tag. This method is not ideal as an overexpression of ETO2 may result in aberrant 
binding, however, it may elucidate the binding motif of the complex in the vicinity of repressed 
LTRs. It may also be possible to carry out pull-down mass-spectrometry assays on the ETO2 




It is clear from the unique activation pattern of THE1B LTRs observed in each cell line that 
different epigenetic repression mechanisms act on different LTRs. In the first instance assessing 
the genome-wide DNA methylation state at repressed LTRs in the HL cell lines would be 
beneficial to determine whether this is the main controlling factor of LTR expression even in the 
generally hypomethylated state of HL cells. Other ERVs have been shown to harbour the 
H3K9me3 repressive chromatin mark which is likely to be deposited by SETDB1 as a result of 
specific KRAB-ZFP binding.  To investigate whether H3K9me3 plays a role in repression of the 
THE1B LTRs ChIP-Seq could be carried out in a control cell line to look for its presence in the 
vicinity of inactive TH1B LTRs. The role of KRAB-ZFP proteins could also be investigated 
through ChIP-Seq of KAP1 the binding partner of many of the KRAB-ZFP proteins.  
4.6.6. Primary Cells 
Finally, it is important to note that all assays within the current study were carried out in HL and 
control cell lines which, although well characterised, are not a completely accurate 
representation of primary HL cells. To determine the relevance of our findings in the clinical 
context it is important to repeat aspects of our work in primary samples. This is a challenging 
prospect as obtaining primary HL cells is a notoriously arduous task due to their low percentage 
within tumour samples. It may be possible to optimise the RACE-Seq technique for very low cell 
numbers, as has been done for many genome-wide sequencing techniques in recent years. A 
simpler approach may be to use RNA-Seq data obtained from primary HL cells and carry out a 
targeted bioinformatics approach to identify active LTRs. Although this approach may not be 
able to identify the full complement of LTR expression shown by RACE-Seq, it may prove useful 




5. SUPPLEMENTARY TABLES 
Supplementary Data Table 1. Closest genes to active LTRs detected by RACE-Seq in 
Reh cells. Gene expression values (FPKM) from RNA-Seq are also shown for each 
gene. 
 
RACE Peak Gene (FPKM) 
chr1 2123459-2123568 PRKCZ (0.37) 
chr1 11467916-11468065 PTCHD2 (0.33) 
chr1 11723228-11723324 FBXO6 (1.99) 
chr1 31945309-31945449 LOC149086 (0) 
chr1 38959152-38959284 LOC339442 (0) 
chr1 57080279-57080415 PRKAA2 (0) 
chr1 57271439-57271571 C1orf168 (0) 
chr1 58185274-58185370 DAB1 (0.99) 
chr1 60251163-60251289 FGGY (2.76) 
chr1 72181715-72181857 NEGR1 (3.55) 
chr1 79645542-79645678 ELTD1 (0) 
chr1 83498791-83498918 TTLL7 (0) 
chr1 91328368-91328538 ZNF644 (5.45) 
chr1 101455533-101455850 DPH5 (4.19) 
chr1 105955070-105955205 LOC100129138 (0) 
chr1 108092966-108093310 VAV3 (6.39) 
chr1 108436106-108436235 VAV3 (6.39) 
chr1 112218475-112218571 RAP1A (2.52) 
chr1 115735413-115735555 NGF (0) 
chr1 116082660-116082801 VANGL1 (0) 
chr1 150280559-150280660 PRPF3 (5.83) 
chr1 153633929-153634046 ILF2 (8.32) 
chr1 157866049-157866184 CD5L (0.77) 
chr1 157867974-157868110 CD5L (0.77) 
chr1 177701417-177701605 SEC16B (0) 
chr1 193832613-193832748 CDC73 (2.7) 
chr1 194317005-194317148 CDC73 (2.7) 
chr1 194699318-194699446 CDC73 (2.7) 
chr1 194780246-194780388 KCNT2 (0) 
chr1 195611798-195611930 KCNT2 (0) 
chr1 198999693-198999916 LOC100131234 (0) 
chr1 209874557-209874702 HSD11B1 (0) 
chr1 211640084-211640229 RD3 (0) 
chr1 215159433-215159559 KCNK2 (0) 
chr1 221760504-221760637 DUSP10 (0.98) 
chr1 234730404-234730527 IRF2BP2 (6.06) 
chr1 236326933-236327067 GPR137B (2.65) 
chr1 245120978-245121151 EFCAB2 (4.25) 
chr10 1496247-1496385 ADARB2-AS1 (0.56) 
chr10 1801338-1801475 ADARB2 (0.06) 
chr10 6278973-6279103 PFKFB3 (2.57) 
chr10 13478502-13478631 BEND7 (0.13) 
chr10 15080561-15080692 OLAH (0.52) 
chr10 23834957-23835098 OTUD1 (1.6) 
chr10 24139694-24139822 KIAA1217 (0.13) 
chr10 26717788-26717915 APBB1IP (5.68) 
chr10 30536793-30536927 MTPAP (3.58) 
chr10 44180164-44180299 ZNF32-AS3 (0) 
chr10 50791274-50791402 CHAT (0.12) 
chr10 52555746-52555887 A1CF (0) 
chr10 53022429-53022552 PRKG1 (0.01) 
chr10 67021523-67021655 ANXA2P3 (0) 
chr10 78271865-78272006 KCNMA1 (0.12) 
chr10 79664370-79664512 DLG5 (2.2) 
chr10 81114899-81115016 ZCCHC24 (0.93) 
chr10 82388098-82388227 SH2D4B (1.65) 
chr10 92353932-92354066 HTR7 (2.72) 
chr10 92426108-92426228 HTR7 (2.72) 
chr10 93656807-93656948 FGFBP3 (1.08) 
chr10 95441248-95441350 PDE6C (0.03) 
chr10 98497237-98497398 PIK3AP1 (7.24) 
chr10 101711795-101711966 DNMBP (2.13) 
chr10 108053831-108053956 SORCS1 (0) 
chr10 110936974-110937109 XPNPEP1 (5.6) 
chr10 115780559-115780702 ADRB1 (0.57) 
chr10 125171640-125171762 BUB3 (8.8) 
chr10 125305960-125306102 GPR26 (0) 
chr11 1285714-1286156 MUC5B (0) 
chr11 3206211-3206351 OSBPL5 (2.69) 
chr11 10830368-10830491 EIF4G2 (8.04) 
chr11 11110831-11110974 GALNTL4 (0) 
chr11 11845428-11845570 USP47 (4.19) 
chr11 13010984-13011140 RASSF10 (0.43) 
chr11 14541835-14541970 PSMA1 (7.59) 
chr11 23658261-23658386 LOC100500938 (0) 
chr11 27911881-27912109 KIF18A (4.63) 
chr11 35071547-35071706 PDHX (4.39) 
chr11 36602021-36602155 RAG1 (8.75) 
chr11 36607823-36608045 RAG2 (7.37) 
chr11 46450246-46450424 AMBRA1 (4.61) 
chr11 57357410-57357530 SERPING1 (3.46) 
chr11 63595036-63595151 MARK2 (3.04) 
chr11 64185765-64185899 RPS6KA4 (4.59) 
chr11 67450457-67450559 ALDH3B2 (0) 
chr11 73685720-73685942 DNAJB13 (0.13) 
chr11 89984349-89984473 CHORDC1 (4.11) 
chr11 98765707-98765834 CNTN5 (0) 
chr11 103987549-103987690 PDGFD (0) 
chr11 109031422-109031563 DDX10 (4.54) 
chr11 111776418-111776533 CRYAB (0.1) 
chr11 113749276-113749609 USP28 (4.66) 
chr11 119773496-119773635 PVRL1 (0.67) 
chr11 126517995-126518114 KIRREL3 (0.05) 
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chr11 127792055-127792177 ETS1 (4.32) 
chr12 6576145-6576288 VAMP1 (2.98) 
chr12 9804052-9804177 CLEC2D (3.8) 
chr12 13420857-13420978 EMP1 (0.17) 
chr12 21810677-21810807 LDHB (10.18) 
chr12 25108470-25108603 BCAT1 (0.01) 
chr12 26087145-26087268 LOC100506451 (0) 
chr12 38625342-38625442 ALG10B (1.4) 
chr12 46380565-46380699 ARID2 (4.2) 
chr12 46544822-46544947 SLC38A1 (4.68) 
chr12 50505950-50506075 C12orf62 (0) 
chr12 56506765-56506876 RPL41 (12.23) 
chr12 59880360-59880489 SLC16A7 (0.08) 
chr12 78714442-78714679 NAV3 (1.55) 
chr12 84255504-84255641 TMTC2 (0) 
chr12 88535708-88535816 CEP290 (2.64) 
chr12 89445744-89445875 LOC728084 (0.22) 
chr12 93335088-93335239 EEA1 (2.82) 
chr12 94027778-94027968 CRADD (3.44) 
chr12 97477865-97477991 NEDD1 (4.86) 
chr12 104864046-104864177 CHST11 (4.28) 
chr12 111298758-111298887 MYL2 (0) 
chr12 111848608-111848767 ATXN2 (2.64) 
chr12 112847270-112847376 PTPN11 (5.34) 
chr12 115803801-115803938 MED13L (4.99) 
chr12 117561629-117561763 FBXO21 (4.55) 
chr12 125597277-125597408 AACS (1.82) 
chr12 126814995-126815112 LOC100128554 (0) 
chr12 129594177-129594319 TMEM132D (0) 
chr13 21751159-21751291 MRP63 (0) 
chr13 21776034-21776159 MRP63 (0) 
chr13 27766731-27766873 USP12 (2.75) 
chr13 28841731-28841873 FLT1 (2.45) 
chr13 31037342-31037464 LINC00426 (4.92) 
chr13 31122395-31122516 USPL1 (3.52) 
chr13 38410175-38410353 TRPC4 (2.49) 
chr13 38558527-38558685 TRPC4 (2.49) 
chr13 38624776-38625015 TRPC4 (2.49) 
chr13 54539416-54539551 MIR1297 (0) 
chr13 56357020-56357162 PRR20C (0) 
chr13 59562742-59562860 DIAPH3 (4.07) 
chr13 60603706-60603831 DIAPH3 (4.07) 
chr13 60982103-60982346 TDRD3 (2.96) 
chr13 63631316-63631432 OR7E156P (0) 
chr13 68917837-68917972 LOC338862 (0) 
chr13 89571375-89571608 SLITRK5 (1.18) 
chr13 89681350-89681456 MIR622 (0) 
chr13 104846787-104846928 SLC10A2 (0) 
chr13 109306691-109306832 MYO16 (0.01) 
chr13 110354394-110354508 IRS2 (1.98) 
chr13 110617233-110617368 IRS2 (1.98) 
chr13 112262578-112262701 C13orf16 (0) 
chr13 114518538-114518683 FAM70B (0) 
chr14 21134849-21134992 ANG (0.89) 
chr14 24037062-24037185 JPH4 (0.07) 
chr14 30348573-30348708 PRKD1 (0) 
chr14 35779976-35780108 KIAA0391 (5.58) 
chr14 38973137-38973271 LOC283547 (0) 
chr14 39011191-39011317 LOC283547 (0) 
chr14 41208380-41208513 LRFN5 (0) 
chr14 50872977-50873211 CDKL1 (1.96) 
chr14 52731145-52731291 PTGDR (2.44) 
chr14 70753641-70753782 SYNJ2BP-COX16 
(0.11) 
chr14 81675607-81675744 GTF2A1 (3.2) 
chr14 81723116-81723231 STON2 (0.7) 
chr14 82889319-82889454 SEL1L (3.87) 
chr14 85271390-85271518 FLRT2 (0) 
chr14 88746234-88746375 KCNK10 (0.31) 
chr14 92630270-92630521 CPSF2 (5.83) 
chr14 93336859-93336998 GOLGA5 (3.59) 
chr14 93338642-93338775 GOLGA5 (3.59) 
chr14 93339790-93339929 GOLGA5 (3.59) 
chr14 96245201-96245325 TCL1A (0.18) 
chr14 97375237-97375365 VRK1 (6.55) 
chr14 97903762-97903895 LOC100129345 (0) 
chr14 100800165-100800276 SLC25A47 (0) 
chr15 33502030-33502169 RYR3 (0.08) 
chr15 34880538-34880676 GOLGA8B (2.41) 
chr15 38318073-38318214 TMCO5A (0) 
chr15 38974421-38974556 C15orf53 (0) 
chr15 43490121-43490263 EPB42 (0.03) 
chr15 46166854-46166984 SQRDL (1.02) 
chr15 49907716-49907835 C15orf33 (0) 
chr15 53315164-53315305 ONECUT1 (0.26) 
chr15 62574055-62574200 C2CD4B (0) 
chr15 69745120-69745258 KIF23 (5.19) 
chr15 70885582-70885712 UACA (1.96) 
chr15 74756744-74756874 LOC440288 (0) 
chr15 75230242-75230468 RPP25 (1.37) 
chr15 78953409-78953517 CHRNB4 (0.21) 
chr15 96603966-96604108 NR2F2 (0) 
chr15 101835319-101835461 PCSK6 (0.3) 
chr16 2011183-2011279 RPS2 (11.27) 
chr16 2011606-2011931 RPS2 (11.27) 
chr16 11931461-11931561 RSL1D1 (6.04) 
chr16 13515180-13515321 SHISA9 (2.83) 
chr16 20035576-20035705 GPR139 (0) 
chr16 21127729-21127888 DNAH3 (0.08) 
chr16 27258614-27258734 NSMCE1 (4.28) 
chr16 31123555-31123837 KAT8 (5.29) 
chr16 54907974-54908106 CRNDE (4.88) 
chr16 60118530-60118661 LOC644649 (0) 
chr16 67978238-67978366 SLC12A4 (2.43) 
chr16 69355949-69356117 COG8 (4.43) 
chr16 76268947-76269137 CNTNAP4 (0) 
chr16 80926391-80926522 C16orf61 (0) 
chr16 88876087-88876225 APRT (6.96) 
chr16 89727676-89727892 C16orf55 (0) 
chr16 90029710-90029826 DEF8 (4.88) 
chr17 1554038-1554161 PRPF8 (5.54) 
chr17 4843930-4844048 RNF167 (4.88) 
chr17 7529654-7529770 SHBG (0) 
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chr17 7760777-7760896 CYB5D1 (2.95) 
chr17 10770809-10770941 PIRT (0) 
chr17 27717442-27717571 MIR4523 (0) 
chr17 30771505-30771629 PSMD11 (3.32) 
chr17 33296817-33296948 ZNF830 (3.9) 
chr17 35075637-35075770 MRM1 (3.56) 
chr17 41395560-41395722 TMEM106A (2.42) 
chr17 46752964-46753088 MIR196A1 (0) 
chr17 65700583-65700727 PITPNC1 (3.5) 
chr17 67559490-67559625 MAP2K6 (2.98) 
chr17 67744804-67744929 MAP2K6 (2.98) 
chr17 69617064-69617194 SOX9 (0) 
chr17 74560556-74560724 ST6GALNAC2 (0.81) 
chr17 77158335-77158486 RBFOX3 (0.13) 
chr17 79336000-79336133 TMEM105 (0) 
chr18 5270335-5270462 ZFP161 (0) 
chr18 8445098-8445240 PTPRM (2.3) 
chr18 8938989-8939113 CCDC165 (0) 
chr18 13149934-13150054 CEP192 (4.77) 
chr18 20857268-20857393 CABLES1 (0.42) 
chr18 29545587-29545718 TRAPPC8 (4.56) 
chr18 32485040-32485192 DTNA (0.02) 
chr18 36807047-36807147 LOC647946 (0) 
chr18 39015049-39015187 KC6 (0) 
chr18 39580615-39580752 PIK3C3 (6.35) 
chr18 44722435-44722566 IER3IP1 (5.25) 
chr18 44812047-44812173 IER3IP1 (5.25) 
chr18 48043839-48043965 MAPK4 (0.02) 
chr18 53264253-53264382 TCF4 (5.34) 
chr18 57212996-57213137 CCBE1 (0.05) 
chr18 61222174-61222295 SERPINB12 (0.19) 
chr18 62453073-62453198 LOC284294 (0) 
chr18 62658709-62658848 LOC284294 (0) 
chr18 71197398-71197532 LOC100505817 (0) 
chr18 71452132-71452262 FBXO15 (0.76) 
chr18 71825364-71825498 C18orf55 (0) 
chr18 72057488-72057601 C18orf63 (0.09) 
chr18 73341580-73341717 C18orf62 (0) 
chr18 73447887-73448014 C18orf62 (0) 
chr18 75705583-75705711 GALR1 (0) 
chr18 77352749-77352873 NFATC1 (1.19) 
chr19 2328397-2328580 SPPL2B (3.52) 
chr19 2477769-2477891 GADD45B (5) 
chr19 3178371-3178504 S1PR4 (6.54) 
chr19 5676822-5676933 C19orf70 (4.75) 
chr19 5978382-5978548 RANBP3 (4.51) 
chr19 6381159-6381428 GTF2F1 (5.27) 
chr19 7320952-7321093 INSR (5.47) 
chr19 7696336-7696479 PCP2 (0.71) 
chr19 11488541-11488674 EPOR (3.06) 
chr19 34046695-34046823 PEPD (4.61) 
chr19 41302697-41302839 MIA-RAB4B (0.45) 
chr19 42891510-42891637 MEGF8 (2.5) 
chr19 47029653-47029793 LOC100506012 (0) 
chr19 47776906-47777022 PRR24 (0) 
chr19 50363565-50363667 PNKP (3.57) 
chr19 50363811-50363976 PNKP (3.57) 
chr19 56824676-56824772 ZNF542 (0) 
chr2 11029080-11029221 KCNF1 (0) 
chr2 11720088-11720329 MIR4429 (0) 
chr2 11821533-11821673 NTSR2 (0) 
chr2 14131243-14131387 FAM84A (0) 
chr2 14375957-14376079 FAM84A (0) 
chr2 22065522-22065647 LOC645949 (0) 
chr2 22445716-22445845 LOC645949 (0) 
chr2 27907978-27908097 SLC4A1AP (4.24) 
chr2 30490026-30490154 LBH (3.92) 
chr2 33931893-33932037 MYADML (0) 
chr2 36275754-36275883 LOC100288911 (0) 
chr2 40144672-40144804 LOC100128590 (0) 
chr2 40808066-40808198 SLC8A1 (3.07) 
chr2 54501233-54501370 ACYP2 (1.76) 
chr2 54621620-54621758 C2orf73 (0.04) 
chr2 60343686-60343828 MIR4432 (0) 
chr2 65275253-65275376 CEP68 (3.33) 
chr2 70645593-70645723 TGFA (0.26) 
chr2 71349617-71350063 MPHOSPH10 (3.6) 
chr2 74154009-74154157 DGUOK (5.54) 
chr2 76532724-76532875 LRRTM4 (0) 
chr2 89375689-89375824 MIR4436A (0) 
chr2 90163095-90163228 MIR4436A (0) 
chr2 100544450-100544579 AFF3 (0.77) 
chr2 111881294-111881411 ACOXL (0) 
chr2 136007260-136007395 ZRANB3 (2.66) 
chr2 136743591-136743689 DARS (6.72) 
chr2 137033983-137034097 CXCR4 (7.16) 
chr2 155062114-155062249 GALNT13 (0) 
chr2 162419058-162419181 SLC4A10 (0.01) 
chr2 177293855-177293995 MTX2 (0) 
chr2 188616708-188616845 TFPI (1.52) 
chr2 191573349-191573480 NAB1 (3.76) 
chr2 196344281-196344407 SLC39A10 (5.44) 
chr2 211777511-211777654 CPS1 (0.64) 
chr2 217363562-217363662 SMARCAL1 (2.95) 
chr2 217363946-217364044 SMARCAL1 (2.95) 
chr2 222529817-222529946 EPHA4 (0.07) 
chr2 224887630-224887764 SERPINE2 (0.45) 
chr2 225291544-225291667 FAM124B (0) 
chr2 239683152-239683293 TWIST2 (0) 
chr2 242670236-242670362 ING5 (3.84) 
chr20 807139-807267 FAM110A (2.73) 
chr20 4557233-4557365 PRNP (3.66) 
chr20 12638321-12638455 SPTLC3 (0.9) 
chr20 18109287-18109434 PET117 (3.72) 
chr20 22940392-22940534 SSTR4 (0) 
chr20 35617257-35617387 RBL1 (4.85) 
chr20 39570752-39570878 TOP1 (4.68) 
chr20 40256511-40256776 CHD6 (3.69) 
chr20 43095404-43095524 TTPAL (1.46) 
chr20 43588896-43589039 LOC100505826 (0) 
chr20 55453491-55453624 TFAP2C (0) 
chr20 55813770-55813907 BMP7 (0) 
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chr20 56058374-56058650 CTCFL (0.95) 
chr20 60715845-60715987 SS18L1 (2.95) 
chr21 16052027-16052161 SAMSN1 (4.49) 
chr21 16061745-16061879 SAMSN1 (4.49) 
chr21 16891388-16891516 USP25 (4.66) 
chr21 17005818-17005943 USP25 (4.66) 
chr21 17248781-17248902 LINC00478 (0) 
chr21 19858103-19858241 TMPRSS15 (0) 
chr21 20834127-20834253 TMPRSS15 (0) 
chr21 23406648-23406783 LINC00308 (0) 
chr21 24043565-24043701 LINC00308 (0) 
chr21 28195424-28195567 ADAMTS1 (0) 
chr21 29420731-29420864 LINC00314 (0) 
chr21 29570152-29570294 LINC00314 (0) 
chr21 35287996-35288136 LOC100506334 (0) 
chr21 37177004-37177138 MIR802 (0) 
chr21 37470446-37470550 LOC100133286 (0.21) 
chr21 38431524-38431642 PIGP (4.23) 
chr21 40110402-40110537 LINC00114 (1.53) 
chr21 40150491-40150618 LINC00114 (1.53) 
chr21 40917295-40917437 SH3BGR (1.48) 
chr21 42312106-42312229 DSCAM (0) 
chr21 45191561-45191690 CSTB (3.95) 
chr21 45276170-45276282 AGPAT3 (4.06) 
chr21 46224459-46224579 SUMO3 (6.79) 
chr21 47013482-47013767 SLC19A1 (4.24) 
chr21 47556854-47556988 FTCD (0.13) 
chr21 47673893-47674021 MCM3AP (4.87) 
chr22 19441977-19442073 UFD1L (5.54) 
chr22 27766484-27766618 MN1 (2.51) 
chr22 39710277-39710414 RPL3 (10.68) 
chr22 46016635-46016760 FBLN1 (0) 
chr22 50051054-50051195 BRD1 (4.09) 
chr22 50133196-50133337 BRD1 (4.09) 
chr3 574690-574821 CHL1 (0.11) 
chr3 12882886-12883025 RPL32 (9.69) 
chr3 20905789-20905925 VENTXP7 (0) 
chr3 22423377-22423625 ZNF385D (0) 
chr3 25824790-25824935 NGLY1 (6.41) 
chr3 26160799-26160962 LOC285326 (0) 
chr3 26188422-26188545 LOC285326 (0) 
chr3 28065186-28065327 CMC1 (4.55) 
chr3 31247508-31247619 GADL1 (0.61) 
chr3 45833137-45833265 LZTFL1 (2.59) 
chr3 51074297-51074429 DOCK3 (0.19) 
chr3 58464625-58464766 KCTD6 (2.44) 
chr3 60781681-60781823 PTPRG (3.04) 
chr3 73261431-73261579 PPP4R2 (6.62) 
chr3 77778479-77778614 ROBO2 (0.01) 
chr3 78354645-78354767 ROBO1 (0.03) 
chr3 79693570-79693698 ROBO1 (0.03) 
chr3 83666176-83666309 LOC440970 (0) 
chr3 89720881-89720981 EPHA3 (0) 
chr3 99563666-99563794 MIR548G (0) 
chr3 104539745-104539845 ALCAM (2.82) 
chr3 107843794-107844001 CD47 (5.01) 
chr3 109282195-109282321 FLJ25363 (0) 
chr3 112151745-112151879 BTLA (0.03) 
chr3 113806447-113806669 KIAA1407 (0.98) 
chr3 116911876-116912011 LSAMP-AS3 (0) 
chr3 120026814-120026935 LRRC58 (3.29) 
chr3 120315155-120315293 HGD (0.24) 
chr3 121753591-121753726 ILDR1 (0) 
chr3 122393307-122393424 PARP14 (5.73) 
chr3 129037052-129037187 H1FX-AS1 (2.5) 
chr3 129037336-129037432 H1FX-AS1 (2.5) 
chr3 129143253-129143387 MBD4 (4.68) 
chr3 131606067-131606199 CPNE4 (0.05) 
chr3 135882660-135882776 PPP2R3A (0.97) 
chr3 140480162-140480296 TRIM42 (0) 
chr3 150321084-150321242 SELT (5.16) 
chr3 151269914-151270050 MIR548H2 (0) 
chr3 151305596-151305728 MIR548H2 (0) 
chr3 157328836-157328958 C3orf55 (0) 
chr3 166641916-166642049 ZBBX (0) 
chr3 169530341-169530476 LRRIQ4 (0.26) 
chr3 173559808-173559945 NLGN1 (0) 
chr3 174991882-174992024 NAALADL2 (0) 
chr3 177345985-177346114 TBL1XR1 (5.41) 
chr3 182796631-182796830 LAMP3 (0.02) 
chr3 183079277-183079409 MCF2L2 (1.97) 
chr3 184443714-184443849 MAGEF1 (4.36) 
chr3 186314755-186314984 DNAJB11 (4.65) 
chr3 190707170-190707294 SNAR-I (0) 
chr3 195913907-195914038 ZDHHC19 (0.41) 
chr4 1250082-1250221 C4orf42 (0) 
chr4 3915912-3916046 FAM86EP (1.67) 
chr4 4552164-4552305 LOC100507266 (0) 
chr4 8289185-8289311 HTRA3 (1.05) 
chr4 11687577-11687710 HS3ST1 (0.81) 
chr4 17425407-17425531 QDPR (2.43) 
chr4 20785021-20785163 KCNIP4 (1.16) 
chr4 22789819-22789945 GBA3 (3.19) 
chr4 23109698-23109839 MIR548AJ2 (0) 
chr4 35507928-35508059 ARAP2 (3.09) 
chr4 38552290-38552425 FLJ13197 (0) 
chr4 40300678-40300802 CHRNA9 (0.07) 
chr4 46725842-46726033 COX7B2 (0) 
chr4 56683246-56683367 LOC644145 (0.32) 
chr4 67823463-67823605 CENPC1 (0) 
chr4 77446319-77446479 SHROOM3 (4.59) 
chr4 77870071-77870202 40787 (5.45) 
chr4 80246570-80246705 LOC100505875 (0) 
chr4 81797529-81797672 C4orf22 (0) 
chr4 95983104-95983234 UNC5C (0) 
chr4 101087854-101088024 DDIT4L (6.33) 
chr4 104337436-104337625 TACR3 (0.1) 
chr4 107615545-107615664 DKK2 (0.02) 
chr4 111140363-111140505 ELOVL6 (0.81) 
chr4 113033330-113033465 C4orf32 (2.91) 
chr4 113759339-113759475 ANK2 (2.32) 
chr4 120221492-120221740 USP53 (0.74) 
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chr4 133184010-133184403 PCDH10 (1.37) 
chr4 142579314-142579441 IL15 (1.26) 
chr4 144658193-144658318 FREM3 (0) 
chr4 145124254-145124375 GYPA (0.09) 
chr4 147887375-147887517 TTC29 (0) 
chr4 153116437-153116579 FBXW7 (6.55) 
chr4 156167736-156167879 NPY2R (0) 
chr4 162585950-162586088 FSTL5 (3.5) 
chr4 166771207-166771333 TLL1 (0) 
chr4 185296924-185297043 IRF2 (5.07) 
chr4 185451425-185451558 IRF2 (5.07) 
chr5 1318061-1318193 CLPTM1L (6.48) 
chr5 5006905-5007027 LOC340094 (0) 
chr5 8952112-8952250 SEMA5A (0.01) 
chr5 11057528-11057662 CTNND2 (0) 
chr5 20922217-20922340 GUSBP1 (5.85) 
chr5 21918618-21918789 CDH12 (0.32) 
chr5 35729920-35730057 SPEF2 (2.44) 
chr5 38868618-38868760 RICTOR (4.03) 
chr5 40604014-40604157 PTGER4 (2.21) 
chr5 43549556-43549701 PAIP1 (5.84) 
chr5 53356296-53356429 ARL15 (1.81) 
chr5 53358354-53358485 ARL15 (1.81) 
chr5 53686642-53686758 HSPB3 (0) 
chr5 66840974-66841094 CD180 (0.12) 
chr5 67794748-67794884 PIK3R1 (4.89) 
chr5 79696220-79696362 ZFYVE16 (3.25) 
chr5 87343402-87343526 TMEM161B (3.66) 
chr5 100963552-100963680 SLCO4C1 (0) 
chr5 115411013-115411136 COMMD10 (4.82) 
chr5 115481477-115481601 COMMD10 (4.82) 
chr5 115518618-115518742 COMMD10 (4.82) 
chr5 120500450-120500594 PRR16 (0) 
chr5 123823907-123824048 ZNF608 (6.58) 
chr5 127541722-127541858 SLC12A2 (2.53) 
chr5 130204729-130204864 HINT1 (8.67) 
chr5 131753988-131754112 SLC22A5 (2.16) 
chr5 138282775-138282908 SIL1 (3.53) 
chr5 139624808-139625018 C5orf32 (0) 
chr5 141019033-141019157 RELL2 (1.74) 
chr5 157249352-157249494 CLINT1 (4.55) 
chr5 157465408-157465537 CLINT1 (4.55) 
chr5 162864559-162864671 NUDCD2 (5.52) 
chr5 163681917-163682074 MAT2B (5.31) 
chr5 166959408-166959537 WWC1 (0) 
chr5 168043828-168043909 PANK3 (5.37) 
chr5 169492575-169492708 DOCK2 (5.65) 
chr5 176884003-176884211 DBN1 (6.86) 
chr5 179264005-179264179 C5orf45 (3.33) 
chr6 3195908-3196040 TUBB2B (0.34) 
chr6 4422166-4422295 CDYL (4.14) 
chr6 5548212-5548354 LYRM4 (5.34) 
chr6 5756640-5756774 FARS2 (4.21) 
chr6 5795597-5795739 FARS2 (4.21) 
chr6 5805585-5805756 FARS2 (4.21) 
chr6 5864969-5865107 FARS2 (4.21) 
chr6 6649291-6649425 LY86-AS1 (0) 
chr6 8672194-8672312 LOC100506207 (0.91) 
chr6 13472198-13472333 GFOD1 (3.52) 
chr6 14911561-14911697 JARID2 (4.42) 
chr6 18522946-18523072 MIR548A1 (0) 
chr6 22402081-22402201 PRL (0.25) 
chr6 31021183-31021327 HCG22 (1.06) 
chr6 33048598-33048695 HLA-DPB1 (4.65) 
chr6 33218245-33218345 RPS18 (12.38) 
chr6 39938955-39939097 MOCS1 (0) 
chr6 40741020-40741158 LRFN2 (3.54) 
chr6 41873596-41873760 USP49 (4.04) 
chr6 45993588-45993720 CLIC5 (4.09) 
chr6 52129274-52129393 MCM3 (8.08) 
chr6 63320765-63320896 KHDRBS2 (0) 
chr6 65553916-65554016 EYS (0.34) 
chr6 67778155-67778387 MCART3P (0) 
chr6 67780069-67780198 MCART3P (0) 
chr6 82804914-82805056 IBTK (4.62) 
chr6 85506210-85506347 TBX18 (0) 
chr6 86417333-86417475 SNHG5 (7.04) 
chr6 100070081-100070216 PRDM13 (0) 
chr6 100412309-100412434 MCHR2 (0) 
chr6 107627530-107627667 SOBP (1.2) 
chr6 111599793-111599902 KIAA1919 (3.09) 
chr6 116238597-116238732 FRK (1.42) 
chr6 116579912-116580018 TSPYL4 (3.69) 
chr6 125351121-125351263 RNF217 (0.75) 
chr6 128696428-128696557 PTPRK (6.16) 
chr6 131429444-131429544 AKAP7 (2.26) 
chr6 134719740-134719871 LOC154092 (0) 
chr6 138200121-138200221 PERP (2.72) 
chr6 139329327-139329469 REPS1 (5.17) 
chr6 145790211-145790337 EPM2A (2.36) 
chr6 156598966-156599132 ARID1B (4.14) 
chr6 156614765-156614886 ARID1B (4.14) 
chr6 164469271-164469406 QKI (3.13) 
chr7 4806876-4806986 KIAA0415 (0) 
chr7 6441885-6442106 RAC1 (4.82) 
chr7 12971266-12971401 ARL4A (0.23) 
chr7 14087829-14087949 ETV1 (0) 
chr7 16891568-16891680 AGR3 (0) 
chr7 44053208-44053332 POLR2J4 (1.75) 
chr7 44545458-44545572 NPC1L1 (0) 
chr7 45412787-45412916 RAMP3 (0) 
chr7 66071823-66071971 KCTD7 (2.2) 
chr7 68782073-68782213 AUTS2 (4.14) 
chr7 69740740-69740862 AUTS2 (4.14) 
chr7 71222097-71222231 CALN1 (1.95) 
chr7 75137117-75137243 PMS2P3 (3.2) 
chr7 76157028-76157154 UPK3B (1.64) 
chr7 82523594-82523877 CACNA2D1 (1.02) 
chr7 92218074-92218232 CDK6 (7.47) 
chr7 92244317-92244552 CDK6 (7.47) 
chr7 92561996-92562119 CDK6 (7.47) 
chr7 93002680-93002815 CCDC132 (4.03) 
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chr7 93586828-93586967 GNG11 (5.2) 
chr7 93652093-93652224 BET1 (3.3) 
chr7 99532790-99532898 GJC3 (0.37) 
chr7 101313579-101313718 MYL10 (0) 
chr7 101982472-101982696 SPDYE6 (1.16) 
chr7 102207456-102207684 SPDYE2 (0) 
chr7 102212913-102213046 RASA4 (1.87) 
chr7 102306538-102306757 SPDYE2L (0) 
chr7 102311989-102312159 SPDYE2L (0) 
chr7 105646449-105646576 CDHR3 (0.04) 
chr7 105648378-105648507 CDHR3 (0.04) 
chr7 117636066-117636208 CTTNBP2 (0.01) 
chr7 119681687-119681822 KCND2 (0) 
chr7 121080886-121081022 FAM3C (2.9) 
chr7 123193294-123193428 NDUFA5 (3.82) 
chr7 125141052-125141148 POT1 (3.66) 
chr7 127172205-127172324 GCC1 (3.15) 
chr7 127769436-127769577 SND1 (6.92) 
chr7 128303374-128303503 FLJ45340 (0) 
chr7 139502615-139502717 HIPK2 (2.52) 
chr7 139677024-139677159 TBXAS1 (0.7) 
chr7 140895540-140895712 LOC100507421 (0) 
chr7 140980248-140980380 LOC100507421 (0) 
chr7 148336218-148336389 C7orf33 (0) 
chr7 151462282-151462405 PRKAG2 (1.21) 
chr7 154998350-154998485 INSIG1 (7.1) 
chr7 158172527-158172657 PTPRN2 (0.13) 
chr8 2980164-2980305 CSMD1 (0.83) 
chr8 3137210-3137322 CSMD1 (0.83) 
chr8 4632314-4632425 CSMD1 (0.83) 
chr8 15199098-15199220 SGCZ (0.11) 
chr8 15274672-15274813 TUSC3 (3.66) 
chr8 16314354-16314677 MSR1 (4.46) 
chr8 16661016-16661116 FGF20 (0) 
chr8 18820518-18820659 PSD3 (4.21) 
chr8 20917364-20917505 LOC286114 (0) 
chr8 22351713-22351847 SORBS3 (3.11) 
chr8 49430533-49430684 EFCAB1 (0) 
chr8 57736361-57736490 IMPAD1 (4.44) 
chr8 58890922-58891057 FAM110B (0) 
chr8 60558667-60558794 TOX (0.02) 
chr8 65415723-65415854 LOC401463 (0) 
chr8 68421177-68421300 ARFGEF1 (4.1) 
chr8 71452837-71452956 TRAM1 (6.16) 
chr8 72804831-72804972 LOC100132891 (0) 
chr8 82963493-82963603 SNX16 (2.26) 
chr8 85828753-85828885 RALYL (0) 
chr8 93281929-93282033 RUNX1T1 (0) 
chr8 100249258-100249385 VPS13B (3.37) 
chr8 111580965-111581106 KCNV1 (0) 
chr8 117816628-117816728 UTP23 (4.14) 
chr8 127019377-127019550 LOC100130231 (0) 
chr8 130034971-130035107 LOC728724 (0) 
chr8 134392062-134392181 ST3GAL1 (3.41) 
chr8 140026425-140026564 COL22A1 (0.01) 
chr8 144272817-144272943 GPIHBP1 (0) 
chr9 2303015-2303158 SMARCA2 (5.59) 
chr9 7989015-7989135 C9orf123 (0) 
chr9 16469380-16469515 BNC2 (0.01) 
chr9 19037512-19037647 FAM154A (0) 
chr9 26752854-26752979 C9orf82 (0) 
chr9 30139771-30139888 MIR873 (0) 
chr9 33917775-33918000 UBAP2 (3.85) 
chr9 38261886-38262022 ALDH1B1 (3.63) 
chr9 83145423-83145564 TLE4 (3.1) 
chr9 83537533-83537668 TLE1 (5.31) 
chr9 83714049-83714183 TLE1 (5.31) 
chr9 92470386-92470521 UNQ6494 (0) 
chr9 93725465-93725584 SYK (5.56) 
chr9 93759281-93759418 LOC100129316 (0) 
chr9 96892984-96893109 PTPDC1 (2.89) 
chr9 100828108-100828242 TRIM14 (3.03) 
chr9 102665041-102665182 STX17 (3.12) 
chr9 103308510-103308643 C9orf30-TMEFF1 (0) 
chr9 103801901-103802038 LPPR1 (0) 
chr9 106225386-106225520 CYLC2 (0) 
chr9 110550881-110551022 KLF4 (0) 
chr9 112407435-112407564 PALM2 (0) 
chr9 116460433-116460567 RGS3 (1.98) 
chr9 116466404-116466526 RGS3 (1.98) 
chr9 117099091-117099188 AKNA (3.93) 
chr9 125196265-125196406 PTGS1 (0.73) 
chr9 125395177-125395313 OR1B1 (0) 
chr9 129547267-129547409 ZBTB43 (2.04) 
chr9 137764383-137764515 FCN2 (0) 
chr9 139548292-139548426 EGFL7 (6.59) 
chrM 5124-5257 -1 (0) 
chrUn_gl000220 109887-110022 RN5-8S1 (0) 
chrUn_gl000220 114671-114919 RN5-8S1 (0) 
chrUn_gl000220 153859-153994 RN5-8S1 (0) 
chrUn_gl000220 158650-158891 RN5-8S1 (0) 
chrX 1863342-1863480 ASMT (0) 
chrX 7029122-7029270 MIR4767 (0) 
chrX 7285584-7285713 STS (1.82) 
chrX 7819833-7819975 VCX (0.09) 
chrX 12102371-12102513 FRMPD4 (0) 
chrX 26928857-26928991 VENTXP1 (0) 
chrX 33733174-33733343 DMD (0.75) 
chrX 33739868-33740003 DMD (0.75) 
chrX 34097574-34097715 FAM47A (0.83) 
chrX 48760226-48760344 PQBP1 (3.94) 
chrX 62192812-62192947 SPIN4 (2.41) 
chrX 68019175-68019316 EFNB1 (4.03) 
chrX 78887098-78887228 ITM2A (0.75) 
chrX 85270289-85270391 DACH2 (0) 
chrX 93946269-93946405 FAM133A (0) 
chrX 93990317-93990446 FAM133A (0) 
chrX 105349131-105349251 MUM1L1 (0) 
chrX 111782272-111782407 ZCCHC16 (0) 
chrX 119138349-119138491 NKAP (3.76) 
chrX 135056048-135056172 SLC9A6 (2.8) 
chrX 153060058-153060247 SSR4 (7.79) 
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chrX 153195426-153195654 NAA10 (6.13) 
chrY 1813342-1813480 ASMT (0) 





Supplementary Data Table 2. Closest genes to active LTRs detected by RACE-Seq in 
Namalwa cells. Gene expression values (FPKM) from RNA-Seq are also shown for 
each gene. 
 
RACE Peak Gene (FPKM) 
chr1 565687-565793 OR4F16 (0) 
chr1 2873191-2873294 ACTRT2 (0) 
chr1 3492137-3492246 MEGF6 (0) 
chr1 11467915-11468064 PTCHD2 (0.08) 
chr1 11640142-11640274 PTCHD2 (0.08) 
chr1 16160830-16161078 SPEN (3.89) 
chr1 24814729-24814843 RCAN3 (1.7) 
chr1 25589898-25590066 RHD (0.88) 
chr1 25660224-25660391 RHD (0.88) 
chr1 31945290-31945453 LOC149086 (0) 
chr1 38959146-38959288 LOC339442 (0) 
chr1 55404744-55404851 TMEM61 (0) 
chr1 57271450-57271561 C1orf168 (0.02) 
chr1 66594411-66594525 PDE4B (3.21) 
chr1 68019995-68020148 SERBP1 (6.87) 
chr1 85839200-85839328 DDAH1 (0.07) 
chr1 87911300-87911404 LOC100505768 (0) 
chr1 91328391-91328524 ZNF644 (4.97) 
chr1 97721043-97721154 DPYD (4.44) 
chr1 101455646-101455978 DPH5 (4.33) 
chr1 101491228-101491359 DPH5 (4.33) 
chr1 101853796-101853916 S1PR1 (1.62) 
chr1 108093064-108093214 VAV3 (0.39) 
chr1 148213989-148214116 PPIAL4D (0) 
chr1 148632427-148632529 PPIAL4E (0) 
chr1 148794459-148794586 PPIAL4D (0) 
chr1 153478547-153478695 S100A6 (0) 
chr1 154281795-154281904 AQP10 (0) 
chr1 159687104-159687209 CRP (0) 
chr1 160682581-160682707 CD48 (7.1) 
chr1 164446863-164446974 PBX1 (0.04) 
chr1 168731055-168731165 MGC4473 (0) 
chr1 171238114-171238225 FMO4 (1.89) 
chr1 177701423-177701557 SEC16B (0) 
chr1 182202214-182202319 GLUL (4.3) 
chr1 193978557-193978671 CDC73 (2.5) 
chr1 197964819-197964935 LHX9 (0) 
chr1 207269193-207269296 C4BPA (0) 
chr1 209874574-209874688 HSD11B1 (0) 
chr1 215159433-215159549 KCNK2 (0) 
chr1 219056302-219056439 LOC643723 (0) 
chr1 224773977-224774092 CNIH3 (0.1) 
chr1 226414505-226414605 MIXL1 (0.36) 
chr1 241575474-241575588 RGS7 (0) 
chr1 243269465-243269608 LOC731275 (0) 
chr1 245121001-245121152 EFCAB2 (3.57) 
chr10 15225856-15225970 NMT2 (0.67) 
chr10 30536812-30536917 MTPAP (3.98) 
chr10 31328037-31328147 ZNF438 (1.55) 
chr10 85909878-85910002 C10orf99 (0) 
chr10 88405003-88405110 OPN4 (0) 
chr10 89370432-89370534 PAPSS2 (0.15) 
chr10 98497235-98497402 PIK3AP1 (6.64) 
chr10 103086554-103086703 BTRC (2.64) 
chr10 107729823-107729931 SORCS1 (0.02) 
chr10 125171650-125171754 BUB3 (7.41) 
chr10 132469163-132469278 MIR378C (0) 
chr10 134073068-134073173 STK32C (0.6) 
chr11 214864-215084 RIC8A (4.98) 
chr11 1285719-1285824 MUC5B (0.02) 
chr11 5526794-5526909 OR51B5 (0) 
chr11 7486962-7487112 SYT9 (0.02) 
chr11 10830384-10830488 EIF4G2 (8.22) 
chr11 13010984-13011131 RASSF10 (0) 
chr11 14541845-14541960 PSMA1 (7.76) 
chr11 21736666-21736782 NELL1 (0) 
chr11 27911830-27912125 KIF18A (4.6) 
chr11 36607827-36608045 RAG2 (5.31) 
chr11 43702273-43702376 HSD17B12 (4.9) 
chr11 46450217-46450387 AMBRA1 (4) 
chr11 73685681-73685984 DNAJB13 (0) 
chr11 76647125-76647268 ACER3 (2.32) 
chr11 89984314-89984482 CHORDC1 (4.22) 
chr11 102217944-102218085 BIRC2 (4.44) 
chr11 113749374-113749523 USP28 (3.92) 
chr11 115797114-115797215 LOC283143 (0) 
chr11 116088771-116088880 LOC283143 (0) 
chr11 119773491-119773639 PVRL1 (0.9) 
chr11 126517987-126518125 KIRREL3 (0.02) 
chr11 128240076-128240191 ETS1 (6.81) 
chr12 1635020-1635188 LOC100292680 (0) 
chr12 1756248-1756377 MIR3649 (0) 
chr12 9797863-9797991 LOC374443 (5.13) 
chr12 9804044-9804181 CLEC2D (5.18) 
chr12 21810684-21810797 LDHB (10.32) 
chr12 22421445-22421575 KIAA0528 (0) 
chr12 25108462-25108607 BCAT1 (6.86) 
chr12 43345713-43345828 PRICKLE1 (0.4) 
chr12 46380557-46380706 ARID2 (3.84) 
chr12 47066210-47066324 SLC38A4 (0) 
chr12 50505955-50506066 C12orf62 (0) 
chr12 56043446-56043549 OR10P1 (0) 
chr12 56506761-56506865 RPL41 (12.42) 
chr12 57081803-57081912 NACA (9.69) 
chr12 65598794-65598905 MSRB3 (0.02) 
chr12 66414345-66414459 HMGA2 (0) 
chr12 76924859-76924965 OSBPL8 (5.19) 
chr12 83014550-83014654 TMTC2 (1.26) 
chr12 85244592-85244748 SLC6A15 (0) 
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chr12 87715690-87715794 MKRN9P (0) 
chr12 91058850-91058961 C12orf37 (0) 
chr12 93335084-93335242 EEA1 (2.9) 
chr12 110995605-110995706 PPTC7 (2.61) 
chr12 111848628-111848749 ATXN2 (3.02) 
chr12 112847271-112847384 PTPN11 (5.71) 
chr12 113471008-113471119 OAS2 (4.76) 
chr12 115345785-115345883 TBX3 (0) 
chr12 116356598-116356713 MED13L (3.13) 
chr12 124328605-124328706 DNAH10 (0.04) 
chr12 125597287-125597398 AACS (2.84) 
chr12 129263089-129263203 SLC15A4 (3.72) 
chr12 129594172-129594323 TMEM132D (0) 
chr13 21751173-21751268 MRP63 (0) 
chr13 28651435-28651586 PAN3-AS1 (1.49) 
chr13 31037352-31037463 LINC00426 (2.45) 
chr13 38410191-38410335 TRPC4 (0) 
chr13 45647999-45648098 KIAA1704 (0) 
chr13 59883237-59883342 DIAPH3 (4.59) 
chr13 63631326-63631429 OR7E156P (0) 
chr13 78003747-78003898 MYCBP2 (5.38) 
chr13 78500948-78501141 EDNRB (0) 
chr13 87778434-87778548 MIR4500HG (0) 
chr13 91723885-91723999 LINC00410 (0) 
chr13 96308340-96308454 DZIP1 (0.51) 
chr13 100104206-100104323 MIR548AN (0) 
chr13 101360611-101360719 TMTC4 (3.41) 
chr13 103752584-103752684 SLC10A2 (1.27) 
chr13 112025171-112025313 C13orf16 (0) 
chr13 114518528-114518686 FAM70B (0) 
chr14 19680939-19681050 POTEG (0) 
chr14 19894334-19894445 POTEM (0) 
chr14 21134864-21134978 ANG (0.29) 
chr14 30348582-30348698 PRKD1 (0) 
chr14 50872776-50873227 CDKL1 (3.04) 
chr14 51651857-51652002 TMX1 (4.07) 
chr14 51960191-51960301 FRMD6 (0.34) 
chr14 56780067-56780181 PELI2 (2.43) 
chr14 60677148-60677263 PPM1A (3.5) 
chr14 71713069-71713167 PCNX (2.51) 
chr14 80186459-80186569 NRXN3 (0.02) 
chr14 81723108-81723221 STON2 (0.85) 
chr14 88746274-88746362 KCNK10 (0) 
chr14 89744494-89744609 FOXN3 (2.63) 
chr14 92630286-92630528 CPSF2 (6) 
chr14 92868969-92869077 RIN3 (0.05) 
chr14 93336869-93336984 GOLGA5 (4.05) 
chr14 93338650-93338765 GOLGA5 (4.05) 
chr14 93339800-93339915 GOLGA5 (4.05) 
chr14 94734966-94735081 SERPINA10 (0.05) 
chr14 96288070-96288173 LOC100507043 (0) 
chr14 97903754-97903899 LOC100129345 (0) 
chr14 100800122-100800292 SLC25A47 (0) 
chr15 23188121-23188273 WHAMMP3 (1.49) 
chr15 33502030-33502182 RYR3 (0.08) 
chr15 37745919-37746021 MEIS2 (1.96) 
chr15 40826581-40826683 MRPL42P5 (0.96) 
chr15 45923317-45923434 SQRDL (1.74) 
chr15 56135259-56135370 PRTG (0.03) 
chr15 62574071-62574186 C2CD4B (0) 
chr15 69745134-69745246 KIF23 (5.18) 
chr15 70885592-70885701 UACA (0.88) 
chr15 74756740-74756878 LOC440288 (0) 
chr15 75230268-75230447 RPP25 (4.2) 
chr15 87581916-87582057 AGBL1 (0) 
chr15 89198635-89198730 ISG20 (4.7) 
chr15 89499696-89499795 MFGE8 (2.62) 
chr15 93946479-93946628 RGMA (0) 
chr15 101835334-101835447 PCSK6 (0.14) 
chr16 8708565-8708679 METTL22 (3.59) 
chr16 15657464-15657574 KIAA0430 (3.1) 
chr16 21127725-21127866 DNAH3 (0.05) 
chr16 23592362-23592466 NDUFAB1 (7.84) 
chr16 27050426-27050537 C16orf82 (0) 
chr16 27147946-27148051 JMJD5 (0) 
chr16 31123571-31123821 KAT8 (5.11) 
chr16 54907968-54908119 CRNDE (5.09) 
chr16 55889901-55890039 CES5A (0) 
chr16 58455103-58455339 GINS3 (5.28) 
chr16 60118540-60118651 LOC644649 (0) 
chr16 69669475-69669625 NFAT5 (2.84) 
chr16 70002236-70002337 CLEC18A (0.04) 
chr16 70225150-70225251 CLEC18C (0) 
chr16 74438090-74438193 CLEC18B (0.13) 
chr16 76268959-76269073 CNTNAP4 (0.07) 
chr16 80926390-80926530 C16orf61 (0) 
chr16 83806987-83807088 CDH13 (0.02) 
chr16 83879075-83879169 HSBP1 (5.92) 
chr16 85360119-85360277 LOC727710 (0) 
chr16 88876100-88876217 APRT (7.52) 
chr17 7529673-7529769 SHBG (0.17) 
chr17 27717452-27717561 MIR4523 (0) 
chr17 30771497-30771628 PSMD11 (5) 
chr17 35075647-35075757 MRM1 (3.7) 
chr17 58140237-58140385 HEATR6 (2.05) 
chr17 64899520-64899627 CACNG5 (0.2) 
chr17 69617074-69617168 SOX9 (0) 
chr17 70016624-70016776 SOX9 (0) 
chr17 73262119-73262266 MIF4GD (3.91) 
chr17 74560542-74560709 ST6GALNAC2 (0.82) 
chr17 79336009-79336125 TMEM105 (0) 
chr17 79891163-79891269 PYCR1 (6.68) 
chr18 18770173-18770322 GREB1L (0.04) 
chr18 26055023-26055136 CDH2 (0) 
chr18 29545582-29545726 TRAPPC8 (4.85) 
chr18 33077777-33077892 MIR3975 (0) 
chr18 42251873-42251981 SETBP1 (1.8) 
chr18 44812039-44812178 IER3IP1 (5.2) 
chr18 45953740-45953842 CTIF (1.09) 
chr18 48043831-48043971 MAPK4 (0) 
chr18 48668633-48668760 MEX3C (5.94) 
chr18 55636112-55636213 NEDD4L (2.21) 
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chr18 56447358-56447482 MALT1 (5.1) 
chr18 57855825-57855937 MC4R (0) 
chr18 75705590-75705701 GALR1 (0) 
chr18 76141404-76141504 SALL3 (0) 
chr18 76717551-76717751 SALL3 (0) 
chr18 77352739-77352881 NFATC1 (3.67) 
chr19 5978361-5978555 RANBP3 (4.98) 
chr19 6413865-6414019 KHSRP (5.98) 
chr19 7696354-7696449 PCP2 (0.82) 
chr19 14281838-14281992 LPHN1 (0) 
chr19 34046691-34046836 PEPD (4.19) 
chr19 34273547-34273648 CHST8 (0) 
chr19 40157661-40157810 LGALS16 (0) 
chr19 42891514-42891627 MEGF8 (2.33) 
chr19 47776921-47777021 PRR24 (0) 
chr19 49993711-49993864 SNORD33 (0) 
chr19 50363571-50363657 PNKP (4.08) 
chr19 50363833-50363953 PNKP (4.08) 
chr19 54846585-54846693 LAIR1 (0.33) 
chr19 56824647-56824764 ZNF542 (0) 
chr2 668003-668228 LOC339822 (0) 
chr2 6102010-6102121 LOC400940 (0) 
chr2 10266050-10266225 C2orf48 (1.6) 
chr2 11720083-11720233 MIR4429 (0) 
chr2 14131239-14131391 FAM84A (0) 
chr2 27907986-27908097 SLC4A1AP (4.33) 
chr2 30554544-30554658 LBH (3.31) 
chr2 30906180-30906320 LCLAT1 (3.35) 
chr2 33306924-33307022 LTBP1 (2.61) 
chr2 33931890-33932042 MYADML (0) 
chr2 36275764-36275873 LOC100288911 (0) 
chr2 38127199-38127309 FAM82A1 (0) 
chr2 40144686-40144774 LOC100128590 (0) 
chr2 49398277-49398388 FSHR (0) 
chr2 53156003-53156112 ASB3 (4.4) 
chr2 54342720-54342847 ACYP2 (2.97) 
chr2 54501248-54501356 ACYP2 (2.97) 
chr2 60343682-60343832 MIR4432 (0) 
chr2 62003030-62003147 FAM161A (2.57) 
chr2 62024772-62024880 FAM161A (2.57) 
chr2 65275035-65275387 CEP68 (2.81) 
chr2 68934399-68934502 ARHGAP25 (1.5) 
chr2 69383725-69383836 ANTXR1 (0) 
chr2 71349610-71350073 MPHOSPH10 (4.98) 
chr2 74154005-74154141 DGUOK (5.99) 
chr2 76532732-76532874 LRRTM4 (0) 
chr2 76571471-76571573 LRRTM4 (0) 
chr2 79213601-79213754 REG3G (0) 
chr2 100544366-100544573 AFF3 (4.05) 
chr2 104629686-104629811 LOC100287010 (0.1) 
chr2 111881302-111881398 ACOXL (0.04) 
chr2 118480734-118480875 DDX18 (6.02) 
chr2 118781948-118782097 CCDC93 (3.2) 
chr2 124350029-124350169 CNTNAP5 (0) 
chr2 128586982-128587130 POLR2D (5.04) 
chr2 132693173-132693323 C2orf27B (0) 
chr2 152470238-152470394 NEB (0.11) 
chr2 155062106-155062253 GALNT13 (0) 
chr2 164518258-164518406 KCNH7 (0.02) 
chr2 170543424-170543576 C2orf77 (0) 
chr2 177293849-177293999 MTX2 (4.43) 
chr2 180167047-180167193 SESTD1 (1.88) 
chr2 191573359-191573470 NAB1 (3.54) 
chr2 192364093-192364242 MYO1B (0) 
chr2 196313207-196313355 SLC39A10 (4) 
chr2 216848784-216848895 PECR (0) 
chr2 217363565-217363652 SMARCAL1 (3.17) 
chr2 217363958-217364045 SMARCAL1 (3.17) 
chr2 224651841-224651946 WDFY1 (3.94) 
chr2 225232401-225232500 FAM124B (0) 
chr2 238378158-238378263 MLPH (0) 
chr2 239683163-239683279 TWIST2 (0) 
chr20 1772415-1772560 LOC100289473 (0) 
chr20 7391918-7392068 HAO1 (0) 
chr20 16859130-16859269 OTOR (0) 
chr20 21797663-21797752 PAX1 (0) 
chr20 35617265-35617434 RBL1 (4.4) 
chr20 39570744-39570900 TOP1 (5.13) 
chr20 40256542-40256675 CHD6 (3.27) 
chr20 43588934-43588999 LOC100505826 (0) 
chr20 56058404-56058553 CTCFL (0.03) 
chr20 57395709-57395818 GNAS-AS1 (2.01) 
chr20 58487911-58488017 SYCP2 (0.34) 
chr21 14599916-14600066 ANKRD30BP2 (0.03) 
chr21 19858095-19858245 TMPRSS15 (1.81) 
chr21 20184882-20184986 TMPRSS15 (1.81) 
chr21 20834136-20834243 TMPRSS15 (1.81) 
chr21 26734081-26734196 LINC00158 (0.24) 
chr21 28372021-28372136 ADAMTS5 (0) 
chr21 29420727-29420870 LINC00314 (0) 
chr21 30638206-30638350 BACH1 (4.22) 
chr21 35284584-35284736 LOC100506334 (0) 
chr21 43881482-43881632 RSPH1 (0.25) 
chr21 46038162-46038264 TSPEAR (0.11) 
chr21 47013485-47013624 SLC19A1 (3.96) 
chr21 47556864-47556978 FTCD (0.09) 
chr21 47673885-47674011 MCM3AP (4.8) 
chr22 16162031-16162142 POTEH (0) 
chr22 27766481-27766617 MN1 (0) 
chr22 28382177-28382337 TTC28-AS1 (2.92) 
chr22 32014338-32014554 PRR14L (3.55) 
chr22 35626932-35627092 HMGXB4 (3.19) 
chr22 41347926-41348012 XPNPEP3 (3.07) 
chr22 46016631-46016768 FBLN1 (0) 
chr22 50051057-50051197 BRD1 (3.79) 
chr3 12882913-12883029 RPL32 (9.77) 
chr3 25824782-25824922 NGLY1 (5.5) 
chr3 26160840-26160944 LOC285326 (0) 
chr3 51074308-51074419 DOCK3 (0.16) 
chr3 51820908-51821023 IQCF6 (0) 
chr3 53231284-53231397 PRKCD (2.03) 
chr3 59819602-59819704 FHIT (2.39) 
204 
 
chr3 62936082-62936193 CADPS (2.87) 
chr3 70928314-70928452 FOXP1 (4.04) 
chr3 80577733-80577876 ROBO1 (0) 
chr3 88354685-88354822 C3orf38 (3.2) 
chr3 99563680-99563784 MIR548G (0) 
chr3 107843761-107844005 CD47 (5.04) 
chr3 110599699-110599785 PVRL3-AS1 (0) 
chr3 116911886-116912001 LSAMP-AS3 (0) 
chr3 118528784-118528899 IGSF11 (0) 
chr3 118529555-118529663 IGSF11 (0) 
chr3 120315147-120315375 HGD (0.09) 
chr3 129037346-129037437 H1FX-AS1 (1.27) 
chr3 130584513-130584629 ATP2C1 (3.9) 
chr3 139891519-139891624 CLSTN2 (0) 
chr3 140480170-140480286 TRIM42 (0) 
chr3 144087395-144087506 C3orf58 (3.35) 
chr3 148677815-148677962 GYG1 (4.51) 
chr3 150321087-150321228 SELT (5.69) 
chr3 151792400-151792514 LOC401093 (0) 
chr3 158770769-158770885 IQCJ (0.12) 
chr3 169530337-169530480 LRRIQ4 (0.36) 
chr3 174991777-174992418 NAALADL2 (0.5) 
chr3 182796648-182796830 LAMP3 (0.08) 
chr3 183670436-183670538 ABCC5 (3.26) 
chr3 185743973-185744122 ETV5 (0.1) 
chr3 188057286-188057387 LPP (3.88) 
chr3 191018563-191018664 CCDC50 (3.59) 
chr3 193563170-193563275 LOC647323 (0) 
chr3 194968496-194968611 ACAP2 (4.65) 
chr3 195913918-195914024 ZDHHC19 (0) 
chr4 53192-53307 ZNF876P (0.31) 
chr4 309644-309748 ZNF732 (0.04) 
chr4 467830-467962 PIGG (2.76) 
chr4 1250135-1250221 C4orf42 (0) 
chr4 2384530-2384679 ZFYVE28 (0.52) 
chr4 4822987-4823141 MSX1 (0.09) 
chr4 16242612-16242717 FLJ39653 (0) 
chr4 34898769-34898883 ARAP2 (2.72) 
chr4 36722659-36722761 DTHD1 (0) 
chr4 38552300-38552415 FLJ13197 (0) 
chr4 42463443-42463589 ATP8A1 (4.39) 
chr4 46725796-46726037 COX7B2 (0) 
chr4 61911261-61911373 LPHN3 (0) 
chr4 63788175-63788263 LPHN3 (0) 
chr4 65213256-65213358 LOC401134 (0) 
chr4 77446326-77446462 SHROOM3 (0.04) 
chr4 77870081-77870192 40787 (5.46) 
chr4 80101015-80101117 LOC100505875 (0) 
chr4 81797509-81797675 C4orf22 (1.8) 
chr4 81952971-81953167 PRKG2 (0) 
chr4 101087876-101088028 DDIT4L (0) 
chr4 104337471-104337614 TACR3 (0) 
chr4 113203286-113203402 TIFA (5.41) 
chr4 113759350-113759455 ANK2 (2.61) 
chr4 120221477-120221773 USP53 (4.58) 
chr4 123001147-123001283 KIAA1109 (2.91) 
chr4 130000058-130000176 C4orf33 (3.17) 
chr4 133184024-133184213 PCDH10 (0) 
chr4 142579328-142579432 IL15 (0.04) 
chr4 168971037-168971153 ANXA10 (0) 
chr4 175285024-175285166 CEP44 (3.67) 
chr4 178653522-178653635 LOC285501 (0) 
chr5 1318002-1318196 CLPTM1L (6.15) 
chr5 1507743-1507854 SLC6A3 (0) 
chr5 2268714-2268834 IRX4 (0) 
chr5 6195529-6195635 FLJ33360 (0) 
chr5 8952108-8952255 SEMA5A (0) 
chr5 11057543-11057653 CTNND2 (0) 
chr5 17123884-17123983 LOC285696 (0) 
chr5 22618992-22619104 CDH12 (0.25) 
chr5 23828371-23828481 PRDM9 (0) 
chr5 38868614-38868764 RICTOR (3.13) 
chr5 40604012-40604197 PTGER4 (1.3) 
chr5 49981571-49981680 PARP8 (3.21) 
chr5 51202158-51202272 ISL1 (0) 
chr5 53686633-53686774 HSPB3 (0) 
chr5 68575714-68575875 CCDC125 (3) 
chr5 77262627-77262729 AP3B1 (5.6) 
chr5 91206664-91206813 LOC100129716 (0) 
chr5 92840276-92840381 FLJ42709 (0) 
chr5 99708329-99708441 LOC100133050 
(0.14) 
chr5 100963543-100963693 SLCO4C1 (0) 
chr5 103717017-103717126 RAB9BP1 (0) 
chr5 105502151-105502247 RAB9BP1 (0) 
chr5 113462037-113462136 KCNN2 (0.06) 
chr5 117818363-117818477 DTWD2 (0.84) 
chr5 120500320-120500617 PRR16 (0) 
chr5 121663268-121663369 SNCAIP (0) 
chr5 123510312-123510415 ZNF608 (3.93) 
chr5 127541731-127541848 SLC12A2 (3.81) 
chr5 131162422-131162527 FNIP1 (3.34) 
chr5 134831318-134831467 NEUROG1 (0) 
chr5 141019043-141019147 RELL2 (4.29) 
chr5 149776168-149776385 CD74 (9.56) 
chr6 3195904-3196044 TUBB2B (0.04) 
chr6 6649301-6649415 LY86-AS1 (1.22) 
chr6 13472208-13472323 GFOD1 (3.86) 
chr6 16990395-16990506 FLJ23152 (0) 
chr6 31021197-31021312 HCG22 (0.23) 
chr6 33029816-33029920 HLA-DPA1 (6.81) 
chr6 35907226-35907331 SLC26A8 (0.03) 
chr6 37717355-37717488 MDGA1 (0) 
chr6 71085430-71085580 FAM135A (3.92) 
chr6 72163935-72164036 LINC00472 (0) 
chr6 74555612-74555761 CD109 (0.01) 
chr6 85506206-85506349 TBX18 (0) 
chr6 86417346-86417461 SNHG5 (5.84) 
chr6 90775000-90775216 BACH2 (6.48) 
chr6 91195836-91195947 MAP3K7 (4.93) 
chr6 98376249-98376363 MIR2113 (0) 
chr6 111599770-111599892 KIAA1919 (3.22) 
chr6 115348269-115348377 FRK (0.54) 
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chr6 119765569-119765673 MAN1A1 (6.33) 
chr6 123225590-123225736 CLVS2 (0) 
chr6 131083093-131083198 LOC100507203 (0) 
chr6 136546672-136546786 FAM54A (0) 
chr6 137314307-137314421 IL20RA (0) 
chr6 138367531-138367645 PERP (0) 
chr6 142287284-142287380 NMBR (0) 
chr6 143981411-143981522 PHACTR2 (0.4) 
chr6 167463692-167463788 FGFR1OP (3.59) 
chr7 1899641-1900049 MAD1L1 (5.21) 
chr7 6441881-6442190 RAC1 (5.99) 
chr7 7558756-7558870 COL28A1 (0.02) 
chr7 12971276-12971391 ARL4A (3.42) 
chr7 14087839-14087941 ETV1 (0) 
chr7 20941907-20942053 RPL23P8 (0) 
chr7 26129297-26129410 NFE2L3 (4.34) 
chr7 38435928-38436037 AMPH (0) 
chr7 44053205-44053336 POLR2J4 (1.79) 
chr7 44054181-44054284 POLR2J4 (1.79) 
chr7 66071810-66071971 KCTD7 (3.41) 
chr7 70419588-70419703 AUTS2 (4.46) 
chr7 70674746-70674895 WBSCR17 (0) 
chr7 72486819-72486933 PMS2L2 (0) 
chr7 72514881-72514995 PMS2L2 (0) 
chr7 74707626-74707740 LOC100093631 
(0.21) 
chr7 74921899-74922072 SPDYE8P (0.39) 
chr7 74949915-74950074 SPDYE8P (0.39) 
chr7 75137116-75137247 PMS2P3 (3.79) 
chr7 76156935-76157156 UPK3B (2.61) 
chr7 82523708-82523823 CACNA2D1 (0.03) 
chr7 87130546-87130647 ABCB1 (0) 
chr7 91884314-91884423 ANKIB1 (3.65) 
chr7 93652087-93652224 BET1 (3.98) 
chr7 99229640-99229810 ZNF498 (0) 
chr7 99532776-99532898 GJC3 (0.08) 
chr7 99923308-99923478 PMS2P1 (5.13) 
chr7 99933458-99933617 PILRB (3.46) 
chr7 101982568-101982699 SPDYE6 (2.4) 
chr7 102207457-102207684 SPDYE2 (0) 
chr7 102208433-102208536 SPDYE2 (0) 
chr7 102212913-102213033 RASA4 (2.93) 
chr7 102306537-102306764 SPDYE2L (0) 
chr7 102307513-102307616 SPDYE2L (0) 
chr7 102311966-102312192 SPDYE2L (0) 
chr7 105646455-105646566 CDHR3 (0.57) 
chr7 106145151-106145265 C7orf74 (0) 
chr7 110148678-110148795 IMMP2L (3.43) 
chr7 117636080-117636194 CTTNBP2 (0) 
chr7 123193286-123193436 NDUFA5 (4.78) 
chr7 124996202-124996342 POT1 (4.2) 
chr7 125141036-125141138 POT1 (4.2) 
chr7 127769423-127769584 SND1 (7.91) 
chr7 128303360-128303475 FLJ45340 (0) 
chr7 130016485-130016596 CPA1 (0) 
chr7 131007219-131007329 MKLN1 (4.05) 
chr7 133550390-133550494 EXOC4 (5.33) 
chr7 134847227-134847375 C7orf49 (5.7) 
chr7 140895581-140895697 LOC100507421 (0) 
chr7 148565395-148565529 EZH2 (5.59) 
chr7 151578399-151578546 LOC100505483 (0) 
chr7 158172537-158172647 PTPRN2 (0.03) 
chr8 1710764-1711040 CLN8 (1.79) 
chr8 15199108-15199214 SGCZ (0) 
chr8 15274672-15274800 TUSC3 (0) 
chr8 16314453-16314604 MSR1 (0.16) 
chr8 16694396-16694511 FGF20 (0) 
chr8 19115703-19115818 LOC100128993 (0) 
chr8 29605536-29605675 LOC286135 (0) 
chr8 31064945-31065058 WRN (2.97) 
chr8 31683928-31684042 NRG1 (0) 
chr8 39462111-39462224 ADAM18 (0) 
chr8 49430503-49430784 EFCAB1 (0.11) 
chr8 66893305-66893454 DNAJC5B (0.13) 
chr8 68684387-68684563 CPA6 (0) 
chr8 71452838-71452959 TRAM1 (6.97) 
chr8 74288472-74288585 LOC100128126 (0) 
chr8 96135058-96135207 PLEKHF2 (4.83) 
chr8 99417949-99418058 KCNS2 (0.1) 
chr8 111494282-111494381 KCNV1 (0) 
chr8 114769767-114769916 CSMD3 (0) 
chr8 117816611-117816765 UTP23 (4.07) 
chr8 117864193-117864296 RAD21-AS1 (0.49) 
chr8 117912409-117912499 RAD21-AS1 (0.49) 
chr8 118275725-118275836 SLC30A8 (0) 
chr8 120955552-120955704 DEPTOR (4.92) 
chr8 121925287-121925392 SNTB1 (4.06) 
chr8 123583734-123583834 ZHX2 (4.14) 
chr8 126545237-126545345 TRIB1 (3.83) 
chr8 134392073-134392171 ST3GAL1 (0.72) 
chr9 2252773-2252886 SMARCA2 (4.07) 
chr9 6313198-6313301 TPD52L3 (0.07) 
chr9 16469390-16469505 BNC2 (0) 
chr9 16917485-16917595 BNC2 (0) 
chr9 22058811-22058924 CDKN2B-AS (0) 
chr9 22197110-22197281 CDKN2B-AS (0) 
chr9 26752846-26752989 C9orf82 (0) 
chr9 30139762-30139893 MIR873 (0) 
chr9 31578578-31578692 ACO1 (3.63) 
chr9 41902191-41902327 MGC21881 (0) 
chr9 44454549-44454685 CNTNAP3B (0) 
chr9 46896404-46896540 KGFLP1 (0.59) 
chr9 66533924-66534061 LOC442421 (0) 
chr9 80056215-80056360 GNA14 (0.07) 
chr9 83714060-83714175 TLE1 (0.36) 
chr9 86720349-86720435 RMI1 (3.06) 
chr9 92470396-92470511 UNQ6494 (0) 
chr9 93759291-93759408 LOC100129316 (0) 
chr9 100153136-100153285 BDAG1 (0) 
chr9 101998630-101998824 SEC61B (8.09) 
chr9 103308502-103308629 C9orf30-TMEFF1 (0) 
chr9 103801913-103802024 LPPR1 (0) 
chr9 116466413-116466516 RGS3 (0.56) 
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chr9 117099076-117099187 AKNA (4.2) 
chr9 124879595-124879703 MIR4478 (0) 
chr9 138273294-138273409 LOC100506599 (0) 
chrUn_gl000220 114674-114821 RN5-8S1 (0) 
chrUn_gl000220 158646-158844 RN5-8S1 (0) 
chrX 4218120-4218225 LOC389906 (3.85) 
chrX 7029124-7029275 MIR4767 (0) 
chrX 11815266-11815371 MSL3 (3.85) 
chrX 13321435-13321549 ATXN3L (0) 
chrX 15498258-15498400 PIR-FIGF (0) 
chrX 18889465-18889615 LOC100132163 (0) 
chrX 26928849-26928995 VENTXP1 (0) 
chrX 34486610-34486710 TMEM47 (0) 
chrX 34587108-34587249 TMEM47 (0) 
chrX 41973802-41973907 CASK (2.28) 
chrX 47003999-47004121 RBM10 (5.15) 
chrX 48760209-48760352 PQBP1 (4.71) 
chrX 68019189-68019304 EFNB1 (1.78) 
chrX 78887112-78887219 ITM2A (0) 
chrX 79478694-79478832 FAM46D (0) 
chrX 82925572-82925687 POU3F4 (0) 
chrX 91733094-91733196 PCDH11X (0) 
chrX 92094170-92094310 PCDH11X (0) 
chrX 105349141-105349244 MUM1L1 (0) 
chrX 113028105-113028258 HTR2C (0) 
chrX 118425457-118425565 PGRMC1 (5.69) 
chrX 124347004-124347090 LOC100129520 (0) 
chrX 131759358-131759456 HS6ST2 (0) 
chrX 135056058-135056174 SLC9A6 (2.87) 
chrX 141171314-141171413 MAGEC2 (0) 
chrX 145722669-145722826 CXorf51A (0) 
chrX 150023844-150023980 CD99L2 (2.2) 
chrX 152370302-152370449 MAGEA1 (0) 
chrX 153060016-153060227 SSR4 (7.72) 





Supplementary Data Table 3. Closest genes to active LTRs detected by RACE-Seq in 
L428 cells. Gene expression values (FPKM) from RNA-Seq are also shown for each 
gene. 
 
RACE Peak Gene (FPKM) 
chr1 2123459-2123567 PRKCZ (2.15) 
chr1 6981705-6981820 CAMTA1 (5.78) 
chr1 8225875-8225988 ERRFI1 (0.1) 
chr1 16160878-16161019 SPEN (3.89) 
chr1 21719060-21719234 ECE1 (2.55) 
chr1 24526768-24526885 IL28RA (0) 
chr1 24814727-24814845 RCAN3 (1.7) 
chr1 30874495-30874611 MATN1 (0.05) 
chr1 40371047-40371152 MYCL1 (0) 
chr1 55404738-55404853 TMEM61 (0) 
chr1 56337634-56337767 PPAP2B (0.03) 
chr1 58368619-58368736 DAB1 (0) 
chr1 62386028-62386169 INADL (0.94) 
chr1 64634984-64635099 ROR1 (4.11) 
chr1 64957070-64957169 CACHD1 (0.17) 
chr1 66594409-66594527 PDE4B (3.21) 
chr1 78588148-78588249 GIPC2 (0.06) 
chr1 81428611-81428730 LPHN2 (0) 
chr1 82218886-82219001 LPHN2 (0) 
chr1 85191690-85191840 SSX2IP (3.88) 
chr1 85429341-85429472 MCOLN2 (4.58) 
chr1 88966312-88966418 PKN2 (3.72) 
chr1 97721041-97721156 DPYD (4.44) 
chr1 97722055-97722174 DPYD (4.44) 
chr1 101455619-101455876 DPH5 (4.33) 
chr1 102479013-102479131 OLFM3 (0) 
chr1 109978215-109978330 PSMA5 (5.97) 
chr1 160597763-160597881 SLAMF1 (0.89) 
chr1 164446861-164446976 PBX1 (0.04) 
chr1 168189759-168189895 SFT2D2 (4.93) 
chr1 168731038-168731179 MGC4473 (0) 
chr1 170803684-170803801 PRRX1 (0) 
chr1 171409389-171409529 PRRC2C (5.82) 
chr1 174173947-174174072 RABGAP1L (6.96) 
chr1 177701431-177701553 SEC16B (0) 
chr1 180528078-180528190 ACBD6 (6.52) 
chr1 181419165-181419282 CACNA1E (0.01) 
chr1 181511712-181511831 CACNA1E (0.01) 
chr1 182202214-182202321 GLUL (4.3) 
chr1 183281078-183281209 NMNAT2 (0) 
chr1 186213435-186213547 MIR548F1 (0) 
chr1 188701637-188701776 FAM5C (0) 
chr1 200247978-200248120 C1orf98 (0) 
chr1 204011683-204011809 LINC00303 (0) 
chr1 216442638-216442753 ESRRG (0.02) 
chr1 219114803-219114942 LOC643723 (0) 
chr1 222360694-222360813 HHIPL2 (0) 
chr1 222401271-222401389 HHIPL2 (0) 
chr1 223461596-223461706 SUSD4 (0) 
chr1 224847884-224848002 CNIH3 (0.1) 
chr1 234081473-234081613 SLC35F3 (0) 
chr1 234831807-234831926 LOC100506810 (0) 
chr1 237780090-237780208 LOC100130331 (0) 
chr1 239712269-239712400 CHRM3 (1.04) 
chr1 241450704-241450823 RGS7 (0) 
chr1 243269481-243269591 LOC731275 (0) 
chr1 244472679-244472797 C1orf100 (0) 
chr1 244830097-244830267 PPPDE1 (0) 
chr1 245353128-245353246 KIF26B (0.02) 
chr10 4915374-4915511 tAKR (0) 
chr10 7144565-7144674 SFMBT2 (3.62) 
chr10 8383285-8383391 GATA3 (0.03) 
chr10 9724534-9724669 SFTA1P (0) 
chr10 9966871-9966989 SFTA1P (0) 
chr10 10066135-10066250 SFTA1P (0) 
chr10 13478510-13478616 BEND7 (0) 
chr10 15548643-15548758 ITGA8 (0) 
chr10 15981514-15981619 FAM188A (3.67) 
chr10 17568234-17568376 PTPLA (0) 
chr10 25302007-25302101 ENKUR (0) 
chr10 25481137-25481239 GPR158 (0) 
chr10 26683181-26683284 APBB1IP (5.36) 
chr10 27660519-27660638 PTCHD3 (0.04) 
chr10 28691711-28691823 LOC220906 (0) 
chr10 34102187-34102325 LOC100505583 (0) 
chr10 47109739-47109879 LOC643650 (0) 
chr10 49498137-49498283 FRMPD2 (0.02) 
chr10 56710195-56710333 PCDH15 (0) 
chr10 56965585-56965750 MTRNR2L5 (0) 
chr10 60256212-60256328 BICC1 (0) 
chr10 62416791-62416948 ANK3 (0.04) 
chr10 68275394-68275501 CTNNA3 (0.01) 
chr10 72672059-72672165 PCBD1 (2.67) 
chr10 75006859-75007005 C10orf103 (0) 
chr10 79468093-79468206 KCNMA1 (0) 
chr10 81629600-81629740 LOC100288974 (0) 
chr10 81955486-81955599 ANXA11 (4.47) 
chr10 85909886-85909897 C10orf99 (0) 
chr10 90305149-90305257 RNLS (2.12) 
chr10 90573504-90573667 LIPM (0) 
chr10 90597573-90597692 LIPM (0) 
chr10 92995502-92995615 LOC100188947 (0) 
chr10 95579267-95579383 LGI1 (0) 
chr10 107729824-107729933 SORCS1 (0.02) 
chr10 108042658-108042795 SORCS1 (0.02) 
chr10 108792838-108792954 SORCS3 (0) 
chr10 111568710-111568820 XPNPEP1 (6.03) 
chr10 112373134-112373249 SMC3 (5.73) 
chr10 118178152-118178271 PNLIPRP3 (0) 
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chr10 125305963-125306095 GPR26 (0) 
chr10 125820855-125820996 CHST15 (4.31) 
chr10 129754048-129754157 PTPRE (2.28) 
chr11 1285717-1285826 MUC5B (0.02) 
chr11 3206233-3206339 OSBPL5 (0) 
chr11 5526781-5526923 OR51B5 (0) 
chr11 9189859-9189972 DENND5A (2.92) 
chr11 10458289-10458407 AMPD3 (0.2) 
chr11 11259654-11259766 GALNTL4 (0) 
chr11 13010988-13011127 RASSF10 (0) 
chr11 17890250-17890367 SERGEF (4.2) 
chr11 19548781-19548901 NAV2 (0.14) 
chr11 26961601-26961716 FIBIN (0) 
chr11 27911882-27912101 KIF18A (4.6) 
chr11 33753564-33753683 FBXO3 (3.99) 
chr11 39491593-39491729 LRRC4C (0) 
chr11 44098364-44098482 ACCS (0) 
chr11 59263853-59263971 OR4D11 (0) 
chr11 63059596-63059714 SLC22A10 (0) 
chr11 70160986-70161106 PPFIA1 (3.79) 
chr11 71881679-71881794 FOLR1 (0) 
chr11 73685709-73686074 DNAJB13 (0) 
chr11 74168900-74169038 LIPT2 (3.27) 
chr11 76647129-76647264 ACER3 (2.32) 
chr11 77554858-77554995 RSF1 (3.75) 
chr11 78905144-78905264 ODZ4 (0) 
chr11 85494206-85494312 SYTL2 (3.76) 
chr11 88268080-88268207 GRM5 (0) 
chr11 92332386-92332500 FAT3 (0) 
chr11 97252984-97253095 JRKL (1.84) 
chr11 98490121-98490255 CNTN5 (0) 
chr11 102304547-102304688 BIRC2 (4.44) 
chr11 110214728-110214855 RDX (4.15) 
chr11 112367295-112367397 C11orf34 (0) 
chr11 115797100-115797226 LOC283143 (0) 
chr11 119773504-119773623 PVRL1 (0.9) 
chr11 126517954-126518150 KIRREL3 (0.02) 
chr11 127264558-127264695 KIRREL3-AS3 (0) 
chr11 128239961-128240254 ETS1 (6.81) 
chr12 9804058-9804165 CLEC2D (5.18) 
chr12 13420858-13420970 EMP1 (0.06) 
chr12 14432832-14432962 ATF7IP (4.78) 
chr12 15659435-15659544 PTPRO (0.17) 
chr12 21810682-21810799 LDHB (10.32) 
chr12 22567635-22567747 KIAA0528 (0) 
chr12 25108459-25108609 BCAT1 (6.86) 
chr12 25445983-25446288 KRAS (3.35) 
chr12 30020945-30021053 TMTC1 (0) 
chr12 39279665-39279770 KIF21A (0) 
chr12 41706344-41706462 PDZRN4 (0) 
chr12 50505958-50506067 C12orf62 (0) 
chr12 59427482-59427600 LRIG3 (0) 
chr12 59880356-59880492 SLC16A7 (2.4) 
chr12 60826109-60826215 SLC16A7 (2.4) 
chr12 63402435-63402554 PPM1H (0.77) 
chr12 64428040-64428146 SRGAP1 (0.05) 
chr12 65915292-65915398 MSRB3 (0.02) 
chr12 66414343-66414461 HMGA2 (0) 
chr12 68066305-68066421 DYRK2 (3.99) 
chr12 68835694-68836256 MDM1 (4.16) 
chr12 73345011-73345124 TRHDE (0.01) 
chr12 88543918-88544036 CEP290 (2.76) 
chr12 88721976-88722114 TMTC3 (2.4) 
chr12 89445751-89445867 LOC728084 (0) 
chr12 91058848-91058964 C12orf37 (0) 
chr12 91351941-91352058 C12orf12 (0) 
chr12 94202036-94202153 CRADD (3.46) 
chr12 97286221-97286340 NEDD1 (4.33) 
chr12 99386279-99386388 ANKS1B (1.22) 
chr12 102685554-102685664 PMCH (2.52) 
chr12 104864054-104864169 CHST11 (0.54) 
chr12 114438145-114438258 RBM19 (4.8) 
chr12 115345771-115345896 TBX3 (0) 
chr12 118419389-118419530 KSR2 (0.01) 
chr12 118419874-118420023 KSR2 (0.01) 
chr12 127254724-127254865 LOC100507206 (0) 
chr12 127468378-127468493 LOC440117 (0) 
chr12 128452964-128453052 FLJ37505 (0) 
chr12 128891783-128891883 TMEM132C (0) 
chr12 129110028-129110143 TMEM132C (0) 
chr12 129594176-129594318 TMEM132D (0) 
chr13 19128876-19128992 ANKRD20A9P (0.39) 
chr13 21665974-21666095 LATS2 (0) 
chr13 27766743-27766860 USP12 (2.69) 
chr13 35314331-35314450 NBEA (1.03) 
chr13 46234667-46234783 SPERT (0) 
chr13 49259270-49259384 CYSLTR2 (0) 
chr13 54539414-54539553 MIR1297 (0) 
chr13 56917553-56917689 PRR20C (0) 
chr13 63631285-63631445 OR7E156P (0) 
chr13 64882038-64882141 OR7E156P (0) 
chr13 65606632-65606783 PCDH9 (4.79) 
chr13 69229703-69229875 LOC338862 (0) 
chr13 69251436-69251586 LOC338862 (0) 
chr13 71010946-71011072 ATXN8OS (0) 
chr13 72893893-72893996 MZT1 (4.9) 
chr13 72916013-72916138 MZT1 (4.9) 
chr13 72976580-72976794 MZT1 (4.9) 
chr13 78003763-78003882 MYCBP2 (5.38) 
chr13 78498975-78499087 EDNRB (0) 
chr13 87346177-87346310 MIR4500HG (0) 
chr13 87778357-87778562 MIR4500HG (0) 
chr13 89896538-89896645 MIR622 (0) 
chr13 96132271-96132389 CLDN10 (0) 
chr13 98395866-98395993 IPO5 (7.68) 
chr13 99772200-99772319 DOCK9 (2.85) 
chr13 100104204-100104324 MIR548AN (0) 
chr13 100113234-100113379 TM9SF2 (6.15) 
chr13 102161444-102161583 NALCN (0) 
chr13 103752582-103752686 SLC10A2 (1.27) 
chr13 104440020-104440162 SLC10A2 (1.27) 
chr14 19680927-19681064 POTEG (0) 
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chr14 19894320-19894456 POTEM (0) 
chr14 21134732-21135029 ANG (0.29) 
chr14 27075087-27075192 NOVA1 (0) 
chr14 29558644-29558776 C14orf23 (0) 
chr14 29593676-29593791 MIR548AI (0) 
chr14 30348581-30348700 PRKD1 (0) 
chr14 35829097-35829203 NFKBIA (4.48) 
chr14 37469986-37470112 SLC25A21 (0) 
chr14 37594005-37594253 SLC25A21 (0) 
chr14 41907146-41907256 LRFN5 (0) 
chr14 43687715-43687829 FSCB (0) 
chr14 48203570-48203676 MIR548Y (0) 
chr14 50053303-50053593 RPS29 (10.33) 
chr14 50873090-50873200 CDKL1 (3.04) 
chr14 51651869-51651986 TMX1 (4.07) 
chr14 51960189-51960305 FRMD6 (0.34) 
chr14 57445260-57445415 OTX2OS1 (0) 
chr14 59502600-59502715 DAAM1 (2.68) 
chr14 60677143-60677281 PPM1A (3.5) 
chr14 69377536-69377674 ACTN1 (0) 
chr14 71411543-71411685 PCNX (2.51) 
chr14 76012924-76013197 FLVCR2 (0.18) 
chr14 89744371-89744627 FOXN3 (2.63) 
chr14 90410505-90410619 TDP1 (4.47) 
chr14 92630310-92630493 CPSF2 (6) 
chr14 93336858-93336998 GOLGA5 (4.05) 
chr14 93338639-93338779 GOLGA5 (4.05) 
chr14 93339789-93339929 GOLGA5 (4.05) 
chr14 94114160-94114286 PRIMA1 (0) 
chr14 97903730-97903934 LOC100129345 (0) 
chr14 100800129-100800299 SLC25A47 (0) 
chr15 23188003-23188295 WHAMMP3 (1.49) 
chr15 34880551-34880664 GOLGA8B (3.08) 
chr15 38339671-38339786 TMCO5A (0) 
chr15 39527801-39527919 C15orf54 (0) 
chr15 42788980-42789116 ZFP106 (0) 
chr15 45103608-45103713 TRIM69 (0.27) 
chr15 47835590-47835708 SEMA6D (0) 
chr15 49907724-49907827 C15orf33 (0) 
chr15 53016821-53016939 ONECUT1 (0) 
chr15 58113629-58113748 GCOM1 (0) 
chr15 66721530-66721655 MAP2K1 (4.28) 
chr15 69745132-69745250 KIF23 (5.18) 
chr15 74756735-74756874 LOC440288 (0) 
chr15 75230266-75230387 RPP25 (4.2) 
chr15 81096283-81096421 KIAA1199 (0) 
chr15 87581914-87582054 AGBL1 (0) 
chr15 91284017-91284135 BLM (5.39) 
chr15 95965601-95965714 LOC145820 (0) 
chr15 96537229-96537371 NR2F2 (0) 
chr16 6147114-6147232 RBFOX1 (0) 
chr16 13354736-13354856 SHISA9 (2.65) 
chr16 13431183-13431302 SHISA9 (2.65) 
chr16 17119508-17119657 XYLT1 (2.68) 
chr16 20035572-20035707 GPR139 (0) 
chr16 21127733-21127858 DNAH3 (0.05) 
chr16 21314303-21314411 RUNDC2B (0) 
chr16 26644119-26644238 C16orf82 (0) 
chr16 27258580-27258734 NSMCE1 (4.78) 
chr16 31123626-31123821 KAT8 (5.11) 
chr16 54907984-54908094 CRNDE (5.09) 
chr16 58455194-58455341 GINS3 (5.28) 
chr16 60118538-60118653 LOC644649 (0) 
chr16 67403545-67403663 TPPP3 (0) 
chr16 76268957-76269075 CNTNAP4 (0.07) 
chr16 76269447-76269554 CNTNAP4 (0.07) 
chr16 80926290-80926626 C16orf61 (0) 
chr16 86380942-86381060 LOC732275 (0) 
chr16 88876084-88876217 APRT (7.52) 
chr17 5522640-5522784 NLRP1 (1.44) 
chr17 25597719-25597860 MIR4522 (0) 
chr17 27717450-27717563 MIR4523 (0) 
chr17 30771513-30771618 PSMD11 (5) 
chr17 31279715-31279834 TMEM98 (0) 
chr17 38946998-38947105 KRT28 (0) 
chr17 42022285-42022405 PPY (0) 
chr17 49498006-49498128 UTP18 (6.18) 
chr17 50681008-50681121 LOC100506650 (0) 
chr17 52433895-52434010 KIF2B (0) 
chr17 64410429-64410541 PRKCA (2.28) 
chr17 64934372-64934491 CACNG4 (0.02) 
chr17 66823157-66823270 ABCA8 (0) 
chr17 69227567-69227700 SOX9 (0) 
chr17 69617072-69617207 SOX9 (0) 
chr17 70016632-70016770 SOX9 (0) 
chr17 71146860-71147015 SSTR2 (0.29) 
chr17 71999238-71999356 LINC00469 (0) 
chr17 73754260-73754605 GALK1 (4.9) 
chr17 74560620-74560714 ST6GALNAC2 (0.82) 
chr17 79335996-79336139 TMEM105 (0) 
chr18 10890477-10890590 PIEZO2 (0.52) 
chr18 19886298-19886390 GATA6 (0) 
chr18 20452935-20453060 RBBP8 (6.03) 
chr18 22537531-22537649 ZNF521 (0.02) 
chr18 30136366-30136483 WBP11P1 (0) 
chr18 32485069-32485203 DTNA (0) 
chr18 32486999-32487105 DTNA (0) 
chr18 33069290-33069426 MIR3975 (0) 
chr18 42251832-42252031 SETBP1 (1.8) 
chr18 44812020-44812208 IER3IP1 (5.2) 
chr18 45721780-45721922 ZBTB7C (0.02) 
chr18 47982707-47982825 SKA1 (5.6) 
chr18 50287463-50287600 DCC (0) 
chr18 55636098-55636225 NEDD4L (2.21) 
chr18 55664170-55664261 NEDD4L (2.21) 
chr18 56447356-56447466 MALT1 (5.1) 
chr18 57161150-57161265 CCBE1 (1.79) 
chr18 58210297-58210409 MC4R (0) 
chr18 59990762-59990875 TNFRSF11A (0) 
chr18 62267760-62267873 LOC284294 (0) 
chr18 62453081-62453192 LOC284294 (0) 
chr18 62658732-62658836 LOC284294 (0) 
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chr18 63016212-63016315 CDH7 (0) 
chr18 65051482-65051594 DSEL (0) 
chr18 68603722-68603833 LOC100505776 (0) 
chr18 68919816-68919920 LOC100505776 (0) 
chr18 68975425-68975567 LOC100505776 (0) 
chr18 69552667-69552809 LOC100505776 (0) 
chr18 69776943-69777067 CBLN2 (0) 
chr18 70147093-70147206 CBLN2 (0) 
chr18 73447895-73448004 C18orf62 (0) 
chr18 75705580-75705715 GALR1 (0) 
chr19 2477781-2477881 GADD45B (4.32) 
chr19 6381159-6381451 GTF2F1 (5.57) 
chr19 7696347-7696468 PCP2 (0.82) 
chr19 13864465-13864577 MRI1 (4.06) 
chr19 16308721-16308840 AP1M1 (4.86) 
chr19 23887328-23887468 ZNF675 (3.88) 
chr19 28620111-28620219 LOC148189 (0) 
chr19 34046697-34046823 PEPD (4.19) 
chr19 35090318-35090437 SCGBL (0) 
chr19 46743645-46743762 IGFL1 (0) 
chr19 50363849-50363937 PNKP (4.08) 
chr2 1318520-1318638 SNTG2 (0.05) 
chr2 3119038-3119156 TSSC1 (5.21) 
chr2 4091294-4091413 LOC100505964 (0) 
chr2 6101997-6102123 LOC400940 (0) 
chr2 7860336-7860496 LOC339788 (0) 
chr2 9255032-9255146 ASAP2 (0.2) 
chr2 10266072-10266268 C2orf48 (1.6) 
chr2 11037116-11037234 KCNF1 (0) 
chr2 11719997-11720229 MIR4429 (0) 
chr2 12007290-12007409 MIR4262 (0) 
chr2 14131243-14131388 FAM84A (0) 
chr2 15444372-15444476 NBAS (4.31) 
chr2 15974652-15974767 MYCNOS (0) 
chr2 16048806-16048921 MYCNOS (0) 
chr2 16909369-16909486 FAM49A (1.22) 
chr2 16995366-16995481 FAM49A (1.22) 
chr2 17253370-17253484 FAM49A (1.22) 
chr2 20263076-20263355 LAPTM4A (2.92) 
chr2 21385745-21385883 APOB (0) 
chr2 27383113-27383218 TCF23 (0) 
chr2 30554542-30554660 LBH (3.31) 
chr2 33931865-33932035 MYADML (0) 
chr2 36275760-36275875 LOC100288911 (0) 
chr2 38035738-38035851 FAM82A1 (0) 
chr2 38391430-38391548 CYP1B1-AS1 (0) 
chr2 44523998-44524149 PREPL (4.44) 
chr2 45337143-45337255 UNQ6975 (0) 
chr2 49305302-49305417 FSHR (0) 
chr2 49398162-49398432 FSHR (0) 
chr2 53155995-53156176 ASB3 (4.4) 
chr2 56503657-56503797 CCDC85A (1.56) 
chr2 64261720-64261823 VPS54 (3.49) 
chr2 65275099-65275295 CEP68 (2.81) 
chr2 67517083-67517227 LOC644838 (0) 
chr2 79213605-79213749 REG3G (0) 
chr2 84790162-84790280 DNAH6 (0.03) 
chr2 99229885-99230002 COA5 (3.74) 
chr2 104629690-104629825 LOC100287010 (0.1) 
chr2 110294435-110294550 40422 (0) 
chr2 110451130-110451245 ANKRD57 (0) 
chr2 110971196-110971314 NPHP1 (0.82) 
chr2 111881290-111881403 ACOXL (0.04) 
chr2 114448583-114448781 SLC35F5 (3.98) 
chr2 116514940-116515055 DPP10 (0) 
chr2 118480741-118480859 DDX18 (6.02) 
chr2 121013791-121014247 TMEM185B (2.2) 
chr2 123811158-123811262 CNTNAP5 (0) 
chr2 128586999-128587114 POLR2D (5.04) 
chr2 132737354-132737467 ANKRD30BL (0) 
chr2 148549202-148549312 ACVR2A (1.46) 
chr2 152470238-152470386 NEB (0.11) 
chr2 155061992-155062392 GALNT13 (0) 
chr2 155342895-155343013 GALNT13 (0) 
chr2 157881105-157881243 GALNT5 (0) 
chr2 160266972-160267101 BAZ2B (0.31) 
chr2 162419054-162419191 SLC4A10 (0.44) 
chr2 163969119-163969230 KCNH7 (0.02) 
chr2 164518262-164518402 KCNH7 (0.02) 
chr2 166178046-166178179 SCN2A (0.02) 
chr2 169280671-169280783 CERS6 (0) 
chr2 176249775-176249893 ATP5G3 (6.29) 
chr2 176251669-176251788 ATP5G3 (6.29) 
chr2 177293847-177293995 MTX2 (4.43) 
chr2 182030652-182030770 UBE2E3 (5.17) 
chr2 187079749-187079858 ZC3H15 (6.66) 
chr2 188969733-188969852 GULP1 (0) 
chr2 191573345-191573534 NAB1 (3.54) 
chr2 191860096-191860214 GLS (5.47) 
chr2 196972875-196973015 STK17B (5.62) 
chr2 198220811-198220929 SF3B1 (7.92) 
chr2 204991755-204991874 ICOS (0) 
chr2 215674336-215674434 ABCA12 (0.03) 
chr2 220553182-220553299 SLC4A3 (0) 
chr2 226802918-226803037 KIAA1486 (0) 
chr2 229227273-229227381 SPHKAP (0) 
chr2 235095748-235095863 SPP2 (0) 
chr2 238125828-238125945 COL6A3 (0.04) 
chr2 241647948-241648061 KIF1A (0) 
chr20 1772427-1772544 LOC100289473 (0) 
chr20 6093809-6093926 LRRN4 (0.25) 
chr20 8354899-8355004 PLCB1 (0) 
chr20 15932709-15932844 MACROD2 (0) 
chr20 15952051-15952169 MACROD2 (0) 
chr20 23478253-23478371 CST8 (0) 
chr20 33650945-33651063 EDEM2 (3.64) 
chr20 34547338-34547447 SCAND1 (4.84) 
chr20 34620302-34620412 C20orf152 (0) 
chr20 39485856-39485960 MAFB (0) 
chr20 42457706-42457821 TOX2 (0) 
chr20 43588896-43589039 LOC100505826 (0) 
chr20 48944827-48944926 LOC284751 (0) 
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chr20 52716951-52717088 BCAS1 (0.1) 
chr20 55453499-55453615 TFAP2C (0) 
chr20 56058420-56058538 CTCFL (0.03) 
chr20 56343862-56343991 PMEPA1 (1.71) 
chr21 14555344-14555460 ANKRD30BP2 (0.03) 
chr21 15971645-15971782 SAMSN1 (2.33) 
chr21 16042596-16042711 SAMSN1 (2.33) 
chr21 16052023-16052208 SAMSN1 (2.33) 
chr21 16118794-16118905 SAMSN1 (2.33) 
chr21 17296940-17297092 USP25 (4.25) 
chr21 17832232-17832327 LINC00478 (0) 
chr21 19858084-19858262 TMPRSS15 (1.81) 
chr21 20834124-20834257 TMPRSS15 (1.81) 
chr21 20852686-20852805 TMPRSS15 (1.81) 
chr21 21066614-21066754 LINC00320 (0) 
chr21 23058563-23058681 LINC00317 (0) 
chr21 24750219-24750338 D21S2088E (0) 
chr21 25309325-25309445 D21S2088E (0) 
chr21 26839466-26839573 LINC00158 (0.24) 
chr21 27082030-27082146 ATP5J (6.23) 
chr21 28372021-28372138 ADAMTS5 (0) 
chr21 30447265-30447383 CCT8 (8.09) 
chr21 30638210-30638351 BACH1 (4.22) 
chr21 31330501-31330639 GRIK1 (0.05) 
chr21 31799625-31799734 KRTAP13-3 (0) 
chr21 35624520-35624647 LINC00310 (0.56) 
chr21 36066843-36066971 CLIC6 (0) 
chr21 47013481-47013766 SLC19A1 (3.96) 
chr21 47556862-47556980 FTCD (0.09) 
chr21 47673888-47674013 MCM3AP (4.8) 
chr22 16162017-16162153 POTEH (0) 
chr22 29656693-29656823 EMID1 (0.13) 
chr22 34186149-34186291 LARGE (3.51) 
chr22 35458729-35458854 ISX (0.16) 
chr22 35626942-35627088 HMGXB4 (3.19) 
chr22 40269979-40270091 ENTHD1 (0) 
chr22 45493403-45493516 LOC100506714 (0) 
chr22 45513703-45513791 LOC100506714 (0) 
chr22 46016641-46016752 FBLN1 (0) 
chr22 46067721-46067847 ATXN10 (5.12) 
chr22 47702793-47702898 LOC339685 (0) 
chr3 278939-279042 CNTN6 (0) 
chr3 3168676-3168824 IL5RA (0) 
chr3 6917115-6917266 LOC100288428 (0) 
chr3 8226505-8226622 LOC100288428 (0) 
chr3 13965278-13965383 LOC100132526 (0) 
chr3 29254183-29254293 RBMS3 (0.21) 
chr3 32972910-32973047 CCR4 (0.05) 
chr3 43665965-43666101 ANO10 (1.65) 
chr3 52740136-52740275 SPCS1 (5.41) 
chr3 53231270-53231411 PRKCD (2.03) 
chr3 61504851-61505007 PTPRG (0.05) 
chr3 62300695-62300814 LOC100506994 (0) 
chr3 66471313-66471450 LRIG1 (3.69) 
chr3 72529245-72529486 RYBP (1.48) 
chr3 72529487-72529575 RYBP (1.48) 
chr3 77707849-77707963 ROBO2 (0) 
chr3 79363572-79363708 ROBO1 (0) 
chr3 80577749-80577860 ROBO1 (0) 
chr3 83433624-83433733 LOC440970 (0) 
chr3 87306525-87306644 CHMP2B (3.03) 
chr3 88082264-88082398 CGGBP1 (3.95) 
chr3 88593131-88593238 C3orf38 (3.2) 
chr3 98829913-98830055 DCBLD2 (2.28) 
chr3 99563633-99563830 MIR548G (0) 
chr3 99976565-99976679 TBC1D23 (3.52) 
chr3 102001158-102001285 ZPLD1 (0.02) 
chr3 102577929-102578064 ZPLD1 (0.02) 
chr3 103960075-103960190 MIR548A3 (0) 
chr3 106921644-106921873 LOC100302640 (0) 
chr3 107843796-107843997 CD47 (5.04) 
chr3 112032952-112033107 CD200 (0.04) 
chr3 112101271-112101413 CD200 (0.04) 
chr3 113806465-113806583 KIAA1407 (1.2) 
chr3 114500665-114500781 ZBTB20 (0.74) 
chr3 116407860-116408002 LSAMP-AS3 (0) 
chr3 116688247-116688541 LSAMP-AS3 (0) 
chr3 116911873-116912015 LSAMP-AS3 (0) 
chr3 118528782-118528901 IGSF11 (0) 
chr3 121698403-121698518 ILDR1 (0.45) 
chr3 121734415-121734524 CD86 (2.35) 
chr3 121753599-121753714 ILDR1 (0.45) 
chr3 131606062-131606198 CPNE4 (0.03) 
chr3 141754570-141754718 TFDP2 (5.21) 
chr3 148677831-148677946 GYG1 (4.51) 
chr3 149146318-149146425 TM4SF4 (0) 
chr3 150321107-150321230 SELT (5.69) 
chr3 160479537-160479655 PPM1L (0.38) 
chr3 163199738-163199856 LOC647107 (0) 
chr3 166801087-166801205 ZBBX (0) 
chr3 166909343-166909455 ZBBX (0) 
chr3 172671982-172672090 SPATA16 (0) 
chr3 174991754-174992117 NAALADL2 (0.5) 
chr3 175815778-175815890 NAALADL2 (0.5) 
chr3 177345983-177346118 TBL1XR1 (5.56) 
chr3 183079268-183079409 MCF2L2 (0.65) 
chr3 184175713-184175852 CHRD (0) 
chr3 185743989-185744106 ETV5 (0.1) 
chr3 188057283-188057411 LPP (3.88) 
chr3 189121164-189121298 TPRG1 (0.03) 
chr3 193563168-193563276 LOC647323 (0) 
chr3 195913909-195914038 ZDHHC19 (0) 
chr3 196669747-196669837 LOC152217 (0) 
chr4 3915920-3916038 FAM86EP (2.17) 
chr4 5068800-5068919 STK32B (0) 
chr4 12763410-12763516 HSP90AB2P (0) 
chr4 14809489-14809628 LOC441009 (0) 
chr4 29023038-29023141 MIR4275 (0) 
chr4 33796983-33797100 ARAP2 (2.72) 
chr4 34272599-34272705 ARAP2 (2.72) 
chr4 34540850-34540968 ARAP2 (2.72) 
chr4 38552259-38552428 FLJ13197 (0) 
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chr4 41914704-41914826 TMEM33 (4.62) 
chr4 42465377-42465492 ATP8A1 (4.39) 
chr4 42980951-42981076 GRXCR1 (0) 
chr4 61911247-61911387 LPHN3 (0) 
chr4 63136311-63136458 LPHN3 (0) 
chr4 73079586-73079726 NPFFR2 (0) 
chr4 77446327-77446452 SHROOM3 (0.04) 
chr4 77791142-77791259 ANKRD56 (0) 
chr4 88654236-88654350 IBSP (0) 
chr4 89947689-89947790 FAM13A (0.58) 
chr4 94224152-94224259 GRID2 (0.02) 
chr4 95983086-95983264 UNC5C (0) 
chr4 112723789-112723919 C4orf32 (3.88) 
chr4 117150691-117150799 MIR1973 (0) 
chr4 120221493-120221733 USP53 (4.58) 
chr4 122127028-122127156 TNIP3 (0) 
chr4 123001164-123001273 KIAA1109 (2.91) 
chr4 133184029-133184156 PCDH10 (0) 
chr4 134283845-134283963 PCDH10 (0) 
chr4 138978550-138978668 LOC641364 (0) 
chr4 142579319-142579445 IL15 (0.04) 
chr4 150430085-150430227 DCLK2 (0.06) 
chr4 155657151-155657302 LRAT (0) 
chr4 160900894-160901003 RAPGEF2 (4.8) 
chr4 166771215-166771321 TLL1 (0) 
chr4 176499390-176499510 GPM6A (2.49) 
chr4 179189048-179189158 LOC285501 (0) 
chr4 185451433-185451663 IRF2 (3.59) 
chr4 188077177-188077292 LOC339975 (0) 
chr4 188154413-188154531 LOC339975 (0) 
chr4 189441858-189441973 LOC401164 (0) 
chr4 189444112-189444228 LOC401164 (0) 
chr5 2058890-2059010 IRX4 (0) 
chr5 2115723-2115842 IRX4 (0) 
chr5 2268698-2268846 IRX4 (0) 
chr5 5006913-5007025 LOC340094 (0) 
chr5 5039964-5040109 ADAMTS16 (0.05) 
chr5 10311294-10311410 CMBL (0.08) 
chr5 12079986-12080121 CTNND2 (0) 
chr5 13372760-13372878 DNAH5 (0.04) 
chr5 14202804-14202930 TRIO (4.21) 
chr5 17259222-17259328 LOC285696 (0) 
chr5 17884805-17884914 LOC401177 (0) 
chr5 18697900-18698125 CDH18 (0.03) 
chr5 20922217-20922370 GUSBP1 (4.91) 
chr5 22618978-22619118 CDH12 (0.25) 
chr5 23443620-23443727 PRDM9 (0) 
chr5 30855646-30855744 CDH6 (0) 
chr5 34280086-34280201 C1QTNF3-AMACR 
(0.5) 
chr5 34349766-34349883 C1QTNF3-AMACR 
(0.5) 
chr5 35560178-35560293 SPEF2 (0) 
chr5 36277925-36278073 RANBP3L (0.07) 
chr5 38415872-38415978 EGFLAM (0) 
chr5 38868631-38868748 RICTOR (3.13) 
chr5 40225322-40225466 PTGER4 (1.3) 
chr5 40323412-40323516 PTGER4 (1.3) 
chr5 41281455-41281568 C6 (0) 
chr5 41478921-41479009 PLCXD3 (0) 
chr5 42101089-42101218 FBXO4 (1.84) 
chr5 43068939-43069143 LOC100132356 (2.25) 
chr5 51202097-51202386 ISL1 (0) 
chr5 55240473-55240730 IL31RA (0) 
chr5 59995862-59995954 DEPDC1B (3.19) 
chr5 66118929-66119031 MAST4 (0.3) 
chr5 66786403-66786520 CD180 (4.65) 
chr5 67794749-67794886 PIK3R1 (3.04) 
chr5 68604295-68604424 CDK7 (4.46) 
chr5 79114595-79114749 CMYA5 (0.1) 
chr5 83032193-83032311 HAPLN1 (0) 
chr5 86938164-86938277 CCNH (5.95) 
chr5 91206689-91206797 LOC100129716 (0) 
chr5 95382454-95382594 MIR583 (0) 
chr5 99708314-99708455 LOC100133050 (0.14) 
chr5 100208301-100208443 ST8SIA4 (3.28) 
chr5 100217485-100217646 ST8SIA4 (3.28) 
chr5 115481489-115481595 COMMD10 (4.62) 
chr5 116556682-116556814 SEMA6A (0.22) 
chr5 119410254-119410366 PRR16 (0) 
chr5 120500390-120500593 PRR16 (0) 
chr5 122037086-122037195 SNX2 (4.6) 
chr5 129630694-129630813 CHSY3 (0) 
chr5 130802299-130802418 RAPGEF6 (4.08) 
chr5 132839582-132839693 FSTL4 (0) 
chr5 139624820-139625001 C5orf32 (0) 
chr5 141019041-141019149 RELL2 (4.29) 
chr5 142589739-142589852 ARHGAP26 (1.67) 
chr5 142970524-142970648 NR3C1 (4.29) 
chr5 144779312-144779427 PRELID2 (0) 
chr5 149472094-149472212 PDGFRB (0.06) 
chr5 149776150-149776390 CD74 (9.56) 
chr5 151338389-151338530 GLRA1 (0.3) 
chr5 151482694-151482800 GLRA1 (0.3) 
chr5 161353888-161354007 GABRA1 (0) 
chr5 162864555-162864671 NUDCD2 (5.42) 
chr5 163798356-163798491 MAT2B (4.63) 
chr5 174478455-174478573 MIR4634 (0) 
chr5 176830518-176830635 F12 (0.42) 
chr6 3195908-3196040 TUBB2B (0.04) 
chr6 6649189-6649447 LY86-AS1 (1.22) 
chr6 9766829-9766988 TFAP2A (0) 
chr6 11295205-11295297 NEDD9 (2.46) 
chr6 12677103-12677218 PHACTR1 (1.67) 
chr6 16402134-16402269 ATXN1 (0.35) 
chr6 18522954-18523066 MIR548A1 (0) 
chr6 27686879-27686989 LOC100507173 (0) 
chr6 31021182-31021328 HCG22 (0.23) 
chr6 32430708-32430827 HLA-DRA (8.53) 
chr6 36321474-36321706 ETV7 (0) 
chr6 37717359-37717484 MDGA1 (0) 
chr6 40741031-40741154 LRFN2 (0) 
chr6 43099194-43099326 PTK7 (2.47) 
chr6 48855979-48856067 MUT (3.12) 
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chr6 54604850-54604968 FAM83B (0) 
chr6 55495535-55495650 HMGCLL1 (0) 
chr6 67778166-67778279 MCART3P (0) 
chr6 71339465-71339584 SMAP1 (4.21) 
chr6 72372797-72372932 RIMS1 (0) 
chr6 77054334-77054469 IMPG1 (0) 
chr6 79307602-79307715 IRAK1BP1 (2.91) 
chr6 81662236-81662480 BCKDHB (4.44) 
chr6 81926824-81926942 FAM46A (0.1) 
chr6 82247253-82247395 FAM46A (0.1) 
chr6 82296403-82296542 FAM46A (0.1) 
chr6 82804931-82805039 IBTK (4.33) 
chr6 83909290-83909408 RWDD2A (2.54) 
chr6 84815043-84815158 MRAP2 (0) 
chr6 85506212-85506347 TBX18 (0) 
chr6 85718574-85718681 TBX18 (0) 
chr6 89244212-89244322 RNGTT (4.82) 
chr6 91602251-91602391 MAP3K7 (4.93) 
chr6 92685430-92685545 MIR4643 (0) 
chr6 94989559-94989674 TSG1 (0) 
chr6 98376247-98376365 MIR2113 (0) 
chr6 101149203-101149338 ASCC3 (5.01) 
chr6 102996032-102996144 GRIK2 (0) 
chr6 111612239-111612370 REV3L (4.31) 
chr6 113777038-113777146 MARCKS (1.09) 
chr6 115034063-115034231 HS3ST5 (0) 
chr6 115267892-115267987 HS3ST5 (0) 
chr6 115409554-115409703 FRK (0.54) 
chr6 117763596-117763709 ROS1 (0) 
chr6 120326837-120326968 MAN1A1 (6.33) 
chr6 125169243-125169359 NKAIN2 (0) 
chr6 128299543-128299650 PTPRK (0) 
chr6 131430514-131430633 AKAP7 (1.04) 
chr6 134433538-134433667 HMGA1P7 (0) 
chr6 134719719-134719914 LOC154092 (0) 
chr6 136546662-136546804 FAM54A (0) 
chr6 138128308-138128426 TNFAIP3 (1.46) 
chr6 138440545-138440660 PERP (0) 
chr6 139370341-139370522 C6orf115 (0) 
chr6 140908984-140909113 MIR4465 (0) 
chr6 145790218-145790325 EPM2A (3.12) 
chr6 147173630-147173734 LOC729178 (0) 
chr6 150580005-150580120 PPP1R14C (0.19) 
chr6 153038695-153038810 VIP (0) 
chr6 155951973-155952486 NOX3 (0) 
chr6 162163307-162163426 PARK2 (0.02) 
chr6 164942237-164942364 C6orf118 (0) 
chr6 166913063-166913180 RPS6KA2 (1.03) 
chr7 1561148-1561266 MAFK (4.36) 
chr7 2889073-2889189 GNA12 (3.77) 
chr7 12574886-12574976 SCIN (0) 
chr7 12971259-12971405 ARL4A (3.42) 
chr7 14277920-14278029 DGKB (0) 
chr7 30872880-30872995 FAM188B (0.94) 
chr7 34329154-34329273 AAA1 (0) 
chr7 36031055-36031170 39326 (6.76) 
chr7 37743963-37744077 GPR141 (0) 
chr7 45412787-45412920 RAMP3 (0) 
chr7 46727534-46727632 TNS3 (3.96) 
chr7 48169599-48169712 UPP1 (0) 
chr7 49774986-49775100 VWC2 (0) 
chr7 50330068-50330200 IKZF1 (6.94) 
chr7 53535984-53536102 FLJ45974 (0) 
chr7 63512747-63512859 ZNF727 (0) 
chr7 68782085-68782205 AUTS2 (4.46) 
chr7 70713087-70713190 WBSCR17 (0) 
chr7 71222105-71222224 CALN1 (0.01) 
chr7 81315457-81315565 HGF (0.55) 
chr7 82523706-82523825 CACNA2D1 (0.03) 
chr7 87492680-87492811 DBF4 (6.02) 
chr7 89020756-89020873 ZNF804B (0.05) 
chr7 92218103-92218227 CDK6 (5.13) 
chr7 92572171-92572289 CDK6 (5.13) 
chr7 93652080-93652244 BET1 (3.98) 
chr7 93878939-93879049 COL1A2 (0) 
chr7 96380361-96380465 SHFM1 (7.65) 
chr7 97430391-97430496 ASNS (7.04) 
chr7 106131454-106131568 C7orf74 (0) 
chr7 106145137-106145284 C7orf74 (0) 
chr7 106224344-106224456 C7orf74 (0) 
chr7 112709785-112709896 GPR85 (0.17) 
chr7 112947887-112948003 LOC401397 (0) 
chr7 115936062-115936180 TES (0.19) 
chr7 116907999-116908119 WNT2 (0) 
chr7 117636023-117636260 CTTNBP2 (0) 
chr7 120702879-120703019 C7orf58 (0) 
chr7 121403786-121403901 PTPRZ1 (0) 
chr7 122851385-122851500 SLC13A1 (0.13) 
chr7 123193290-123193432 NDUFA5 (4.78) 
chr7 124996207-124996337 POT1 (4.2) 
chr7 125121557-125121684 POT1 (4.2) 
chr7 125140951-125141158 POT1 (4.2) 
chr7 128761668-128761807 LOC407835 (0) 
chr7 130708011-130708131 MKLN1 (4.05) 
chr7 144859699-144859858 TPK1 (1.35) 
chr7 147082062-147082175 MIR548I4 (0) 
chr7 147084001-147084116 MIR548I4 (0) 
chr7 147607689-147607806 MIR548T (0) 
chr7 151578411-151578530 LOC100505483 (0) 
chr7 154998358-154998485 INSIG1 (6.36) 
chr7 156162743-156162878 LOC285889 (0) 
chr7 158172523-158172672 PTPRN2 (0.03) 
chr8 15199095-15199290 SGCZ (0) 
chr8 15274672-15274804 TUSC3 (0) 
chr8 16314447-16314600 MSR1 (0.16) 
chr8 19075653-19075770 SH2D4A (0) 
chr8 20368449-20368564 LZTS1 (2.67) 
chr8 23864217-23864329 STC1 (0) 
chr8 27787781-27787925 SCARA5 (0) 
chr8 37340572-37340732 ZNF703 (0.03) 
chr8 61402648-61402756 RAB2A (4.17) 
chr8 63655403-63655521 NKAIN3 (0) 
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chr8 67001335-67001448 DNAJC5B (0.13) 
chr8 68684429-68684545 CPA6 (0) 
chr8 69152000-69152115 PREX2 (0) 
chr8 70216755-70216874 SULF1 (0.01) 
chr8 71413673-71413788 TRAM1 (6.97) 
chr8 74288470-74288588 LOC100128126 (0) 
chr8 76041799-76041908 CRISPLD1 (0) 
chr8 78434057-78434175 PEX2 (3.58) 
chr8 80659316-80659434 HEY1 (0.34) 
chr8 86851851-86852020 REXO1L2P (0) 
chr8 90358680-90358861 RIPK2 (3.05) 
chr8 90757029-90757140 RIPK2 (3.05) 
chr8 92453599-92453708 SLC26A7 (0) 
chr8 94351961-94352080 LOC642924 (0) 
chr8 101344583-101344689 RNF19A (4.02) 
chr8 101977446-101977551 YWHAZ (7.09) 
chr8 105714553-105714672 LRP12 (0) 
chr8 105734582-105734694 LRP12 (0) 
chr8 107552919-107553034 OXR1 (4.03) 
chr8 112386802-112386941 CSMD3 (0) 
chr8 113767676-113767779 CSMD3 (0) 
chr8 118532934-118533073 EXT1 (2.94) 
chr8 118580736-118580849 MED30 (5.13) 
chr8 118776761-118776879 EXT1 (2.94) 
chr8 119919115-119919258 TNFRSF11B (0.04) 
chr8 120835697-120835807 DSCC1 (4.64) 
chr8 123279495-123279605 ZHX2 (4.14) 
chr8 123583731-123583836 ZHX2 (4.14) 
chr8 124685073-124685200 ANXA13 (0) 
chr8 124724434-124724546 FAM91A1 (3.56) 
chr8 124840804-124840911 FAM91A1 (3.56) 
chr8 125755053-125755171 MTSS1 (1.58) 
chr8 126545235-126545345 TRIB1 (3.83) 
chr8 127019454-127019594 LOC100130231 (0) 
chr8 134392054-134392185 ST3GAL1 (0.72) 
chr8 135340956-135341163 ZFAT (2.56) 
chr8 135368506-135368621 ZFAT (2.56) 
chr8 135784079-135784192 MIR30B (0) 
chr8 136876322-136876465 KHDRBS3 (1.19) 
chr8 138931603-138931722 FAM135B (0) 
chr8 144899823-144899968 PUF60 (6.87) 
chr9 2252773-2252888 SMARCA2 (4.07) 
chr9 2388633-2388744 FLJ35024 (0) 
chr9 3307049-3307162 RFX3 (2.61) 
chr9 5580609-5580744 PDCD1LG2 (0.21) 
chr9 11393643-11393751 PTPRD (0.01) 
chr9 16917483-16917600 BNC2 (0) 
chr9 16983808-16983924 BNC2 (0) 
chr9 18838059-18838198 ADAMTSL1 (0) 
chr9 19037520-19037638 FAM154A (0) 
chr9 19252110-19252245 DENND4C (3.58) 
chr9 22058798-22058938 CDKN2B-AS (0) 
chr9 24481116-24481218 ELAVL2 (0) 
chr9 25462603-25462710 TUSC1 (0) 
chr9 26157484-26157608 LOC100506422 (0) 
chr9 26748174-26748325 C9orf82 (0) 
chr9 26752818-26752992 C9orf82 (0) 
chr9 29724573-29724688 MIR873 (0) 
chr9 30139758-30139902 MIR873 (0) 
chr9 30601396-30601508 MIR873 (0) 
chr9 30925182-30925294 ACO1 (3.63) 
chr9 31194211-31194319 ACO1 (3.63) 
chr9 31578562-31578706 ACO1 (3.63) 
chr9 31724422-31724541 ACO1 (3.63) 
chr9 39630751-39630860 LOC653501 (0) 
chr9 41775783-41775887 LOC653501 (0) 
chr9 47022872-47022975 KGFLP1 (0.59) 
chr9 75488945-75489060 ALDH1A1 (0) 
chr9 80438503-80438622 GNAQ (0) 
chr9 80847492-80847635 CEP78 (4.14) 
chr9 92470357-92470525 UNQ6494 (0) 
chr9 93759289-93759408 LOC100129316 (0) 
chr9 100153163-100153269 BDAG1 (0) 
chr9 101928114-101928230 TGFBR1 (3.91) 
chr9 101998600-101998832 SEC61B (8.09) 
chr9 102000159-102000428 SEC61B (8.09) 
chr9 102015355-102015485 SEC61B (8.09) 
chr9 103308510-103308643 C9orf30-TMEFF1 (0) 
chr9 103801899-103802040 LPPR1 (0) 
chr9 106120928-106121044 CYLC2 (0) 
chr9 106503290-106503430 SMC2 (5.15) 
chr9 110420567-110420676 KLF4 (0) 
chr9 113082632-113082750 SVEP1 (0) 
chr9 130883425-130883557 PTGES2 (5.11) 
chr9 130887602-130887692 LOC389791 (0) 
chr9 133272510-133272649 ASS1 (2.46) 
chr9 137764379-137764519 FCN2 (0) 
chr9 138273293-138273412 LOC100506599 (0) 
chrUn_gl000220 118422-118476 RN5-8S1 (0) 
chrX 3935857-3935966 LOC389906 (3.85) 
chrX 4346910-4347028 LOC389906 (3.85) 
chrX 4352535-4352646 LOC389906 (3.85) 
chrX 5461067-5461174 NLGN4X (0) 
chrX 5613347-5613489 NLGN4X (0) 
chrX 6458606-6458726 VCX3A (0) 
chrX 7285579-7285715 STS (3.93) 
chrX 8427959-8428099 VCX3B (0) 
chrX 12250420-12250526 FRMPD4 (0) 
chrX 18889481-18889600 LOC100132163 (0) 
chrX 22821880-22821985 DDX53 (0) 
chrX 24526235-24526344 PCYT1B (0.16) 
chrX 26432707-26432825 VENTXP1 (0) 
chrX 26928847-26929043 VENTXP1 (0) 
chrX 31831584-31831702 DMD (1.07) 
chrX 34421962-34422104 TMEM47 (0) 
chrX 34587110-34587245 TMEM47 (0) 
chrX 36466302-36466419 CXorf30 (0) 
chrX 36694826-36694969 CXorf30 (0) 
chrX 39293033-39293152 LOC286442 (0) 
chrX 45149477-45149608 CXorf36 (0) 
chrX 46182419-46182534 ZNF673 (0) 
chrX 69216691-69216832 EDA (0.89) 
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chrX 74566456-74566592 ZDHHC15 (0.07) 
chrX 78154791-78154906 MIR4328 (0) 
chrX 78885074-78885189 ITM2A (0) 
chrX 78887097-78887242 ITM2A (0) 
chrX 89349733-89349834 TGIF2LX (0) 
chrX 92660015-92660123 NAP1L3 (0) 
chrX 92797978-92798085 NAP1L3 (0) 
chrX 93500187-93500298 FAM133A (0) 
chrX 93990317-93990450 FAM133A (0) 
chrX 95720766-95720872 LOC643486 (0) 
chrX 96883273-96883503 DIAPH2 (4.29) 
chrX 97926999-97927109 LOC442459 (0) 
chrX 105349136-105349250 MUM1L1 (0) 
chrX 111587631-111587770 TRPC5 (0.04) 
chrX 113028122-113028240 HTR2C (0) 
chrX 118425449-118425567 PGRMC1 (5.69) 
chrX 119195832-119195956 RHOXF2B (0.01) 
chrX 119308217-119308341 RHOXF2B (0.01) 
chrX 119371632-119371742 ZBTB33 (3.72) 
chrX 124346974-124347092 LOC100129520 (0) 
chrX 135056076-135056164 SLC9A6 (2.87) 
chrX 138072661-138072794 FGF13 (0) 
chrX 145724218-145724336 CXorf51A (0) 
chrX 151963457-151963569 MAGEA3 (0) 
chrX 152170887-152171010 PNMA5 (0) 
chrX 153060010-153060235 SSR4 (7.72) 





Supplementary Data Table 4. Closest genes to active LTRs detected by RACE-Seq in 
L1236 cells. Gene expression values (FPKM) from RNA-Seq are also shown for each 
gene. 
 
RACE Peak Gene (FPKM) 
chr1 2123459-2123591 PRKCZ (1.73) 
chr1 4036165-4036289 LOC728716 (0) 
chr1 6981707-6981818 CAMTA1 (3.87) 
chr1 8225877-8225978 ERRFI1 (0.04) 
chr1 8245003-8245104 SLC45A1 (0.35) 
chr1 18313499-18313645 IGSF21 (0) 
chr1 21719062-21719233 ECE1 (3.16) 
chr1 24814729-24814843 RCAN3 (2.3) 
chr1 55404740-55404851 TMEM61 (0) 
chr1 56337652-56337774 PPAP2B (1.79) 
chr1 57271444-57271564 C1orf168 (0.02) 
chr1 58368618-58368740 DAB1 (0.07) 
chr1 58606898-58607023 DAB1 (0.07) 
chr1 62386050-62386173 INADL (2.88) 
chr1 64634986-64635097 ROR1 (0) 
chr1 81428611-81428728 LPHN2 (0) 
chr1 82218882-82219062 LPHN2 (0) 
chr1 85429340-85429464 MCOLN2 (7.2) 
chr1 97721043-97721154 DPYD (4.65) 
chr1 97722062-97722172 DPYD (4.65) 
chr1 101455649-101455761 DPH5 (5.54) 
chr1 103338945-103339054 COL11A1 (0) 
chr1 118996484-118996595 SPAG17 (0.29) 
chr1 148213989-148214106 PPIAL4D (0) 
chr1 148632437-148632554 PPIAL4E (0) 
chr1 148794469-148794586 PPIAL4D (0) 
chr1 154281789-154281908 AQP10 (0.07) 
chr1 157867982-157868106 CD5L (0.11) 
chr1 158194472-158194583 CD1A (0) 
chr1 160597759-160597885 SLAMF1 (2.1) 
chr1 164446863-164446974 PBX1 (1.11) 
chr1 168731046-168731171 MGC4473 (0) 
chr1 170803680-170803801 PRRX1 (0.07) 
chr1 171170877-171170991 FMO2 (0) 
chr1 173439099-173439212 LOC100506023 
(0.44) 
chr1 174173961-174174073 RABGAP1L (6) 
chr1 174569167-174569282 RABGAP1L (6) 
chr1 179370863-179370988 SOAT1 (2.7) 
chr1 182202212-182202325 GLUL (0.15) 
chr1 182261512-182261619 GLUL (0.15) 
chr1 182505793-182505904 RGSL1 (0) 
chr1 183281086-183281207 NMNAT2 (0) 
chr1 186213426-186213551 MIR548F1 (0) 
chr1 188701651-188701762 FAM5C (0) 
chr1 191367830-191367935 LOC440704 (0) 
chr1 193446094-193446207 CDC73 (3.09) 
chr1 200247878-200248112 C1orf98 (0) 
chr1 210249989-210250101 SYT14 (0.05) 
chr1 219114811-219114930 LOC643723 (0) 
chr1 219180057-219180170 LOC643723 (0) 
chr1 220976461-220976585 MOSC1 (0) 
chr1 222238026-222238137 DUSP10 (3.15) 
chr1 222401273-222401393 HHIPL2 (0.07) 
chr1 234081473-234081607 SLC35F3 (0.14) 
chr1 234831802-234831924 LOC100506810 (0) 
chr1 236326943-236327057 GPR137B (1.35) 
chr1 241575474-241575588 RGS7 (0.43) 
chr1 243269481-243269593 LOC731275 (0) 
chr1 244472681-244472795 C1orf100 (0.14) 
chr1 244830105-244830229 PPPDE1 (0) 
chr1 245353128-245353244 KIF26B (0.04) 
chr10 2941449-2941551 PFKP (6.57) 
chr10 3780202-3780343 KLF6 (4.38) 
chr10 4915382-4915500 tAKR (0) 
chr10 7144562-7144708 SFMBT2 (1.47) 
chr10 8383281-8383423 GATA3 (4.91) 
chr10 9407412-9407522 GATA3 (4.91) 
chr10 9724547-9724659 SFTA1P (0) 
chr10 12774465-12774593 CAMK1D (4.54) 
chr10 13478503-13478616 BEND7 (0.33) 
chr10 14256010-14256124 FRMD4A (0.59) 
chr10 15225850-15225976 NMT2 (3.24) 
chr10 15548645-15548756 ITGA8 (0) 
chr10 17568240-17568368 PTPLA (0) 
chr10 25301979-25302099 ENKUR (0) 
chr10 28691710-28691821 LOC220906 (0) 
chr10 46734506-46734625 BMS1P5 (1.11) 
chr10 47109748-47109871 LOC643650 (0) 
chr10 48924280-48924395 BMS1P5 (1.11) 
chr10 49498151-49498250 FRMPD2 (3.61) 
chr10 52464613-52464743 ASAH2B (0) 
chr10 56965559-56965710 MTRNR2L5 (0) 
chr10 60256209-60256328 BICC1 (0.02) 
chr10 62416788-62416929 ANK3 (4.87) 
chr10 68275397-68275499 CTNNA3 (1.55) 
chr10 77592459-77592570 C10orf11 (0) 
chr10 78271873-78271998 KCNMA1 (4.84) 
chr10 79468100-79468235 KCNMA1 (4.84) 
chr10 81629606-81629734 LOC100288974 (0) 
chr10 81955500-81955597 ANXA11 (5.46) 
chr10 82388108-82388217 SH2D4B (0.07) 
chr10 89145915-89146038 FAM22D (0) 
chr10 89404413-89404536 PAPSS2 (0.26) 
chr10 89408781-89408892 PAPSS2 (0.26) 
chr10 90573498-90573670 LIPM (0.28) 
chr10 92765106-92765255 ANKRD1 (0.12) 
chr10 103086566-103086693 BTRC (2.52) 
chr10 106162985-106163111 CCDC147 (0) 
chr10 107729822-107729931 SORCS1 (0.02) 
chr10 108042672-108042781 SORCS1 (0.02) 
chr10 110437471-110437590 XPNPEP1 (4.99) 
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chr10 110936986-110937101 XPNPEP1 (4.99) 
chr11 1285723-1285824 MUC5B (0.01) 
chr11 5526796-5526909 OR51B5 (0) 
chr11 9189854-9189976 DENND5A (5.28) 
chr11 10458285-10458416 AMPD3 (0.67) 
chr11 10830387-10830483 EIF4G2 (7.55) 
chr11 13010998-13011113 RASSF10 (0.02) 
chr11 17890254-17890377 SERGEF (4.16) 
chr11 25613603-25613721 LUZP2 (2.29) 
chr11 25613928-25614020 LUZP2 (2.29) 
chr11 29181704-29181805 METTL15 (3.43) 
chr11 29999917-30000038 KCNA4 (0) 
chr11 39491602-39491721 LRRC4C (0) 
chr11 44098361-44098486 ACCS (0) 
chr11 63059599-63059713 SLC22A10 (0) 
chr11 64185778-64185891 RPS6KA4 (3.3) 
chr11 73685839-73685925 DNAJB13 (0.25) 
chr11 74168914-74169013 LIPT2 (2.05) 
chr11 77726216-77726319 KCTD14 (0) 
chr11 78905146-78905262 ODZ4 (0) 
chr11 84202351-84202468 DLG2 (0.15) 
chr11 98458625-98458748 CNTN5 (0.04) 
chr11 102217944-102218056 BIRC2 (5.19) 
chr11 109187966-109188074 C11orf87 (0) 
chr11 110214736-110214853 RDX (4.47) 
chr11 113749386-113749511 USP28 (3.67) 
chr11 115797093-115797230 LOC283143 (0) 
chr11 123538403-123538512 SCN3B (0.02) 
chr11 126517976-126518143 KIRREL3 (0) 
chr11 128240069-128240263 ETS1 (3.16) 
chr12 9804062-9804163 CLEC2D (5.3) 
chr12 23286637-23286750 SOX5 (1.54) 
chr12 25108425-25108700 BCAT1 (6.22) 
chr12 25446058-25446173 KRAS (6.67) 
chr12 25890980-25891090 IFLTD1 (0) 
chr12 28298986-28299112 CCDC91 (3.26) 
chr12 30020947-30021049 TMTC1 (3.96) 
chr12 41706302-41706471 PDZRN4 (0) 
chr12 56506773-56506865 RPL41 (12.63) 
chr12 58713396-58713536 XRCC6BP1 (5.39) 
chr12 58748926-58749035 XRCC6BP1 (5.39) 
chr12 59427478-59427604 LRIG3 (3.87) 
chr12 59880364-59880481 SLC16A7 (0.06) 
chr12 60826111-60826213 SLC16A7 (0.06) 
chr12 61195153-61195273 FAM19A2 (0.28) 
chr12 62603102-62603199 FAM19A2 (0.28) 
chr12 63402431-63402553 PPM1H (4.09) 
chr12 66414341-66414465 HMGA2 (0.04) 
chr12 68835708-68836226 MDM1 (4.04) 
chr12 72622999-72623120 LOC283392 (0) 
chr12 73345008-73345128 TRHDE (0) 
chr12 81171245-81171364 LIN7A (0.05) 
chr12 88543924-88544049 CEP290 (2.75) 
chr12 88721988-88722100 TMTC3 (3.24) 
chr12 88991667-88991781 KITLG (0) 
chr12 89445754-89445865 LOC728084 (1.18) 
chr12 91058843-91058963 C12orf37 (0) 
chr12 92955015-92955121 CLLU1 (0) 
chr12 93335096-93335215 EEA1 (3.92) 
chr12 94202038-94202151 CRADD (2.35) 
chr12 97286223-97286338 NEDD1 (4.69) 
chr12 99978457-99978571 ANKS1B (0.7) 
chr12 108294566-108294717 LOC728739 (3.24) 
chr12 110494591-110494706 C12orf76 (2.82) 
chr12 115345770-115345895 TBX3 (1.48) 
chr12 116356598-116356719 MED13L (3.72) 
chr12 117561639-117561753 FBXO21 (3) 
chr12 118419888-118420029 KSR2 (1.9) 
chr12 118421849-118422030 KSR2 (1.9) 
chr12 125597285-125597404 AACS (4.1) 
chr12 125905871-125905985 TMEM132B (0.29) 
chr12 127254733-127254855 LOC100507206 (0) 
chr12 129594156-129594311 TMEM132D (0.1) 
chr12 132087450-132087565 SFSWAP (4.65) 
chr13 19128872-19128993 ANKRD20A9P (0.38) 
chr13 46234669-46234781 SPERT (0) 
chr13 53400049-53400171 MIR759 (0) 
chr13 54539430-54539539 MIR1297 (0) 
chr13 56917567-56917681 PRR20C (0) 
chr13 59883238-59883348 DIAPH3 (3.32) 
chr13 63631258-63631454 OR7E156P (0) 
chr13 65606636-65606751 PCDH9 (1.79) 
chr13 69229719-69229813 LOC338862 (0) 
chr13 69251448-69251589 LOC338862 (0) 
chr13 71010960-71011058 ATXN8OS (0) 
chr13 72916017-72916137 MZT1 (5.09) 
chr13 72959912-72960027 MZT1 (5.09) 
chr13 77307128-77307242 KCTD12 (1.05) 
chr13 78003759-78003886 MYCBP2 (4.15) 
chr13 85672105-85672206 SLITRK6 (0.26) 
chr13 87346186-87346302 MIR4500HG (0) 
chr13 99772196-99772321 DOCK9 (2.28) 
chr13 100104200-100104324 MIR548AN (0) 
chr13 100113268-100113363 TM9SF2 (5.94) 
chr13 102161456-102161577 NALCN (0.02) 
chr13 102351896-102351997 FGF14 (0.09) 
chr13 107224998-107225098 ARGLU1 (5.34) 
chr14 19680937-19681050 POTEG (0) 
chr14 19894334-19894445 POTEM (0.07) 
chr14 21134748-21135027 ANG (4.45) 
chr14 24037066-24037176 JPH4 (0.31) 
chr14 27075089-27075194 NOVA1 (0.05) 
chr14 30348576-30348704 PRKD1 (0.3) 
chr14 37469962-37470105 SLC25A21 (5.6) 
chr14 37593913-37594182 SLC25A21 (5.6) 
chr14 45260471-45260593 C14orf28 (2.21) 
chr14 50053306-50053595 RPS29 (11.22) 
chr14 50329289-50329485 NEMF (4.12) 
chr14 50403197-50403314 ARF6 (4.98) 
chr14 50872978-50873201 CDKL1 (0.96) 
chr14 51651869-51651985 TMX1 (4.75) 
chr14 51960191-51960303 FRMD6 (2.41) 
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chr14 56263318-56263431 C14orf34 (0) 
chr14 60677146-60677269 PPM1A (4.87) 
chr14 67273777-67273886 GPHN (2.51) 
chr14 69377551-69377660 ACTN1 (3.05) 
chr14 76012920-76013216 FLVCR2 (1.31) 
chr14 81723126-81723220 STON2 (1.63) 
chr14 82079718-82079804 SEL1L (6.39) 
chr14 84620644-84620759 FLRT2 (0.01) 
chr14 86559143-86559257 FLRT2 (0.01) 
chr14 88317134-88317246 GALC (0) 
chr14 89744488-89744634 FOXN3 (5.06) 
chr14 90164122-90164238 FOXN3 (5.06) 
chr14 90410503-90410617 TDP1 (3.65) 
chr14 92630326-92630506 CPSF2 (4.84) 
chr14 93336830-93336990 GOLGA5 (4.28) 
chr14 93338653-93338765 GOLGA5 (4.28) 
chr14 93339800-93339915 GOLGA5 (4.28) 
chr14 94114156-94114281 PRIMA1 (0) 
chr14 97903734-97903995 LOC100129345 
(0.04) 
chr14 101879706-101879820 DIO3OS (0) 
chr14 103269237-103269341 TRAF3 (3.09) 
chr14 105222933-105223083 SIVA1 (5.88) 
chr15 23188096-23188261 WHAMMP3 (2.1) 
chr15 29002972-29003163 LOC100289656 (0) 
chr15 31425037-31425152 TRPM1 (0) 
chr15 33502048-33502155 RYR3 (0.04) 
chr15 37490008-37490113 MEIS2 (3.03) 
chr15 38339672-38339774 TMCO5A (0) 
chr15 39527788-39527922 C15orf54 (0) 
chr15 39945911-39946028 FSIP1 (3.39) 
chr15 42788974-42789114 ZFP106 (0) 
chr15 47835592-47835706 SEMA6D (0) 
chr15 50024005-50024131 DTWD1 (2.92) 
chr15 53016823-53016937 ONECUT1 (0.45) 
chr15 56135253-56135372 PRTG (0) 
chr15 58113625-58113752 GCOM1 (0) 
chr15 58552280-58552406 AQP9 (0.4) 
chr15 69745133-69745248 KIF23 (5.61) 
chr15 72537233-72537352 PARP6 (4.19) 
chr15 75230259-75230449 RPP25 (4.01) 
chr15 76721427-76721546 SCAPER (2.68) 
chr15 81096287-81096415 KIAA1199 (0) 
chr15 87581908-87582049 AGBL1 (0) 
chr15 91284013-91284136 BLM (4.14) 
chr15 93173103-93173214 FAM174B (0.05) 
chr15 94198465-94198575 RGMA (0) 
chr15 96537143-96537363 NR2F2 (3.19) 
chr16 6494500-6494624 RBFOX1 (0.06) 
chr16 16573477-16573596 PKD1P1 (3.02) 
chr16 17119472-17119752 XYLT1 (1.62) 
chr16 17992390-17992516 XYLT1 (1.62) 
chr16 18027413-18027522 XYLT1 (1.62) 
chr16 20035580-20035697 GPR139 (0) 
chr16 21127741-21127850 DNAH3 (0.08) 
chr16 21314298-21314409 RUNDC2B (0) 
chr16 27401044-27401167 IL21R (5.69) 
chr16 31123626-31123821 KAT8 (4.64) 
chr16 54907982-54908107 CRNDE (5.11) 
chr16 55106598-55106709 IRX5 (1.68) 
chr16 58455214-58455320 GINS3 (3.65) 
chr16 60118534-60118657 LOC644649 (0) 
chr16 67978248-67978356 SLC12A4 (2.45) 
chr16 70912081-70912207 HYDIN (0.04) 
chr16 76268955-76269120 CNTNAP4 (0.25) 
chr16 80926276-80926554 C16orf61 (0) 
chr16 82142909-82143033 HSD17B2 (0.09) 
chr16 86632960-86633056 FOXL1 (0) 
chr16 88876097-88876202 APRT (7.54) 
chr17 5522642-5522776 NLRP1 (4.92) 
chr17 7529674-7529768 SHBG (0.14) 
chr17 11111585-11111678 SHISA6 (0) 
chr17 27717452-27717561 MIR4523 (0) 
chr17 38946994-38947101 KRT28 (0) 
chr17 42022293-42022391 PPY (0.36) 
chr17 50544008-50544134 CA10 (0) 
chr17 52433897-52434010 KIF2B (0) 
chr17 59322439-59322558 BCAS3 (2.44) 
chr17 63698843-63698956 CEP112 (0.51) 
chr17 65700593-65700719 PITPNC1 (2.32) 
chr17 66823159-66823270 ABCA8 (0.05) 
chr17 69227575-69227691 SOX9 (2.1) 
chr17 69617068-69617228 SOX9 (2.1) 
chr17 70016636-70016762 SOX9 (2.1) 
chr17 71146867-71146994 SSTR2 (1.42) 
chr17 73754311-73754585 GALK1 (3.9) 
chr17 79336003-79336131 TMEM105 (0.04) 
chr18 308294-308406 COLEC12 (0.09) 
chr18 10890481-10890588 PIEZO2 (0.17) 
chr18 22537540-22537653 ZNF521 (1.1) 
chr18 29545600-29545708 TRAPPC8 (4.3) 
chr18 30136377-30136484 WBP11P1 (0.53) 
chr18 42251873-42251999 SETBP1 (1.94) 
chr18 44812025-44812303 IER3IP1 (5.43) 
chr18 47982679-47982829 SKA1 (4.54) 
chr18 50287475-50287586 DCC (0) 
chr18 54833285-54833402 BOD1P (0) 
chr18 55558331-55558453 ATP8B1 (0.05) 
chr18 55636106-55636213 NEDD4L (1.74) 
chr18 56447355-56447479 MALT1 (3.14) 
chr18 57855825-57855936 MC4R (0) 
chr18 59990764-59990875 TNFRSF11A (3.82) 
chr18 68975439-68975554 LOC100505776 (0) 
chr18 69552680-69552786 LOC100505776 (0) 
chr18 69969229-69969344 CBLN2 (0) 
chr18 70147095-70147202 CBLN2 (0) 
chr18 75705590-75705707 GALR1 (0) 
chr19 6381159-6381431 GTF2F1 (5.86) 
chr19 7696348-7696449 PCP2 (0.73) 
chr19 23887336-23887460 ZNF675 (4.26) 
chr19 34046707-34046809 PEPD (4.18) 
chr19 35090320-35090435 SCGBL (0) 
chr19 46743641-46743764 IGFL1 (0) 
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chr19 51876984-51877108 NKG7 (1.2) 
chr2 184858-184960 SH3YL1 (1.26) 
chr2 1318516-1318642 SNTG2 (0) 
chr2 3351202-3351309 TTC15 (0) 
chr2 6101996-6102129 LOC400940 (0.03) 
chr2 6924926-6925041 LINC00487 (0) 
chr2 7472125-7472227 LOC100506274 
(0.21) 
chr2 7860347-7860498 LOC339788 (0) 
chr2 8072087-8072203 LINC00299 (0.12) 
chr2 9255027-9255148 ASAP2 (0.16) 
chr2 11037118-11037229 KCNF1 (0) 
chr2 11720095-11720241 MIR4429 (0) 
chr2 12007286-12007412 MIR4262 (0) 
chr2 12756709-12756824 TRIB2 (0.67) 
chr2 14131251-14131427 FAM84A (0) 
chr2 16048802-16048921 MYCNOS (0) 
chr2 16909365-16909481 FAM49A (1.13) 
chr2 16995368-16995479 FAM49A (1.13) 
chr2 20062809-20062917 FLJ12334 (0) 
chr2 20263062-20263254 LAPTM4A (4.57) 
chr2 30554538-30554660 LBH (0.62) 
chr2 33931903-33932027 MYADML (0) 
chr2 44524007-44524143 PREPL (5.27) 
chr2 49305302-49305421 FSHR (0) 
chr2 53155997-53156175 ASB3 (4.66) 
chr2 54501248-54501356 ACYP2 (2.17) 
chr2 54621638-54621750 C2orf73 (0) 
chr2 54908781-54908892 SPTBN1 (2.46) 
chr2 56503666-56503792 CCDC85A (0.28) 
chr2 57858313-57858435 VRK2 (5.75) 
chr2 58083384-58083497 VRK2 (5.75) 
chr2 64261716-64261825 VPS54 (4.62) 
chr2 67517091-67517312 LOC644838 (0) 
chr2 68054682-68054785 C1D (4.44) 
chr2 72126688-72126802 DYSF (0.08) 
chr2 75769217-75769334 FAM176A (0) 
chr2 78508399-78508511 SNAR-H (0) 
chr2 79213617-79213761 REG3G (0) 
chr2 99349273-99349384 MGAT4A (2.64) 
chr2 104629696-104629824 LOC100287010 
(0.06) 
chr2 111969397-111969514 BCL2L11 (1.67) 
chr2 114448626-114448738 SLC35F5 (4.73) 
chr2 118480742-118480899 DDX18 (6.25) 
chr2 121014049-121014233 TMEM185B (4.24) 
chr2 123811160-123811257 CNTNAP5 (0) 
chr2 128586992-128587118 POLR2D (5.04) 
chr2 143874853-143874981 ARHGAP15 (3.76) 
chr2 152470255-152470378 NEB (0.2) 
chr2 155061994-155062379 GALNT13 (2.13) 
chr2 155342889-155343017 GALNT13 (2.13) 
chr2 157881120-157881229 GALNT5 (0) 
chr2 159145373-159145497 CCDC148 (1.34) 
chr2 160266975-160267099 BAZ2B (0.42) 
chr2 160740620-160740727 PLA2R1 (0) 
chr2 165373612-165373739 COBLL1 (1.08) 
chr2 166178052-166178171 SCN2A (1.41) 
chr2 169280673-169280781 CERS6 (3.59) 
chr2 170543442-170543558 C2orf77 (0) 
chr2 176249754-176249912 ATP5G3 (6.54) 
chr2 177293855-177293982 MTX2 (6.02) 
chr2 181802410-181802508 UBE2E3 (4.44) 
chr2 191573353-191573535 NAB1 (4.71) 
chr2 192364112-192364224 MYO1B (0.02) 
chr2 194838673-194838784 PCGEM1 (0) 
chr2 196972871-196973014 STK17B (7.6) 
chr2 204991750-204991877 ICOS (0.02) 
chr2 205278783-205278892 PARD3B (0.35) 
chr2 215986511-215986621 ABCA12 (0.13) 
chr2 220855577-220855691 MIR4268 (0) 
chr2 224923576-224923691 SERPINE2 (2.86) 
chr2 229227270-229227385 SPHKAP (0) 
chr2 238363279-238363394 MLPH (0.04) 
chr2 241647950-241648059 KIF1A (0.03) 
chr20 15932717-15932836 MACROD2 (0.03) 
chr20 22529162-22529277 LINC00261 (0) 
chr20 23478254-23478369 CST8 (0) 
chr20 24876120-24876221 CST7 (1.11) 
chr20 33650940-33651063 EDEM2 (4.41) 
chr20 34620298-34620411 C20orf152 (0) 
chr20 34642431-34642557 LOC647979 (0) 
chr20 37260027-37260164 ARHGAP40 (0) 
chr20 39485858-39485958 MAFB (0.1) 
chr20 42457708-42457819 TOX2 (1.84) 
chr20 55350163-55350266 TFAP2C (0) 
chr20 55453501-55453612 TFAP2C (0) 
chr20 56058422-56058536 CTCFL (0) 
chr20 56343871-56343983 PMEPA1 (0.01) 
chr20 57395705-57395824 GNAS-AS1 (0.82) 
chr20 59732883-59733004 CDH4 (0) 
chr21 14555340-14555461 ANKRD30BP2 (0.02) 
chr21 15971611-15971779 SAMSN1 (9.19) 
chr21 16042592-16042733 SAMSN1 (9.19) 
chr21 16052031-16052209 SAMSN1 (9.19) 
chr21 17296948-17297063 USP25 (4.82) 
chr21 19858107-19858233 TMPRSS15 (0.03) 
chr21 20834123-20834249 TMPRSS15 (0.03) 
chr21 21066625-21066740 LINC00320 (0) 
chr21 23058563-23058679 LINC00317 (0) 
chr21 23119246-23119371 LINC00317 (0) 
chr21 23406652-23406779 LINC00308 (0) 
chr21 25309300-25309447 D21S2088E (3.62) 
chr21 28372029-28372135 ADAMTS5 (0) 
chr21 30638218-30638377 BACH1 (3.71) 
chr21 31330474-31330627 GRIK1 (0) 
chr21 31799627-31799731 KRTAP13-3 (0) 
chr21 33200816-33200925 HUNK (0) 
chr21 35624530-35624645 LINC00310 (0.2) 
chr21 47556864-47556978 FTCD (0.1) 
chr21 47673874-47674014 MCM3AP (4.81) 
chr22 16162031-16162142 POTEH (0) 
chr22 34186158-34186282 LARGE (3.76) 
chr22 35458727-35458875 ISX (3.83) 
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chr22 35626948-35627081 HMGXB4 (3.71) 
chr22 40269976-40270095 ENTHD1 (0.71) 
chr22 45493399-45493520 LOC100506714 (0) 
chr22 46016643-46016750 FBLN1 (0.1) 
chr22 47702795-47702896 LOC339685 (0) 
chr22 50051075-50051178 BRD1 (3.08) 
chr3 278941-279041 CNTN6 (0) 
chr3 3168709-3168801 IL5RA (5.6) 
chr3 6210153-6210251 GRM7 (0.01) 
chr3 6917127-6917255 LOC100288428 (0) 
chr3 15644425-15644536 BTD (2.59) 
chr3 16154022-16154136 GALNTL2 (0) 
chr3 16946319-16946417 PLCL2 (3.03) 
chr3 32972924-32973034 CCR4 (7.45) 
chr3 53231284-53231397 PRKCD (1.99) 
chr3 60781690-60781815 PTPRG (3.1) 
chr3 61504753-61504995 PTPRG (3.1) 
chr3 64311657-64311762 PRICKLE2 (0.1) 
chr3 66471325-66471435 LRIG1 (0.2) 
chr3 71987292-71987403 PROK2 (0) 
chr3 72529259-72529381 RYBP (4.61) 
chr3 72529489-72529575 RYBP (4.61) 
chr3 72534111-72534225 RYBP (4.61) 
chr3 76967441-76967553 ROBO2 (1.33) 
chr3 77707841-77707967 ROBO2 (1.33) 
chr3 79531584-79531709 ROBO1 (0.16) 
chr3 88082274-88082384 CGGBP1 (6.69) 
chr3 97777470-97777580 GABRR3 (0) 
chr3 98829925-98830047 DCBLD2 (1.85) 
chr3 99563646-99563809 MIR548G (0) 
chr3 103960071-103960190 MIR548A3 (0) 
chr3 106921750-106921879 LOC100302640 (0) 
chr3 107843764-107843993 CD47 (6.32) 
chr3 112032970-112033067 CD200 (2.74) 
chr3 113806566-113806581 KIAA1407 (1.72) 
chr3 116911862-116912051 LSAMP-AS3 (0) 
chr3 118528780-118528905 IGSF11 (0.15) 
chr3 121698367-121698522 ILDR1 (2.13) 
chr3 121753598-121753718 ILDR1 (2.13) 
chr3 131606070-131606192 CPNE4 (2.09) 
chr3 134314094-134314194 KY (0) 
chr3 140480167-140480292 TRIM42 (0) 
chr3 141754580-141754708 TFDP2 (4.63) 
chr3 141760310-141760424 TFDP2 (4.63) 
chr3 148677827-148677950 GYG1 (3.77) 
chr3 150321108-150321232 SELT (6.24) 
chr3 158770763-158770887 IQCJ (0) 
chr3 163199739-163199854 LOC647107 (0) 
chr3 166330668-166330793 ZBBX (0.48) 
chr3 166641930-166642041 ZBBX (0.48) 
chr3 166801089-166801203 ZBBX (0.48) 
chr3 172296185-172296296 NCEH1 (2.77) 
chr3 174991780-174992233 NAALADL2 (0.48) 
chr3 175815802-175815927 NAALADL2 (0.48) 
chr3 177345991-177346110 TBL1XR1 (5.83) 
chr3 180448260-180448377 CCDC39 (0.85) 
chr3 183079282-183079397 MCF2L2 (1.58) 
chr3 185743984-185744110 ETV5 (0.4) 
chr3 188057286-188057387 LPP (2.28) 
chr3 189121168-189121295 TPRG1 (0.74) 
chr3 195913917-195914024 ZDHHC19 (0) 
chr3 196507222-196507331 PAK2 (4.41) 
chr4 1250129-1250254 C4orf42 (0) 
chr4 5068800-5068923 STK32B (0.1) 
chr4 5129635-5129749 STK32B (0.1) 
chr4 11687585-11687702 HS3ST1 (3.11) 
chr4 14809486-14809611 LOC441009 (0) 
chr4 16242612-16242723 FLJ39653 (0) 
chr4 19987710-19987833 SLIT2 (0) 
chr4 26566767-26566876 TBC1D19 (1.74) 
chr4 34540852-34540966 ARAP2 (3.67) 
chr4 34898769-34898883 ARAP2 (3.67) 
chr4 38552239-38552437 FLJ13197 (0) 
chr4 42465352-42465529 ATP8A1 (4.82) 
chr4 42980950-42981073 GRXCR1 (0) 
chr4 44017714-44017819 KCTD8 (0) 
chr4 47206706-47206825 GABRB1 (0) 
chr4 57694758-57694873 SPINK2 (1.61) 
chr4 59024219-59024332 LOC255130 (0) 
chr4 59812611-59812723 LOC255130 (0) 
chr4 61911261-61911373 LPHN3 (0) 
chr4 65366099-65366209 TECRL (0) 
chr4 73079597-73079712 NPFFR2 (0) 
chr4 74586700-74586811 IL8 (0) 
chr4 77791137-77791263 ANKRD56 (0) 
chr4 77870075-77870202 40787 (4.41) 
chr4 87261512-87261616 MAPK10 (0) 
chr4 88963360-88963470 PKD2 (1.68) 
chr4 89947687-89947788 FAM13A (2.74) 
chr4 94224142-94224263 GRID2 (0.02) 
chr4 94260926-94261028 GRID2 (0.02) 
chr4 95983112-95983224 UNC5C (0.81) 
chr4 104337489-104337600 TACR3 (0) 
chr4 106750617-106750764 NPNT (0) 
chr4 112723785-112723921 C4orf32 (2.35) 
chr4 113203287-113203406 TIFA (4.56) 
chr4 115335685-115335774 UGT8 (1.74) 
chr4 118926275-118926374 NDST3 (0) 
chr4 120221574-120221725 USP53 (1.96) 
chr4 120584048-120584152 PDE5A (2.35) 
chr4 123001166-123001265 KIAA1109 (3.57) 
chr4 123440513-123440628 IL2 (0) 
chr4 133184038-133184148 PCDH10 (0.03) 
chr4 134283847-134283961 PCDH10 (0.03) 
chr4 141227266-141227388 SCOC (5.5) 
chr4 142579321-142579436 IL15 (2.79) 
chr4 149680947-149681055 NR3C2 (2.03) 
chr4 150430093-150430219 DCLK2 (0.04) 
chr4 155657179-155657289 LRAT (0) 
chr4 166771211-166771345 TLL1 (0.01) 
chr4 168581999-168582116 SPOCK3 (0.15) 
chr4 176499363-176499512 GPM6A (0) 
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chr4 178583094-178583275 LOC285501 (0) 
chr4 182732734-182732856 MGC45800 (0) 
chr4 184724159-184724276 C4orf41 (0) 
chr4 185451429-185451555 IRF2 (4.67) 
chr4 188077179-188077290 LOC339975 (0) 
chr4 189441860-189441969 LOC401164 (0) 
chr5 2058886-2059014 IRX4 (0) 
chr5 2115726-2115840 IRX4 (0) 
chr5 2268679-2268945 IRX4 (0) 
chr5 2332278-2332398 IRX2 (0) 
chr5 5006908-5007019 LOC340094 (0) 
chr5 5039976-5040077 ADAMTS16 (2.74) 
chr5 6123067-6123177 FLJ33360 (0.08) 
chr5 10311297-10311408 CMBL (0.09) 
chr5 12079994-12080113 CTNND2 (0.01) 
chr5 13596631-13596748 DNAH5 (0.12) 
chr5 17259224-17259326 LOC285696 (0.09) 
chr5 17884801-17884914 LOC401177 (0) 
chr5 22618985-22619111 CDH12 (0.05) 
chr5 31080627-31080737 CDH6 (0) 
chr5 31975319-31975433 PDZD2 (0.33) 
chr5 36277939-36278059 RANBP3L (0.62) 
chr5 38415868-38415982 EGFLAM (0) 
chr5 40027631-40027756 DAB2 (0.01) 
chr5 40225285-40225490 PTGER4 (7) 
chr5 40532030-40532142 PTGER4 (7) 
chr5 43068909-43069135 LOC100132356 
(2.72) 
chr5 51202146-51202386 ISL1 (2.39) 
chr5 53686645-53686761 HSPB3 (0) 
chr5 66118930-66119035 MAST4 (3.22) 
chr5 68604297-68604426 CDK7 (5.08) 
chr5 76805968-76806077 WDR41 (4.5) 
chr5 80923976-80924089 SSBP2 (4.36) 
chr5 83032195-83032309 HAPLN1 (0) 
chr5 91206680-91206795 LOC100129716 (0) 
chr5 92840294-92840522 FLJ42709 (0) 
chr5 95382458-95382588 MIR583 (0) 
chr5 99708323-99708448 LOC100133050 
(0.81) 
chr5 100208259-100208435 ST8SIA4 (6.21) 
chr5 100217498-100217742 ST8SIA4 (6.21) 
chr5 116556696-116556808 SEMA6A (3.45) 
chr5 120183541-120183627 PRR16 (0.22) 
chr5 120355474-120355584 PRR16 (0.22) 
chr5 120500406-120500580 PRR16 (0.22) 
chr5 127541726-127541854 SLC12A2 (4.13) 
chr5 130802301-130802416 RAPGEF6 (4.77) 
chr5 133512341-133512430 PPP2CA (6.68) 
chr5 141019043-141019147 RELL2 (3.09) 
chr5 142970515-142970691 NR3C1 (6.66) 
chr5 144779314-144779431 PRELID2 (0.04) 
chr5 146717830-146717923 DPYSL3 (0.24) 
chr5 147076722-147076846 JAKMIP2 (2.63) 
chr5 149472094-149472216 PDGFRB (0.02) 
chr5 151338398-151338625 GLRA1 (0.21) 
chr5 159929909-159930033 MIR146A (0) 
chr5 163798359-163798492 MAT2B (6.69) 
chr5 166959414-166959533 WWC1 (2.01) 
chr5 167396323-167396439 WWC1 (2.01) 
chr5 174478457-174478569 MIR4634 (0) 
chr5 179216403-179216520 LTC4S (0) 
chr6 3195918-3196026 TUBB2B (0.64) 
chr6 6562598-6562690 LY86-AS1 (0) 
chr6 6649190-6649450 LY86-AS1 (0) 
chr6 9766831-9766960 TFAP2A (2.5) 
chr6 12677099-12677217 PHACTR1 (0.17) 
chr6 19356206-19356312 ID4 (0) 
chr6 27686873-27686994 LOC100507173 (0) 
chr6 27714722-27714836 LOC100131289 (0) 
chr6 37717364-37717471 MDGA1 (0.93) 
chr6 40741029-40741148 LRFN2 (0) 
chr6 43099206-43099312 PTK7 (0.08) 
chr6 45528051-45528172 RUNX2 (6.34) 
chr6 52860430-52860732 GSTA4 (1.9) 
chr6 54604845-54604971 FAM83B (0.05) 
chr6 55495531-55495654 HMGCLL1 (0) 
chr6 79307606-79307713 IRAK1BP1 (2.86) 
chr6 81662243-81662401 BCKDHB (6.31) 
chr6 82247266-82247381 FAM46A (3.64) 
chr6 82296408-82296534 FAM46A (3.64) 
chr6 82804933-82805037 IBTK (5.3) 
chr6 83909286-83909412 RWDD2A (3.3) 
chr6 85506220-85506337 TBX18 (0) 
chr6 89244214-89244320 RNGTT (4.83) 
chr6 91602259-91602422 MAP3K7 (4.57) 
chr6 97203089-97203215 GPR63 (2.81) 
chr6 98376241-98376369 MIR2113 (0) 
chr6 101149216-101149328 ASCC3 (5.66) 
chr6 102996034-102996142 GRIK2 (0.01) 
chr6 111382668-111382781 GSTM2P1 (0.17) 
chr6 111612257-111612368 REV3L (4.38) 
chr6 115034077-115034192 HS3ST5 (0.04) 
chr6 115267892-115267987 HS3ST5 (0.04) 
chr6 115409557-115409671 FRK (0.22) 
chr6 118184273-118184383 SLC35F1 (0.14) 
chr6 120326818-120327007 MAN1A1 (4.03) 
chr6 123987298-123987412 TRDN (0.03) 
chr6 128299545-128299650 PTPRK (2.54) 
chr6 129085148-129085268 LAMA2 (0.43) 
chr6 131430510-131430631 AKAP7 (3.05) 
chr6 131797809-131797936 ARG1 (0.61) 
chr6 132852311-132852429 TAAR9 (0.24) 
chr6 134433560-134433659 HMGA1P7 (0.33) 
chr6 134719721-134719979 LOC154092 (0) 
chr6 134929124-134929217 LOC154092 (0) 
chr6 136546666-136546792 FAM54A (0) 
chr6 138128310-138128413 TNFAIP3 (8.35) 
chr6 138177459-138177568 TNFAIP3 (8.35) 
chr6 138440546-138440658 PERP (7.27) 
chr6 139036350-139036447 LOC100507462 
(0.83) 
chr6 139370337-139370463 C6orf115 (0) 
chr6 140908992-140909117 MIR4465 (0) 
chr6 140985139-140985241 MIR4465 (0) 
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chr6 150580005-150580124 PPP1R14C (1.41) 
chr6 150740825-150740940 IYD (0) 
chr6 155952304-155952575 NOX3 (0) 
chr6 155953769-155953893 NOX3 (0) 
chr6 158215249-158215363 SNX9 (1.65) 
chr6 164280067-164280186 QKI (5.25) 
chr6 164942252-164942361 C6orf118 (0) 
chr6 166913065-166913178 RPS6KA2 (2.03) 
chr7 1561144-1561279 MAFK (3.34) 
chr7 4283121-4283236 SDK1 (1.51) 
chr7 8385305-8385414 ICA1 (1.3) 
chr7 11606833-11606935 THSD7A (0.15) 
chr7 12971270-12971538 ARL4A (0.1) 
chr7 16319547-16319646 LOC100506025 (0) 
chr7 18749638-18749753 HDAC9 (0.27) 
chr7 25115084-25115197 CYCS (5.07) 
chr7 30872880-30872999 FAM188B (0.77) 
chr7 32029916-32030029 PDE1C (0.02) 
chr7 34329150-34329329 AAA1 (0) 
chr7 36031051-36031174 39326 (5.15) 
chr7 37592996-37593108 ELMO1 (5.48) 
chr7 37904359-37904468 SFRP4 (0.04) 
chr7 38122165-38122280 STARD3NL (4.8) 
chr7 38539474-38539600 AMPH (4.98) 
chr7 44233862-44233962 GCK (0) 
chr7 45412789-45412912 RAMP3 (0) 
chr7 47833044-47833130 C7orf69 (0) 
chr7 50330074-50330213 IKZF1 (6.21) 
chr7 70419582-70419708 AUTS2 (2.13) 
chr7 70713102-70713188 WBSCR17 (0) 
chr7 71222101-71222226 CALN1 (0.01) 
chr7 81315455-81315563 HGF (0.05) 
chr7 87492694-87492798 DBF4 (5.53) 
chr7 88768105-88768215 ZNF804B (0) 
chr7 89020751-89020870 ZNF804B (0) 
chr7 92218048-92218229 CDK6 (5.53) 
chr7 93652003-93652261 BET1 (3.71) 
chr7 93878939-93879061 COL1A2 (0) 
chr7 96380355-96380506 SHFM1 (6.91) 
chr7 97089535-97089661 TAC1 (0) 
chr7 99532776-99532894 GJC3 (0.63) 
chr7 103710101-103710271 ORC5 (5.16) 
chr7 106145145-106145276 C7orf74 (0) 
chr7 106224351-106224454 C7orf74 (0) 
chr7 112709785-112709894 GPR85 (0.01) 
chr7 112947889-112948002 LOC401397 (0) 
chr7 117636073-117636203 CTTNBP2 (0.03) 
chr7 118561345-118561470 ANKRD7 (1.72) 
chr7 120702887-120703011 C7orf58 (0) 
chr7 121403784-121403905 PTPRZ1 (0.02) 
chr7 123193298-123193430 NDUFA5 (4.05) 
chr7 124996210-124996335 POT1 (5.6) 
chr7 125121567-125121682 POT1 (5.6) 
chr7 125141019-125141162 POT1 (5.6) 
chr7 125329632-125329753 GRM8 (0.24) 
chr7 128761678-128761807 LOC407835 (2.65) 
chr7 130708007-130708155 MKLN1 (3.79) 
chr7 131007219-131007333 MKLN1 (3.79) 
chr7 131636720-131636844 PLXNA4 (0.02) 
chr7 131641284-131641392 PLXNA4 (0.02) 
chr7 132183099-132183206 CHCHD3 (6.7) 
chr7 139677042-139677163 TBXAS1 (0.29) 
chr7 140980252-140980376 LOC100507421 (0) 
chr7 143715948-143716065 OR6B1 (0) 
chr7 144859727-144859846 TPK1 (1.99) 
chr7 145916108-145916209 CNTNAP2 (0.06) 
chr7 147084001-147084120 MIR548I4 (0) 
chr7 148677002-148677091 PDIA4 (5.46) 
chr7 151578407-151578534 LOC100505483 (0) 
chr7 151661580-151661693 GALNT11 (0.34) 
chr7 154998368-154998477 INSIG1 (6.73) 
chr7 158172531-158172653 PTPRN2 (3.04) 
chr8 3888825-3888940 CSMD1 (0.01) 
chr8 15199070-15199324 SGCZ (0.06) 
chr8 15274687-15274794 TUSC3 (0.03) 
chr8 15364049-15364163 TUSC3 (0.03) 
chr8 15823500-15823598 MSR1 (0.43) 
chr8 16314428-16314592 MSR1 (0.43) 
chr8 16999619-16999745 ZDHHC2 (5.14) 
chr8 17456345-17456457 PDGFRL (3.1) 
chr8 19075655-19075768 SH2D4A (4.18) 
chr8 20917371-20917497 LOC286114 (0) 
chr8 25215711-25215838 DOCK5 (0.39) 
chr8 27787789-27787915 SCARA5 (0) 
chr8 37340621-37340722 ZNF703 (0.67) 
chr8 40153211-40153326 C8orf4 (0.07) 
chr8 49430556-49430670 EFCAB1 (0) 
chr8 52353707-52353818 PXDNL (0.04) 
chr8 55074608-55074731 MRPL15 (3.92) 
chr8 63655409-63655519 NKAIN3 (0) 
chr8 68684431-68684546 CPA6 (0) 
chr8 69152000-69152119 PREX2 (0) 
chr8 74288465-74288592 LOC100128126 (0) 
chr8 77114204-77114363 LOC100192378 (0) 
chr8 77484424-77484515 LOC100192378 (0) 
chr8 78434063-78434164 PEX2 (5.59) 
chr8 80062445-80062564 IL7 (1.46) 
chr8 90757032-90757135 RIPK2 (4.56) 
chr8 94351963-94352101 LOC642924 (0) 
chr8 95395020-95395123 RAD54B (3.55) 
chr8 96135076-96135191 PLEKHF2 (3.08) 
chr8 99417954-99418058 KCNS2 (0) 
chr8 103897842-103897946 AZIN1 (7.92) 
chr8 104576009-104576120 RIMS2 (0.35) 
chr8 105291431-105291517 RIMS2 (0.35) 
chr8 105714555-105714670 LRP12 (0) 
chr8 112386816-112386930 CSMD3 (1.05) 
chr8 114710579-114710696 CSMD3 (1.05) 
chr8 117688590-117688725 EIF3H (8.59) 
chr8 117816613-117816745 UTP23 (4.82) 
chr8 117828019-117828116 RAD21 (9.05) 
chr8 117864193-117864298 RAD21-AS1 (1.55) 
223 
 
chr8 118275719-118275838 SLC30A8 (0.34) 
chr8 118670550-118670662 MED30 (6.28) 
chr8 118776757-118776879 EXT1 (4.37) 
chr8 119919131-119919245 TNFRSF11B (0) 
chr8 124685069-124685211 ANXA13 (0) 
chr8 125755056-125755169 MTSS1 (0.82) 
chr8 126362800-126362917 NSMCE2 (5.42) 
chr8 127019461-127019586 LOC100130231 (0) 
chr8 131084636-131084759 ASAP1 (2.19) 
chr8 135341052-135341156 ZFAT (3) 
chr8 135368508-135368619 ZFAT (3) 
chr8 135784073-135784196 MIR30B (0) 
chr8 136876329-136876457 KHDRBS3 (4.25) 
chr8 140026433-140026598 COL22A1 (6.22) 
chr8 143218660-143218765 MIR4472-1 (0) 
chr8 144274111-144274216 GPIHBP1 (0.03) 
chr9 1930284-1930410 SMARCA2 (7.12) 
chr9 2388628-2388748 FLJ35024 (0) 
chr9 3742808-3742933 GLIS3 (0.72) 
chr9 5580617-5580736 PDCD1LG2 (3.23) 
chr9 9442061-9442288 PTPRD (0) 
chr9 16917479-16917601 BNC2 (0.57) 
chr9 18838067-18838190 ADAMTSL1 (0.01) 
chr9 19252122-19252231 DENND4C (4.34) 
chr9 26157481-26157606 LOC100506422 
(0.03) 
chr9 26748184-26748317 C9orf82 (0) 
chr9 26752810-26753095 C9orf82 (0) 
chr9 29724574-29724687 MIR873 (0) 
chr9 30139741-30139992 MIR873 (0) 
chr9 31578572-31578696 ACO1 (4.23) 
chr9 39630744-39630857 LOC653501 (0) 
chr9 41775775-41775890 LOC653501 (0) 
chr9 41902210-41902324 MGC21881 (0) 
chr9 47022840-47023012 KGFLP1 (0.06) 
chr9 66083508-66083648 LOC442421 (0) 
chr9 72456607-72456721 C9orf135 (0) 
chr9 80847500-80847633 CEP78 (4.25) 
chr9 83714053-83714178 TLE1 (2.63) 
chr9 92470390-92470513 UNQ6494 (0.03) 
chr9 93759291-93759405 LOC100129316 (0.9) 
chr9 100153151-100153273 BDAG1 (0) 
chr9 101928116-101928341 TGFBR1 (2.94) 
chr9 101998558-101998836 SEC61B (6.83) 
chr9 102000166-102000480 SEC61B (6.83) 
chr9 103801907-103802030 LPPR1 (0) 
chr9 106503302-106503416 SMC2 (4.79) 
chr9 107092611-107092735 OR13F1 (0) 
chr9 110559661-110559786 KLF4 (0) 
chr9 113854454-113854578 LPAR1 (0.02) 
chr9 117446585-117446696 LOC100505478 (0) 
chr9 119787205-119787329 ASTN2 (1.46) 
chr9 124879597-124879710 MIR4478 (0) 
chr9 137764387-137764511 FCN2 (0) 
chr9 138273289-138273417 LOC100506599 (0) 
chrM 2791-3172 -1 (0) 
chrUn_gl000220 118319-118497 RN5-8S1 (0) 
chrX 5330736-5330843 NLGN4X (0) 
chrX 5373177-5373288 NLGN4X (0) 
chrX 5613355-5613481 NLGN4X (0) 
chrX 6140887-6140998 NLGN4X (0) 
chrX 6458602-6458730 VCX3A (0) 
chrX 7285588-7285711 STS (1.09) 
chrX 8427966-8428091 VCX3B (0) 
chrX 10657284-10657384 MID1 (1.57) 
chrX 13321433-13321555 ATXN3L (0.54) 
chrX 13469093-13469201 EGFL6 (0.07) 
chrX 15216882-15217009 ASB9 (2.18) 
chrX 18889475-18889603 LOC100132163 (0) 
chrX 22375020-22375135 ZNF645 (0) 
chrX 24526239-24526348 PCYT1B (0.72) 
chrX 26432707-26432823 VENTXP1 (0) 
chrX 26928846-26929104 VENTXP1 (0) 
chrX 28025373-28025478 DCAF8L1 (0.07) 
chrX 29678083-29678184 IL1RAPL1 (0.05) 
chrX 29789980-29790075 IL1RAPL1 (0.05) 
chrX 30398888-30398987 NR0B1 (0) 
chrX 34421976-34422090 TMEM47 (0) 
chrX 34587120-34587237 TMEM47 (0) 
chrX 36466282-36466427 CXorf30 (0) 
chrX 36694824-36694961 CXorf30 (0) 
chrX 39393821-39393926 LOC286442 (0) 
chrX 42824391-42824513 PPP1R2P9 (0) 
chrX 74566470-74566578 ZDHHC15 (0.02) 
chrX 78154790-78154910 MIR4328 (0) 
chrX 78885076-78885187 ITM2A (0.14) 
chrX 78886993-78887239 ITM2A (0.14) 
chrX 82083735-82083832 POU3F4 (0) 
chrX 85270256-85270382 DACH2 (0) 
chrX 86638139-86638258 KLHL4 (3.87) 
chrX 88861723-88861837 TGIF2LX (0) 
chrX 92094184-92094292 PCDH11X (0) 
chrX 93502113-93502222 FAM133A (0.55) 
chrX 93633542-93633657 FAM133A (0.55) 
chrX 93990323-93990442 FAM133A (0.55) 
chrX 95720773-95720870 LOC643486 (0) 
chrX 96883268-96883421 DIAPH2 (4.55) 
chrX 111587628-111587753 TRPC5 (0.23) 
chrX 111782276-111782403 ZCCHC16 (0) 
chrX 113028118-113028244 HTR2C (0) 
chrX 117030753-117030867 KLHL13 (0.13) 
chrX 118425457-118425565 PGRMC1 (6.49) 
chrX 119138358-119138483 NKAP (5.5) 
chrX 119195846-119195943 RHOXF2B (0) 
chrX 119308224-119308327 RHOXF2B (0) 
chrX 124346976-124347090 LOC100129520 
(0.04) 
chrX 131759358-131759455 HS6ST2 (0) 
chrX 140455351-140455489 SPANXC (0) 
chrX 140722648-140722761 SPANXA2-OT1 (0) 
chrX 141161893-141162004 MAGEC2 (0) 
chrX 141168314-141168428 MAGEC2 (0) 
chrX 146956821-146956919 FMR1-AS1 (0.17) 
chrX 150044247-150044371 CD99L2 (4.32) 
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chrX 152370320-152370432 MAGEA1 (0) 
chrX 153060062-153060217 SSR4 (7.77) 






Supplementary Data Table 5. Closest genes to active LTRs detected by RACE-Seq in 
KM-H2 cells. Gene expression values (FPKM) from RNA-Seq are also shown for each 
gene. 
 
RACE Peak Gene (FPKM) 
chr1 135124-135227 LOC729737 (0.47) 
chr1 3492135-3492248 MEGF6 (0.02) 
chr1 3536145-3536238 TPRG1L (3.83) 
chr1 3835054-3835173 LOC100133612 (0) 
chr1 4036166-4036290 LOC728716 (0) 
chr1 6784220-6784312 DNAJC11 (4.35) 
chr1 7036985-7037100 CAMTA1 (4.55) 
chr1 7040763-7040852 CAMTA1 (4.55) 
chr1 7968801-7968917 TNFRSF9 (3.31) 
chr1 8225875-8225984 ERRFI1 (0.16) 
chr1 8245000-8245106 SLC45A1 (0) 
chr1 8900213-8900318 ENO1 (9.6) 
chr1 11467937-11468043 PTCHD2 (0.55) 
chr1 14328921-14329042 PRDM2 (4.48) 
chr1 18905856-18905949 PAX7 (0.01) 
chr1 19839395-19839514 CAPZB (5.49) 
chr1 21719072-21719178 ECE1 (4.02) 
chr1 24325553-24325666 SRSF10 (0.02) 
chr1 24526768-24526884 IL28RA (0) 
chr1 24814726-24814865 RCAN3 (2) 
chr1 35198466-35198549 GJB5 (0.08) 
chr1 38959164-38959272 LOC339442 (0) 
chr1 42259806-42259910 HIVEP3 (2.64) 
chr1 43094328-43094433 PPIH (6.66) 
chr1 43217321-43217407 LEPRE1 (0) 
chr1 53806983-53807084 LRP8 (5.26) 
chr1 55203474-55203574 PARS2 (2.6) 
chr1 55404744-55404853 TMEM61 (0) 
chr1 56854440-56854553 PPAP2B (3.53) 
chr1 57271454-57271557 C1orf168 (0.13) 
chr1 58368620-58368736 DAB1 (0) 
chr1 58606900-58607019 DAB1 (0) 
chr1 59980384-59980502 FGGY (2.29) 
chr1 60201768-60201865 FGGY (2.29) 
chr1 60255942-60256048 HOOK1 (0) 
chr1 62386060-62386163 INADL (1.64) 
chr1 65464423-65464526 JAK1 (5.85) 
chr1 65553383-65553483 MIR101-1 (0) 
chr1 66594408-66594527 PDE4B (1.5) 
chr1 67673268-67673386 IL23R (0.01) 
chr1 71406208-71406326 PTGER3 (0.65) 
chr1 72944797-72944912 NEGR1 (0.98) 
chr1 73938542-73938647 LRRIQ3 (0.79) 
chr1 78588137-78588249 GIPC2 (0.02) 
chr1 78919473-78919576 PTGFR (0) 
chr1 79017335-79017440 PTGFR (0) 
chr1 80201070-80201176 ELTD1 (0) 
chr1 81428611-81428730 LPHN2 (0) 
chr1 81721811-81721926 LPHN2 (0) 
chr1 82218894-82219001 LPHN2 (0) 
chr1 83498805-83498908 TTLL7 (1.78) 
chr1 84498158-84498276 TTLL7 (1.78) 
chr1 85191720-85191827 SSX2IP (2.41) 
chr1 93727503-93727601 CCDC18 (3.53) 
chr1 93866909-93866998 DR1 (5.06) 
chr1 95152048-95152168 SLC44A3 (0.03) 
chr1 97721047-97721146 DPYD (3.04) 
chr1 97722060-97722174 DPYD (3.04) 
chr1 98070998-98071092 DPYD (3.04) 
chr1 101455655-101455880 DPH5 (4.02) 
chr1 101491248-101491341 DPH5 (4.02) 
chr1 101808582-101808695 S1PR1 (2) 
chr1 102403107-102403214 OLFM3 (0) 
chr1 102479013-102479131 OLFM3 (0) 
chr1 108093076-108093198 VAV3 (0.02) 
chr1 111053783-111053902 KCNA10 (0) 
chr1 111543829-111543931 LRIF1 (4.36) 
chr1 118258820-118258923 FAM46C (0.55) 
chr1 118996482-118996657 SPAG17 (0.08) 
chr1 146669168-146669287 FMO5 (0.03) 
chr1 146786689-146786794 CHD1L (5.19) 
chr1 148213993-148214114 PPIAL4D (0) 
chr1 148632429-148632550 PPIAL4E (0) 
chr1 148794461-148794582 PPIAL4D (0) 
chr1 152401709-152401826 CRNN (0.02) 
chr1 154281793-154281908 AQP10 (0.19) 
chr1 157866064-157866170 CD5L (0.44) 
chr1 157867990-157868096 CD5L (0.44) 
chr1 158194470-158194585 CD1A (0) 
chr1 160682597-160682685 CD48 (2.12) 
chr1 163511954-163512059 NUF2 (5.26) 
chr1 164446858-164446979 PBX1 (0.33) 
chr1 164519526-164519608 PBX1 (0.33) 
chr1 164633935-164634045 PBX1 (0.33) 
chr1 165429234-165429335 RXRG (0.19) 
chr1 166747089-166747200 POGK (5.82) 
chr1 167160219-167160324 POU2F1 (3.3) 
chr1 168731052-168731167 MGC4473 (0) 
chr1 169842378-169842465 SCYL3 (3.87) 
chr1 170585242-170585411 PRRX1 (0.14) 
chr1 170803684-170803801 PRRX1 (0.14) 
chr1 171409397-171409517 PRRC2C (5.62) 
chr1 172215096-172215201 DNM3 (0.59) 
chr1 173439088-173439214 LOC100506023 (0.61) 
chr1 174173949-174174066 RABGAP1L (4.4) 
chr1 174569165-174569284 RABGAP1L (4.4) 
chr1 174571374-174571490 RABGAP1L (4.4) 
chr1 177701423-177701556 SEC16B (0.14) 
chr1 178636257-178636376 MIR4424 (0) 
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chr1 178913875-178913994 RALGPS2 (0.02) 
chr1 179370863-179370986 SOAT1 (3.23) 
chr1 179445123-179445221 AXDND1 (0.1) 
chr1 180528084-180528184 ACBD6 (5.78) 
chr1 181511716-181511814 CACNA1E (5.12) 
chr1 182202215-182202321 GLUL (0) 
chr1 182247077-182247175 GLUL (0) 
chr1 182505791-182505906 RGSL1 (0) 
chr1 183281079-183281204 NMNAT2 (0) 
chr1 183418541-183418705 DKFZP564C196 (0) 
chr1 186213428-186213566 MIR548F1 (0) 
chr1 186715860-186715963 PTGS2 (0) 
chr1 188701645-188701764 FAM5C (0) 
chr1 191367827-191367937 LOC440704 (0.18) 
chr1 193446098-193446205 CDC73 (1.88) 
chr1 195754706-195754824 KCNT2 (0) 
chr1 197197938-197198058 ZBTB41 (2.83) 
chr1 197964817-197964936 LHX9 (3.66) 
chr1 200247989-200248108 C1orf98 (0) 
chr1 204011679-204011815 LINC00303 (0) 
chr1 209874572-209874690 HSD11B1 (0) 
chr1 210249985-210250118 SYT14 (1.22) 
chr1 211714288-211714389 SLC30A1 (4.36) 
chr1 213070988-213071126 FLVCR1 (4.53) 
chr1 215405122-215405240 KCTD3 (3.31) 
chr1 216310651-216310771 USH2A (0.21) 
chr1 216757102-216757205 ESRRG (0.17) 
chr1 219114821-219114924 LOC643723 (0) 
chr1 220394100-220394183 RAB3GAP2 (4.41) 
chr1 220532669-220532787 RAB3GAP2 (4.41) 
chr1 220976469-220976575 MOSC1 (0) 
chr1 222238030-222238133 DUSP10 (2.87) 
chr1 222360694-222360812 HHIPL2 (0.16) 
chr1 222401271-222401389 HHIPL2 (0.16) 
chr1 223312317-223312422 SUSD4 (2.91) 
chr1 224847891-224847996 CNIH3 (0.1) 
chr1 234081483-234081603 SLC35F3 (4.64) 
chr1 234312901-234313004 SLC35F3 (4.64) 
chr1 234730410-234730519 IRF2BP2 (6.15) 
chr1 234831806-234831917 LOC100506810 (0) 
chr1 236326941-236327059 GPR137B (3.63) 
chr1 237144761-237144898 RYR2 (0.14) 
chr1 238533010-238533127 LOC339535 (0) 
chr1 241450705-241450821 RGS7 (0.01) 
chr1 241575471-241575590 RGS7 (0.01) 
chr1 242218073-242218174 PLD5 (0.04) 
chr1 243269479-243269597 LOC731275 (0) 
chr1 244472685-244472791 C1orf100 (0) 
chr1 244528720-244528826 ADSS (5.3) 
chr1 244830105-244830225 PPPDE1 (0) 
chr1 245121026-245121138 EFCAB2 (0.76) 
chr1 245353128-245353258 KIF26B (0.02) 
chr10 2941453-2941547 PFKP (5.85) 
chr10 3780218-3780318 KLF6 (2.54) 
chr10 4915274-4915501 tAKR (0) 
chr10 7144562-7144674 SFMBT2 (0.46) 
chr10 7316477-7316571 SFMBT2 (0.46) 
chr10 8383281-8383391 GATA3 (4.33) 
chr10 9407410-9407528 GATA3 (4.33) 
chr10 9724552-9724652 SFTA1P (0) 
chr10 10862041-10862159 SFTA1P (0) 
chr10 11389670-11389770 CELF2 (2.45) 
chr10 12774469-12774618 CAMK1D (4.41) 
chr10 13478504-13478618 BEND7 (0) 
chr10 14256008-14256126 FRMD4A (0.59) 
chr10 15080558-15080682 OLAH (0.24) 
chr10 15225854-15225972 NMT2 (2.13) 
chr10 15548643-15548758 ITGA8 (0) 
chr10 15981505-15981631 FAM188A (4.27) 
chr10 17277260-17277382 VIM (8.97) 
chr10 17568246-17568364 PTPLA (0) 
chr10 19520530-19520632 ARL5B (2.57) 
chr10 20647714-20647816 PLXDC2 (0) 
chr10 21068198-21068298 NEBL (0.19) 
chr10 24566570-24566658 KIAA1217 (0.18) 
chr10 24821478-24821579 ARHGAP21 (4.35) 
chr10 25176404-25176495 PRTFDC1 (0) 
chr10 25301982-25302101 ENKUR (0.05) 
chr10 25481137-25481238 GPR158 (0.06) 
chr10 30351545-30351651 KIAA1462 (2.5) 
chr10 34732403-34732502 PARD3 (0.05) 
chr10 36588897-36588981 FZD8 (0) 
chr10 38193739-38193840 ZNF25 (2.33) 
chr10 45397168-45397283 LOC220980 (0) 
chr10 47109752-47109870 LOC643650 (0) 
chr10 49394570-49394678 FRMPD2 (2.15) 
chr10 49498149-49498252 FRMPD2 (2.15) 
chr10 50791282-50791400 CHAT (0) 
chr10 52464617-52464735 ASAH2B (0.3) 
chr10 52820931-52821035 PRKG1 (1.17) 
chr10 57338466-57338584 MTRNR2L5 (0) 
chr10 59821017-59821137 IPMK (2) 
chr10 59933169-59933279 IPMK (2) 
chr10 62312661-62312770 ANK3 (0.98) 
chr10 62416804-62416915 ANK3 (0.98) 
chr10 64018897-64018994 RTKN2 (0.52) 
chr10 67021529-67021647 ANXA2P3 (0.13) 
chr10 69291679-69291794 CTNNA3 (0.5) 
chr10 72878637-72878736 UNC5B (0) 
chr10 75006850-75007045 C10orf103 (0) 
chr10 77592457-77592572 C10orf11 (0) 
chr10 77870431-77870538 C10orf11 (0) 
chr10 78271864-78271998 KCNMA1 (3.55) 
chr10 79468100-79468235 KCNMA1 (3.55) 
chr10 81114911-81115006 ZCCHC24 (2.24) 
chr10 81629612-81629730 LOC100288974 (0) 
chr10 82104458-82104572 DYDC2 (0.34) 
chr10 82388111-82388213 SH2D4B (0.07) 
chr10 84608586-84608692 NRG3 (0) 
chr10 85909896-85910014 C10orf99 (0.05) 
chr10 86904150-86904251 LOC100507470 (0) 
chr10 88405001-88405112 OPN4 (0) 
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chr10 89145919-89146037 FAM22D (0) 
chr10 89404417-89404536 PAPSS2 (0.16) 
chr10 89408785-89408888 PAPSS2 (0.16) 
chr10 92426123-92426214 HTR7 (0.01) 
chr10 92763169-92763286 ANKRD1 (0.07) 
chr10 92765110-92765236 ANKRD1 (0.07) 
chr10 93095169-93095273 LOC100188947 (0) 
chr10 95943481-95943605 PLCE1 (0.28) 
chr10 106162989-106163107 CCDC147 (0) 
chr10 107729820-107729936 SORCS1 (3.83) 
chr10 108046161-108046266 SORCS1 (3.83) 
chr10 109115335-109115458 SORCS1 (3.83) 
chr10 109262913-109263028 SORCS1 (3.83) 
chr10 109482761-109482876 SORCS1 (3.83) 
chr10 110936990-110937091 XPNPEP1 (5.01) 
chr10 111357871-111357972 XPNPEP1 (5.01) 
chr10 112373134-112373249 SMC3 (4.76) 
chr10 116081825-116081943 AFAP1L2 (0.71) 
chr10 117803536-117803629 GFRA1 (0.04) 
chr10 118178158-118178261 PNLIPRP3 (0.02) 
chr10 118455941-118456045 HSPA12A (0) 
chr10 118588707-118588837 ENO4 (0.1) 
chr10 119062313-119062430 SLC18A2 (1.26) 
chr10 123123688-123123807 FGFR2 (0) 
chr10 123479796-123479902 ATE1 (4.55) 
chr10 123751370-123751468 NSMCE4A (5.9) 
chr10 125171648-125171754 BUB3 (6.4) 
chr10 125305963-125306085 GPR26 (0) 
chr10 125820867-125820986 CHST15 (0.09) 
chr10 128565687-128565799 DOCK1 (0.12) 
chr10 131050865-131050983 MGMT (3.8) 
chr10 132469161-132469280 MIR378C (0) 
chr11 214884-215035 RIC8A (4.38) 
chr11 2497040-2497143 KCNQ1 (0) 
chr11 2644349-2644461 KCNQ1 (0) 
chr11 3090769-3090879 CARS (5.28) 
chr11 3206241-3206333 OSBPL5 (0) 
chr11 3402161-3402280 LOC650368 (0) 
chr11 5526791-5526927 OR51B5 (0.1) 
chr11 6756086-6756205 GVINP1 (0.51) 
chr11 7698385-7698522 CYB5R2 (4.96) 
chr11 9189817-9189970 DENND5A (4.66) 
chr11 10458289-10458406 AMPD3 (1.08) 
chr11 13010992-13011127 RASSF10 (0) 
chr11 14541845-14541974 PSMA1 (7.33) 
chr11 19548787-19548893 NAV2 (0.17) 
chr11 25389367-25389480 LUZP2 (0) 
chr11 26500986-26501092 ANO3 (1.59) 
chr11 26755471-26755592 SLC5A12 (0.08) 
chr11 26963481-26963594 FIBIN (0) 
chr11 27363533-27363634 CCDC34 (3) 
chr11 27911940-27912094 KIF18A (3.37) 
chr11 32154175-32154293 RCN1 (4.1) 
chr11 33753564-33753676 FBXO3 (3.49) 
chr11 36607845-36607947 RAG2 (0) 
chr11 37150918-37151027 C11orf74 (0.04) 
chr11 37827793-37827898 C11orf74 (0.04) 
chr11 39284098-39284201 LRRC4C (0) 
chr11 41206403-41206506 LRRC4C (0) 
chr11 45437648-45437741 SYT13 (0.01) 
chr11 46193468-46193551 PHF21A (2.92) 
chr11 46450246-46450405 AMBRA1 (4.36) 
chr11 60677262-60677365 PRPF19 (4.95) 
chr11 61235289-61235395 C11orf66 (0) 
chr11 63059597-63059714 SLC22A10 (0.29) 
chr11 63595051-63595135 MARK2 (2.65) 
chr11 64185770-64185887 RPS6KA4 (3.33) 
chr11 67450464-67450556 ALDH3B2 (0) 
chr11 68903626-68903757 TPCN2 (1.35) 
chr11 70160995-70161085 PPFIA1 (3.58) 
chr11 71881685-71881788 FOLR1 (0) 
chr11 73685721-73685921 DNAJB13 (0) 
chr11 74145705-74145814 KCNE3 (0.01) 
chr11 77554876-77554977 RSF1 (3.48) 
chr11 78787418-78787524 ODZ4 (0) 
chr11 78905144-78905263 ODZ4 (0) 
chr11 82918080-82918191 ANKRD42 (2.36) 
chr11 84202355-84202470 DLG2 (0.08) 
chr11 85494213-85494306 SYTL2 (1.7) 
chr11 85631078-85631196 CCDC83 (0.09) 
chr11 88419877-88419996 GRM5 (1.74) 
chr11 92332399-92332500 FAT3 (0) 
chr11 94969583-94969695 SESN3 (3.41) 
chr11 95682839-95682936 MTMR2 (2.8) 
chr11 97997125-97997227 CNTN5 (1.82) 
chr11 98490141-98490244 CNTN5 (1.82) 
chr11 102217944-102218085 BIRC2 (5.29) 
chr11 102759211-102759329 MMP12 (0) 
chr11 110183027-110183139 RDX (4.02) 
chr11 110214740-110214855 RDX (4.02) 
chr11 113749387-113749507 USP28 (3.82) 
chr11 114997252-114997378 CADM1 (2.78) 
chr11 115453099-115453183 CADM1 (2.78) 
chr11 115797096-115797220 LOC283143 (0) 
chr11 115965792-115965903 LOC283143 (0) 
chr11 116088773-116088876 LOC283143 (0) 
chr11 119483054-119483159 PVRL1 (2.9) 
chr11 119773507-119773623 PVRL1 (2.9) 
chr11 123538407-123538510 SCN3B (0.18) 
chr11 126517974-126518115 KIRREL3 (0.09) 
chr11 127264576-127264677 KIRREL3-AS3 (0) 
chr11 128240074-128240193 ETS1 (5.28) 
chr11 129009537-129009649 ARHGAP32 (1.79) 
chr12 1189820-1189940 RAD52 (2.96) 
chr12 1635084-1635168 LOC100292680 (0) 
chr12 4514536-4514651 FGF23 (0) 
chr12 6852659-6852777 MLF2 (6.52) 
chr12 9797863-9797993 LOC374443 (0.42) 
chr12 9804066-9804159 CLEC2D (3.38) 
chr12 10800431-10800541 STYK1 (0.32) 
chr12 12261926-12262034 MIR1244-1 (0) 
chr12 12971653-12971773 DDX47 (5.74) 
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chr12 14296899-14297014 GRIN2B (0.32) 
chr12 14432849-14432944 ATF7IP (4.61) 
chr12 21810688-21810799 LDHB (10.4) 
chr12 22280557-22280656 CMAS (5) 
chr12 22421450-22421584 KIAA0528 (0) 
chr12 22983609-22983728 ETNK1 (5.72) 
chr12 23286635-23286753 SOX5 (0.7) 
chr12 25108451-25108596 BCAT1 (5.63) 
chr12 25446062-25446167 KRAS (4.63) 
chr12 25890981-25891086 IFLTD1 (0) 
chr12 28298990-28299108 CCDC91 (4.41) 
chr12 30020945-30021046 TMTC1 (2.15) 
chr12 33171264-33171366 PKP2 (0) 
chr12 40506886-40506992 SLC2A13 (2.48) 
chr12 40597566-40597675 LRRK2 (0.05) 
chr12 41473402-41473508 CNTN1 (0.34) 
chr12 41706344-41706462 PDZRN4 (0) 
chr12 42008364-42008465 PDZRN4 (0) 
chr12 44675857-44675975 NELL2 (0.12) 
chr12 46544812-46544941 SLC38A1 (0.58) 
chr12 50505957-50506075 C12orf62 (0) 
chr12 56043450-56043540 OR10P1 (0) 
chr12 58564583-58564683 XRCC6BP1 (3.8) 
chr12 58713402-58713505 XRCC6BP1 (3.8) 
chr12 59427482-59427598 LRIG3 (2.26) 
chr12 59517578-59517681 LRIG3 (2.26) 
chr12 59880368-59880483 SLC16A7 (1.5) 
chr12 60826106-60826215 SLC16A7 (1.5) 
chr12 61195157-61195273 FAM19A2 (0.19) 
chr12 61923504-61923608 FAM19A2 (0.19) 
chr12 62608126-62608229 FAM19A2 (0.19) 
chr12 62841257-62841360 MON2 (2.72) 
chr12 63402435-63402553 PPM1H (3.63) 
chr12 66414342-66414479 HMGA2 (0) 
chr12 68835835-68836256 MDM1 (2.99) 
chr12 71633155-71633274 TSPAN8 (0) 
chr12 72623002-72623116 LOC283392 (0) 
chr12 74595298-74595401 LOC100507377 (0.51) 
chr12 76365243-76365358 PHLDA1 (0.6) 
chr12 77730026-77730145 E2F7 (2.33) 
chr12 81171248-81171364 LIN7A (0) 
chr12 82124159-82124241 PPFIA2 (0.02) 
chr12 83839056-83839174 TMTC2 (1.57) 
chr12 85872024-85872126 ALX1 (0) 
chr12 86547473-86547576 MGAT4C (0.43) 
chr12 88535708-88535816 CEP290 (2.62) 
chr12 88543925-88544036 CEP290 (2.62) 
chr12 88721992-88722102 TMTC3 (2.17) 
chr12 88991665-88991784 KITLG (4.15) 
chr12 89445752-89445867 LOC728084 (0) 
chr12 89541372-89541475 LOC728084 (0) 
chr12 91058848-91058963 C12orf37 (0) 
chr12 92739751-92739856 CLLU1OS (0) 
chr12 92955007-92955125 CLLU1 (0) 
chr12 93335100-93335215 EEA1 (2.61) 
chr12 94202042-94202147 CRADD (2.02) 
chr12 95100203-95100310 TMCC3 (0.07) 
chr12 97225910-97226024 NEDD1 (3.84) 
chr12 97286224-97286309 NEDD1 (3.84) 
chr12 97477865-97477982 NEDD1 (3.84) 
chr12 102054514-102054618 CHPT1 (1.73) 
chr12 102685554-102685665 PMCH (0.72) 
chr12 102739289-102739377 IGF1 (0.13) 
chr12 103421726-103421845 ASCL1 (0) 
chr12 104093186-104093286 NT5DC3 (1.25) 
chr12 108077731-108077836 PWP1 (5.2) 
chr12 108294605-108294714 LOC728739 (2.95) 
chr12 108479105-108479211 WSCD2 (0) 
chr12 109775293-109775380 FOXN4 (0.06) 
chr12 111565570-111565676 CUX2 (0.3) 
chr12 111848625-111848749 ATXN2 (2.68) 
chr12 112847271-112847384 PTPN11 (4.95) 
chr12 114244952-114245040 RBM19 (5.14) 
chr12 114438141-114438258 RBM19 (5.14) 
chr12 115061119-115061208 TBX3 (1.55) 
chr12 115345763-115345890 TBX3 (1.55) 
chr12 115803815-115803923 MED13L (3.63) 
chr12 115826213-115826320 MED13L (3.63) 
chr12 115965956-115966075 MED13L (3.63) 
chr12 116356601-116356706 MED13L (3.63) 
chr12 117561636-117561755 FBXO21 (3.25) 
chr12 118792525-118792633 TAOK3 (3.59) 
chr12 120398589-120398693 CCDC64 (3.66) 
chr12 121675802-121675981 CAMKK2 (2.84) 
chr12 125597291-125597394 AACS (3.95) 
chr12 125905869-125905987 TMEM132B (0.02) 
chr12 125973092-125973195 TMEM132B (0.02) 
chr12 126533999-126534113 LOC400084 (0) 
chr12 127128423-127128541 LOC387895 (0) 
chr12 127254736-127254866 LOC100507206 (0) 
chr12 127468384-127468487 LOC440117 (0) 
chr12 128045151-128045257 FLJ37505 (0.29) 
chr12 128194281-128194387 FLJ37505 (0.29) 
chr12 129263088-129263205 SLC15A4 (3.42) 
chr12 129594079-129594310 TMEM132D (0) 
chr12 130769019-130769134 PIWIL1 (0.14) 
chr12 131698628-131698767 LOC116437 (0) 
chr13 19128875-19128991 ANKRD20A9P (1.16) 
chr13 21665981-21666077 LATS2 (0.39) 
chr13 27766745-27766857 USP12 (3.93) 
chr13 28651452-28651570 PAN3-AS1 (2.24) 
chr13 29118653-29118759 FLT1 (0) 
chr13 31501576-31501681 LOC100507064 (0) 
chr13 35205298-35205402 NBEA (1.28) 
chr13 36506660-36506759 MIR548F5 (0) 
chr13 36946963-36947067 SPG20 (0) 
chr13 38410207-38410323 TRPC4 (0.01) 
chr13 45647997-45648100 KIAA1704 (0) 
chr13 46234665-46234783 SPERT (0.02) 
chr13 47730203-47730317 HTR2A (0) 
chr13 49259276-49259384 CYSLTR2 (4.58) 
chr13 52997141-52997244 THSD1 (0.85) 
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chr13 54539428-54539541 MIR1297 (0) 
chr13 56917565-56917678 PRR20C (0) 
chr13 58716873-58716989 PCDH17 (0) 
chr13 59134882-59134997 PCDH17 (0) 
chr13 59883236-59883344 DIAPH3 (2.77) 
chr13 60982144-60982347 TDRD3 (3.89) 
chr13 62840882-62840985 PCDH20 (0) 
chr13 63631303-63631433 OR7E156P (0) 
chr13 68267457-68267577 PCDH9 (3.81) 
chr13 69251468-69251583 LOC338862 (0) 
chr13 70322448-70322562 KLHL1 (1.38) 
chr13 71231369-71231486 ATXN8OS (0.05) 
chr13 72664298-72664416 DACH1 (0.44) 
chr13 72916027-72916129 MZT1 (3.37) 
chr13 76798442-76798540 LMO7 (2.18) 
chr13 77307132-77307238 KCTD12 (0.04) 
chr13 78003763-78003882 MYCBP2 (3.09) 
chr13 78500970-78501078 EDNRB (0.1) 
chr13 79320204-79320294 RNF219 (3.51) 
chr13 84882890-84882995 SLITRK1 (0) 
chr13 87346181-87346298 MIR4500HG (0.56) 
chr13 88848754-88848860 SLITRK5 (0.52) 
chr13 89964572-89964686 MIR622 (0) 
chr13 92540381-92540465 GPC5 (1.33) 
chr13 93591201-93591311 GPC5 (1.33) 
chr13 93611467-93611586 GPC5 (1.33) 
chr13 99439638-99439733 DOCK9 (1.92) 
chr13 99772193-99772313 DOCK9 (1.92) 
chr13 100104204-100104321 MIR548AN (0) 
chr13 100113263-100113369 TM9SF2 (4.69) 
chr13 101360615-101360708 TMTC4 (2.18) 
chr13 102161456-102161573 NALCN (0.02) 
chr13 103752583-103752686 SLC10A2 (0.05) 
chr13 103919748-103919861 SLC10A2 (0.05) 
chr13 103997782-103997883 SLC10A2 (0.05) 
chr13 108682808-108682913 FAM155A (0.04) 
chr13 108843832-108843931 LIG4 (2.65) 
chr13 110617242-110617358 IRS2 (1.96) 
chr13 110974057-110974166 COL4A2 (0) 
chr13 111594774-111594893 ANKRD10 (5.16) 
chr13 112025193-112025287 C13orf16 (0) 
chr13 113799969-113800074 PROZ (0.18) 
chr14 19680937-19681052 POTEG (0) 
chr14 19894332-19894447 POTEM (0.11) 
chr14 20925343-20925436 TMEM55B (3.8) 
chr14 21134860-21135028 ANG (4.09) 
chr14 24104085-24104196 DHRS2 (8.9) 
chr14 28645719-28645820 LOC100505967 (0) 
chr14 30348580-30348701 PRKD1 (1.39) 
chr14 30515075-30515206 PRKD1 (1.39) 
chr14 37469995-37470101 SLC25A21 (1.98) 
chr14 37594019-37594141 SLC25A21 (1.98) 
chr14 38825620-38825735 CLEC14A (0) 
chr14 41208395-41208501 LRFN5 (0) 
chr14 44143114-44143217 FSCB (0.12) 
chr14 45260477-45260583 C14orf28 (1.48) 
chr14 49188861-49188979 RPS29 (10.97) 
chr14 50053389-50053591 RPS29 (10.97) 
chr14 50872998-50873202 CDKL1 (1.41) 
chr14 51651877-51651980 TMX1 (4.38) 
chr14 51869186-51869290 LOC283553 (0) 
chr14 51960189-51960307 FRMD6 (1.47) 
chr14 52372553-52372658 GNG2 (5.29) 
chr14 54453587-54453699 BMP4 (0) 
chr14 56263321-56263427 C14orf34 (0) 
chr14 56780071-56780177 PELI2 (0.08) 
chr14 57484550-57484657 OTX2OS1 (0) 
chr14 57871385-57871494 C14orf105 (0.07) 
chr14 60677146-60677321 PPM1A (3.79) 
chr14 66447217-66447316 FUT8 (5.85) 
chr14 66521580-66521695 FUT8 (5.85) 
chr14 67271815-67271930 GPHN (3.11) 
chr14 67273779-67273886 GPHN (3.11) 
chr14 69377549-69377657 ACTN1 (1.23) 
chr14 70202928-70203010 KIAA0247 (0) 
chr14 70729399-70729519 ADAM21P1 (0.12) 
chr14 71673290-71673387 PCNX (3.09) 
chr14 71713067-71713163 PCNX (3.09) 
chr14 76012909-76013263 FLVCR2 (0.74) 
chr14 78414926-78415029 ADCK1 (1.74) 
chr14 80785911-80786026 LOC100628307 (0) 
chr14 80945720-80945838 CEP128 (1.7) 
chr14 81675618-81675703 GTF2A1 (3) 
chr14 81723112-81723230 STON2 (0) 
chr14 83317256-83317362 SEL1L (4.82) 
chr14 86559141-86559257 FLRT2 (0.01) 
chr14 86674032-86674144 FLRT2 (0.01) 
chr14 87240614-87240741 LOC283585 (0) 
chr14 88073541-88073650 GALC (0) 
chr14 88317138-88317244 GALC (0) 
chr14 88388292-88388422 GALC (0) 
chr14 89471489-89471608 TTC8 (3.1) 
chr14 89522339-89522457 FOXN3 (1.66) 
chr14 89744491-89744611 FOXN3 (1.66) 
chr14 90164132-90164232 FOXN3 (1.66) 
chr14 90339470-90339577 TDP1 (4.72) 
chr14 90514137-90514255 TDP1 (4.72) 
chr14 92630319-92630504 CPSF2 (5.18) 
chr14 92753561-92753666 SLC24A4 (0) 
chr14 92868973-92869073 RIN3 (0.04) 
chr14 93336867-93337020 GOLGA5 (4.44) 
chr14 93338648-93338782 GOLGA5 (4.44) 
chr14 93339798-93339934 GOLGA5 (4.44) 
chr14 93366476-93366595 CHGA (0.29) 
chr14 94114160-94114277 PRIMA1 (0) 
chr14 94143688-94143805 PRIMA1 (0) 
chr14 94288209-94288327 PRIMA1 (0) 
chr14 94762672-94762788 SERPINA10 (0.06) 
chr14 94884443-94884549 SERPINA11 (0) 
chr14 94886389-94886519 SERPINA11 (0) 
chr14 97903770-97903885 LOC100129345 (0.41) 
chr14 98498455-98498550 C14orf64 (0) 
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chr14 98748846-98748948 C14orf64 (0) 
chr14 100800131-100800265 SLC25A47 (0) 
chr14 105222904-105223078 SIVA1 (6.53) 
chr14 105771045-105771160 BRF1 (3.97) 
chr15 23188081-23188257 WHAMMP3 (2.27) 
chr15 26619162-26619268 GABRB3 (0) 
chr15 29002980-29003086 LOC100289656 (0) 
chr15 32495824-32495931 CHRNA7 (0.02) 
chr15 33054496-33054615 FMN1 (0.02) 
chr15 33502046-33502157 RYR3 (0.15) 
chr15 37490006-37490118 MEIS2 (3.28) 
chr15 38339671-38339771 TMCO5A (0) 
chr15 38582796-38582916 FAM98B (2.64) 
chr15 39527796-39527913 C15orf54 (0.16) 
chr15 39945916-39946031 FSIP1 (2.27) 
chr15 42788990-42789100 ZFP106 (0) 
chr15 44530090-44530200 FRMD5 (1.14) 
chr15 45103618-45103707 TRIM69 (0.58) 
chr15 47835588-47835708 SEMA6D (0) 
chr15 48312659-48312750 SLC24A5 (0.67) 
chr15 48362570-48362688 SLC24A5 (0.67) 
chr15 49907724-49907827 C15orf33 (0) 
chr15 50024008-50024132 DTWD1 (2.67) 
chr15 53016821-53016939 ONECUT1 (0.44) 
chr15 53597013-53597105 WDR72 (0.06) 
chr15 54071963-54072066 WDR72 (0.06) 
chr15 54902018-54902113 UNC13C (0.01) 
chr15 56135263-56135366 PRTG (0) 
chr15 56689988-56690087 MNS1 (0.17) 
chr15 57832483-57832599 CGNL1 (0) 
chr15 58113629-58113748 GCOM1 (0) 
chr15 58552284-58552403 AQP9 (0.29) 
chr15 60181631-60181734 FOXB1 (0.35) 
chr15 62574069-62574188 C2CD4B (0) 
chr15 65536702-65536820 PARP16 (3.7) 
chr15 69745127-69745247 KIF23 (5.65) 
chr15 70656463-70656581 TLE3 (2.88) 
chr15 70885590-70885702 UACA (0.01) 
chr15 71983002-71983105 THSD4 (0.02) 
chr15 75230267-75230432 RPP25 (0.56) 
chr15 76721437-76721540 SCAPER (3.02) 
chr15 80976586-80976704 FAM108C1 (0) 
chr15 81096291-81096409 KIAA1199 (0) 
chr15 87581908-87582042 AGBL1 (0) 
chr15 88076999-88077114 LINC00052 (0) 
chr15 88186360-88186457 LINC00052 (0) 
chr15 88246997-88247116 LINC00052 (0) 
chr15 89198642-89198730 ISG20 (4.56) 
chr15 91284016-91284134 BLM (4.4) 
chr15 91803964-91804085 SV2B (0.05) 
chr15 93173107-93173208 FAM174B (1.84) 
chr15 95232723-95232813 MCTP2 (0.01) 
chr15 95749213-95749314 LOC400456 (0) 
chr15 95751457-95751570 LOC400456 (0) 
chr15 96537241-96537376 NR2F2 (2.44) 
chr15 97795260-97795360 SPATA8 (0) 
chr15 100438376-100438491 ADAMTS17 (0.04) 
chr15 100947071-100947164 CERS3 (0.08) 
chr15 101835338-101835443 PCSK6 (0.34) 
chr15 102182661-102182796 TARSL2 (3.54) 
chr15 102347613-102347745 OR4F6 (0) 
chr16 5120972-5121073 ALG1 (1.97) 
chr16 6147114-6147232 RBFOX1 (0.92) 
chr16 7826358-7826459 RBFOX1 (0.92) 
chr16 8036749-8036855 RBFOX1 (0.92) 
chr16 8149819-8149935 RBFOX1 (0.92) 
chr16 8708563-8708681 METTL22 (2.61) 
chr16 10002939-10003039 GRIN2A (0.01) 
chr16 11060464-11060574 CLEC16A (4.66) 
chr16 12543915-12544015 SNX29 (2.6) 
chr16 12753698-12753802 CPPED1 (2.86) 
chr16 13145039-13145151 SHISA9 (2.49) 
chr16 13354736-13354856 SHISA9 (2.49) 
chr16 15027011-15027113 NPIP (0) 
chr16 15342891-15342973 MIR3180-4 (0) 
chr16 15370192-15370293 MPV17L (0) 
chr16 15666758-15666858 KIAA0430 (2.5) 
chr16 15667941-15668044 KIAA0430 (2.5) 
chr16 16593363-16593481 PKD1P1 (3.62) 
chr16 16757508-16757610 PKD1P1 (3.62) 
chr16 17119539-17119648 XYLT1 (0.62) 
chr16 17992400-17992506 XYLT1 (0.62) 
chr16 18298360-18298473 MIR3180-3 (0) 
chr16 18306408-18306526 MIR3180-3 (0) 
chr16 18326114-18326236 MIR3180-3 (0) 
chr16 20035584-20035699 GPR139 (0) 
chr16 21127745-21127850 DNAH3 (0.07) 
chr16 21314303-21314411 RUNDC2B (0) 
chr16 22871503-22871621 HS3ST2 (0) 
chr16 22910970-22911074 HS3ST2 (0) 
chr16 23715753-23715866 ERN2 (0.02) 
chr16 26644127-26644232 C16orf82 (0) 
chr16 27258628-27258717 NSMCE1 (5.3) 
chr16 27401056-27401157 IL21R (5.7) 
chr16 29525594-29525702 LOC440354 (0) 
chr16 30265579-30265687 LOC613037 (0.68) 
chr16 31123645-31123810 KAT8 (4.76) 
chr16 54907984-54908103 CRNDE (4.44) 
chr16 55106596-55106711 IRX5 (1.37) 
chr16 55331542-55331660 IRX6 (0) 
chr16 55935090-55935208 CES5A (0) 
chr16 56762981-56763084 NUP93 (5.51) 
chr16 58455184-58455322 GINS3 (3.79) 
chr16 59721352-59721445 LOC644649 (0) 
chr16 60118537-60118658 LOC644649 (0) 
chr16 66365666-66365772 CDH5 (0.01) 
chr16 69355935-69356037 COG8 (4.51) 
chr16 70912086-70912205 HYDIN (0.02) 
chr16 75918806-75918909 TERF2IP (5.84) 
chr16 76268959-76269087 CNTNAP4 (0.04) 
chr16 78208089-78208206 WWOX (4.9) 
chr16 80926395-80926514 C16orf61 (0) 
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chr16 82142915-82143029 HSD17B2 (0) 
chr16 82721058-82721164 CDH13 (0) 
chr16 86380948-86381054 LOC732275 (0) 
chr16 86632908-86633046 FOXL1 (0.07) 
chr16 87294579-87294677 C16orf95 (2.55) 
chr16 88876084-88876229 APRT (7.15) 
chr17 5522646-5522773 NLRP1 (4.87) 
chr17 7529674-7529768 SHBG (0.04) 
chr17 8892074-8892171 PIK3R5 (1.49) 
chr17 10170290-10170409 MYH13 (0) 
chr17 10195103-10195230 MYH13 (0) 
chr17 20515269-20515414 CDRT15L2 (0) 
chr17 25702008-25702111 LOC440419 (0) 
chr17 27717445-27717563 MIR4523 (0) 
chr17 30771499-30771623 PSMD11 (5.2) 
chr17 31279721-31279828 TMEM98 (0) 
chr17 35704142-35704243 ACACA (4.15) 
chr17 38946998-38947101 KRT28 (0) 
chr17 42022291-42022387 PPY (0) 
chr17 44488571-44488701 ARL17A (0.39) 
chr17 44706151-44706269 NSF (3.34) 
chr17 46736655-46736765 MIR196A1 (0) 
chr17 49498016-49498121 UTP18 (5.55) 
chr17 50375185-50375290 CA10 (0.66) 
chr17 53451535-53451756 MMD (4.08) 
chr17 55229433-55229539 AKAP1 (4.24) 
chr17 59322437-59322596 BCAS3 (3.21) 
chr17 63958878-63958991 CEP112 (0.74) 
chr17 64410444-64410534 PRKCA (4.93) 
chr17 64934372-64934491 CACNG4 (0.02) 
chr17 66823157-66823272 ABCA8 (0.33) 
chr17 68979387-68979502 KCNJ2 (3.44) 
chr17 69227585-69227682 SOX9 (1.45) 
chr17 69617077-69617177 SOX9 (1.45) 
chr17 70002228-70002337 SOX9 (1.45) 
chr17 70016639-70016760 SOX9 (1.45) 
chr17 70032649-70032764 SOX9 (1.45) 
chr17 70063246-70063359 SOX9 (1.45) 
chr17 70340935-70341050 LOC100499467 (0) 
chr17 70421503-70421612 LOC100499467 (0) 
chr17 70435831-70435937 LOC100499467 (0) 
chr17 70493443-70493540 LOC100499467 (0) 
chr17 70510422-70510528 LOC100499467 (0) 
chr17 70989027-70989153 SLC39A11 (3.68) 
chr17 71146870-71146990 SSTR2 (0.03) 
chr17 72514915-72515024 CD300LB (0) 
chr17 73262119-73262280 MIF4GD (4.13) 
chr17 74560626-74560724 ST6GALNAC2 (0.62) 
chr17 76095495-76095602 TNRC6C (1.43) 
chr17 76663088-76663183 CYTH1 (6.01) 
chr17 79336004-79336127 TMEM105 (0) 
chr18 308291-308409 COLEC12 (0) 
chr18 1275070-1275178 LINC00470 (0) 
chr18 1928434-1928541 LINC00470 (0) 
chr18 4216086-4216252 DLGAP1 (0) 
chr18 5270339-5270454 ZFP161 (0) 
chr18 10341456-10341568 APCDD1 (0) 
chr18 13281972-13282054 C18orf1 (0) 
chr18 13998316-13998424 ZNF519 (2.48) 
chr18 15135167-15135282 LOC644669 (0.02) 
chr18 20452939-20453087 RBBP8 (5.16) 
chr18 22537538-22537657 ZNF521 (0.05) 
chr18 28720938-28721057 DSC1 (0) 
chr18 28794449-28794566 DSC1 (0) 
chr18 29545595-29545710 TRAPPC8 (4.37) 
chr18 32485083-32485174 DTNA (1.94) 
chr18 33069296-33069402 MIR3975 (0) 
chr18 33325342-33325446 GALNT1 (5.29) 
chr18 36053200-36053300 LOC647946 (0) 
chr18 36093082-36093194 LOC647946 (0) 
chr18 43454452-43454558 EPG5 (2.37) 
chr18 44812046-44812167 IER3IP1 (5.42) 
chr18 47982707-47982825 SKA1 (4.18) 
chr18 50287481-50287567 DCC (0) 
chr18 51188649-51188764 DCC (0) 
chr18 53849326-53849432 LOC100505474 (0) 
chr18 54833283-54833402 BOD1P (0) 
chr18 55558335-55558453 ATP8B1 (0.71) 
chr18 55636098-55636214 NEDD4L (3.2) 
chr18 55664166-55664276 NEDD4L (3.2) 
chr18 55879585-55879690 NEDD4L (3.2) 
chr18 56447362-56447466 MALT1 (6.3) 
chr18 57333311-57333414 CCBE1 (0.02) 
chr18 57730289-57730380 PMAIP1 (5.72) 
chr18 58124559-58124668 MC4R (0.53) 
chr18 58210303-58210401 MC4R (0.53) 
chr18 59702329-59702430 PIGN (3.22) 
chr18 61428946-61429054 SERPINB7 (0) 
chr18 68975443-68975546 LOC100505776 (0) 
chr18 69552676-69552800 LOC100505776 (0) 
chr18 69776943-69777067 CBLN2 (0.02) 
chr18 69941156-69941270 CBLN2 (0.02) 
chr18 70147098-70147198 CBLN2 (0.02) 
chr18 71197412-71197518 LOC100505817 (0) 
chr18 72234153-72234274 CNDP1 (0) 
chr18 75207172-75207301 GALR1 (0) 
chr18 75437137-75437252 GALR1 (0) 
chr18 75705586-75705708 GALR1 (0) 
chr19 1085162-1085250 POLR2E (4.89) 
chr19 2041859-2042015 MKNK2 (6.66) 
chr19 6323451-6323576 CLPP (5.57) 
chr19 6381159-6381241 GTF2F1 (5.16) 
chr19 6381340-6381431 GTF2F1 (5.16) 
chr19 6413849-6414014 KHSRP (5.17) 
chr19 14751624-14751752 EMR3 (0) 
chr19 23887340-23887460 ZNF675 (3.87) 
chr19 28620111-28620219 LOC148189 (0) 
chr19 34046707-34046814 PEPD (4.69) 
chr19 35090318-35090437 SCGBL (0) 
chr19 35284902-35285014 ZNF599 (1.42) 
chr19 46743644-46743762 IGFL1 (0) 
chr19 49792758-49792876 SLC6A16 (0.33) 
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chr19 49993711-49993864 SNORD33 (12.13) 
chr19 50363849-50363968 PNKP (3.31) 
chr2 184856-184963 SH3YL1 (2.72) 
chr2 316125-316229 FAM150B (0.66) 
chr2 668027-668116 LOC339822 (0) 
chr2 1318526-1318632 SNTG2 (0) 
chr2 1445809-1445922 SNTG2 (0) 
chr2 4091301-4091386 LOC100505964 (0) 
chr2 6101976-6102124 LOC400940 (0) 
chr2 7860370-7860470 LOC339788 (0) 
chr2 8072077-8072221 LINC00299 (0) 
chr2 9255038-9255140 ASAP2 (0.97) 
chr2 9818806-9818916 YWHAQ (8.77) 
chr2 11037122-11037223 KCNF1 (0) 
chr2 11720099-11720217 MIR4429 (0) 
chr2 12007268-12007410 MIR4262 (0) 
chr2 14131255-14131387 FAM84A (0.01) 
chr2 16048806-16048921 MYCNOS (0) 
chr2 16995366-16995481 FAM49A (1.55) 
chr2 17093091-17093203 FAM49A (1.55) 
chr2 18110579-18110674 KCNS3 (0) 
chr2 20263110-20263232 LAPTM4A (5.27) 
chr2 21385753-21385871 APOB (0) 
chr2 21657429-21657530 LOC645949 (0.14) 
chr2 23312478-23312579 KLHL29 (0.31) 
chr2 24674827-24674938 ITSN2 (4.66) 
chr2 24773241-24773358 NCOA1 (4.31) 
chr2 25067850-25067970 CENPO (4.11) 
chr2 27907986-27908097 SLC4A1AP (5.32) 
chr2 30554532-30554660 LBH (3.21) 
chr2 33931891-33932027 MYADML (0) 
chr2 36275760-36275875 LOC100288911 (0) 
chr2 40010065-40010177 THUMPD2 (3.94) 
chr2 40808088-40808184 SLC8A1 (3.55) 
chr2 41517312-41517415 LOC388942 (0) 
chr2 43317979-43318094 ZFP36L2 (2.44) 
chr2 44275097-44275215 LRPPRC (6.81) 
chr2 44524018-44524137 PREPL (5.17) 
chr2 47081263-47081366 LOC100134259 (0) 
chr2 49305304-49305417 FSHR (0.19) 
chr2 50243647-50243748 NRXN1 (0.26) 
chr2 52334372-52334481 NRXN1 (0.26) 
chr2 53155999-53156176 ASB3 (4.3) 
chr2 53641860-53641969 ASB3 (4.3) 
chr2 53885710-53885810 ASB3 (4.3) 
chr2 54342736-54342833 ACYP2 (1.97) 
chr2 54501246-54501358 ACYP2 (1.97) 
chr2 54621638-54621758 C2orf73 (0.06) 
chr2 54908745-54908896 SPTBN1 (1.41) 
chr2 55757335-55757443 SMEK2 (5.36) 
chr2 56503657-56503789 CCDC85A (1.18) 
chr2 57189213-57189320 CCDC85A (1.18) 
chr2 57858301-57858431 VRK2 (4.96) 
chr2 58083391-58083493 VRK2 (4.96) 
chr2 58972566-58972675 FLJ30838 (0) 
chr2 60343702-60343810 MIR4432 (0) 
chr2 62502615-62502715 B3GNT2 (4.75) 
chr2 64261720-64261823 VPS54 (5.11) 
chr2 65275117-65275277 CEP68 (3.51) 
chr2 65943129-65943232 SPRED2 (2.41) 
chr2 67517096-67517215 LOC644838 (0) 
chr2 69383723-69383824 ANTXR1 (0.03) 
chr2 70645610-70645727 TGFA (0.24) 
chr2 72126693-72126800 DYSF (0.59) 
chr2 74154009-74154137 DGUOK (5.98) 
chr2 75769209-75769330 FAM176A (0) 
chr2 76215892-76216001 C2orf3 (0) 
chr2 77564717-77564814 LRRTM4 (0.4) 
chr2 78274128-78274232 SNAR-H (0) 
chr2 79000887-79001004 REG3G (0) 
chr2 79213618-79213737 REG3G (0) 
chr2 80258492-80258604 CTNNA2 (0.22) 
chr2 84402081-84402187 FUNDC2P2 (0.14) 
chr2 85590817-85590899 ELMOD3 (3.19) 
chr2 86082383-86082486 ST3GAL5 (5.06) 
chr2 87855332-87855441 LINC00152 (5.04) 
chr2 89113051-89113167 MIR4436A (0) 
chr2 99229898-99230002 COA5 (4.36) 
chr2 104629698-104629823 LOC100287010 (0) 
chr2 108004251-108004335 LOC729121 (0) 
chr2 110294435-110294550 40422 (0) 
chr2 110971202-110971308 NPHP1 (1.78) 
chr2 111881302-111881390 ACOXL (1.43) 
chr2 111969407-111969508 BCL2L11 (3.96) 
chr2 112424662-112424776 ANAPC1 (4.36) 
chr2 114448623-114448728 SLC35F5 (4.11) 
chr2 116514941-116515055 DPP10 (0.01) 
chr2 117359539-117359671 DPP10 (0.01) 
chr2 118781970-118782077 CCDC93 (4.19) 
chr2 121014122-121014225 TMEM185B (3.93) 
chr2 123442080-123442199 TSN (6.24) 
chr2 123545441-123545542 TSN (6.24) 
chr2 123811164-123811253 CNTNAP5 (0) 
chr2 124350042-124350153 CNTNAP5 (0) 
chr2 126822370-126822490 GYPC (6.01) 
chr2 128586998-128587114 POLR2D (4.6) 
chr2 128721337-128721441 SAP130 (3.32) 
chr2 132737349-132737467 ANKRD30BL (0) 
chr2 140700407-140700514 LRP1B (0.08) 
chr2 143874853-143874977 ARHGAP15 (0.29) 
chr2 144852044-144852147 ZEB2 (4.63) 
chr2 146923044-146923152 PABPC1P2 (1.92) 
chr2 148233321-148233437 ACVR2A (1.08) 
chr2 148549202-148549311 ACVR2A (1.08) 
chr2 151986540-151986656 RBM43 (1.64) 
chr2 152470256-152470378 NEB (0.11) 
chr2 153573867-153573968 ARL6IP6 (3.24) 
chr2 155062121-155062248 GALNT13 (0.17) 
chr2 155342895-155343014 GALNT13 (0.17) 
chr2 155361898-155362019 GALNT13 (0.17) 
chr2 157881118-157881233 GALNT5 (0.03) 
chr2 158033328-158033427 GALNT5 (0.03) 
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chr2 158535723-158535832 ACVR1C (0.88) 
chr2 159145379-159145487 CCDC148 (0.41) 
chr2 160266991-160267095 BAZ2B (0.53) 
chr2 160916227-160916341 PLA2R1 (2.99) 
chr2 161986910-161986998 TANK (5.78) 
chr2 162419066-162419179 SLC4A10 (0.09) 
chr2 164518273-164518394 KCNH7 (0.05) 
chr2 165856169-165856265 SLC38A11 (0.04) 
chr2 166629797-166629903 CSRNP3 (0) 
chr2 166994033-166994144 SCN9A (0) 
chr2 168797605-168797731 STK39 (5.54) 
chr2 169272637-169272730 CERS6 (0) 
chr2 169280674-169280783 CERS6 (0) 
chr2 170543440-170543560 C2orf77 (0) 
chr2 173750244-173750363 RAPGEF4 (0.12) 
chr2 176249781-176249868 ATP5G3 (5.97) 
chr2 177293859-177293983 MTX2 (4.68) 
chr2 178507650-178507765 PDE11A (0) 
chr2 179090373-179090489 OSBPL6 (1.62) 
chr2 180795645-180795762 CWC22 (4.18) 
chr2 184637903-184638004 NUP35 (4.77) 
chr2 186272255-186272421 FSIP2 (0.59) 
chr2 187638435-187638537 FAM171B (3.71) 
chr2 190375513-190375612 WDR75 (6.63) 
chr2 191573357-191573532 NAB1 (4.55) 
chr2 192364110-192364226 MYO1B (0) 
chr2 192610059-192610166 OBFC2A (0) 
chr2 193582278-193582394 PCGEM1 (0) 
chr2 195427214-195427313 SLC39A10 (2.16) 
chr2 196972884-196973003 STK17B (3.69) 
chr2 197475976-197476083 HECW2 (0) 
chr2 198351754-198351881 HSPD1 (8) 
chr2 198453984-198454092 RFTN2 (0.18) 
chr2 203683398-203683498 ICA1L (2.36) 
chr2 205278781-205278896 PARD3B (0.12) 
chr2 206489307-206489426 PARD3B (0.12) 
chr2 206843616-206843727 INO80D (2.22) 
chr2 207101364-207101503 GPR1 (0.27) 
chr2 210661398-210661515 UNC80 (0) 
chr2 211143700-211143818 MYL1 (0) 
chr2 214195618-214195727 SPAG16 (3.69) 
chr2 215986515-215986626 ABCA12 (0.12) 
chr2 216848784-216848897 PECR (5.17) 
chr2 217211722-217211815 SMARCAL1 (3.27) 
chr2 223623786-223623882 MOGAT1 (0) 
chr2 223852857-223852972 ACSL3 (4.94) 
chr2 224532898-224533011 SCG2 (0.05) 
chr2 224604011-224604129 AP1S3 (2.23) 
chr2 224923580-224923693 SERPINE2 (0.05) 
chr2 226307618-226307724 KIAA1486 (0) 
chr2 227408293-227408413 IRS1 (1.41) 
chr2 227965887-227965986 COL4A3 (0) 
chr2 228512348-228512464 C2orf83 (0) 
chr2 228970442-228970562 SPHKAP (0) 
chr2 233227045-233227149 ALPP (0) 
chr2 234503043-234503162 UGT1A8 (0) 
chr2 234505178-234505280 UGT1A8 (0) 
chr2 234718914-234719033 HJURP (4.44) 
chr2 234896491-234896587 TRPM8 (0) 
chr2 235095754-235095857 SPP2 (0) 
chr2 235781887-235781996 SH3BP4 (0.04) 
chr2 237409720-237409817 IQCA1 (0) 
chr2 237799438-237799532 COPS8 (4.89) 
chr2 238125828-238125942 COL6A3 (0.01) 
chr2 238363276-238363390 MLPH (0.03) 
chr2 238378153-238378266 MLPH (0.03) 
chr2 238960152-238960267 UBE2F (3.56) 
chr20 807147-807258 FAM110A (1.94) 
chr20 1772431-1772544 LOC100289473 (0) 
chr20 5333002-5333122 PROKR2 (0) 
chr20 10337881-10337994 MKKS (2.88) 
chr20 10773554-10773669 JAG1 (0.9) 
chr20 10799147-10799253 JAG1 (0.9) 
chr20 15569695-15569814 MACROD2 (0.05) 
chr20 15932721-15932836 MACROD2 (0.05) 
chr20 16447185-16447291 KIF16B (2.95) 
chr20 19169699-19169802 SLC24A3 (0) 
chr20 20223715-20223830 C20orf26 (0) 
chr20 22529160-22529279 LINC00261 (0) 
chr20 23478252-23478392 CST8 (0) 
chr20 24876117-24876226 CST7 (0.08) 
chr20 33650951-33651063 EDEM2 (5.18) 
chr20 34547342-34547441 SCAND1 (5.31) 
chr20 34620301-34620409 C20orf152 (0) 
chr20 37915034-37915153 LOC339568 (0) 
chr20 39447152-39447258 MAFB (1.5) 
chr20 40256554-40256653 CHD6 (3.93) 
chr20 42386546-42386656 GTSF1L (0) 
chr20 42457712-42457815 TOX2 (0) 
chr20 42670726-42670844 TOX2 (0) 
chr20 43493102-43493205 YWHAB (6.61) 
chr20 45313032-45313147 SLC2A10 (0) 
chr20 47373375-47373493 ARFGEF2 (4.21) 
chr20 50613837-50613955 ZFP64 (2.67) 
chr20 50650372-50650530 ZFP64 (2.67) 
chr20 52716969-52717070 BCAS1 (5.77) 
chr20 55453505-55453610 TFAP2C (0.01) 
chr20 55474561-55474658 TFAP2C (0.01) 
chr20 56058420-56058539 CTCFL (0) 
chr20 56343875-56343980 PMEPA1 (0) 
chr20 57395711-57395814 GNAS-AS1 (0.77) 
chr20 58487915-58488010 SYCP2 (4.25) 
chr20 60028955-60029075 CDH4 (0.02) 
chr21 14555344-14555459 ANKRD30BP2 (0) 
chr21 16042596-16042712 SAMSN1 (5.92) 
chr21 16052035-16052153 SAMSN1 (5.92) 
chr21 17005826-17005935 USP25 (4.45) 
chr21 17071913-17072007 USP25 (4.45) 
chr21 17296952-17297059 USP25 (4.45) 
chr21 17832236-17832339 LINC00478 (0) 
chr21 19371847-19371966 CHODL (0.69) 
chr21 19858111-19858229 TMPRSS15 (4.3) 
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chr21 20599549-20599650 TMPRSS15 (4.3) 
chr21 20834126-20834303 TMPRSS15 (4.3) 
chr21 20873380-20873542 TMPRSS15 (4.3) 
chr21 23374333-23374437 LINC00308 (0) 
chr21 23406656-23406775 LINC00308 (0) 
chr21 24131048-24131158 D21S2088E (0.27) 
chr21 25309325-25309445 D21S2088E (0.27) 
chr21 25358760-25358868 D21S2088E (0.27) 
chr21 26839466-26839572 LINC00158 (1.5) 
chr21 26874728-26874851 MIR155HG (6.77) 
chr21 27727431-27727534 CYYR1 (1.33) 
chr21 27842836-27842938 APP (0.35) 
chr21 28372027-28372132 ADAMTS5 (0.26) 
chr21 29244367-29244470 LINC00113 (0) 
chr21 30577507-30577607 C21orf7 (0) 
chr21 30638221-30638343 BACH1 (4.45) 
chr21 30806576-30806695 BACH1 (4.45) 
chr21 31330520-31330627 GRIK1 (0.19) 
chr21 31799631-31799728 KRTAP13-3 (0) 
chr21 32652652-32652767 TIAM1 (1.05) 
chr21 32745693-32745817 TIAM1 (1.05) 
chr21 32777872-32777971 TIAM1 (1.05) 
chr21 33139478-33139583 SCAF4 (3.3) 
chr21 33903282-33903397 C21orf63 (0) 
chr21 35284586-35284699 LOC100506334 (0) 
chr21 42077432-42077547 DSCAM (0) 
chr21 42274876-42274979 DSCAM (0) 
chr21 42789589-42789704 MX1 (6.63) 
chr21 43017196-43017296 LINC00111 (0) 
chr21 43881506-43881598 RSPH1 (0.18) 
chr21 45191563-45191679 CSTB (5.04) 
chr21 46224477-46224565 SUMO3 (5.51) 
chr21 47013482-47013648 SLC19A1 (2.25) 
chr21 47278810-47278896 PCBP3 (0.66) 
chr21 47460876-47460983 COL6A1 (0) 
chr21 47556862-47556980 FTCD (0.02) 
chr21 47673880-47674013 MCM3AP (4.46) 
chr22 16162029-16162144 POTEH (0.13) 
chr22 28760240-28760343 CHEK2 (3.17) 
chr22 33355197-33355311 SYN3 (0.01) 
chr22 34186161-34186281 LARGE (1.87) 
chr22 34618938-34619064 LARGE (1.87) 
chr22 35458737-35458857 ISX (0.42) 
chr22 35626959-35627070 HMGXB4 (3.21) 
chr22 36075763-36075876 APOL6 (4.09) 
chr22 40269980-40270103 ENTHD1 (0) 
chr22 41347924-41348038 XPNPEP3 (2.29) 
chr22 45493403-45493518 LOC100506714 (0) 
chr22 46016641-46016752 FBLN1 (0) 
chr22 46067721-46067847 ATXN10 (4.06) 
chr22 47702799-47702892 LOC339685 (0) 
chr22 48054488-48054597 FLJ46257 (0) 
chr22 49839316-49839424 C22orf34 (0.54) 
chr3 278945-279038 CNTN6 (0.04) 
chr3 3168701-3168802 IL5RA (4.86) 
chr3 3827416-3827529 LRRN1 (0.18) 
chr3 4467495-4467600 ITPR1 (4.93) 
chr3 6210151-6210263 GRM7 (0) 
chr3 6277500-6277603 GRM7 (0) 
chr3 6917133-6917251 LOC100288428 (0) 
chr3 12882891-12883013 RPL32 (9.04) 
chr3 16154026-16154132 GALNTL2 (0) 
chr3 17065000-17065082 PLCL2 (3.74) 
chr3 17245159-17245280 TBC1D5 (4.32) 
chr3 18343483-18343595 SATB1 (3.36) 
chr3 20903851-20903974 VENTXP7 (0) 
chr3 21377362-21377468 VENTXP7 (0) 
chr3 22628939-22629029 UBE2E2 (1.84) 
chr3 26584188-26584278 LRRC3B (0) 
chr3 30108004-30108107 RBMS3 (0.34) 
chr3 32972923-32973036 CCR4 (4.57) 
chr3 43665994-43666099 ANO10 (2.53) 
chr3 48402343-48402460 FBXW12 (0) 
chr3 51074312-51074415 DOCK3 (1.4) 
chr3 51792252-51792371 IQCF6 (1.31) 
chr3 53231288-53231394 PRKCD (2.85) 
chr3 54546899-54547000 CACNA2D3 (0) 
chr3 55330875-55330967 WNT5A (1.1) 
chr3 55539200-55539305 ERC2 (0.24) 
chr3 55875381-55875487 ERC2 (0.24) 
chr3 60031038-60031159 FHIT (0.79) 
chr3 61504864-61504993 PTPRG (3.88) 
chr3 65329582-65329687 MAGI1 (3.24) 
chr3 67561918-67562024 SUCLG2 (4.72) 
chr3 72529272-72529368 RYBP (3.84) 
chr3 72529491-72529575 RYBP (3.84) 
chr3 74181980-74182091 CNTN3 (0.09) 
chr3 76949168-76949325 ROBO2 (0.87) 
chr3 76967439-76967558 ROBO2 (0.87) 
chr3 77033079-77033189 ROBO2 (0.87) 
chr3 77707853-77707963 ROBO2 (0.87) 
chr3 79363575-79363691 ROBO1 (0.88) 
chr3 79531543-79531711 ROBO1 (0.88) 
chr3 80577750-80577854 ROBO1 (0.88) 
chr3 81808146-81808255 GBE1 (3.95) 
chr3 86473101-86473201 CADM2 (0) 
chr3 88082278-88082380 CGGBP1 (5.27) 
chr3 95835908-95836027 EPHA6 (0.3) 
chr3 95837839-95837956 EPHA6 (0.3) 
chr3 96156540-96156655 EPHA6 (0.3) 
chr3 99563660-99563786 MIR548G (0) 
chr3 100304825-100304907 TMEM45A (0.51) 
chr3 102339952-102340064 ZPLD1 (0) 
chr3 102377762-102377877 ZPLD1 (0) 
chr3 102444416-102444534 ZPLD1 (0) 
chr3 106540146-106540252 LOC100302640 (0) 
chr3 106921754-106921873 LOC100302640 (0) 
chr3 107843866-107843989 CD47 (4) 
chr3 111071740-111071843 PVRL3 (0) 
chr3 112032973-112033069 CD200 (1.39) 
chr3 112238004-112238119 ATG3 (6.82) 
chr3 116858045-116858160 LSAMP-AS3 (0) 
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chr3 116911884-116912003 LSAMP-AS3 (0) 
chr3 118528782-118528905 IGSF11 (0.18) 
chr3 121734421-121734521 CD86 (6.63) 
chr3 125960813-125960916 ALDH1L1 (0.07) 
chr3 131606075-131606190 CPNE4 (0.77) 
chr3 134314082-134314197 KY (0.18) 
chr3 141754585-141754710 TFDP2 (5.07) 
chr3 144087399-144087513 C3orf58 (4.39) 
chr3 145759514-145759629 PLOD2 (3.54) 
chr3 148677831-148677946 GYG1 (4.55) 
chr3 149175976-149176077 TM4SF4 (0.02) 
chr3 150321093-150321230 SELT (5.31) 
chr3 153709387-153709494 ARHGEF26-AS1 (0.13) 
chr3 156716844-156716945 LEKR1 (1.23) 
chr3 158347110-158347227 GFM1 (5.45) 
chr3 158611965-158612080 MFSD1 (4.54) 
chr3 158770767-158770885 IQCJ (0.02) 
chr3 159922615-159922709 C3orf80 (0.09) 
chr3 160479536-160479655 PPM1L (3.6) 
chr3 162366365-162366467 LOC647107 (0) 
chr3 163289161-163289280 LOC647107 (0) 
chr3 166330671-166330789 ZBBX (0.37) 
chr3 166801087-166801205 ZBBX (0.37) 
chr3 168494265-168494374 EGFEM1P (0.14) 
chr3 169898619-169898774 PHC3 (3.17) 
chr3 172295179-172295307 NCEH1 (3.02) 
chr3 172296159-172296300 NCEH1 (3.02) 
chr3 172298047-172298162 NCEH1 (3.02) 
chr3 172340113-172340207 NCEH1 (3.02) 
chr3 172671978-172672102 SPATA16 (0.02) 
chr3 173559827-173559927 NLGN1 (1.26) 
chr3 173745786-173745904 NAALADL2 (0.69) 
chr3 174991893-174992029 NAALADL2 (0.69) 
chr3 175453316-175453406 NAALADL2 (0.69) 
chr3 176175057-176175170 TBL1XR1 (5.41) 
chr3 177345991-177346106 TBL1XR1 (5.41) 
chr3 179344882-179344989 NDUFB5 (6.54) 
chr3 179803419-179803525 PEX5L (3.57) 
chr3 180448260-180448373 CCDC39 (1.37) 
chr3 182779789-182779915 LAMP3 (2.43) 
chr3 182796648-182796750 LAMP3 (2.43) 
chr3 183079289-183079399 MCF2L2 (1.83) 
chr3 183743156-183743268 HTR3D (0) 
chr3 184175733-184175834 CHRD (0) 
chr3 185743988-185744104 ETV5 (1.2) 
chr3 189121157-189121294 TPRG1 (3.88) 
chr3 190934883-190934971 UTS2D (0) 
chr3 191018561-191018667 CCDC50 (3.83) 
chr3 194241781-194241883 FLJ34208 (0) 
chr3 195913921-195914038 ZDHHC19 (0.03) 
chr3 196507224-196507327 PAK2 (4.46) 
chr4 53196-53297 ZNF876P (0) 
chr4 3915920-3916038 FAM86EP (1.14) 
chr4 4605314-4605426 LOC100507266 (0) 
chr4 5115538-5115651 STK32B (0.02) 
chr4 7755773-7755893 AFAP1 (2.94) 
chr4 10679265-10679347 CLNK (3.35) 
chr4 11569917-11570006 HS3ST1 (1.63) 
chr4 11687592-11687692 HS3ST1 (1.63) 
chr4 12763419-12763510 HSP90AB2P (0) 
chr4 14809490-14809619 LOC441009 (0) 
chr4 15519425-15519538 CC2D2A (0.26) 
chr4 15521242-15521345 CC2D2A (0.26) 
chr4 16242610-16242725 FLJ39653 (0) 
chr4 16489657-16489773 LDB2 (0.05) 
chr4 17454168-17454272 QDPR (2.71) 
chr4 17480257-17480377 QDPR (2.71) 
chr4 20338836-20338939 SLIT2 (0.01) 
chr4 24102853-24102953 PPARGC1A (0.03) 
chr4 26566771-26566872 TBC1D19 (1.61) 
chr4 29173579-29173682 MIR4275 (0) 
chr4 30554013-30554130 PCDH7 (0.04) 
chr4 31217610-31217716 PCDH7 (0.04) 
chr4 34898763-34898885 ARAP2 (2.49) 
chr4 35258081-35258200 ARAP2 (2.49) 
chr4 35503512-35503630 ARAP2 (2.49) 
chr4 35596342-35596445 ARAP2 (2.49) 
chr4 38552282-38552417 FLJ13197 (0) 
chr4 38824545-38824670 TLR6 (0.33) 
chr4 40345338-40345424 RBM47 (0.04) 
chr4 40970986-40971105 APBB2 (0.16) 
chr4 41848119-41848214 TMEM33 (3.26) 
chr4 42463412-42463595 ATP8A1 (3.68) 
chr4 42465377-42465492 ATP8A1 (3.68) 
chr4 42980969-42981058 GRXCR1 (0.04) 
chr4 45735752-45735865 GABRG1 (0.17) 
chr4 47206716-47206819 GABRB1 (0.11) 
chr4 57694756-57694875 SPINK2 (0.07) 
chr4 58142274-58142397 LOC255130 (0) 
chr4 58729403-58729518 LOC255130 (0) 
chr4 59024205-59024330 LOC255130 (0) 
chr4 59812607-59812725 LOC255130 (0) 
chr4 61911259-61911375 LPHN3 (0) 
chr4 63360970-63361077 LPHN3 (0) 
chr4 63391558-63391678 LPHN3 (0) 
chr4 73079595-73079714 NPFFR2 (0) 
chr4 73780243-73780350 COX18 (2.74) 
chr4 76350013-76350114 RCHY1 (1.92) 
chr4 76456879-76456992 THAP6 (2.56) 
chr4 77446337-77446446 SHROOM3 (0.76) 
chr4 77791140-77791271 ANKRD56 (0) 
chr4 77870079-77870194 40787 (4.33) 
chr4 80050034-80050147 LOC100505875 (0) 
chr4 80655579-80655674 GDEP (0) 
chr4 84209739-84209858 COQ2 (3.06) 
chr4 86886307-86886411 ARHGAP24 (2.14) 
chr4 87261516-87261612 MAPK10 (0.69) 
chr4 88654238-88654344 IBSP (0) 
chr4 93082479-93082597 GRID2 (1.05) 
chr4 95983104-95983224 UNC5C (0.23) 
chr4 104337487-104337602 TACR3 (0.08) 
chr4 104417100-104417218 TACR3 (0.08) 
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chr4 106750617-106750737 NPNT (0.2) 
chr4 107701379-107701485 DKK2 (0.09) 
chr4 108446708-108446820 PAPSS1 (5.5) 
chr4 108693606-108693719 SGMS2 (1.3) 
chr4 109395605-109395705 LOC285456 (0) 
chr4 112378833-112378927 C4orf32 (2.2) 
chr4 112723789-112723911 C4orf32 (2.2) 
chr4 112993734-112993836 C4orf32 (2.2) 
chr4 113040984-113041083 C4orf32 (2.2) 
chr4 113203297-113203400 TIFA (5.53) 
chr4 115335689-115335793 UGT8 (0.96) 
chr4 116889234-116889339 MIR1973 (0) 
chr4 117048159-117048278 MIR1973 (0) 
chr4 118060028-118060127 TRAM1L1 (0) 
chr4 118400844-118400943 TRAM1L1 (0) 
chr4 119495435-119495544 CEP170P1 (1.74) 
chr4 120221587-120221715 USP53 (3.29) 
chr4 120584052-120584148 PDE5A (5.11) 
chr4 121756727-121756840 PRDM5 (0.08) 
chr4 123001164-123001267 KIAA1109 (3.1) 
chr4 123440504-123440632 IL2 (0) 
chr4 125297655-125297775 ANKRD50 (1.9) 
chr4 132879653-132879768 PCDH10 (0.62) 
chr4 132978324-132978474 PCDH10 (0.62) 
chr4 133184042-133184154 PCDH10 (0.62) 
chr4 134283851-134283957 PCDH10 (0.62) 
chr4 135286868-135286978 PABPC4L (0) 
chr4 138978550-138978669 LOC641364 (0) 
chr4 141227266-141227384 SCOC (4.17) 
chr4 141901827-141901923 TBC1D9 (0.02) 
chr4 142579326-142579432 IL15 (1.65) 
chr4 142807079-142807169 INPP4B (1.8) 
chr4 146543400-146543501 C4orf51 (0) 
chr4 149511611-149511729 NR3C2 (0.64) 
chr4 149680951-149681051 NR3C2 (0.64) 
chr4 153067696-153067818 FBXW7 (4.72) 
chr4 154815726-154815821 SFRP2 (0) 
chr4 155657177-155657292 LRAT (0.01) 
chr4 156572039-156572150 GUCY1A3 (0.14) 
chr4 156672824-156672939 GUCY1B3 (0.05) 
chr4 159126872-159126969 TMEM144 (0) 
chr4 164336760-164336880 TKTL2 (0) 
chr4 166771215-166771324 TLL1 (0.64) 
chr4 166813154-166813259 TLL1 (0.64) 
chr4 167848505-167848625 SPOCK3 (0.46) 
chr4 168580068-168580157 SPOCK3 (0.46) 
chr4 168582003-168582106 SPOCK3 (0.46) 
chr4 168971035-168971153 ANXA10 (0.03) 
chr4 169457679-169457775 PALLD (0.28) 
chr4 170719791-170719897 C4orf27 (3.92) 
chr4 178653520-178653622 LOC285501 (0) 
chr4 179212629-179212737 LOC285501 (0) 
chr4 184724163-184724266 C4orf41 (0) 
chr4 185451439-185451544 IRF2 (4.52) 
chr4 187680188-187680318 FAT1 (0.09) 
chr4 188077180-188077282 LOC339975 (0.08) 
chr4 188154413-188154533 LOC339975 (0.08) 
chr4 189441863-189441971 LOC401164 (0) 
chr4 189444112-189444226 LOC401164 (0) 
chr4 189893225-189893329 LOC401164 (0) 
chr5 1318021-1318174 CLPTM1L (6.27) 
chr5 1507741-1507856 SLC6A3 (0) 
chr5 2058889-2059010 IRX4 (0) 
chr5 2069744-2069864 IRX4 (0) 
chr5 2115723-2115842 IRX4 (0) 
chr5 2268717-2268836 IRX4 (0) 
chr5 2332283-2332394 IRX2 (0) 
chr5 4526910-4527015 LOC340094 (0) 
chr5 5006913-5007021 LOC340094 (0) 
chr5 5039972-5040073 ADAMTS16 (0.66) 
chr5 5789402-5789506 KIAA0947 (0) 
chr5 6056596-6056709 FLJ33360 (0.19) 
chr5 6082280-6082380 FLJ33360 (0.19) 
chr5 6517903-6518049 UBE2QL1 (0) 
chr5 6548437-6548534 LOC255167 (0) 
chr5 9949864-9949979 LOC285692 (0.04) 
chr5 10311295-10311410 CMBL (0.01) 
chr5 11057547-11057649 CTNND2 (0) 
chr5 12079996-12080109 CTNND2 (0) 
chr5 13596636-13596734 DNAH5 (0.28) 
chr5 14202806-14202920 TRIO (5.41) 
chr5 15639558-15639657 FBXL7 (0) 
chr5 16197516-16197619 40603 (0) 
chr5 17259222-17259328 LOC285696 (0.27) 
chr5 17860476-17860582 LOC401177 (0) 
chr5 20855999-20856116 GUSBP1 (4.38) 
chr5 20922232-20922326 GUSBP1 (4.38) 
chr5 21659369-21659487 GUSBP1 (4.38) 
chr5 22464242-22464356 CDH12 (0.16) 
chr5 22618990-22619107 CDH12 (0.16) 
chr5 22776047-22776165 CDH12 (0.16) 
chr5 22922695-22922808 CDH12 (0.16) 
chr5 25010801-25010919 LOC340107 (0.02) 
chr5 26541851-26541954 CDH9 (0.28) 
chr5 31975323-31975429 PDZD2 (0.21) 
chr5 33162264-33162391 LOC340113 (0) 
chr5 34280092-34280186 C1QTNF3-AMACR 
(0.08) 
chr5 34349766-34349883 C1QTNF3-AMACR 
(0.08) 
chr5 35331315-35331471 PRLR (0) 
chr5 35560184-35560287 SPEF2 (0.06) 
chr5 35729928-35730047 SPEF2 (0.06) 
chr5 36277942-36278061 RANBP3L (0.48) 
chr5 37869232-37869337 GDNF (0) 
chr5 38415878-38415978 EGFLAM (0) 
chr5 38851984-38852103 RICTOR (3.6) 
chr5 38868631-38868748 RICTOR (3.6) 
chr5 40027659-40027746 DAB2 (0.01) 
chr5 40225334-40225453 PTGER4 (6.44) 
chr5 40532028-40532144 PTGER4 (6.44) 
chr5 40561036-40561154 PTGER4 (6.44) 
chr5 41690642-41690760 OXCT1 (5.09) 
chr5 42101101-42101210 FBXO4 (3.67) 
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chr5 43069013-43069134 LOC100132356 (2.74) 
chr5 44397007-44397106 FGF10 (0) 
chr5 44852994-44853112 MRPS30 (5.1) 
chr5 49981573-49981676 PARP8 (2.38) 
chr5 50205883-50205985 PARP8 (2.38) 
chr5 51202156-51202274 ISL1 (0.22) 
chr5 53651045-53651148 ARL15 (1.59) 
chr5 53686589-53686765 HSPB3 (0) 
chr5 57808750-57808869 GAPT (0) 
chr5 66245259-66245364 MAST4 (0.17) 
chr5 66786403-66786520 CD180 (0.01) 
chr5 66930448-66930551 CD180 (0.01) 
chr5 67794767-67794870 PIK3R1 (4.36) 
chr5 68604295-68604413 CDK7 (5.05) 
chr5 73129539-73129658 RGNEF (0) 
chr5 75833894-75834012 IQGAP2 (0.25) 
chr5 78160095-78160194 ARSB (2.69) 
chr5 79114571-79114753 CMYA5 (0.16) 
chr5 80924003-80924103 SSBP2 (3.18) 
chr5 82113761-82113876 MIR3977 (0) 
chr5 82307545-82307634 TMEM167A (4.35) 
chr5 89187883-89188002 MIR3660 (0) 
chr5 90581012-90581109 ARRDC3 (3.35) 
chr5 91206688-91206797 LOC100129716 (0) 
chr5 95382469-95382582 MIR583 (0) 
chr5 99434278-99434381 LOC100133050 (0.22) 
chr5 99708327-99708443 LOC100133050 (0.22) 
chr5 100208313-100208432 ST8SIA4 (4.66) 
chr5 100217513-100217625 ST8SIA4 (4.66) 
chr5 107090431-107090533 EFNA5 (0.21) 
chr5 111555013-111555116 EPB41L4A (1.07) 
chr5 115411010-115411162 COMMD10 (4.57) 
chr5 115664219-115664325 COMMD10 (4.57) 
chr5 120183520-120183648 PRR16 (2.65) 
chr5 120288457-120288574 PRR16 (2.65) 
chr5 120500416-120500582 PRR16 (2.65) 
chr5 121689337-121689454 SNCAIP (0.05) 
chr5 123491350-123491459 ZNF608 (0.14) 
chr5 123748532-123748651 ZNF608 (0.14) 
chr5 127541728-127541850 SLC12A2 (4.02) 
chr5 129630700-129630797 CHSY3 (0) 
chr5 130802299-130802412 RAPGEF6 (4.19) 
chr5 134860307-134860403 NEUROG1 (0) 
chr5 137381825-137381927 FAM13B (4.01) 
chr5 142589738-142589865 ARHGAP26 (1.74) 
chr5 142970524-142970655 NR3C1 (4.93) 
chr5 144779312-144779427 PRELID2 (0.01) 
chr5 144790723-144790809 PRELID2 (0.01) 
chr5 145170670-145170772 GRXCR2 (0) 
chr5 146717834-146717940 DPYSL3 (0.08) 
chr5 147076722-147076842 JAKMIP2 (1.99) 
chr5 147218677-147218767 SPINK1 (0) 
chr5 148778488-148778594 MIR143HG (0) 
chr5 149472097-149472212 PDGFRB (0.1) 
chr5 149776186-149776341 CD74 (9.61) 
chr5 151338401-151338520 GLRA1 (0.11) 
chr5 151482691-151482806 GLRA1 (0.11) 
chr5 151695971-151696065 NMUR2 (0) 
chr5 152317687-152317782 NMUR2 (0) 
chr5 155332779-155332879 SGCD (0) 
chr5 156816194-156816292 CYFIP2 (4.78) 
chr5 156825163-156825281 CYFIP2 (4.78) 
chr5 159863822-159863914 PTTG1 (6.89) 
chr5 159929912-159930029 MIR146A (0) 
chr5 166959420-166959523 WWC1 (0.99) 
chr5 167396327-167396442 WWC1 (0.99) 
chr5 173014101-173014188 LOC285593 (0.45) 
chr5 174452918-174453027 MIR4634 (0) 
chr5 174496162-174496271 MIR4634 (0) 
chr5 179216396-179216522 LTC4S (0.95) 
chr5 179264005-179264217 C5orf45 (3.55) 
chr6 3195914-3196037 TUBB2B (1.62) 
chr6 5555330-5555497 LYRM4 (3.34) 
chr6 9766834-9766947 TFAP2A (0.45) 
chr6 10281393-10281510 TFAP2A (0.45) 
chr6 10293780-10293875 TFAP2A (0.45) 
chr6 12677095-12677215 PHACTR1 (0.2) 
chr6 16990393-16990508 FLJ23152 (0) 
chr6 20184061-20184179 E2F3 (2.76) 
chr6 23961997-23962098 NRSN1 (0.36) 
chr6 25946123-25946232 SLC17A2 (0) 
chr6 27686871-27686989 LOC100507173 (0) 
chr6 27714720-27714850 LOC100131289 (0) 
chr6 30015025-30015121 ZNRD1-AS1 (1.83) 
chr6 31021195-31021317 HCG22 (0.25) 
chr6 32430708-32430827 HLA-DRA (8.69) 
chr6 32686694-32686798 HLA-DQA2 (0.21) 
chr6 33048597-33048720 HLA-DPB1 (4.54) 
chr6 37717371-37717473 MDGA1 (0.08) 
chr6 40741033-40741144 LRFN2 (0) 
chr6 50388982-50389100 TFAP2D (0) 
chr6 50774205-50774324 TFAP2B (0.01) 
chr6 52033951-52034071 IL17A (0) 
chr6 52129232-52129381 MCM3 (7.88) 
chr6 52860576-52860715 GSTA4 (1.4) 
chr6 54604856-54604960 FAM83B (0) 
chr6 55495538-55495647 HMGCLL1 (0) 
chr6 55999567-55999668 COL21A1 (0.12) 
chr6 58364721-58364829 GUSBP4 (1.96) 
chr6 71085452-71085556 FAM135A (2.17) 
chr6 71339471-71339574 SMAP1 (2.92) 
chr6 71700263-71700362 B3GAT2 (0.49) 
chr6 74677013-74677116 CD109 (1.72) 
chr6 76941246-76941350 IMPG1 (0) 
chr6 77054352-77054453 IMPG1 (0) 
chr6 77440355-77440470 IMPG1 (0) 
chr6 78271665-78271774 HTR1B (0) 
chr6 78900393-78900499 IRAK1BP1 (1.54) 
chr6 80096708-80096825 LCA5 (0.47) 
chr6 81005039-81005127 TTK (3.84) 
chr6 81662247-81662473 BCKDHB (3.21) 
chr6 82247264-82247400 FAM46A (1.54) 
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chr6 82804938-82805039 IBTK (3.07) 
chr6 83909289-83909408 RWDD2A (2.02) 
chr6 85506230-85506333 TBX18 (0) 
chr6 91195840-91195943 MAP3K7 (2.83) 
chr6 91602269-91602384 MAP3K7 (2.83) 
chr6 91964490-91964593 MIR4643 (0) 
chr6 92685430-92685545 MIR4643 (0) 
chr6 94989565-94989662 TSG1 (0) 
chr6 97203110-97203205 GPR63 (0.99) 
chr6 98376247-98376365 MIR2113 (0) 
chr6 101149221-101149330 ASCC3 (3.43) 
chr6 102996032-102996142 GRIK2 (0.19) 
chr6 107227590-107227689 LOC100422737 (0) 
chr6 107229517-107229620 LOC100422737 (0) 
chr6 109681293-109681392 CD164 (5.33) 
chr6 111382666-111382783 GSTM2P1 (0) 
chr6 111612254-111612384 REV3L (1.94) 
chr6 111932660-111932763 TRAF3IP2 (0.11) 
chr6 115034075-115034193 HS3ST5 (0.14) 
chr6 115267885-115267990 HS3ST5 (0.14) 
chr6 115409565-115409661 FRK (0.51) 
chr6 118184271-118184387 SLC35F1 (0.03) 
chr6 119419348-119419454 FAM184A (0.49) 
chr6 120326828-120326957 MAN1A1 (2.08) 
chr6 124340116-124340222 NKAIN2 (0.04) 
chr6 125806803-125806895 HDDC2 (3.53) 
chr6 127883832-127883934 C6orf58 (0.12) 
chr6 128299549-128299646 PTPRK (0.14) 
chr6 129085151-129085264 LAMA2 (0) 
chr6 131083089-131083200 LOC100507203 (0) 
chr6 131797818-131797926 ARG1 (0.18) 
chr6 132057480-132057586 ENPP3 (3.47) 
chr6 132852309-132852427 TAAR9 (0) 
chr6 134433549-134433661 HMGA1P7 (0) 
chr6 134719760-134719853 LOC154092 (0) 
chr6 135388195-135388292 HBS1L (3.23) 
chr6 135972502-135972605 LINC00271 (0) 
chr6 136048260-136048366 LINC00271 (0) 
chr6 136546670-136546788 FAM54A (0) 
chr6 137314305-137314423 IL20RA (0) 
chr6 137697522-137697629 OLIG3 (0) 
chr6 139370342-139370460 C6orf115 (0) 
chr6 140908994-140909107 MIR4465 (0) 
chr6 140916426-140916522 MIR4465 (0) 
chr6 141027317-141027415 MIR4465 (0) 
chr6 141386468-141386574 MIR4465 (0) 
chr6 141752351-141752471 NMBR (0) 
chr6 143292120-143292237 HIVEP2 (0) 
chr6 143981409-143981524 PHACTR2 (1.04) 
chr6 144702811-144702915 UTRN (1.73) 
chr6 144951533-144951638 UTRN (1.73) 
chr6 147981815-147981931 SAMD5 (0) 
chr6 148337801-148337903 SASH1 (0.02) 
chr6 149188757-149188876 UST (1.02) 
chr6 150580005-150580151 PPP1R14C (0) 
chr6 150814918-150815031 IYD (0) 
chr6 150821865-150821992 IYD (0) 
chr6 152492097-152492216 SYNE1 (0.66) 
chr6 155952338-155952462 NOX3 (0) 
chr6 158215253-158215359 SNX9 (0) 
chr6 160723841-160723946 SLC22A2 (0) 
chr6 162163307-162163426 PARK2 (0) 
chr6 164280077-164280178 QKI (1.84) 
chr6 164933423-164933539 C6orf118 (0) 
chr6 164942238-164942363 C6orf118 (0) 
chr6 166913045-166913180 RPS6KA2 (0.41) 
chr6 168193542-168193662 C6orf124 (0) 
chr6 168493645-168493763 FRMD1 (0) 
chr7 1561148-1561266 MAFK (2.99) 
chr7 3188635-3188744 CARD11 (0.03) 
chr7 3717022-3717132 SDK1 (0) 
chr7 4008538-4008640 SDK1 (0) 
chr7 4283120-4283238 SDK1 (0) 
chr7 7558770-7558866 COL28A1 (0.04) 
chr7 7865057-7865167 LOC729852 (0) 
chr7 8564376-8564477 NXPH1 (0.37) 
chr7 11606831-11606931 THSD7A (0.21) 
chr7 12082302-12082387 TMEM106B (2.54) 
chr7 12971249-12971396 ARL4A (4.2) 
chr7 16319545-16319648 LOC100506025 (0) 
chr7 20941927-20942041 RPL23P8 (0) 
chr7 25115084-25115199 CYCS (4.23) 
chr7 26540970-26541059 LOC441204 (0) 
chr7 26677956-26678064 SKAP2 (2.95) 
chr7 27401188-27401313 EVX1 (0) 
chr7 32029920-32030025 PDE1C (0.05) 
chr7 34329154-34329316 AAA1 (0) 
chr7 35341568-35341661 LOC401324 (0) 
chr7 36031055-36031182 39326 (4.38) 
chr7 36362214-36362304 KIAA0895 (1.53) 
chr7 36683419-36683528 AOAH (3.58) 
chr7 37904355-37904470 SFRP4 (0) 
chr7 38122171-38122276 STARD3NL (4.2) 
chr7 38539479-38539597 AMPH (0.36) 
chr7 42422379-42422490 GLI3 (0) 
chr7 45412793-45412908 RAMP3 (0) 
chr7 47833047-47833130 C7orf69 (0) 
chr7 48169599-48169712 UPP1 (0.25) 
chr7 50329994-50330211 IKZF1 (5.99) 
chr7 53535984-53536102 FLJ45974 (0) 
chr7 53837812-53837905 FLJ45974 (0) 
chr7 56279908-56280009 LOC389493 (0) 
chr7 63512753-63512852 ZNF727 (0.08) 
chr7 66071824-66071971 KCTD7 (2.35) 
chr7 67902596-67902704 STAG3L4 (1.74) 
chr7 68782091-68782199 AUTS2 (1.63) 
chr7 70419585-70419705 AUTS2 (1.63) 
chr7 70713085-70713190 WBSCR17 (0) 
chr7 71222111-71222217 CALN1 (0.01) 
chr7 80851353-80851454 SEMA3C (0) 
chr7 81140645-81140765 HGF (1.39) 
chr7 81229765-81229865 HGF (1.39) 
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chr7 81315457-81315601 HGF (1.39) 
chr7 81962725-81962843 CACNA2D1 (0) 
chr7 82203115-82203230 CACNA2D1 (0) 
chr7 82225263-82225426 CACNA2D1 (0) 
chr7 86883011-86883123 C7orf23 (0) 
chr7 89020756-89020868 ZNF804B (0) 
chr7 90068972-90069089 CLDN12 (0.9) 
chr7 91884312-91884425 ANKIB1 (3.63) 
chr7 92218106-92218226 CDK6 (4) 
chr7 92535484-92535618 CDK6 (4) 
chr7 92572177-92572283 CDK6 (4) 
chr7 93652097-93652223 BET1 (2.14) 
chr7 93878939-93879051 COL1A2 (0) 
chr7 96380375-96380465 SHFM1 (5.84) 
chr7 96796585-96796682 ACN9 (0) 
chr7 97088990-97089091 TAC1 (0) 
chr7 97089539-97089658 TAC1 (0) 
chr7 99006234-99006348 BUD31 (4.49) 
chr7 99229641-99229787 ZNF498 (0) 
chr7 99532774-99532891 GJC3 (0.13) 
chr7 99933463-99933584 PILRB (2.19) 
chr7 105241233-105241323 ATXN7L1 (0.09) 
chr7 105646453-105646568 CDHR3 (0) 
chr7 106145149-106145272 C7orf74 (0) 
chr7 112947879-112947998 LOC401397 (0) 
chr7 114423250-114423356 FOXP2 (1.41) 
chr7 114490185-114490314 MDFIC (2.3) 
chr7 116885885-116886002 ST7 (4.71) 
chr7 116908005-116908113 WNT2 (0) 
chr7 117636035-117636198 CTTNBP2 (0) 
chr7 118519275-118519374 ANKRD7 (0.46) 
chr7 118561350-118561466 ANKRD7 (0.46) 
chr7 121403786-121403901 PTPRZ1 (0) 
chr7 123193302-123193420 NDUFA5 (2.71) 
chr7 123972571-123972718 TMEM229A (0) 
chr7 124996219-124996327 POT1 (2.9) 
chr7 125121571-125121676 POT1 (2.9) 
chr7 125141034-125141144 POT1 (2.9) 
chr7 128761680-128761798 LOC407835 (0.23) 
chr7 130016489-130016592 CPA1 (0) 
chr7 130708012-130708131 MKLN1 (2.49) 
chr7 131007219-131007301 MKLN1 (2.49) 
chr7 131636733-131636843 PLXNA4 (0) 
chr7 133550394-133550496 EXOC4 (3.68) 
chr7 134539713-134539826 CALD1 (0.07) 
chr7 134847271-134847359 C7orf49 (3.82) 
chr7 135015914-135016024 CNOT4 (2.33) 
chr7 135843385-135843485 LUZP6 (5.11) 
chr7 139677036-139677165 TBXAS1 (1.38) 
chr7 140746063-140746183 LOC100507421 (0) 
chr7 140895579-140895699 LOC100507421 (0) 
chr7 140980256-140980375 LOC100507421 (0) 
chr7 141208400-141208523 LOC100507421 (0) 
chr7 143715952-143716055 OR6B1 (0) 
chr7 143872842-143872945 CTAGE4 (0) 
chr7 144831255-144831361 TPK1 (1.37) 
chr7 144859696-144859846 TPK1 (1.37) 
chr7 145721365-145721471 CNTNAP2 (0.09) 
chr7 145800390-145800496 CNTNAP2 (0.09) 
chr7 145916108-145916211 CNTNAP2 (0.09) 
chr7 147082066-147082169 MIR548I4 (0) 
chr7 148086457-148086543 MIR548T (0) 
chr7 148565409-148565525 EZH2 (4.04) 
chr7 151462297-151462391 PRKAG2 (0.82) 
chr7 151578411-151578535 LOC100505483 (0) 
chr7 151661584-151661691 GALNT11 (0.16) 
chr7 153193188-153193285 DPP6 (0) 
chr7 154907505-154907611 HTR5A (0) 
chr7 154998368-154998485 INSIG1 (6.38) 
chr7 155037501-155037598 INSIG1 (6.38) 
chr7 156162761-156162862 LOC285889 (0) 
chr7 156330202-156330310 LINC00244 (0) 
chr7 158172533-158172705 PTPRN2 (3.38) 
chr8 1785043-1785163 ARHGEF10 (0) 
chr8 2220367-2220470 MYOM2 (0.2) 
chr8 2573162-2573279 CSMD1 (0.01) 
chr8 3888821-3888936 CSMD1 (0.01) 
chr8 4632322-4632422 CSMD1 (0.01) 
chr8 4768519-4768613 CSMD1 (0.01) 
chr8 4774618-4774708 CSMD1 (0.01) 
chr8 9794691-9794795 MIR124-1 (0) 
chr8 11080485-11080578 XKR6 (0) 
chr8 14838052-14838152 SGCZ (0.97) 
chr8 15199105-15199214 SGCZ (0.97) 
chr8 15274685-15274796 TUSC3 (1.72) 
chr8 15364047-15364165 TUSC3 (1.72) 
chr8 16314468-16314593 MSR1 (0.33) 
chr8 16892587-16892692 EFHA2 (0) 
chr8 16999622-16999741 ZDHHC2 (3.06) 
chr8 17456355-17456462 PDGFRL (0.54) 
chr8 19075659-19075764 SH2D4A (0.61) 
chr8 19973498-19973626 SLC18A1 (0) 
chr8 21321247-21321350 GFRA2 (0) 
chr8 22826596-22826720 RHOBTB2 (1.67) 
chr8 24092605-24092723 ADAM28 (0) 
chr8 24958606-24958725 DOCK5 (0.03) 
chr8 25215721-25215819 DOCK5 (0.03) 
chr8 28314984-28315088 FBXO16 (1.04) 
chr8 28530464-28530583 EXTL3 (2.08) 
chr8 29874155-29874274 MIR548O2 (0) 
chr8 30076043-30076149 DCTN6 (3.64) 
chr8 30742891-30742990 TEX15 (0.01) 
chr8 31408816-31408924 NRG1 (0) 
chr8 31683926-31684044 NRG1 (0) 
chr8 33524627-33524733 DUSP26 (0) 
chr8 34662893-34663008 UNC5D (0) 
chr8 34730865-34730969 UNC5D (0) 
chr8 37340625-37340719 ZNF703 (0.12) 
chr8 40153209-40153328 C8orf4 (0) 
chr8 49430553-49430672 EFCAB1 (0) 
chr8 52532155-52532273 PXDNL (0.13) 
chr8 58890930-58891049 FAM110B (0) 
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chr8 63655416-63655515 NKAIN3 (0) 
chr8 63686241-63686347 NKAIN3 (0) 
chr8 64079032-64079150 YTHDF3 (3.17) 
chr8 69961266-69961367 LOC100505718 (0) 
chr8 74288476-74288582 LOC100128126 (0) 
chr8 75482540-75482658 FLJ39080 (0) 
chr8 76774200-76774318 HNF4G (0.96) 
chr8 80062451-80062554 IL7 (0.91) 
chr8 88823894-88824013 DCAF4L2 (0) 
chr8 90757036-90757131 RIPK2 (3.72) 
chr8 94079268-94079369 LOC389676 (0) 
chr8 94351961-94352087 LOC642924 (0) 
chr8 95103850-95103955 CDH17 (0) 
chr8 95481559-95481666 KIAA1429 (3.44) 
chr8 97439495-97439601 SDC2 (0.04) 
chr8 99362835-99362954 NIPAL2 (2.69) 
chr8 99417953-99418054 KCNS2 (0.08) 
chr8 103211647-103211753 RRM2B (2.32) 
chr8 104576013-104576116 RIMS2 (1.1) 
chr8 112386814-112386931 CSMD3 (0.11) 
chr8 114261342-114261443 CSMD3 (0.11) 
chr8 114589565-114589668 CSMD3 (0.11) 
chr8 116294158-116294246 TRPS1 (0.18) 
chr8 117688599-117688698 EIF3H (6.32) 
chr8 117864193-117864298 RAD21-AS1 (0.13) 
chr8 117910451-117910570 RAD21-AS1 (0.13) 
chr8 118275729-118275832 SLC30A8 (0) 
chr8 118532938-118533058 EXT1 (2.52) 
chr8 118776761-118776879 EXT1 (2.52) 
chr8 119919135-119919241 TNFRSF11B (0) 
chr8 119997049-119997166 TNFRSF11B (0) 
chr8 120835700-120835806 DSCC1 (2.24) 
chr8 123277325-123277443 ZHX2 (2.83) 
chr8 123579819-123579933 ZHX2 (2.83) 
chr8 123583738-123583830 ZHX2 (2.83) 
chr8 123973802-123973902 ZHX2 (2.83) 
chr8 124685073-124685199 ANXA13 (0) 
chr8 124724440-124724538 FAM91A1 (3.35) 
chr8 124840804-124840911 FAM91A1 (3.35) 
chr8 126362804-126362907 NSMCE2 (3.78) 
chr8 126545238-126545338 TRIB1 (0.97) 
chr8 127019462-127019582 LOC100130231 (0) 
chr8 131482412-131482508 ASAP1 (1.61) 
chr8 131892277-131892379 ASAP1 (1.61) 
chr8 132168967-132169069 ADCY8 (0) 
chr8 134392077-134392167 ST3GAL1 (2.76) 
chr8 135341048-135341157 ZFAT (1.96) 
chr8 135345747-135345865 ZFAT (1.96) 
chr8 135784077-135784192 MIR30B (0) 
chr8 136324165-136324269 LOC286094 (0) 
chr8 136706843-136706951 KHDRBS3 (0.62) 
chr8 137459499-137459602 KHDRBS3 (0.62) 
chr8 138316697-138316803 FAM135B (0.18) 
chr8 138523188-138523294 FAM135B (0.18) 
chr8 140471359-140471465 KCNK9 (0.15) 
chr8 143218658-143218767 MIR4472-1 (0) 
chr8 144274105-144274218 GPIHBP1 (0) 
chr9 1930288-1930406 SMARCA2 (6.3) 
chr9 2388636-2388738 FLJ35024 (0) 
chr9 2676163-2676280 VLDLR (0.04) 
chr9 3742812-3742930 GLIS3 (0.04) 
chr9 5580630-5580726 PDCD1LG2 (4.25) 
chr9 9442123-9442283 PTPRD (0.53) 
chr9 11393649-11393751 PTPRD (0.53) 
chr9 16917482-16917596 BNC2 (0.01) 
chr9 16983807-16983927 BNC2 (0.01) 
chr9 17192909-17193029 BNC2 (0.01) 
chr9 17889077-17889181 SH3GL2 (0.57) 
chr9 18333349-18333453 ADAMTSL1 (0.05) 
chr9 18340710-18340827 ADAMTSL1 (0.05) 
chr9 18693980-18694080 ADAMTSL1 (0.05) 
chr9 18701978-18702090 ADAMTSL1 (0.05) 
chr9 18838071-18838191 ADAMTSL1 (0.05) 
chr9 19037526-19037632 FAM154A (0) 
chr9 19252124-19252227 DENND4C (3.79) 
chr9 19956526-19956639 SLC24A2 (0.11) 
chr9 20584524-20584695 KIAA1797 (0) 
chr9 22058806-22058926 CDKN2B-AS (0) 
chr9 22197149-22197265 CDKN2B-AS (0) 
chr9 25462604-25462709 TUSC1 (0.05) 
chr9 26157484-26157604 LOC100506422 (0) 
chr9 26634190-26634293 C9orf82 (0) 
chr9 26748188-26748313 C9orf82 (0) 
chr9 26752854-26752977 C9orf82 (0) 
chr9 29724570-29724688 MIR873 (0) 
chr9 30139770-30139887 MIR873 (0) 
chr9 31578570-31578695 ACO1 (3.85) 
chr9 32075067-32075170 ACO1 (3.85) 
chr9 32316509-32316640 ACO1 (3.85) 
chr9 32455358-32455440 DDX58 (2.69) 
chr9 34367028-34367140 KIAA1161 (0.24) 
chr9 39630751-39630859 LOC653501 (0) 
chr9 41775780-41775890 LOC653501 (0) 
chr9 41902199-41902311 MGC21881 (0) 
chr9 44454571-44454674 CNTNAP3B (0) 
chr9 46896420-46896532 KGFLP1 (0.7) 
chr9 47022868-47022978 KGFLP1 (0.7) 
chr9 66533933-66534045 LOC442421 (0) 
chr9 74272377-74272483 TMEM2 (1.49) 
chr9 80759387-80759489 CEP78 (3.96) 
chr9 80847504-80847623 CEP78 (3.96) 
chr9 81318037-81318156 PSAT1 (5.1) 
chr9 81341587-81341703 PSAT1 (5.1) 
chr9 81704897-81705016 TLE4 (1.42) 
chr9 83259872-83259976 TLE4 (1.42) 
chr9 83714057-83714178 TLE1 (0.55) 
chr9 84176118-84176221 TLE1 (0.55) 
chr9 88530868-88530985 NAA35 (3.4) 
chr9 89152579-89152667 ZCCHC6 (2.76) 
chr9 90562273-90562360 CDK20 (0) 
chr9 92470358-92470513 UNQ6494 (0.06) 
chr9 93759289-93759405 LOC100129316 (0.02) 
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chr9 94504359-94504478 ROR2 (0) 
chr9 95909126-95909232 NINJ1 (2.7) 
chr9 96160505-96160622 FAM120AOS (1.83) 
chr9 96893001-96893095 PTPDC1 (2.79) 
chr9 97479997-97480111 C9orf3 (2.21) 
chr9 99317543-99317633 HABP4 (2.21) 
chr9 100153153-100153273 BDAG1 (0) 
chr9 101928111-101928233 TGFBR1 (1.38) 
chr9 101998622-101998809 SEC61B (6.24) 
chr9 102000216-102000395 SEC61B (6.24) 
chr9 103308522-103308625 C9orf30-TMEFF1 (0) 
chr9 103801909-103802086 LPPR1 (0) 
chr9 106120936-106121044 CYLC2 (0.06) 
chr9 106503308-106503412 SMC2 (3.69) 
chr9 107040222-107040324 SMC2 (3.69) 
chr9 107092615-107092732 OR13F1 (0) 
chr9 110420565-110420676 KLF4 (0) 
chr9 110559690-110559776 KLF4 (0) 
chr9 112989705-112989808 TXN (6.74) 
chr9 113082632-113082750 SVEP1 (0) 
chr9 113251644-113251750 SVEP1 (0) 
chr9 113854456-113854574 LPAR1 (0) 
chr9 115127701-115127804 HSDL2 (3.21) 
chr9 116586999-116587105 ZNF618 (0.19) 
chr9 117446574-117446697 LOC100505478 (0.21) 
chr9 118380982-118381099 37226 (0) 
chr9 118595096-118595193 LINC00474 (0) 
chr9 119680313-119680420 ASTN2 (0.4) 
chr9 119787209-119787327 ASTN2 (0.4) 
chr9 124879593-124879705 MIR4478 (0) 
chr9 126698983-126699083 DENND1A (1.88) 
chr9 133272524-133272637 ASS1 (0.08) 
chr9 137337042-137337138 RXRA (0.14) 
chr9 137764389-137764507 FCN2 (0) 
chr9 138273293-138273411 LOC100506599 (0) 
chr9 138324366-138324480 LOC100506599 (0) 
chr9_gl000200_random 2743-2844 -1 (0) 
chrM 2824-3146 -1 (0) 
chrUn_gl000220 114686-114809 RN5-8S1 (0) 
chrUn_gl000220 117521-118081 RN5-8S1 (0) 
chrUn_gl000220 158692-158846 RN5-8S1 (0) 
chrUn_gl000220 159709-159964 RN5-8S1 (0) 
chrX 1798394-1798495 ASMT (0) 
chrX 3347882-3347996 MXRA5 (0) 
chrX 5613358-5613477 NLGN4X (0) 
chrX 6140883-6141002 NLGN4X (0) 
chrX 6547031-6547137 VCX3A (0) 
chrX 7285592-7285707 STS (0.54) 
chrX 8340180-8340275 VCX3B (0) 
chrX 12102382-12102502 FRMPD4 (0) 
chrX 13079454-13079557 FAM9C (0) 
chrX 13321433-13321551 ATXN3L (0) 
chrX 13469091-13469201 EGFL6 (0) 
chrX 15216905-15216999 ASB9 (1.35) 
chrX 15498274-15498385 PIR-FIGF (0) 
chrX 15920118-15920219 AP1S2 (1.92) 
chrX 18889481-18889600 LOC100132163 (0) 
chrX 24315443-24315561 FAM48B2 (0) 
chrX 24526240-24526344 PCYT1B (0.05) 
chrX 24701328-24701434 PCYT1B (0.05) 
chrX 26928813-26928984 VENTXP1 (0) 
chrX 27257510-27257610 SMEK3P (0) 
chrX 29789964-29790071 IL1RAPL1 (0) 
chrX 30291458-30291576 MAGEB1 (0.98) 
chrX 34421974-34422092 TMEM47 (0) 
chrX 34587124-34587227 TMEM47 (0) 
chrX 34760321-34760434 TMEM47 (0) 
chrX 35687970-35688090 MAGEB16 (0) 
chrX 36466302-36466419 CXorf30 (0) 
chrX 39293036-39293152 LOC286442 (0) 
chrX 39294007-39294115 LOC286442 (0) 
chrX 40291668-40291786 ATP6AP2 (4.06) 
chrX 42294702-42294811 PPP1R2P9 (0) 
chrX 44523851-44523957 FUNDC1 (2.53) 
chrX 45149486-45149596 CXorf36 (0) 
chrX 46182425-46182528 ZNF673 (0) 
chrX 47004001-47004120 RBM10 (4.28) 
chrX 47685031-47685133 ZNF81 (2.24) 
chrX 50948842-50948960 NUDT10 (0) 
chrX 52726199-52726486 SSX2 (0) 
chrX 52790072-52790233 SPANXN5 (0) 
chrX 55885949-55886070 RRAGB (2.18) 
chrX 63613921-63614024 MTMR8 (0.58) 
chrX 64738215-64738315 LAS1L (4) 
chrX 68884205-68884289 EDA (0.07) 
chrX 69000552-69000659 EDA (0.07) 
chrX 69429630-69429733 DGAT2L6 (0.08) 
chrX 77795559-77795674 ZCCHC5 (0.05) 
chrX 77922158-77922265 ZCCHC5 (0.05) 
chrX 78885080-78885183 ITM2A (0) 
chrX 78887054-78887223 ITM2A (0) 
chrX 78899251-78899363 ITM2A (0) 
chrX 80772009-80772122 SH3BGRL (5.02) 
chrX 84594122-84594235 POF1B (2.4) 
chrX 86301704-86301811 DACH2 (0.08) 
chrX 86638149-86638252 KLHL4 (2.81) 
chrX 88861727-88861833 TGIF2LX (0) 
chrX 90388782-90388897 PABPC5 (0) 
chrX 93500193-93500292 FAM133A (0) 
chrX 93633542-93633659 FAM133A (0) 
chrX 93990323-93990438 FAM133A (0) 
chrX 94748385-94748491 LOC643486 (0) 
chrX 95720766-95720878 LOC643486 (0) 
chrX 97927003-97927109 LOC442459 (0) 
chrX 99121883-99121973 PCDH19 (0.04) 
chrX 102074127-102074247 LOC100287765 (0) 
chrX 103472562-103472665 ESX1 (0) 
chrX 105349145-105349246 MUM1L1 (0) 
chrX 106449536-106449663 NUP62CL (1.54) 
chrX 111587637-111587743 TRPC5 (0.13) 
chrX 111782280-111782399 ZCCHC16 (0) 
chrX 113028122-113028240 HTR2C (0) 
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chrX 114435601-114435704 RBMXL3 (0) 
chrX 114594404-114594511 LUZP4 (0) 
chrX 115822027-115822134 CXorf61 (0) 
chrX 116331751-116331869 KLHL13 (0.08) 
chrX 116735089-116735198 KLHL13 (0.08) 
chrX 117030757-117030863 KLHL13 (0.08) 
chrX 118425454-118425567 PGRMC1 (4.53) 
chrX 122893877-122893974 THOC2 (4.28) 
chrX 124346974-124347092 LOC100129520 (0) 
chrX 131296408-131296521 FRMD7 (0.04) 
chrX 133733450-133733532 LOC100506757 (0) 
chrX 135056062-135056165 SLC9A6 (2.83) 
chrX 135287948-135288041 MAP7D3 (3.16) 
chrX 137256678-137256784 LOC158696 (0) 
chrX 138072656-138072802 FGF13 (2.78) 
chrX 140455357-140455472 SPANXC (0) 
chrX 141161889-141162006 MAGEC2 (0) 
chrX 141168311-141168430 MAGEC2 (0) 
chrX 141831144-141831247 SPANXN4 (0) 
chrX 142132418-142132524 SPANXN4 (0) 
chrX 142216047-142216164 SPANXN4 (0) 
chrX 144262021-144262118 SPANXN1 (0.26) 
chrX 145724218-145724334 CXorf51A (0) 
chrX 146956819-146956925 FMR1-AS1 (0.11) 
chrX 148774536-148774638 MAGEA11 (0) 
chrX 151047187-151047309 MAGEA4 (0) 
chrX 151057503-151057591 MAGEA4 (0) 
chrX 151963457-151963569 MAGEA3 (0) 
chrX 152370324-152370427 MAGEA1 (0) 
chrX 153060084-153060217 SSR4 (7.14) 





Supplementary Data Table 6. Closest genes to active LTRs detected by RACE-Seq in 
Reh cells treated with PMA. Gene expression values (FPKM) from RNA-Seq are also 
shown for each gene. 
 
RACE Peak Gene (FPKM) 
chr1 565650-565804 OR4F16 (0) 
chr1 2123363-2123568 PRKCZ (1.89) 
chr1 2208881-2209013 SKI (2.43) 
chr1 11467932-11468049 PTCHD2 (1.71) 
chr1 14803711-14803826 KAZN (3.45) 
chr1 16998071-16998192 MIR3675 (0) 
chr1 18215517-18215648 ACTL8 (0.22) 
chr1 18905848-18905957 PAX7 (0) 
chr1 19236099-19236221 IFFO2 (3.77) 
chr1 31945312-31945443 LOC149086 (0) 
chr1 36164901-36164997 C1orf216 (2.39) 
chr1 38959158-38959277 LOC339442 (0) 
chr1 41601131-41601246 SCMH1 (4.37) 
chr1 42166571-42166684 HIVEP3 (2.38) 
chr1 42187896-42188000 HIVEP3 (2.38) 
chr1 42233846-42234018 HIVEP3 (2.38) 
chr1 43094319-43094441 PPIH (6.97) 
chr1 43952641-43952759 SZT2 (2.51) 
chr1 51397087-51397215 FAF1 (5.7) 
chr1 54632345-54632474 CYB5RL (1.86) 
chr1 55203462-55203586 PARS2 (2.42) 
chr1 57080282-57080409 PRKAA2 (0) 
chr1 58185280-58185394 DAB1 (0) 
chr1 58368622-58368738 DAB1 (0) 
chr1 60201756-60201876 FGGY (4.46) 
chr1 60898919-60899019 C1orf87 (0) 
chr1 68020006-68020135 SERBP1 (6.32) 
chr1 68791579-68791709 WLS (3.67) 
chr1 72181725-72181847 NEGR1 (0.23) 
chr1 75349869-75349985 TYW3 (4.4) 
chr1 76917907-76918022 ST6GALNAC3 (0) 
chr1 79007296-79007421 PTGFR (0) 
chr1 79645553-79645647 ELTD1 (0) 
chr1 79862755-79862866 ELTD1 (0) 
chr1 83498797-83498909 TTLL7 (3.08) 
chr1 88166158-88166276 LOC100505768 (0) 
chr1 99503267-99503382 LOC100129620 (0) 
chr1 101418637-101418745 DPH5 (4.95) 
chr1 101455664-101455890 DPH5 (4.95) 
chr1 102834806-102834920 OLFM3 (0) 
chr1 105158459-105158578 LOC100129138 (0) 
chr1 107779355-107779475 NTNG1 (0) 
chr1 107781279-107781396 NTNG1 (0) 
chr1 108093073-108093214 VAV3 (0) 
chr1 108436114-108436288 VAV3 (0) 
chr1 108547892-108548000 VAV3 (0) 
chr1 112068984-112069124 ADORA3 (0.08) 
chr1 115735419-115735545 NGF (0) 
chr1 116082664-116082795 VANGL1 (0) 
chr1 117994214-117994388 MAN1A2 (3.95) 
chr1 118258812-118258927 FAM46C (1.07) 
chr1 118996484-118996599 SPAG17 (0.29) 
chr1 119198990-119199105 TBX15 (0.04) 
chr1 119906782-119906900 HAO2 (0.1) 
chr1 145277583-145277706 NBPF10 (1.59) 
chr1 148632439-148632534 PPIAL4E (0) 
chr1 148794462-148794579 PPIAL4D (0) 
chr1 153478561-153478681 S100A6 (4.13) 
chr1 153633935-153634053 ILF2 (7.77) 
chr1 157866056-157866178 CD5L (0.06) 
chr1 157867977-157868108 CD5L (0.06) 
chr1 163078387-163078558 RGS4 (0) 
chr1 163448435-163448557 NUF2 (5.69) 
chr1 163511946-163512067 NUF2 (5.69) 
chr1 163678154-163678249 NUF2 (5.69) 
chr1 164633931-164634051 PBX1 (3.59) 
chr1 166747083-166747204 POGK (5.58) 
chr1 168731051-168731169 MGC4473 (0) 
chr1 169842279-169842492 SCYL3 (3.93) 
chr1 170803682-170803797 PRRX1 (1.61) 
chr1 171409395-171409523 PRRC2C (5.65) 
chr1 174173928-174174062 RABGAP1L (5.6) 
chr1 174571371-174571502 RABGAP1L (5.6) 
chr1 177429205-177429318 FAM5B (0) 
chr1 177701423-177701596 SEC16B (0.28) 
chr1 186217855-186217970 MIR548F1 (0) 
chr1 186715852-186715969 PTGS2 (0.24) 
chr1 188005721-188005847 PLA2G4A (2.15) 
chr1 188564197-188564315 FAM5C (0) 
chr1 188701644-188701766 FAM5C (0) 
chr1 191457317-191457457 RGS18 (0.1) 
chr1 194317011-194317142 CDC73 (2.73) 
chr1 194699325-194699436 CDC73 (2.73) 
chr1 194780252-194780382 KCNT2 (0.04) 
chr1 194835292-194835387 KCNT2 (0.04) 
chr1 198999779-198999910 LOC100131234 (0) 
chr1 199647390-199647502 NR5A2 (1.22) 
chr1 200247987-200248114 C1orf98 (0) 
chr1 201798358-201798459 IPO9 (5.08) 
chr1 204011709-204011799 LINC00303 (0.66) 
chr1 204026517-204026644 SOX13 (1.6) 
chr1 204598621-204598783 LRRN2 (0.15) 
chr1 209874568-209874696 HSD11B1 (0.28) 
chr1 210730901-210731030 HHAT (3.48) 
chr1 211640091-211640221 RD3 (0.03) 
chr1 215159425-215159553 KCNK2 (0) 
chr1 216757098-216757213 ESRRG (0.1) 
chr1 222238018-222238155 DUSP10 (3.72) 
chr1 226532797-226532918 PARP1 (6.85) 
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chr1 228000689-228000801 PRSS38 (0.38) 
chr1 234312893-234313008 SLC35F3 (0) 
chr1 234347775-234347898 SLC35F3 (0) 
chr1 234831811-234831919 LOC100506810 (0) 
chr1 236326912-236327066 GPR137B (0.1) 
chr1 236558790-236558898 EDARADD (0.92) 
chr1 237144761-237144891 RYR2 (0.74) 
chr1 238221057-238221171 LOC100130331 (0) 
chr1 240800370-240800474 GREM2 (0) 
chr1 245121020-245121144 EFCAB2 (0.35) 
chr1 247361696-247361919 MIR3916 (0) 
chr10 528281-528393 DIP2C (1.54) 
chr10 1112737-1112868 WDR37 (3.04) 
chr10 1189512-1189647 WDR37 (3.04) 
chr10 1496248-1496383 ADARB2-AS1 (0) 
chr10 1801346-1801467 ADARB2 (0.78) 
chr10 2051633-2051768 ADARB2 (0.78) 
chr10 2105561-2105749 LOC282980 (0) 
chr10 2107495-2107632 LOC282980 (0) 
chr10 2213216-2213355 LOC399708 (0) 
chr10 3556036-3556158 KLF6 (2.93) 
chr10 4263550-4263669 LOC100216001 (0) 
chr10 4442466-4442584 LOC100216001 (0) 
chr10 6278979-6279097 PFKFB3 (2.36) 
chr10 7144559-7144680 SFMBT2 (1.69) 
chr10 8541543-8541638 GATA3 (2.99) 
chr10 15080567-15080682 OLAH (0.24) 
chr10 17277243-17277399 VIM (9.93) 
chr10 17568244-17568362 PTPLA (0) 
chr10 17953654-17953744 MRC1 (0) 
chr10 18200537-18200657 MRC1 (0) 
chr10 23198724-23198837 ARMC3 (0.12) 
chr10 23834963-23835091 OTUD1 (2.37) 
chr10 24139708-24139816 KIAA1217 (2.88) 
chr10 24335406-24335514 KIAA1217 (2.88) 
chr10 26015668-26015789 GPR158 (2.77) 
chr10 26041401-26041525 GPR158 (2.77) 
chr10 30536804-30536921 MTPAP (3.36) 
chr10 31991149-31991243 ARHGAP12 (2.98) 
chr10 37937174-37937303 MTRNR2L7 (0) 
chr10 43389485-43389614 BMS1 (3.79) 
chr10 49394558-49394686 FRMPD2 (0.25) 
chr10 52555752-52555883 A1CF (0) 
chr10 56965591-56965718 MTRNR2L5 (0) 
chr10 62312659-62312774 ANK3 (2.15) 
chr10 64018895-64019017 RTKN2 (0.27) 
chr10 64188129-64188320 ZNF365 (0.46) 
chr10 65005133-65005241 JMJD1C (2.75) 
chr10 65720470-65720599 REEP3 (2.47) 
chr10 67021529-67021649 ANXA2P3 (0) 
chr10 72866084-72866206 UNC5B (0.04) 
chr10 75006858-75006997 C10orf103 (0) 
chr10 76340346-76340436 KAT6B (2.39) 
chr10 78271871-78272000 KCNMA1 (4.64) 
chr10 78913897-78914004 C10orf11 (1.76) 
chr10 79664376-79664505 DLG5 (0.05) 
chr10 81075202-81075298 ZMIZ1 (0.48) 
chr10 81114905-81114999 ZCCHC24 (0.59) 
chr10 81955474-81955605 ANXA11 (4.61) 
chr10 82388100-82388224 SH2D4B (0) 
chr10 85909892-85910011 C10orf99 (0) 
chr10 88404999-88405089 OPN4 (0.06) 
chr10 91931347-91931479 LOC643529 (0) 
chr10 93095167-93095274 LOC100188947 (0) 
chr10 93656817-93656938 FGFBP3 (1.59) 
chr10 98497245-98497374 PIK3AP1 (3.83) 
chr10 98509988-98510246 PIK3AP1 (3.83) 
chr10 101709917-101710045 DNMBP (2.22) 
chr10 108053838-108053944 SORCS1 (0) 
chr10 109262915-109263030 SORCS1 (0) 
chr10 109732090-109732226 SORCS1 (0) 
chr10 110936984-110937099 XPNPEP1 (5.57) 
chr10 112302087-112302245 SMC3 (4.84) 
chr10 114166710-114166832 ACSL5 (4.1) 
chr10 115780565-115780696 ADRB1 (0) 
chr10 120248598-120248735 PRLHR (0) 
chr10 120432082-120432205 C10orf46 (0) 
chr10 121376858-121376979 TIAL1 (3.79) 
chr10 125305958-125306094 GPR26 (0) 
chr10 132469158-132469286 MIR378C (0) 
chr10 132517772-132517895 MIR378C (0) 
chr10 134947503-134947608 GPR123 (0) 
chr11 1286011-1286150 MUC5B (0) 
chr11 3206227-3206354 OSBPL5 (0) 
chr11 3402155-3402287 LOC650368 (0) 
chr11 4999292-4999410 MMP26 (0) 
chr11 6756080-6756205 GVINP1 (1.52) 
chr11 8489642-8489760 TRIM66 (2.18) 
chr11 9189857-9189970 DENND5A (5.68) 
chr11 9212018-9212137 TMEM41B (4.01) 
chr11 10830371-10830495 EIF4G2 (7.22) 
chr11 11110837-11110969 GALNTL4 (0) 
chr11 11845433-11845560 USP47 (4.16) 
chr11 13010990-13011140 RASSF10 (0) 
chr11 14541842-14541964 PSMA1 (7.42) 
chr11 23658269-23658384 LOC100500938 (0) 
chr11 26268340-26268474 ANO3 (0.38) 
chr11 27911861-27912104 KIF18A (3.71) 
chr11 34460431-34460541 CAT (5.03) 
chr11 35071553-35071684 PDHX (4.67) 
chr11 36607831-36607969 RAG2 (0.05) 
chr11 37566533-37566656 C11orf74 (4.14) 
chr11 39491597-39491731 LRRC4C (1.91) 
chr11 40352112-40352232 LRRC4C (1.91) 
chr11 42275923-42276040 LOC100507205 (0) 
chr11 46450159-46450402 AMBRA1 (3.79) 
chr11 57357416-57357524 SERPING1 (0) 
chr11 59900683-59900813 MS4A2 (0) 
chr11 63595042-63595155 MARK2 (2.69) 
chr11 64185766-64185893 RPS6KA4 (3.4) 
chr11 73685720-73685946 DNAJB13 (0) 
chr11 74168910-74169032 LIPT2 (1.26) 
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chr11 74371087-74371207 POLD3 (3.99) 
chr11 80926103-80926228 MIR4300 (0) 
chr11 84040489-84040644 DLG2 (0.53) 
chr11 84202353-84202466 DLG2 (0.53) 
chr11 88417944-88418066 GRM5 (0.07) 
chr11 88419874-88419998 GRM5 (0.07) 
chr11 94658597-94658704 CWC15 (5.3) 
chr11 96732865-96732981 JRKL (2.61) 
chr11 97252978-97253101 JRKL (2.61) 
chr11 98765707-98765828 CNTN5 (0.03) 
chr11 102217943-102218088 BIRC2 (5.06) 
chr11 102718551-102718664 MMP3 (0) 
chr11 103987555-103987685 PDGFD (1.54) 
chr11 108338014-108338165 C11orf65 (1.35) 
chr11 109031417-109031557 DDX10 (3.86) 
chr11 109479295-109479416 C11orf87 (0) 
chr11 109645774-109645891 ZC3H12C (2.51) 
chr11 109674654-109674776 ZC3H12C (2.51) 
chr11 110183030-110183143 RDX (5.77) 
chr11 110201565-110201671 RDX (5.77) 
chr11 110214738-110214857 RDX (5.77) 
chr11 112367293-112367397 C11orf34 (0) 
chr11 113749381-113749523 USP28 (3.16) 
chr11 126518001-126518109 KIRREL3 (0.35) 
chr11 127963611-127963701 ETS1 (3.3) 
chr11 128240075-128240195 ETS1 (3.3) 
chr12 1635061-1635174 LOC100292680 (0) 
chr12 6576151-6576282 VAMP1 (2.39) 
chr12 9392490-9392597 LOC100499405 (0) 
chr12 10691290-10691405 KLRAP1 (1.91) 
chr12 13420864-13420972 EMP1 (0.05) 
chr12 15916997-15917126 EPS8 (1.58) 
chr12 19737519-19737656 AEBP2 (2.68) 
chr12 21810682-21810801 LDHB (9.76) 
chr12 24875773-24875912 BCAT1 (4.95) 
chr12 24877922-24878044 BCAT1 (4.95) 
chr12 24928810-24928931 BCAT1 (4.95) 
chr12 25005009-25005135 BCAT1 (4.95) 
chr12 25108470-25108602 BCAT1 (4.95) 
chr12 31836534-31836666 AMN1 (2.5) 
chr12 38625317-38625436 ALG10B (2.82) 
chr12 39872574-39872698 KIF21A (4.31) 
chr12 41725501-41725620 PDZRN4 (0) 
chr12 43345709-43345831 PRICKLE1 (0.52) 
chr12 50505942-50506078 C12orf62 (0) 
chr12 52042299-52042428 SCN8A (2.04) 
chr12 57032941-57033055 BAZ2A (4.28) 
chr12 57081796-57081916 NACA (10.24) 
chr12 59880362-59880485 SLC16A7 (1.17) 
chr12 63821157-63821286 DPY19L2 (1.07) 
chr12 66032534-66032647 RPSAP52 (0.24) 
chr12 66316652-66316773 HMGA2 (0.72) 
chr12 66414345-66414463 HMGA2 (0.72) 
chr12 66451357-66451465 LLPH (5.17) 
chr12 68381098-68381225 IFNG (0.18) 
chr12 68837765-68837886 MDM1 (2.92) 
chr12 76056310-76056441 KRR1 (4.96) 
chr12 76220673-76220793 PHLDA1 (3.3) 
chr12 76365241-76365363 PHLDA1 (3.3) 
chr12 78714548-78714667 NAV3 (1.43) 
chr12 84255508-84255639 TMTC2 (2.18) 
chr12 85244603-85244703 SLC6A15 (0) 
chr12 86547472-86547580 MGAT4C (0) 
chr12 87108273-87108443 MGAT4C (0) 
chr12 87391528-87391643 MGAT4C (0) 
chr12 88535708-88535866 CEP290 (3.18) 
chr12 89445746-89445925 LOC728084 (0.16) 
chr12 89447703-89447829 LOC728084 (0.16) 
chr12 90631320-90631440 LOC338758 (0) 
chr12 90674641-90674766 LOC338758 (0) 
chr12 90676542-90676684 LOC338758 (0) 
chr12 91041254-91041362 C12orf37 (0) 
chr12 93335094-93335221 EEA1 (3.46) 
chr12 93551924-93552052 LOC643339 (0.28) 
chr12 93559065-93559186 LOC643339 (0.28) 
chr12 94027833-94027960 CRADD (4.66) 
chr12 98488747-98488877 MIR4303 (0) 
chr12 104864053-104864171 CHST11 (2.44) 
chr12 105927820-105927933 C12orf75 (5.49) 
chr12 111298763-111298881 MYL2 (0) 
chr12 111374368-111374487 LOC100131138 (0) 
chr12 111568929-111569050 CUX2 (0) 
chr12 111571167-111571343 CUX2 (0) 
chr12 111848596-111848767 ATXN2 (3.58) 
chr12 112847260-112847398 PTPN11 (5.76) 
chr12 113470990-113471113 OAS2 (3.33) 
chr12 113784690-113784808 PLBD2 (2.34) 
chr12 113975423-113975541 LHX5 (0) 
chr12 115803793-115803936 MED13L (6.03) 
chr12 118792519-118792643 TAOK3 (4.39) 
chr12 121629159-121629275 P2RX7 (1.73) 
chr12 124961824-124961950 ZNF664-FAM101A 
(0.28) 
chr12 126796474-126796595 LOC100128554 (0) 
chr12 126815001-126815110 LOC100128554 (0) 
chr12 126872770-126872888 LOC100128554 (0) 
chr12 128045126-128045264 FLJ37505 (0.11) 
chr12 128203053-128203161 FLJ37505 (0.11) 
chr12 129594182-129594314 TMEM132D (0) 
chr12 131697998-131698106 LOC116437 (0) 
chr12 132102692-132102790 SFSWAP (4.69) 
chr13 19128858-19129000 ANKRD20A9P (1.85) 
chr13 19156190-19156371 ANKRD20A9P (1.85) 
chr13 21776041-21776149 MRP63 (0) 
chr13 28841735-28841866 FLT1 (0.64) 
chr13 30861501-30861623 LINC00426 (0) 
chr13 31037352-31037447 LINC00426 (0) 
chr13 31501568-31501689 LOC100507064 (0) 
chr13 32559756-32559877 EEF1DP3 (0.28) 
chr13 35302383-35302496 NBEA (1.18) 
chr13 36946955-36947074 SPG20 (3.01) 
chr13 38410190-38410329 TRPC4 (0.12) 
chr13 38558533-38558664 TRPC4 (0.12) 
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chr13 38624893-38624987 TRPC4 (0.12) 
chr13 38704304-38704421 UFM1 (5.98) 
chr13 39160372-39160494 FREM2 (1.21) 
chr13 43331542-43331648 C13orf30 (0) 
chr13 43393870-43393993 C13orf30 (0) 
chr13 47497650-47497806 HTR2A (0) 
chr13 47553270-47553378 HTR2A (0) 
chr13 48620633-48620774 MED4 (3.59) 
chr13 49458136-49458266 FNDC3A (2.04) 
chr13 56357026-56357153 PRR20C (0) 
chr13 56917306-56917425 PRR20C (0) 
chr13 58720242-58720373 PCDH17 (0) 
chr13 59883235-59883346 DIAPH3 (3.53) 
chr13 60525397-60525519 TDRD3 (3) 
chr13 60529470-60529595 TDRD3 (3) 
chr13 60603708-60603823 DIAPH3 (3.53) 
chr13 60982109-60982346 TDRD3 (3) 
chr13 63306782-63306948 OR7E156P (0) 
chr13 63450393-63450514 OR7E156P (0) 
chr13 63452319-63452450 OR7E156P (0) 
chr13 63457663-63457769 OR7E156P (0) 
chr13 63631308-63631430 OR7E156P (0) 
chr13 64636567-64636758 OR7E156P (0) 
chr13 64665486-64665626 OR7E156P (0) 
chr13 68917841-68917966 LOC338862 (0) 
chr13 69251469-69251578 LOC338862 (0) 
chr13 71293196-71293334 ATXN8OS (0) 
chr13 72664296-72664417 DACH1 (0.04) 
chr13 73801912-73802036 KLF5 (2.1) 
chr13 74103606-74103721 KLF12 (2.33) 
chr13 77845769-77845894 FBXL3 (3.47) 
chr13 80607661-80607791 SPRY2 (0.36) 
chr13 80618388-80618496 SPRY2 (0.36) 
chr13 80721414-80721513 SPRY2 (0.36) 
chr13 83966970-83967093 SLITRK1 (0.99) 
chr13 84202953-84203101 SLITRK1 (0.99) 
chr13 85625707-85625827 SLITRK6 (0) 
chr13 86270246-86270362 SLITRK6 (0) 
chr13 87087729-87087845 SLITRK6 (0) 
chr13 87127778-87127905 SLITRK6 (0) 
chr13 87778354-87778556 MIR4500HG (0.25) 
chr13 89571479-89571603 SLITRK5 (0) 
chr13 89681323-89681465 MIR622 (0) 
chr13 89964556-89964696 MIR622 (0) 
chr13 91013207-91013319 MIR622 (0) 
chr13 91297129-91297257 LINC00410 (0) 
chr13 91782665-91782796 LINC00410 (0) 
chr13 92528240-92528421 GPC5 (1.71) 
chr13 92530202-92530334 GPC5 (1.71) 
chr13 92570314-92570441 GPC5 (1.71) 
chr13 93498337-93498525 GPC5 (1.71) 
chr13 95054946-95055050 GPC6 (0.42) 
chr13 95073232-95073374 GPC6 (0.42) 
chr13 100104202-100104322 MIR548AN (0) 
chr13 100113264-100113372 TM9SF2 (5.09) 
chr13 101031876-101031984 PCCA (2.41) 
chr13 101444308-101444430 TMTC4 (2.39) 
chr13 102161454-102161577 NALCN (0) 
chr13 103985021-103985152 SLC10A2 (0.04) 
chr13 109109861-109109977 MYO16 (1.19) 
chr13 109306697-109306826 MYO16 (1.19) 
chr13 110354375-110354516 IRS2 (0) 
chr13 110617240-110617358 IRS2 (0) 
chr13 111594768-111594899 ANKRD10 (4.8) 
chr13 111602188-111602328 ANKRD10 (4.8) 
chr13 111627519-111627644 ANKRD10 (4.8) 
chr13 114518544-114518676 FAM70B (0) 
chr13 114571050-114571161 LOC100506394 (0) 
chr14 19680940-19681054 POTEG (1.96) 
chr14 19894330-19894449 POTEM (3.72) 
chr14 20925343-20925447 TMEM55B (3.72) 
chr14 21134861-21134982 ANG (2.1) 
chr14 21458360-21458479 SLC39A2 (0) 
chr14 23019278-23019403 DAD1 (7.3) 
chr14 24037056-24037186 JPH4 (3.05) 
chr14 25018572-25018687 CTSG (0) 
chr14 26714702-26714820 NOVA1 (0) 
chr14 32523895-32524012 C14orf128 (0) 
chr14 35343884-35344005 BAZ1A (4.35) 
chr14 35409138-35409359 SRP54 (6.09) 
chr14 37158307-37158419 SLC25A21 (0.49) 
chr14 37469988-37470107 SLC25A21 (0.49) 
chr14 38800238-38800358 CLEC14A (0) 
chr14 38973140-38973269 LOC283547 (0) 
chr14 39011198-39011311 LOC283547 (0) 
chr14 39967036-39967159 FBXO33 (2.52) 
chr14 42457948-42458078 LRFN5 (0) 
chr14 46341498-46341618 MIS18BP1 (4.33) 
chr14 47426112-47426213 MDGA2 (0) 
chr14 50053365-50053593 RPS29 (11.35) 
chr14 50403195-50403316 ARF6 (4.87) 
chr14 50872979-50873207 CDKL1 (3.15) 
chr14 51960187-51960303 FRMD6 (2.44) 
chr14 52372551-52372659 GNG2 (5.09) 
chr14 52646918-52647043 PTGDR (0) 
chr14 54382593-54382706 BMP4 (0) 
chr14 54453584-54453699 BMP4 (0) 
chr14 54613693-54613854 BMP4 (0) 
chr14 54779660-54779768 CDKN3 (6.04) 
chr14 58274585-58274700 C14orf37 (0.5) 
chr14 61566646-61566762 SLC38A6 (2.57) 
chr14 62697537-62697651 FLJ43390 (0) 
chr14 64713074-64713164 ESR2 (0.69) 
chr14 65846854-65846974 FUT8 (4.17) 
chr14 66117119-66117288 FUT8 (4.17) 
chr14 66521578-66521693 FUT8 (4.17) 
chr14 66969784-66969899 GPHN (0.13) 
chr14 69192829-69192949 ZFP36L1 (5.15) 
chr14 70753651-70753772 SYNJ2BP-COX16 (0) 
chr14 71825449-71825574 SNORD56B (0) 
chr14 81413278-81413419 CEP128 (2.6) 
chr14 81675598-81675738 GTF2A1 (3.23) 
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chr14 81723121-81723230 STON2 (0.29) 
chr14 82495018-82495287 SEL1L (5.13) 
chr14 82661029-82661151 SEL1L (5.13) 
chr14 82889326-82889448 SEL1L (5.13) 
chr14 83317248-83317369 SEL1L (5.13) 
chr14 83764442-83764570 SEL1L (5.13) 
chr14 84620635-84620767 FLRT2 (0) 
chr14 85271396-85271512 FLRT2 (0) 
chr14 85654494-85654612 FLRT2 (0) 
chr14 86029811-86029914 LOC283585 (0) 
chr14 86633038-86633158 FLRT2 (0) 
chr14 87430415-87430542 LOC283585 (0) 
chr14 87700394-87700516 LOC283585 (0) 
chr14 87766493-87766614 LOC283585 (0) 
chr14 88338606-88338741 GALC (2.52) 
chr14 88351594-88351704 GALC (2.52) 
chr14 88746240-88746372 KCNK10 (0.2) 
chr14 90186522-90186644 EFCAB11 (2.99) 
chr14 90480179-90480287 KCNK13 (0.58) 
chr14 92630281-92630508 CPSF2 (5.59) 
chr14 93328732-93328847 GOLGA5 (4.56) 
chr14 93338644-93338774 GOLGA5 (4.56) 
chr14 93339794-93339923 GOLGA5 (4.56) 
chr14 93366486-93366597 CHGA (0.1) 
chr14 95920000-95920122 C14orf49 (0) 
chr14 96245203-96245318 TCL1A (3.14) 
chr14 97375242-97375368 VRK1 (6.4) 
chr14 97644017-97644114 VRK1 (6.4) 
chr14 97646057-97646218 VRK1 (6.4) 
chr14 97903764-97903886 LOC100129345 (0) 
chr14 99005428-99005561 C14orf177 (0) 
chr14 99523030-99523159 BCL11B (0.44) 
chr14 100545306-100545430 EVL (1.16) 
chr14 100800131-100800272 SLC25A47 (0) 
chr14 105140391-105140504 MIR4710 (0) 
chr15 23188131-23188263 WHAMMP3 (1.88) 
chr15 27622604-27622726 OCA2 (0) 
chr15 33502044-33502168 RYR3 (0.06) 
chr15 34880553-34880662 GOLGA8B (2.9) 
chr15 38318066-38318210 TMCO5A (0) 
chr15 38332250-38332531 TMCO5A (0) 
chr15 38339666-38339819 TMCO5A (0) 
chr15 38428136-38428285 SPRED1 (2.25) 
chr15 38531423-38531538 SPRED1 (2.25) 
chr15 38562723-38562830 FAM98B (1.87) 
chr15 38974430-38974554 C15orf53 (0.63) 
chr15 43054197-43054317 TTBK2 (3.16) 
chr15 43490131-43490253 EPB42 (0.06) 
chr15 45103610-45103715 TRIM69 (0.53) 
chr15 48365095-48365207 SLC24A5 (0.09) 
chr15 49907722-49907826 C15orf33 (0) 
chr15 53315174-53315295 ONECUT1 (0.12) 
chr15 54902011-54902121 UNC13C (2.18) 
chr15 56651045-56651177 TEX9 (1.2) 
chr15 56689930-56690100 MNS1 (0) 
chr15 61881207-61881349 VPS13C (4.36) 
chr15 62574063-62574210 C2CD4B (0) 
chr15 66721537-66721645 MAP2K1 (4.79) 
chr15 69745130-69745249 KIF23 (5.36) 
chr15 70656459-70656597 TLE3 (3.84) 
chr15 70815599-70815704 UACA (0) 
chr15 70885588-70885705 UACA (0) 
chr15 71982996-71983117 THSD4 (0.02) 
chr15 75230265-75230442 RPP25 (3.43) 
chr15 75918192-75918304 SNUPN (4.77) 
chr15 77910854-77910958 LOC253044 (0) 
chr15 80478579-80478673 FAH (5.2) 
chr15 81579196-81579299 IL16 (0.77) 
chr15 91284011-91284137 BLM (4.23) 
chr15 91803961-91804086 SV2B (0.96) 
chr15 95751455-95751569 LOC400456 (0) 
chr15 96603973-96604103 NR2F2 (0.9) 
chr15 97592377-97592507 SPATA8 (0.27) 
chr15 99941440-99941602 LRRC28 (3.27) 
chr15 101835329-101835465 PCSK6 (0.74) 
chr15 102182678-102182802 TARSL2 (3.86) 
chr16 7839029-7839155 RBFOX1 (1.97) 
chr16 10251375-10251489 GRIN2A (0.51) 
chr16 13515186-13515315 SHISA9 (3.53) 
chr16 15629660-15629787 KIAA0430 (3.09) 
chr16 15657459-15657582 KIAA0430 (3.09) 
chr16 15666746-15666876 KIAA0430 (3.09) 
chr16 15667927-15668050 KIAA0430 (3.09) 
chr16 19103046-19103172 COQ7 (3.41) 
chr16 20035578-20035701 GPR139 (0) 
chr16 21127739-21127866 DNAH3 (0.05) 
chr16 27258606-27258735 NSMCE1 (6.52) 
chr16 31123645-31123821 KAT8 (5.29) 
chr16 31769860-31769974 ZNF720 (1.23) 
chr16 51457136-51457257 SALL1 (0) 
chr16 51660959-51661093 LOC388276 (0) 
chr16 51666347-51666455 LOC388276 (0) 
chr16 51890865-51890984 LOC388276 (0) 
chr16 53109515-53109646 CHD9 (2.31) 
chr16 54510840-54510975 IRX3 (0) 
chr16 54907978-54908100 CRNDE (0.56) 
chr16 58455205-58455323 GINS3 (3.7) 
chr16 60118540-60118655 LOC644649 (0) 
chr16 60128450-60128577 LOC644649 (0) 
chr16 61287015-61287144 CDH8 (0.67) 
chr16 67293724-67293823 SLC9A5 (2.49) 
chr16 67978246-67978360 SLC12A4 (3.35) 
chr16 76268953-76269081 CNTNAP4 (3.2) 
chr16 77446490-77446618 ADAMTS18 (0) 
chr16 77530867-77530985 ADAMTS18 (0) 
chr16 78128713-78128842 WWOX (4.75) 
chr16 80704255-80704371 CDYL2 (3.31) 
chr16 81755280-81755384 CMIP (2.57) 
chr16 82399045-82399154 MPHOSPH6 (4.72) 
chr16 82965238-82965360 CDH13 (0.04) 
chr16 82984069-82984244 CDH13 (0.04) 
chr16 83252490-83252618 CDH13 (0.04) 
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chr16 88876083-88876202 APRT (7.99) 
chr16 89571780-89571802 SPG7 (4.72) 
chr17 7529674-7529769 SHBG (0) 
chr17 7760698-7760886 CYB5D1 (1.32) 
chr17 12070265-12070405 MAP2K4 (4.09) 
chr17 13684382-13684513 HS3ST3A1 (0.27) 
chr17 15683356-15683485 MEIS3P1 (0) 
chr17 18154163-18154266 FLII (5.62) 
chr17 21274032-21274147 KCNJ12 (0) 
chr17 27717448-27717563 MIR4523 (0) 
chr17 30771479-30771628 PSMD11 (4.73) 
chr17 34465546-34465666 TBC1D3B (0) 
chr17 39878891-39879017 HAP1 (0) 
chr17 46752970-46753095 MIR196A1 (0) 
chr17 48224527-48224688 PPP1R9B (5.27) 
chr17 48940277-48940446 LOC400604 (0) 
chr17 50544006-50544136 CA10 (0) 
chr17 59322447-59322556 BCAS3 (4.34) 
chr17 62011806-62011903 CD79B (0.22) 
chr17 62060132-62060247 SCN4A (0.03) 
chr17 65700590-65700721 PITPNC1 (3.32) 
chr17 66823148-66823274 ABCA8 (0) 
chr17 67521671-67521817 MAP2K6 (0.58) 
chr17 67550270-67550438 MAP2K6 (0.58) 
chr17 67559491-67559624 MAP2K6 (0.58) 
chr17 67595773-67595903 MAP2K6 (0.58) 
chr17 67696430-67696553 MAP2K6 (0.58) 
chr17 67744806-67744934 MAP2K6 (0.58) 
chr17 67781899-67782021 MAP2K6 (0.58) 
chr17 67906893-67906997 KCNJ16 (0) 
chr17 68028148-68028270 KCNJ16 (0) 
chr17 68338976-68339097 KCNJ2 (2.38) 
chr17 68394927-68395049 KCNJ2 (2.38) 
chr17 68572859-68572980 KCNJ2 (2.38) 
chr17 69617070-69617184 SOX9 (0.12) 
chr17 70387123-70387301 LOC100499467 (0) 
chr17 72514913-72515028 CD300LB (0) 
chr17 72931464-72931579 OTOP3 (0.06) 
chr17 73262112-73262280 MIF4GD (4.77) 
chr17 73754326-73754585 GALK1 (3.49) 
chr17 74560618-74560718 ST6GALNAC2 (0.39) 
chr17 77158349-77158502 RBFOX3 (0.51) 
chr17 78622681-78622794 RPTOR (3.05) 
chr17 79336006-79336127 TMEM105 (0) 
chr18 548595-548715 CETN1 (0) 
chr18 6123474-6123564 L3MBTL4 (0.15) 
chr18 8445102-8445234 PTPRM (1.33) 
chr18 13035334-13035463 CEP192 (4.18) 
chr18 15031453-15031611 ANKRD30B (3.44) 
chr18 15109912-15110004 LOC644669 (0) 
chr18 15135158-15135289 LOC644669 (0) 
chr18 20857274-20857381 CABLES1 (0.05) 
chr18 22276324-22276450 LOC729950 (0) 
chr18 26055019-26055140 CDH2 (0) 
chr18 29545591-29545716 TRAPPC8 (3.56) 
chr18 32485066-32485191 DTNA (2.03) 
chr18 33077773-33077886 MIR3975 (0) 
chr18 36807053-36807182 LOC647946 (0) 
chr18 39394632-39394741 PIK3C3 (3.68) 
chr18 39438755-39438862 PIK3C3 (3.68) 
chr18 39455678-39455837 PIK3C3 (3.68) 
chr18 39580619-39580748 PIK3C3 (3.68) 
chr18 39695462-39695595 PIK3C3 (3.68) 
chr18 42251871-42251993 SETBP1 (0.11) 
chr18 43569317-43569446 PSTPIP2 (0) 
chr18 44722454-44722556 IER3IP1 (5.73) 
chr18 44812053-44812162 IER3IP1 (5.73) 
chr18 55879577-55879698 NEDD4L (2.99) 
chr18 56447358-56447472 MALT1 (3.64) 
chr18 57213002-57213132 CCBE1 (0.08) 
chr18 59702321-59702440 PIGN (3.03) 
chr18 61222171-61222295 SERPINB12 (0) 
chr18 61427010-61427131 SERPINB7 (0) 
chr18 61428938-61429064 SERPINB7 (0) 
chr18 62453065-62453169 LOC284294 (0) 
chr18 62658730-62658842 LOC284294 (0) 
chr18 63882058-63882186 CDH19 (0.02) 
chr18 65728267-65728397 LOC643542 (0) 
chr18 65906195-65906316 LOC643542 (0) 
chr18 65936807-65936924 LOC643542 (0) 
chr18 66096421-66096566 TMX3 (3.7) 
chr18 66231147-66231330 TMX3 (3.7) 
chr18 71197391-71197530 LOC100505817 (0) 
chr18 71452136-71452256 FBXO15 (0.24) 
chr18 71657465-71657567 FBXO15 (0.24) 
chr18 72731699-72731841 ZNF407 (2.24) 
chr18 72785986-72786133 ZNF407 (2.24) 
chr18 72816048-72816170 ZNF407 (2.24) 
chr18 73341586-73341711 C18orf62 (0) 
chr18 73447893-73448005 C18orf62 (0) 
chr18 75422023-75422146 GALR1 (0) 
chr19 5676828-5676925 C19orf70 (6.17) 
chr19 5916284-5916394 RANBP3 (4.5) 
chr19 6000617-6000735 RFX2 (2.59) 
chr19 6323445-6323586 CLPP (6.09) 
chr19 6381159-6381431 GTF2F1 (5.99) 
chr19 6413804-6414014 KHSRP (5.84) 
chr19 7320964-7321085 INSR (0.01) 
chr19 7696346-7696458 PCP2 (0.52) 
chr19 8431208-8431320 LOC100507567 (0) 
chr19 11488473-11488668 EPOR (2.01) 
chr19 13864455-13864593 MRI1 (3.65) 
chr19 16308721-16308846 AP1M1 (5.45) 
chr19 17615076-17615215 PGLS (5.17) 
chr19 23887334-23887465 ZNF675 (2.88) 
chr19 28819641-28819766 LOC148189 (0) 
chr19 29087923-29088016 LOC148145 (0) 
chr19 30054649-30054764 LOC284395 (0) 
chr19 30534170-30534299 C19orf2 (0) 
chr19 31735176-31735302 TSHZ3 (0) 
chr19 34046701-34046817 PEPD (4.18) 
chr19 38874210-38874328 GGN (1.5) 
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chr19 42891509-42891631 MEGF8 (2.67) 
chr19 47029663-47029783 LOC100506012 (0) 
chr19 47568234-47568332 ZC3H4 (2.6) 
chr19 47776903-47777024 PRR24 (0) 
chr19 50363569-50363659 PNKP (3.28) 
chr19 50363843-50363942 PNKP (3.28) 
chr19 56824639-56824777 ZNF542 (0) 
chr19 57999415-57999547 ZNF419 (1.78) 
chr19 58011545-58011677 ZNF773 (2.71) 
chr2 682715-682829 TMEM18 (5.1) 
chr2 1635917-1636054 PXDN (0) 
chr2 1803670-1803763 MYT1L (0) 
chr2 2431270-2431388 MYT1L (0) 
chr2 2535700-2535790 MYT1L (0) 
chr2 3955082-3955204 LOC100505964 (0) 
chr2 4295740-4295862 LOC100505964 (0) 
chr2 4980726-4980847 LOC727982 (0) 
chr2 5566446-5566585 SOX11 (0) 
chr2 5683386-5683494 SOX11 (0) 
chr2 6101996-6102129 LOC400940 (0.44) 
chr2 6334660-6334790 LOC400940 (0.44) 
chr2 6924918-6925047 LINC00487 (0) 
chr2 7239993-7240096 RNF144A (0) 
chr2 7780411-7780534 LOC100506274 (0.16) 
chr2 8034492-8034623 LOC339788 (0) 
chr2 8856192-8856312 KIDINS220 (4.58) 
chr2 11029086-11029215 KCNF1 (0) 
chr2 11402709-11402832 ROCK2 (4.02) 
chr2 11720093-11720223 MIR4429 (0) 
chr2 11821535-11821647 NTSR2 (0) 
chr2 12603365-12603488 TRIB2 (1.85) 
chr2 12756710-12756828 TRIB2 (1.85) 
chr2 13095355-13095478 LOC100506474 (0) 
chr2 14131250-14131381 FAM84A (0) 
chr2 14375963-14376071 FAM84A (0) 
chr2 15038793-15038900 FAM84A (0) 
chr2 15054104-15054222 NBAS (4.28) 
chr2 15633228-15633336 NBAS (4.28) 
chr2 16165995-16166118 MYCN (0) 
chr2 17884009-17884131 VSNL1 (0.14) 
chr2 18005042-18005193 MSGN1 (0) 
chr2 18351344-18351467 KCNS3 (0) 
chr2 18730633-18730751 RDH14 (3.67) 
chr2 20678251-20678385 RHOB (0.44) 
chr2 22065539-22065652 LOC645949 (0.33) 
chr2 24674824-24674941 ITSN2 (4.41) 
chr2 25109961-25110076 DNAJC27 (1.31) 
chr2 25876155-25876286 ASXL2 (3.13) 
chr2 27907983-27908115 SLC4A1AP (4.36) 
chr2 30490026-30490160 LBH (0.07) 
chr2 30554540-30554662 LBH (0.07) 
chr2 30594330-30594466 LCLAT1 (3.12) 
chr2 32951900-32952026 TTC27 (4.08) 
chr2 33931900-33932032 MYADML (0) 
chr2 36275756-36275881 LOC100288911 (0) 
chr2 36384369-36384477 LOC100288911 (0) 
chr2 40808075-40808252 SLC8A1 (2.01) 
chr2 40838102-40838291 SLC8A1 (2.01) 
chr2 42205655-42205776 LOC400950 (0) 
chr2 44406267-44406380 PPM1B (5.2) 
chr2 44524017-44524129 PREPL (4.61) 
chr2 45819216-45819342 PRKCE (1.83) 
chr2 47684532-47684647 MSH2 (5.75) 
chr2 54342708-54342842 ACYP2 (2.92) 
chr2 54501240-54501368 ACYP2 (2.92) 
chr2 54621635-54621762 C2orf73 (0) 
chr2 58485795-58485913 FANCL (5.41) 
chr2 60343696-60343818 MIR4432 (0) 
chr2 65275130-65275286 CEP68 (3.79) 
chr2 66582856-66582981 MIR4778 (0) 
chr2 66972395-66972517 MEIS1 (3.65) 
chr2 67042192-67042316 MEIS1 (3.65) 
chr2 67342569-67342698 LOC644838 (0) 
chr2 67735498-67735618 ETAA1 (4.68) 
chr2 68054669-68054856 C1D (4.88) 
chr2 68623157-68623291 FBXO48 (1.76) 
chr2 70645597-70645722 TGFA (1.41) 
chr2 74154006-74154156 DGUOK (6.69) 
chr2 75769219-75769335 FAM176A (0) 
chr2 76532754-76532860 LRRTM4 (3.2) 
chr2 78007895-78008025 SNAR-H (0) 
chr2 80719333-80719440 CTNNA2 (2.35) 
chr2 89375691-89375814 MIR4436A (0) 
chr2 90163103-90163226 MIR4436A (0) 
chr2 92195966-92196069 ACTR3BP2 (0) 
chr2 99285791-99285906 MGAT4A (2.16) 
chr2 99349273-99349388 MGAT4A (2.16) 
chr2 99920751-99920882 LYG1 (1.71) 
chr2 100544442-100544573 AFF3 (1.35) 
chr2 101786016-101786141 TBC1D8 (1.35) 
chr2 104629707-104629819 LOC100287010 (0.21) 
chr2 110451127-110451247 ANKRD57 (0) 
chr2 110905815-110905951 NPHP1 (0.88) 
chr2 110911705-110911863 NPHP1 (0.88) 
chr2 110913820-110913991 NPHP1 (0.88) 
chr2 111881300-111881401 ACOXL (1.19) 
chr2 114448621-114448731 SLC35F5 (3.61) 
chr2 114603519-114603639 ACTR3 (5.6) 
chr2 132619286-132619442 C2orf27B (0) 
chr2 132693184-132693313 C2orf27B (0) 
chr2 132704195-132704314 C2orf27B (0) 
chr2 132737343-132737473 ANKRD30BL (0) 
chr2 136007265-136007387 ZRANB3 (1.98) 
chr2 141815155-141815295 LRP1B (0.04) 
chr2 143874854-143874984 ARHGAP15 (6.12) 
chr2 147581166-147581279 PABPC1P2 (0.17) 
chr2 148077919-148078031 ACVR2A (2.74) 
chr2 148177658-148177781 ACVR2A (2.74) 
chr2 150985221-150985342 RND3 (0.35) 
chr2 151919017-151919147 RBM43 (1.56) 
chr2 153572505-153572662 ARL6IP6 (3.62) 
chr2 153573782-153573970 ARL6IP6 (3.62) 
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chr2 155062116-155062243 GALNT13 (0.03) 
chr2 157879192-157879307 GALNT5 (6) 
chr2 158033320-158033436 GALNT5 (6) 
chr2 159145375-159145495 CCDC148 (0.67) 
chr2 162419060-162419183 SLC4A10 (0.09) 
chr2 163954253-163954381 KCNH7 (0.91) 
chr2 164518268-164518396 KCNH7 (0.91) 
chr2 166629785-166629915 CSRNP3 (0.05) 
chr2 173750243-173750365 RAPGEF4 (0.09) 
chr2 179946504-179946618 SESTD1 (2.45) 
chr2 182958841-182958952 PDE1A (0.14) 
chr2 184132749-184132879 NUP35 (4.89) 
chr2 189248967-189249086 GULP1 (0) 
chr2 190851947-190852067 MSTN (0.3) 
chr2 191573355-191573478 NAB1 (3.8) 
chr2 192086028-192086137 MYO1B (0.04) 
chr2 196229586-196229715 SLC39A10 (3.03) 
chr2 196344291-196344398 SLC39A10 (3.03) 
chr2 207101094-207101268 GPR1 (0.07) 
chr2 207101284-207101503 GPR1 (0.07) 
chr2 212856951-212857072 ERBB4 (0.06) 
chr2 222529817-222529944 EPHA4 (0) 
chr2 224532895-224533013 SCG2 (0.43) 
chr2 224604006-224604135 AP1S3 (1.87) 
chr2 224887625-224887758 SERPINE2 (4.41) 
chr2 224980281-224980385 SERPINE2 (4.41) 
chr2 224990233-224990355 SERPINE2 (4.41) 
chr2 225291551-225291657 FAM124B (2.07) 
chr2 226884344-226884442 KIAA1486 (0) 
chr2 227408287-227408416 IRS1 (1.04) 
chr2 227642412-227642525 RHBDD1 (2.97) 
chr2 229227267-229227396 SPHKAP (0) 
chr2 231137220-231137343 SP140 (4.53) 
chr2 234485992-234486106 USP40 (0.61) 
chr2 235166328-235166451 SPP2 (0) 
chr2 235192096-235192296 SPP2 (0) 
chr2 235218086-235218217 ARL4C (0.09) 
chr2 238363284-238363392 MLPH (1.27) 
chr2 239491515-239491621 LOC151171 (0) 
chr2 239527007-239527141 LOC151171 (0) 
chr2 239683158-239683297 TWIST2 (2.25) 
chr2 239869549-239869674 FLJ43879 (0) 
chr2 241647942-241648067 KIF1A (0.36) 
chr2 242670240-242670355 ING5 (2.82) 
chr20 1145731-1145886 C20orf46 (0) 
chr20 1828125-1828265 SIRPA (0) 
chr20 4004646-4004775 RNF24 (1.25) 
chr20 4557225-4557363 PRNP (4.41) 
chr20 5332999-5333128 PROKR2 (0) 
chr20 7121440-7121553 BMP2 (0) 
chr20 9134091-9134212 PLCB4 (0) 
chr20 11161916-11162058 LOC339593 (0) 
chr20 12638327-12638448 SPTLC3 (0) 
chr20 15903870-15903991 MACROD2 (0.4) 
chr20 18109316-18109424 PET117 (4.08) 
chr20 19709731-19709898 SLC24A3 (0) 
chr20 22529161-22529281 LINC00261 (0.21) 
chr20 22531141-22531264 LINC00261 (0.21) 
chr20 22940397-22940530 SSTR4 (0) 
chr20 25782621-25782742 FAM182B (0.02) 
chr20 31522523-31522644 SUN5 (0) 
chr20 32482224-32482344 CHMP4B (3.77) 
chr20 40256542-40256675 CHD6 (3.49) 
chr20 42455728-42455841 TOX2 (0.11) 
chr20 42735256-42735378 JPH2 (0.12) 
chr20 43588896-43589040 LOC100505826 (0) 
chr20 49678720-49678847 KCNG1 (0) 
chr20 50879398-50879514 ZFP64 (2.16) 
chr20 52671871-52672000 MIR4756 (0) 
chr20 56058214-56058546 CTCFL (0) 
chr20 56617023-56617140 C20orf85 (0) 
chr20 57102170-57102284 LOC149773 (0) 
chr20 57111923-57112044 LOC149773 (0) 
chr20 58867317-58867438 MIR4533 (0) 
chr20 61368262-61368385 NTSR1 (0) 
chr21 14555335-14555469 ANKRD30BP2 (0.06) 
chr21 14582642-14582839 ANKRD30BP2 (0.06) 
chr21 14599928-14600056 ANKRD30BP2 (0.06) 
chr21 14668572-14668701 MIR3156-3 (0) 
chr21 14702650-14702772 MIR3156-3 (0) 
chr21 14709803-14709960 MIR3156-3 (0) 
chr21 16042590-16042713 SAMSN1 (4.52) 
chr21 16052037-16052155 SAMSN1 (4.52) 
chr21 16215973-16216102 NRIP1 (3.23) 
chr21 16234082-16234203 NRIP1 (3.23) 
chr21 17005828-17005937 USP25 (3.88) 
chr21 17248786-17248900 LINC00478 (0) 
chr21 18054603-18054693 LINC00478 (0) 
chr21 18483327-18483449 C21orf37 (0) 
chr21 19378370-19378482 CHODL (0.07) 
chr21 19858105-19858235 TMPRSS15 (0) 
chr21 20834129-20834251 TMPRSS15 (0) 
chr21 23058566-23058683 LINC00317 (0) 
chr21 23406649-23406791 LINC00308 (0) 
chr21 23966238-23966368 LINC00308 (0) 
chr21 25166166-25166283 D21S2088E (0.44) 
chr21 26637135-26637248 LINC00158 (3.93) 
chr21 26874721-26874855 MIR155HG (6.23) 
chr21 27727427-27727542 CYYR1 (0.19) 
chr21 27842834-27842939 APP (0.48) 
chr21 28195430-28195560 ADAMTS1 (0.04) 
chr21 29277510-29277643 LINC00314 (0) 
chr21 29288683-29288824 LINC00314 (0) 
chr21 29376724-29376865 LINC00314 (0) 
chr21 29413631-29413753 LINC00314 (0) 
chr21 29420711-29420867 LINC00314 (0) 
chr21 29430126-29430257 LINC00314 (0) 
chr21 29570158-29570288 LINC00314 (0) 
chr21 29715685-29715819 LINC00161 (0) 
chr21 30908676-30908804 GRIK1 (0.23) 
chr21 32722912-32723022 TIAM1 (2.03) 
chr21 33903275-33903399 C21orf63 (0) 
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chr21 34359756-34359867 OLIG2 (0) 
chr21 35284586-35284714 LOC100506334 (0) 
chr21 35902210-35902331 RCAN1 (3.06) 
chr21 36529950-36530064 RUNX1 (2.35) 
chr21 36669210-36669331 RUNX1 (2.35) 
chr21 36940982-36941108 MIR802 (0) 
chr21 37177006-37177136 MIR802 (0) 
chr21 37214314-37214435 MIR802 (0) 
chr21 37470446-37470556 LOC100133286 (0) 
chr21 37838671-37838779 CLDN14 (0) 
chr21 40150497-40150608 LINC00114 (0) 
chr21 40917301-40917431 SH3BGR (1.54) 
chr21 41229345-41229475 PCP4 (1.72) 
chr21 41621290-41621413 DSCAM (1.84) 
chr21 42312114-42312223 DSCAM (1.84) 
chr21 42524190-42524307 LINC00323 (0) 
chr21 43039773-43039900 LINC00111 (0) 
chr21 45191562-45191701 CSTB (4.47) 
chr21 46579076-46579187 ADARB1 (1.74) 
chr21 47013493-47013662 SLC19A1 (3.15) 
chr21 47556864-47556982 FTCD (0.21) 
chr22 16162027-16162146 POTEH (2.28) 
chr22 17232428-17232549 XKR3 (0) 
chr22 17358578-17358707 HSFY1P1 (0) 
chr22 27766481-27766608 MN1 (0.06) 
chr22 39130848-39130966 SUN2 (3.75) 
chr22 39635878-39635987 RPL3 (10.38) 
chr22 42907921-42908026 SERHL2 (0.8) 
chr22 44573875-44573996 PARVG (0) 
chr22 46067730-46067848 ATXN10 (4.49) 
chr22 46409276-46409399 LOC730668 (0.22) 
chr22 47512301-47512418 TBC1D22A (2.38) 
chr22 49583686-49583814 LOC100128946 (0) 
chr22 49788681-49788798 C22orf34 (3.53) 
chr22 50051070-50051186 BRD1 (2.59) 
chr22 50133202-50133341 BRD1 (2.59) 
chr3 3168700-3168801 IL5RA (0.65) 
chr3 6210149-6210254 GRM7 (0.1) 
chr3 7382004-7382128 LOC100288428 (0) 
chr3 11448120-11448237 ATG7 (2.6) 
chr3 12817628-12817750 TMEM40 (1.47) 
chr3 12882893-12883039 RPL32 (9.83) 
chr3 17064939-17065118 PLCL2 (4.34) 
chr3 19036703-19036817 KCNH8 (0.04) 
chr3 21998569-21998690 ZNF385D (0) 
chr3 25824794-25824936 NGLY1 (4.92) 
chr3 26160821-26160949 LOC285326 (0) 
chr3 26188417-26188540 LOC285326 (0) 
chr3 28065192-28065322 CMC1 (5.2) 
chr3 28067396-28067494 CMC1 (5.2) 
chr3 31113969-31114155 GADL1 (0.06) 
chr3 36764175-36764289 TRANK1 (0.72) 
chr3 37184373-37184598 LRRFIP2 (4.23) 
chr3 39183424-39183541 CSRNP1 (3.16) 
chr3 40836781-40836894 ZNF621 (1.74) 
chr3 45833145-45833259 LZTFL1 (0.09) 
chr3 52897261-52897355 MUSTN1 (2.81) 
chr3 58464635-58464762 KCTD6 (2.68) 
chr3 60031034-60031131 FHIT (0.21) 
chr3 60781688-60781817 PTPRG (0.33) 
chr3 67561910-67562028 SUCLG2 (5.83) 
chr3 69040966-69041087 TMF1 (4.25) 
chr3 72316188-72316310 LOC201617 (0) 
chr3 72529282-72529575 RYBP (2.79) 
chr3 73261434-73261562 PPP4R2 (6.37) 
chr3 77778485-77778608 ROBO2 (2.13) 
chr3 78611045-78611147 ROBO1 (5.29) 
chr3 79984673-79984791 ROBO1 (5.29) 
chr3 80577743-80577866 ROBO1 (5.29) 
chr3 83666188-83666278 LOC440970 (0) 
chr3 84557474-84557582 LOC440970 (0) 
chr3 84869318-84869440 CADM2 (0.02) 
chr3 87645421-87645542 POU1F1 (0) 
chr3 89819579-89819698 EPHA3 (1.78) 
chr3 95145153-95145281 LOC255025 (0) 
chr3 96154582-96154713 EPHA6 (0) 
chr3 99563661-99563786 MIR548G (0) 
chr3 102377756-102377883 ZPLD1 (0) 
chr3 102574912-102575052 ZPLD1 (0) 
chr3 103436519-103436609 MIR548A3 (0) 
chr3 106953495-106953610 LOC100302640 (0) 
chr3 107843859-107843990 CD47 (3.69) 
chr3 108150274-108150400 MYH15 (0.23) 
chr3 109282201-109282311 FLJ25363 (0) 
chr3 109437796-109437908 FLJ25363 (0) 
chr3 109449782-109449918 FLJ25363 (0) 
chr3 109906643-109906750 FLJ25363 (0) 
chr3 110041166-110041331 PVRL3-AS1 (0) 
chr3 110050519-110050654 PVRL3-AS1 (0) 
chr3 110052452-110052582 PVRL3-AS1 (0) 
chr3 110223933-110224068 PVRL3-AS1 (0) 
chr3 112475278-112475398 CD200R1L (0) 
chr3 113806556-113806849 KIAA1407 (0.57) 
chr3 116911883-116912005 LSAMP-AS3 (0) 
chr3 118528784-118528903 IGSF11 (1.24) 
chr3 119823286-119823423 GSK3B (2.7) 
chr3 125960805-125960924 ALDH1L1 (2.3) 
chr3 131477669-131477797 CPNE4 (2.63) 
chr3 132618659-132618780 NPHP3-AS1 (0) 
chr3 140480163-140480294 TRIM42 (0) 
chr3 143739918-143740038 C3orf58 (3.12) 
chr3 147672662-147672792 ZIC1 (0) 
chr3 150321069-150321232 SELT (4.58) 
chr3 151269928-151270038 MIR548H2 (0) 
chr3 151305605-151305721 MIR548H2 (0) 
chr3 156287838-156287952 SSR3 (5.73) 
chr3 157282505-157282627 C3orf55 (0) 
chr3 160296297-160296421 KPNA4 (4.36) 
chr3 161319990-161320101 OTOL1 (0) 
chr3 161494019-161494147 OTOL1 (0) 
chr3 161668128-161668232 OTOL1 (0) 
chr3 161934237-161934383 OTOL1 (0) 
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chr3 162366357-162366469 LOC647107 (0) 
chr3 162904439-162904558 LOC647107 (0) 
chr3 163199722-163199858 LOC647107 (0) 
chr3 164366444-164366571 SI (0) 
chr3 166641920-166642045 ZBBX (0.34) 
chr3 167888066-167888183 GOLIM4 (4.81) 
chr3 168236523-168236632 EGFEM1P (1.4) 
chr3 169530347-169530470 LRRIQ4 (0) 
chr3 171076088-171076209 PLD1 (0.93) 
chr3 172295191-172295315 NCEH1 (2.55) 
chr3 172296181-172296294 NCEH1 (2.55) 
chr3 173559818-173559935 NLGN1 (0.04) 
chr3 174991887-174992020 NAALADL2 (0.08) 
chr3 177345987-177346120 TBL1XR1 (4.81) 
chr3 177852488-177852596 KCNMB2 (0.88) 
chr3 178692133-178692248 ZMAT3 (4.27) 
chr3 181754497-181754618 SOX2-OT (2.28) 
chr3 183079282-183079403 MCF2L2 (2.71) 
chr3 183985148-183985283 CAMK2N2 (3.18) 
chr3 184443720-184443842 MAGEF1 (5.83) 
chr3 186314754-186314984 DNAJB11 (5.85) 
chr3 189330145-189330269 TP63 (5) 
chr3 190895729-190895834 OSTN (0.69) 
chr3 190934865-190934975 UTS2D (0) 
chr3 191201933-191202073 PYDC2 (0) 
chr3 192492143-192492233 MB21D2 (2.67) 
chr3 194361588-194361698 LSG1 (5.8) 
chr3 194624360-194624476 LOC100507391 (0.25) 
chr3 195913913-195914039 ZDHHC19 (0) 
chr3 197820107-197820243 LOC348840 (0) 
chr4 467844-467966 PIGG (3.99) 
chr4 1042619-1042741 FGFRL1 (2.38) 
chr4 1250127-1250258 C4orf42 (0) 
chr4 1967429-1967635 WHSC1 (5.52) 
chr4 2384540-2384669 ZFYVE28 (1.6) 
chr4 4369974-4370095 D4S234E (0) 
chr4 4552170-4552300 LOC100507266 (0) 
chr4 4925536-4925648 MSX1 (2.49) 
chr4 5068800-5068921 STK32B (0) 
chr4 5129631-5129722 STK32B (0) 
chr4 5551655-5551774 EVC2 (0.05) 
chr4 7642986-7643092 SORCS2 (0.08) 
chr4 7755772-7755895 AFAP1 (1.49) 
chr4 8289191-8289305 HTRA3 (1.21) 
chr4 11687579-11687704 HS3ST1 (0.14) 
chr4 14346848-14346940 LOC152742 (0) 
chr4 15910643-15910769 FGFBP1 (0) 
chr4 19218037-19218164 SLIT2 (1.93) 
chr4 19309252-19309371 SLIT2 (1.93) 
chr4 19987712-19987827 SLIT2 (1.93) 
chr4 20785027-20785157 KCNIP4 (0.93) 
chr4 22304594-22304703 LOC100505912 (0) 
chr4 22789802-22789942 GBA3 (1.26) 
chr4 22999083-22999247 GBA3 (1.26) 
chr4 23103070-23103207 MIR548AJ2 (0) 
chr4 23105174-23105306 MIR548AJ2 (0) 
chr4 23107124-23107236 MIR548AJ2 (0) 
chr4 23109704-23109834 MIR548AJ2 (0) 
chr4 23128754-23128873 MIR548AJ2 (0) 
chr4 26019686-26019811 C4orf52 (0) 
chr4 26042091-26042205 C4orf52 (0) 
chr4 26824726-26824841 STIM2 (3.65) 
chr4 27740178-27740315 STIM2 (3.65) 
chr4 30106407-30106529 PCDH7 (0) 
chr4 30615702-30615938 PCDH7 (0) 
chr4 30648777-30648916 PCDH7 (0) 
chr4 31194645-31194776 PCDH7 (0) 
chr4 35454465-35454575 ARAP2 (3.34) 
chr4 35503508-35503636 ARAP2 (3.34) 
chr4 36617046-36617154 DTHD1 (0) 
chr4 36733685-36733826 DTHD1 (0) 
chr4 36934956-36935070 MIR4801 (0) 
chr4 38420063-38420176 FLJ13197 (0) 
chr4 38552292-38552421 FLJ13197 (0) 
chr4 38824545-38824663 TLR6 (1.88) 
chr4 40300684-40300796 CHRNA9 (0.44) 
chr4 40922228-40922349 APBB2 (0.72) 
chr4 41848113-41848220 TMEM33 (4.37) 
chr4 42465374-42465490 ATP8A1 (3.89) 
chr4 42567010-42567126 ATP8A1 (3.89) 
chr4 45735750-45735867 GABRG1 (0) 
chr4 46725841-46726028 COX7B2 (0) 
chr4 46913998-46914113 COX7B2 (0) 
chr4 47200833-47200934 GABRB1 (0) 
chr4 47638642-47638763 CORIN (0.43) 
chr4 57489850-57489981 HOPX (0.24) 
chr4 58322341-58322470 LOC255130 (0) 
chr4 63711162-63711279 LPHN3 (0) 
chr4 67823473-67823594 CENPC1 (0) 
chr4 71993877-71993992 SLC4A4 (0.07) 
chr4 72628445-72628572 SLC4A4 (0.07) 
chr4 72975921-72976043 ADAMTS3 (0.18) 
chr4 73079594-73079716 NPFFR2 (0) 
chr4 74682247-74682366 CXCL6 (0) 
chr4 74992724-74992846 CXCL2 (0.12) 
chr4 76072999-76073174 PARM1 (5.62) 
chr4 76458840-76458953 THAP6 (3.25) 
chr4 77446335-77446468 SHROOM3 (0.39) 
chr4 77870073-77870200 40787 (5.92) 
chr4 79102043-79102148 FRAS1 (0) 
chr4 79327531-79327661 FRAS1 (0) 
chr4 81797535-81797661 C4orf22 (0) 
chr4 85577970-85578093 CDS1 (1.48) 
chr4 86478326-86478424 ARHGAP24 (2.74) 
chr4 86696554-86696674 ARHGAP24 (2.74) 
chr4 86886304-86886419 ARHGAP24 (2.74) 
chr4 93716479-93716600 GRID2 (0) 
chr4 95983106-95983234 UNC5C (0.18) 
chr4 96664529-96664646 PDHA2 (0) 
chr4 98356729-98356842 C4orf37 (0) 
chr4 101074258-101074391 DDIT4L (0.36) 
chr4 101087879-101088018 DDIT4L (0.36) 
253 
 
chr4 104337479-104337612 TACR3 (0) 
chr4 104417098-104417215 TACR3 (0) 
chr4 104422746-104422853 TACR3 (0) 
chr4 107615537-107615671 DKK2 (0.07) 
chr4 111140368-111140499 ELOVL6 (3.99) 
chr4 111520230-111520340 PITX2 (0.76) 
chr4 113033337-113033459 C4orf32 (3.52) 
chr4 113759346-113759456 ANK2 (2.64) 
chr4 114320974-114321096 ANK2 (2.64) 
chr4 115335677-115335804 UGT8 (1.67) 
chr4 116791424-116791537 MIR1973 (0) 
chr4 118060012-118060146 TRAM1L1 (0) 
chr4 118179206-118179319 TRAM1L1 (0) 
chr4 118400832-118400955 TRAM1L1 (0) 
chr4 119003984-119004133 NDST3 (0.02) 
chr4 120221489-120221773 USP53 (1.32) 
chr4 121220558-121220686 MAD2L1 (6.66) 
chr4 122761359-122761481 BBS7 (3.71) 
chr4 127780559-127780678 INTU (0) 
chr4 130755766-130755888 C4orf33 (4.03) 
chr4 132405716-132405829 PCDH10 (0) 
chr4 133184021-133184155 PCDH10 (0) 
chr4 133604114-133604218 PCDH10 (0) 
chr4 139589035-139589152 CCRN4L (4.59) 
chr4 139653397-139653509 CCRN4L (4.59) 
chr4 139673476-139673580 CCRN4L (4.59) 
chr4 144792053-144792181 GYPE (0) 
chr4 144912848-144912991 GYPB (0) 
chr4 145016102-145016239 GYPA (0) 
chr4 147887382-147887512 TTC29 (0) 
chr4 153116443-153116573 FBXW7 (5.43) 
chr4 154994458-154994568 DCHS2 (0) 
chr4 156167742-156167873 NPY2R (0) 
chr4 162021482-162021598 FSTL5 (0.96) 
chr4 162585960-162586082 FSTL5 (0.96) 
chr4 164336758-164336849 TKTL2 (0.07) 
chr4 168581999-168582114 SPOCK3 (0) 
chr4 172396393-172396507 GALNTL6 (0) 
chr4 174782105-174782220 NBLA00301 (0) 
chr4 175285029-175285255 CEP44 (3.86) 
chr4 175319470-175319593 MIR4276 (0) 
chr4 181040090-181040221 LINC00290 (0) 
chr4 183734096-183734218 ODZ3 (0) 
chr4 185296924-185297046 IRF2 (3.48) 
chr4 185451416-185451557 IRF2 (3.48) 
chr4 188216606-188216735 LOC339975 (0) 
chr4 189441213-189441338 LOC401164 (0) 
chr4 189444110-189444226 LOC401164 (0) 
chr5 1318016-1318190 CLPTM1L (5.41) 
chr5 1507739-1507858 SLC6A3 (0) 
chr5 2071651-2071772 IRX4 (0.12) 
chr5 5006902-5007019 LOC340094 (0) 
chr5 6271931-6272062 FLJ33360 (0.25) 
chr5 9974495-9974614 LOC285692 (0) 
chr5 11057535-11057666 CTNND2 (0) 
chr5 11253584-11253704 CTNND2 (0) 
chr5 12079994-12080115 CTNND2 (0) 
chr5 12873507-12873622 TAG (0) 
chr5 14034559-14034685 DNAH5 (0) 
chr5 17209315-17209439 LOC285696 (0) 
chr5 17259216-17259334 LOC285696 (0) 
chr5 17288606-17288724 BASP1 (5.46) 
chr5 21218508-21218598 GUSBP1 (4.19) 
chr5 21800943-21801062 CDH12 (2.93) 
chr5 21918618-21918769 CDH12 (2.93) 
chr5 22618984-22619110 CDH12 (2.93) 
chr5 23828374-23828485 PRDM9 (0) 
chr5 25124445-25124567 LOC340107 (0) 
chr5 25536644-25536764 LOC340107 (0) 
chr5 25674171-25674278 LOC340107 (0) 
chr5 28016477-28016597 LOC643401 (0) 
chr5 30476257-30476378 CDH6 (0) 
chr5 38868624-38868756 RICTOR (3.53) 
chr5 40604022-40604201 PTGER4 (5.73) 
chr5 42101095-42101215 FBXO4 (2.74) 
chr5 42103042-42103151 FBXO4 (2.74) 
chr5 43069011-43069133 LOC100132356 (2.23) 
chr5 43549536-43549694 PAIP1 (5.4) 
chr5 51138566-51138687 ISL1 (0.32) 
chr5 53356302-53356425 ARL15 (2) 
chr5 53609465-53609578 ARL15 (2) 
chr5 56597922-56598031 GPBP1 (5.09) 
chr5 58733708-58733839 PDE4D (2.77) 
chr5 64897187-64897307 PPWD1 (4.02) 
chr5 65167650-65167782 NLN (2.96) 
chr5 65375436-65375526 ERBB2IP (4.42) 
chr5 66786402-66786522 CD180 (0) 
chr5 66966030-66966145 CD180 (0) 
chr5 67794754-67794880 PIK3R1 (3.64) 
chr5 68473336-68473561 CENPH (6.04) 
chr5 78857431-78857542 HOMER1 (3.84) 
chr5 79409388-79409509 SERINC5 (2.67) 
chr5 79696226-79696356 ZFYVE16 (2.45) 
chr5 82028369-82028494 MIR3977 (0) 
chr5 82307545-82307636 TMEM167A (4.12) 
chr5 82623867-82623988 VCAN (0.03) 
chr5 83032177-83032313 HAPLN1 (0) 
chr5 83670614-83670722 EDIL3 (0) 
chr5 87343408-87343520 TMEM161B (3.65) 
chr5 88714524-88714730 MEF2C (1.64) 
chr5 89589329-89589450 CETN3 (4.19) 
chr5 91206673-91206808 LOC100129716 (0) 
chr5 92840287-92840416 FLJ42709 (0) 
chr5 95382456-95382588 MIR583 (0) 
chr5 95865465-95865591 PCSK1 (0.17) 
chr5 97403795-97403956 RGMB (1.62) 
chr5 97816271-97816385 RGMB (1.62) 
chr5 98092686-98092824 RGMB (1.62) 
chr5 98343946-98344074 LOC100289230 (1.17) 
chr5 99445400-99445533 LOC100133050 (0) 
chr5 100208311-100208433 ST8SIA4 (3.13) 
chr5 100219454-100219558 ST8SIA4 (3.13) 
254 
 
chr5 100362636-100362758 ST8SIA4 (3.13) 
chr5 100963562-100963674 SLCO4C1 (0) 
chr5 108113416-108113513 FER (2.87) 
chr5 111257558-111257697 C5orf13 (0) 
chr5 111494298-111494466 EPB41L4A-AS1 (4.46) 
chr5 115518620-115518735 COMMD10 (4.07) 
chr5 116556692-116556807 SEMA6A (1.4) 
chr5 117818356-117818485 DTWD2 (1.89) 
chr5 119713260-119713375 PRR16 (0) 
chr5 119741799-119741935 PRR16 (0) 
chr5 120500455-120500584 PRR16 (0) 
chr5 121935243-121935354 SNCAIP (2.54) 
chr5 123491336-123491461 ZNF608 (1.96) 
chr5 123748528-123748657 ZNF608 (1.96) 
chr5 123823912-123824042 ZNF608 (1.96) 
chr5 129630687-129630815 CHSY3 (0) 
chr5 133619054-133619185 CDKL3 (1.25) 
chr5 139624818-139624927 C5orf32 (0) 
chr5 141019039-141019151 RELL2 (1.85) 
chr5 145374036-145374175 SH3RF2 (0.91) 
chr5 149028343-149028473 ARHGEF37 (0.17) 
chr5 149472092-149472218 PDGFRB (0) 
chr5 149776171-149776415 CD74 (9.46) 
chr5 150199307-150199435 C5orf62 (0) 
chr5 151257268-151257390 GLRA1 (0.4) 
chr5 154423824-154423946 KIF4B (0) 
chr5 154450696-154450818 KIF4B (0) 
chr5 154452619-154452740 KIF4B (0) 
chr5 156640117-156640235 ITK (0.52) 
chr5 157249362-157249484 CLINT1 (4.87) 
chr5 157465418-157465525 CLINT1 (4.87) 
chr5 157832016-157832140 EBF1 (1.89) 
chr5 163213711-163213832 MAT2B (4.37) 
chr5 163681927-163682042 MAT2B (4.37) 
chr5 166959410-166959545 WWC1 (2.33) 
chr5 169492585-169492698 DOCK2 (6.23) 
chr5 171404636-171404758 STK10 (3.67) 
chr5 172107987-172108092 NEURL1B (0.02) 
chr5 172712384-172712515 STC2 (0) 
chr5 174452916-174453031 MIR4634 (0) 
chr5 175192952-175193062 CPLX2 (0.04) 
chr5 176883916-176884139 DBN1 (4.72) 
chr5 177625153-177625260 HNRNPAB (6.87) 
chr5 178824706-178824828 ADAMTS2 (0.13) 
chr5 179216405-179216521 LTC4S (1.11) 
chr5 179264031-179264214 C5orf45 (4.78) 
chr6 3195918-3196030 TUBB2B (5.57) 
chr6 4422170-4422289 CDYL (2.94) 
chr6 5548217-5548434 LYRM4 (5.56) 
chr6 5555330-5555499 LYRM4 (5.56) 
chr6 5795607-5795729 FARS2 (5.38) 
chr6 5805608-5805737 FARS2 (5.38) 
chr6 5864969-5865102 FARS2 (5.38) 
chr6 6580563-6580678 LY86-AS1 (0) 
chr6 7313289-7313433 CAGE1 (0.35) 
chr6 8064558-8064663 EEF1E1 (6.1) 
chr6 11295129-11295321 NEDD9 (3.89) 
chr6 13472206-13472327 GFOD1 (2.27) 
chr6 15123088-15123220 JARID2 (2.43) 
chr6 20431841-20431964 CDKAL1 (4.12) 
chr6 21169973-21170118 CDKAL1 (4.12) 
chr6 22734334-22734452 HDGFL1 (0) 
chr6 23996964-23997102 NRSN1 (0.32) 
chr6 24014151-24014281 NRSN1 (0.32) 
chr6 24024069-24024187 NRSN1 (0.32) 
chr6 25946121-25946232 SLC17A2 (0) 
chr6 25985933-25986160 TRIM38 (3.29) 
chr6 31021188-31021318 HCG22 (0.76) 
chr6 34231234-34231344 C6orf1 (4.83) 
chr6 36321585-36321703 ETV7 (0.1) 
chr6 39938962-39939092 MOCS1 (0.03) 
chr6 40741027-40741160 LRFN2 (0) 
chr6 45993575-45993732 CLIC5 (0.17) 
chr6 52860445-52860716 GSTA4 (2.05) 
chr6 53855796-53855918 MLIP (0) 
chr6 54889433-54889548 FAM83B (0) 
chr6 63320779-63320886 KHDRBS2 (0) 
chr6 63355169-63355285 KHDRBS2 (0) 
chr6 64450184-64450311 EYS (0.26) 
chr6 65553886-65554007 EYS (0.26) 
chr6 67104453-67104575 MCART3P (0) 
chr6 67778160-67778281 MCART3P (0) 
chr6 67780075-67780190 MCART3P (0) 
chr6 67869770-67869884 MCART3P (0) 
chr6 72119979-72120096 LINC00472 (0) 
chr6 72166018-72166145 LINC00472 (0) 
chr6 77223860-77223981 IMPG1 (0) 
chr6 81662242-81662388 BCKDHB (3.13) 
chr6 82486881-82486988 FAM46A (0.82) 
chr6 82804929-82805054 IBTK (3.86) 
chr6 84544298-84544412 RIPPLY2 (0) 
chr6 84673644-84673773 CYB5R4 (3.79) 
chr6 85506218-85506339 TBX18 (0) 
chr6 86417339-86417469 SNHG5 (7.23) 
chr6 87772755-87772877 CGA (0.31) 
chr6 89207315-89207423 RNGTT (3.85) 
chr6 89244214-89244328 RNGTT (3.85) 
chr6 89270862-89270981 RNGTT (3.85) 
chr6 90681362-90681486 BACH2 (0.06) 
chr6 91964482-91964598 MIR4643 (0) 
chr6 92373717-92373824 MIR4643 (0) 
chr6 96333985-96334134 FUT9 (0.61) 
chr6 100070087-100070210 PRDM13 (1.93) 
chr6 103230605-103230727 GRIK2 (0.04) 
chr6 107229505-107229624 LOC100422737 (2.05) 
chr6 110565753-110565859 C6orf186 (0) 
chr6 110630750-110630866 C6orf186 (0) 
chr6 110783166-110783296 SLC22A16 (0) 
chr6 111599798-111599892 KIAA1919 (2.66) 
chr6 112801158-112801288 RFPL4B (0.11) 
chr6 113055478-113055596 RFPL4B (0.11) 
chr6 113777052-113777147 MARCKS (5.21) 
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chr6 113832310-113832414 MARCKS (5.21) 
chr6 116910843-116910975 RSPH4A (0.31) 
chr6 119419339-119419460 FAM184A (2.53) 
chr6 123225588-123225733 CLVS2 (0) 
chr6 123445554-123445679 CLVS2 (0) 
chr6 125169241-125169362 NKAIN2 (0) 
chr6 125171188-125171309 NKAIN2 (0) 
chr6 125256174-125256297 RNF217 (0) 
chr6 125271779-125271885 RNF217 (0) 
chr6 125351126-125351257 RNF217 (0) 
chr6 127969611-127969728 C6orf58 (3.11) 
chr6 129908666-129908787 ARHGAP18 (2.43) 
chr6 131083087-131083202 LOC100507203 (0) 
chr6 131429412-131429534 AKAP7 (1.55) 
chr6 134031887-134032002 MGC34034 (0) 
chr6 134551540-134551656 SGK1 (1.91) 
chr6 134719740-134719865 LOC154092 (0) 
chr6 136048251-136048371 LINC00271 (0.09) 
chr6 136546672-136546790 FAM54A (0) 
chr6 137600512-137600634 IFNGR1 (4.17) 
chr6 137613988-137614110 IFNGR1 (4.17) 
chr6 138155096-138155227 TNFAIP3 (3.64) 
chr6 138177451-138177575 TNFAIP3 (3.64) 
chr6 139329331-139329463 REPS1 (4.28) 
chr6 139370325-139370467 C6orf115 (0) 
chr6 140710464-140710589 MIR3668 (0) 
chr6 141825587-141825709 NMBR (0) 
chr6 143378672-143378790 AIG1 (4) 
chr6 144238307-144238411 PLAGL1 (0.27) 
chr6 145790207-145790350 EPM2A (1.5) 
chr6 146028718-146028850 LOC100507557 (0.31) 
chr6 146030568-146030703 LOC100507557 (0.31) 
chr6 146051146-146051264 LOC100507557 (0.31) 
chr6 147165424-147165533 LOC729178 (0) 
chr6 147943947-147944041 SAMD5 (0.04) 
chr6 150740807-150740948 IYD (0) 
chr6 150814912-150815033 IYD (0) 
chr6 152397391-152397513 SYNE1 (0.52) 
chr6 154681665-154681778 IPCEF1 (0) 
chr6 156179417-156179533 NOX3 (0) 
chr6 156614775-156614880 ARID1B (2.46) 
chr6 157125637-157125879 ARID1B (2.46) 
chr6 158215240-158215371 SNX9 (0.03) 
chr6 159017717-159017848 TMEM181 (3.52) 
chr6 160085754-160085855 SOD2 (5.12) 
chr6 162490273-162490394 PACRG (0) 
chr6 164280065-164280190 QKI (4.02) 
chr6 164469281-164469397 QKI (4.02) 
chr6 165448876-165448999 C6orf118 (0.12) 
chr6 168477218-168477336 FRMD1 (0.07) 
chr7 1899529-1900067 MAD1L1 (3.94) 
chr7 2157229-2157319 MAD1L1 (3.94) 
chr7 3202569-3202698 CARD11 (0.75) 
chr7 4259016-4259138 SDK1 (1.11) 
chr7 4444647-4444782 SDK1 (1.11) 
chr7 4806877-4806972 KIAA0415 (0) 
chr7 7194485-7194576 C1GALT1 (2.62) 
chr7 7865054-7865169 LOC729852 (0) 
chr7 11776593-11776699 THSD7A (0) 
chr7 12082291-12082414 TMEM106B (2.76) 
chr7 12971267-12971401 ARL4A (0.07) 
chr7 14087835-14087941 ETV1 (0.02) 
chr7 15898080-15898211 MEOX2 (0) 
chr7 16761403-16761503 BZW2 (6.07) 
chr7 17014271-17014397 AGR3 (0) 
chr7 17307952-17308069 AHR (3.76) 
chr7 19298407-19298525 FERD3L (0) 
chr7 26129289-26129418 NFE2L3 (5.02) 
chr7 32029898-32030036 PDE1C (0.08) 
chr7 34207882-34208011 BMPER (0.22) 
chr7 34329153-34329275 AAA1 (0) 
chr7 37904353-37904476 SFRP4 (0.07) 
chr7 44053216-44053326 POLR2J4 (1.25) 
chr7 44545460-44545574 NPC1L1 (0) 
chr7 45412789-45412914 RAMP3 (0) 
chr7 48512547-48512678 ABCA13 (1.64) 
chr7 49336977-49337106 CDC14C (0) 
chr7 49444789-49444985 VWC2 (0) 
chr7 49453993-49454121 VWC2 (0) 
chr7 49851016-49851132 ZPBP (0) 
chr7 66071809-66071988 KCTD7 (2.2) 
chr7 67592715-67592832 STAG3L4 (2.64) 
chr7 68113239-68113357 AUTS2 (1.02) 
chr7 68368643-68368764 AUTS2 (1.02) 
chr7 68509858-68509952 AUTS2 (1.02) 
chr7 68782079-68782210 AUTS2 (1.02) 
chr7 69740687-69740852 AUTS2 (1.02) 
chr7 70741573-70741663 WBSCR17 (2.32) 
chr7 71222099-71222225 CALN1 (0.26) 
chr7 71401871-71401992 CALN1 (0.26) 
chr7 71508868-71508977 CALN1 (0.26) 
chr7 75137123-75137283 PMS2P3 (3.38) 
chr7 76157033-76157146 UPK3B (1.46) 
chr7 78809667-78809789 MAGI2 (0.32) 
chr7 78811584-78811719 MAGI2 (0.32) 
chr7 79922983-79923108 GNAI1 (0) 
chr7 80173990-80174111 GNAT3 (0) 
chr7 81140639-81140768 HGF (6.76) 
chr7 81315453-81315571 HGF (6.76) 
chr7 82225303-82225427 CACNA2D1 (3.05) 
chr7 82523700-82523849 CACNA2D1 (3.05) 
chr7 83261812-83261935 SEMA3A (0.83) 
chr7 83290416-83290555 SEMA3E (0.34) 
chr7 83383708-83383883 SEMA3E (0.34) 
chr7 83449448-83449584 SEMA3A (0.83) 
chr7 83472782-83472912 SEMA3A (0.83) 
chr7 83510567-83510689 SEMA3A (0.83) 
chr7 84045574-84045703 SEMA3A (0.83) 
chr7 88642219-88642349 ZNF804B (0) 
chr7 88768077-88768225 ZNF804B (0) 
chr7 91096078-91096186 FZD1 (2.45) 
chr7 92244323-92244568 CDK6 (4.68) 
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chr7 92373549-92373663 CDK6 (4.68) 
chr7 92561993-92562117 CDK6 (4.68) 
chr7 93586838-93586959 GNG11 (2.01) 
chr7 93652075-93652228 BET1 (3.59) 
chr7 95542827-95542953 DYNC1I1 (1.07) 
chr7 96380352-96380471 SHFM1 (6.65) 
chr7 99006226-99006344 BUD31 (6.42) 
chr7 99229631-99229867 ZNF498 (0) 
chr7 101313587-101313708 MYL10 (0) 
chr7 101982578-101982689 SPDYE6 (1.06) 
chr7 102207468-102207583 SPDYE2 (0) 
chr7 102212937-102213045 RASA4 (1.74) 
chr7 102306548-102306658 SPDYE2L (0) 
chr7 102311991-102312125 SPDYE2L (0) 
chr7 105648378-105648505 CDHR3 (0.02) 
chr7 106145143-106145286 C7orf74 (0) 
chr7 114780613-114780707 MDFIC (5.66) 
chr7 116103685-116103810 CAV2 (3.28) 
chr7 116227049-116227179 CAV1 (6.19) 
chr7 116633337-116633458 ST7 (4.06) 
chr7 116907998-116908121 WNT2 (0.07) 
chr7 117081159-117081256 ASZ1 (0) 
chr7 117634141-117634262 CTTNBP2 (0.03) 
chr7 117636072-117636203 CTTNBP2 (0.03) 
chr7 118561343-118561472 ANKRD7 (0.43) 
chr7 119568480-119568576 KCND2 (0.65) 
chr7 121158265-121158366 FAM3C (3.21) 
chr7 121403786-121403903 PTPRZ1 (0) 
chr7 121590110-121590231 PTPRZ1 (0) 
chr7 123193302-123193422 NDUFA5 (3.54) 
chr7 123746459-123746572 TMEM229A (0) 
chr7 124228251-124228369 GPR37 (0) 
chr7 124996208-124996332 POT1 (3.76) 
chr7 125469005-125469115 GRM8 (2.22) 
chr7 125757184-125757300 GRM8 (2.22) 
chr7 125865644-125865744 GRM8 (2.22) 
chr7 125916766-125916882 GRM8 (2.22) 
chr7 127172211-127172319 GCC1 (2.51) 
chr7 133403913-133404044 EXOC4 (5.64) 
chr7 133519714-133519839 EXOC4 (5.64) 
chr7 135015912-135016024 CNOT4 (3.6) 
chr7 135777668-135777761 LUZP6 (6.46) 
chr7 139677026-139677157 TBXAS1 (1.15) 
chr7 140895572-140895705 LOC100507421 (0) 
chr7 141657244-141657375 CLEC5A (0.17) 
chr7 143203011-143203116 LOC285965 (0) 
chr7 143715940-143716067 OR6B1 (0) 
chr7 143912886-143913013 OR2A1 (0) 
chr7 144032163-144032290 OR2A42 (0) 
chr7 147229759-147229888 MIR548I4 (0) 
chr7 148336253-148336383 C7orf33 (4.98) 
chr7 151462290-151462399 PRKAG2 (1.16) 
chr7 153161865-153161986 DPP6 (1.14) 
chr7 154199594-154199717 DPP6 (1.14) 
chr7 154544316-154544430 DPP6 (1.14) 
chr7 154998362-154998489 INSIG1 (7.7) 
chr7 155154320-155154414 INSIG1 (7.7) 
chr7 156558030-156558162 LMBR1 (5.09) 
chr7 156652902-156653027 NOM1 (5.17) 
chr7 157677286-157677409 PTPRN2 (5.06) 
chr7 158172529-158172655 PTPRN2 (5.06) 
chr7 158546785-158546903 ESYT2 (5.85) 
chr7 158692389-158692508 WDR60 (2.17) 
chr8 1710850-1710964 CLN8 (0.43) 
chr8 2220366-2220478 MYOM2 (1.86) 
chr8 2347312-2347434 MYOM2 (1.86) 
chr8 2735368-2735545 CSMD1 (2.87) 
chr8 2980170-2980300 CSMD1 (2.87) 
chr8 4632320-4632426 CSMD1 (2.87) 
chr8 8779595-8779707 MFHAS1 (4.12) 
chr8 9915200-9915328 MSRA (4.76) 
chr8 10143888-10144012 MSRA (4.76) 
chr8 13488629-13488749 C8orf48 (0) 
chr8 15199100-15199214 SGCZ (0.35) 
chr8 15274678-15274806 TUSC3 (0.19) 
chr8 16314431-16314621 MSR1 (4.21) 
chr8 16607140-16607258 FGF20 (0) 
chr8 18820522-18820653 PSD3 (3.96) 
chr8 19075647-19075776 SH2D4A (0.31) 
chr8 20917367-20917499 LOC286114 (0) 
chr8 22478352-22478546 BIN3 (3.56) 
chr8 23618276-23618392 NKX2-6 (0) 
chr8 25957412-25957531 EBF2 (1.61) 
chr8 27787787-27787918 SCARA5 (0.33) 
chr8 28162858-28162988 PNOC (0) 
chr8 32293613-32293736 NRG1 (0.63) 
chr8 47360155-47360253 LINC00293 (0) 
chr8 49430546-49430678 EFCAB1 (0) 
chr8 51097806-51097928 SNTG1 (0) 
chr8 52213619-52213756 PXDNL (1.8) 
chr8 52215990-52216109 PXDNL (1.8) 
chr8 52643299-52643410 PXDNL (1.8) 
chr8 55074557-55074747 MRPL15 (3.64) 
chr8 55444230-55444347 SOX17 (0) 
chr8 58890928-58891050 FAM110B (0.06) 
chr8 59220739-59220861 UBXN2B (3.31) 
chr8 60650322-60650442 CA8 (2.06) 
chr8 60850776-60850891 CA8 (2.06) 
chr8 63655404-63655547 NKAIN3 (0) 
chr8 64579000-64579160 LOC286184 (0) 
chr8 66353812-66353917 LOC286186 (0) 
chr8 66792827-66792955 PDE7A (3) 
chr8 71452839-71452956 TRAM1 (5.71) 
chr8 72804836-72804979 LOC100132891 (0) 
chr8 74498135-74498268 STAU2 (3.57) 
chr8 75012269-75012389 LY96 (2.01) 
chr8 82963475-82963631 SNX16 (1.4) 
chr8 83116810-83116949 SNX16 (1.4) 
chr8 83161079-83161191 SNX16 (1.4) 
chr8 85839152-85839259 RALYL (0) 
chr8 90366501-90366616 RIPK2 (3.82) 
chr8 96135068-96135197 PLEKHF2 (2.06) 
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chr8 97400855-97400973 PTDSS1 (5.24) 
chr8 99918572-99918681 OSR2 (1.4) 
chr8 101141485-101141575 FBXO43 (1.8) 
chr8 102002266-102002389 YWHAZ (6.43) 
chr8 104284589-104284695 FZD6 (0.8) 
chr8 104576009-104576124 RIMS2 (0.43) 
chr8 106056315-106056445 ZFPM2 (0) 
chr8 109353477-109353605 EIF3E (7.95) 
chr8 111580975-111581096 KCNV1 (0) 
chr8 114769781-114769902 CSMD3 (0.04) 
chr8 117864193-117864298 RAD21-AS1 (1.71) 
chr8 118532943-118533061 EXT1 (4.89) 
chr8 121838784-121838919 SNTB1 (0.5) 
chr8 121875299-121875411 SNTB1 (0.5) 
chr8 121947688-121947800 SNTB1 (0.5) 
chr8 121951793-121951902 SNTB1 (0.5) 
chr8 124250507-124250631 ZHX1 (3.82) 
chr8 124503997-124504118 FBXO32 (1.27) 
chr8 124685059-124685190 ANXA13 (0) 
chr8 124692264-124692385 ANXA13 (0) 
chr8 125740159-125740318 MTSS1 (2.31) 
chr8 125755048-125755206 MTSS1 (2.31) 
chr8 125773036-125773195 MTSS1 (2.31) 
chr8 126333127-126333279 NSMCE2 (4.45) 
chr8 126360901-126361025 NSMCE2 (4.45) 
chr8 126545229-126545352 TRIB1 (2.35) 
chr8 127019457-127019588 LOC100130231 (0) 
chr8 129255857-129255986 MIR1208 (0) 
chr8 130034999-130035094 LOC728724 (0) 
chr8 134249541-134249659 WISP1 (0.07) 
chr8 134392068-134392175 ST3GAL1 (1) 
chr8 135340956-135341142 ZFAT (2.04) 
chr8 135630238-135630359 ZFAT (2.04) 
chr8 140261510-140261641 COL22A1 (3.81) 
chr8 141965424-141965543 PTK2 (3.39) 
chr8 144272815-144272951 GPIHBP1 (0) 
chr8 144274107-144274220 GPIHBP1 (0) 
chr8 144672141-144672251 TIGD5 (1.93) 
chr9 2303022-2303152 SMARCA2 (5.44) 
chr9 3304641-3304768 RFX3 (2.3) 
chr9 9190406-9190527 PTPRD (0.04) 
chr9 9442149-9442266 PTPRD (0.04) 
chr9 12475847-12475968 TYRP1 (0) 
chr9 13384169-13384278 FLJ41200 (0) 
chr9 19037513-19037644 FAM154A (0) 
chr9 20012215-20012356 SLC24A2 (0.08) 
chr9 22058803-22058932 CDKN2B-AS (0) 
chr9 25435260-25435365 TUSC1 (0) 
chr9 26157467-26157599 LOC100506422 (0) 
chr9 26752856-26752975 C9orf82 (0) 
chr9 27075433-27075563 IFT74 (4.72) 
chr9 30559198-30559299 MIR873 (0) 
chr9 31578569-31578700 ACO1 (5.06) 
chr9 32357080-32357188 ACO1 (5.06) 
chr9 32796955-32797086 TMEM215 (0) 
chr9 33917876-33917997 UBAP2 (4.35) 
chr9 38261895-38262012 ALDH1B1 (3.91) 
chr9 41902205-41902313 MGC21881 (0) 
chr9 42234197-42234325 ANKRD20A2 (0.1) 
chr9 42778394-42778549 FOXD4L2 (0) 
chr9 42842794-42842970 AQP7P3 (0.71) 
chr9 44454563-44454671 CNTNAP3B (0) 
chr9 46896418-46896526 KGFLP1 (0.93) 
chr9 66533939-66534047 LOC442421 (0) 
chr9 67015830-67015977 LOC100133920 (0) 
chr9 67304408-67304555 AQP7P1 (0.25) 
chr9 69666379-69666496 LOC100133920 (0) 
chr9 69750941-69751103 LOC100133920 (0) 
chr9 69801825-69802017 LOC100133920 (0) 
chr9 70117634-70117796 FOXD4L5 (0.46) 
chr9 70368075-70368241 FOXD4L4 (0) 
chr9 70629019-70629153 CBWD3 (1.64) 
chr9 72951817-72951942 KLF9 (1.75) 
chr9 74272369-74272487 TMEM2 (2.69) 
chr9 75887760-75887868 ANXA1 (5.56) 
chr9 81325675-81325812 PSAT1 (6.06) 
chr9 81341581-81341707 PSAT1 (6.06) 
chr9 83145433-83145538 TLE4 (1.11) 
chr9 83147352-83147481 TLE4 (1.11) 
chr9 83714051-83714180 TLE1 (0.99) 
chr9 83956434-83956555 TLE1 (0.99) 
chr9 86181034-86181164 FRMD3 (0.36) 
chr9 89152562-89152673 ZCCHC6 (3.72) 
chr9 90965448-90965569 SPIN1 (3.19) 
chr9 90971262-90971383 SPIN1 (3.19) 
chr9 92470388-92470519 UNQ6494 (3.28) 
chr9 92979115-92979231 LOC286370 (0) 
chr9 93273812-93273938 LOC340515 (0) 
chr9 93581721-93581843 SYK (1.82) 
chr9 93583644-93583765 SYK (1.82) 
chr9 93759287-93759409 LOC100129316 (0) 
chr9 95872954-95873083 NINJ1 (5.87) 
chr9 100828114-100828235 TRIM14 (3.62) 
chr9 102665046-102665176 STX17 (3.25) 
chr9 103308506-103308652 C9orf30-TMEFF1 (0) 
chr9 103801905-103802032 LPPR1 (0) 
chr9 105180427-105180550 CYLC2 (0) 
chr9 106225392-106225514 CYLC2 (0) 
chr9 110550887-110551016 KLF4 (0.09) 
chr9 116448131-116448263 RGS3 (1.87) 
chr9 116460439-116460561 RGS3 (1.87) 
chr9 116520605-116520721 ZNF618 (0) 
chr9 116529195-116529323 ZNF618 (0) 
chr9 117099092-117099187 AKNA (3.28) 
chr9 117297625-117297761 DFNB31 (2.62) 
chr9 117446529-117446705 LOC100505478 (0) 
chr9 117490904-117491028 LOC100505478 (0) 
chr9 118284246-118284369 37226 (0) 
chr9 120280747-120280860 ASTN2 (2.7) 
chr9 124430168-124430297 DAB2IP (3.26) 
chr9 125196271-125196401 PTGS1 (1.51) 
chr9 129547273-129547403 ZBTB43 (2.96) 
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chr9 130232519-130232641 LRSAM1 (3.46) 
chr9 134967412-134967553 MED27 (4.51) 
chrM 2802-3137 -1 (0) 
chrM 5118-5251 -1 (0) 
chrUn_gl000220 114688-115211 RN5-8S1 (0) 
chrUn_gl000220 153851-154000 RN5-8S1 (0) 
chrUn_gl000220 158643-159185 RN5-8S1 (0) 
chrX 5831942-5832070 NLGN4X (1.6) 
chrX 6140886-6141001 NLGN4X (1.6) 
chrX 7029127-7029265 MIR4767 (0) 
chrX 7285586-7285711 STS (0.76) 
chrX 7819838-7819969 VCX (0.98) 
chrX 8276428-8276549 VCX2 (1.06) 
chrX 11142876-11143004 HCCS (4.14) 
chrX 13079453-13079565 FAM9C (1) 
chrX 13321463-13321556 ATXN3L (0) 
chrX 18048947-18049048 BEND2 (0) 
chrX 18889475-18889602 LOC100132163 (0) 
chrX 26928857-26928989 VENTXP1 (0) 
chrX 29678080-29678188 IL1RAPL1 (0.08) 
chrX 33733184-33733306 DMD (3.58) 
chrX 33739875-33739997 DMD (3.58) 
chrX 34097584-34097705 FAM47A (0.55) 
chrX 34353273-34353395 FAM47A (0.55) 
chrX 34587118-34587239 TMEM47 (0.18) 
chrX 37287143-37287250 LANCL3 (0.18) 
chrX 39293027-39293158 LOC286442 (0) 
chrX 39293998-39294127 LOC286442 (0) 
chrX 42824389-42824515 PPP1R2P9 (0) 
chrX 45418774-45418900 MIR221 (0) 
chrX 45899146-45899274 MIR222 (0) 
chrX 46031914-46032047 ZNF673 (0) 
chrX 46182417-46182540 ZNF673 (0) 
chrX 47003999-47004120 RBM10 (4.93) 
chrX 68019181-68019310 EFNB1 (4.08) 
chrX 69216696-69216826 EDA (0.18) 
chrX 74128724-74128853 ABCB7 (3.63) 
chrX 77795563-77795676 ZCCHC5 (0) 
chrX 78899252-78899364 ITM2A (0.61) 
chrX 82925564-82925694 POU3F4 (3.95) 
chrX 85270259-85270386 DACH2 (0) 
chrX 87041373-87041492 KLHL4 (1.96) 
chrX 90994410-90994540 PCDH11X (0.41) 
chrX 93990319-93990444 FAM133A (0) 
chrX 94539489-94539610 LOC643486 (0) 
chrX 95481421-95481543 LOC643486 (0) 
chrX 105349133-105349264 MUM1L1 (0.38) 
chrX 109756901-109757012 TDGF1P3 (0) 
chrX 110100670-110100801 CHRDL1 (0.1) 
chrX 110720529-110720646 DKFZp686D0853 (0) 
chrX 111587632-111587742 TRPC5 (0.4) 
chrX 111782275-111782405 ZCCHC16 (0) 
chrX 114659135-114659258 LUZP4 (0.24) 
chrX 118875618-118875749 ANKRD58 (0) 
chrX 119138356-119138485 NKAP (5.04) 
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